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The papers in this volume derive from pre-circulated statements, plenary presentations 
and respondent commentary prepared for the Workshop. 
Most of the Workshop materials are included in this collection, though some participants 
elected not to submit their statements for publication. 
All papers have been edited for inclusion in this collection, and authors’ biographies and 
editors’ introductions have been added. 
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About the Author 
Susan Sherwin is Munro Professor of Philosophy and a Professor of Women's Studies at 
Dalhousie University. Her principal area of research is in feminist health care ethics. She 
is the author of No Longer Patient: Feminist Ethics and Health Care (Temple University 
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Research Network which jointly produced The Politics of Women's Health: Exploring 
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About the Article 
In these Opening Comments, Sue Sherwin explains the history of the Working Group on 
Women, Health and the New Genetics, and the goals of the national Strategic Workshop 
held on February 11 and 12, 2000 at York University in Toronto. At issue for concerned 
observers of the federal government’s policy agenda for biotechnology, Sherwin 
suggests, are “basic questions of values.” It is precisely the imperative of value definition 
and judgment which necessitates democratic rather than bureaucratic policy 
development in this burgeoning field. Yet the government’s approach to defining values, 
Sherwin argues, has been inadequate at best, and incoherent at worst. Drawing on her 
own work in the field of feminist health care ethics, Sherwin seeks to “clarify and order 
the values underlying the Canadian Biotechnology Strategy” by investigating different 
meanings of ‘freedom’ and ‘choice.’ She advocates what she calls “relational autonomy” 
as a way to approach these ideals. Finally, Sherwin considers the structures and 
processes through which values – other than those advanced by industry – can be 
brought to bear in the development and deployment of policies. Despite the difficulty of 
such a task, Sherwin commends the importance of engaging citizens in the development 
of Canada-specific approaches to the assessment, promotion and restriction of 
biotechnology. Only in this way, Sherwin argues, can our policies “reflect and help to 






Nearly two years ago, a small group 
calling itself the Working Group on Women 
and the New Genetics was formed under 
the auspices of NNEWH (National 
Network on Environments and Women’s 
Health). As a group of Canadian 
academics and community activists 
sharing a concern with issues related to 
women, health and genetic knowledge, we 
structured our investigations around 
feminist principles of social justice. 
Specifically, we were concerned with the 
absence of concentrated gender-specific 
research investigating the impact of the 
new genetics agenda on women. With 
some seed money from NNEWH, we 
began a series of teleconferences around 
the need for greater research in the realm 
of women’s health and the new genetics. 
The membership of this working group 
evolved a bit and soon settled into a core 
team.1 
 
The February 2000 workshop was actually 
the second in a series of two national 
strategic workshops. Last February 
(1999), we organized a preliminary 
workshop in Winnipeg to which we invited 
a small group of community activists 
concerned with women’s health issues. 
They were asked to reflect on their 
understanding of the implications of new 
                                               
1 The Working Group for 1999-2000 consists 
of: Patricia Lee, Fiona Miller, Roxanne 
Mykitiuk, Yvonne Peters, Sari Tudiver, myself, 
and our reluctant but fearless and much 
overworked leader, Lorna Weir, Department of 
Sociology, York University, Toronto. Though 
Ann Rochon Ford has had to give up active 
membership in the group, she was a very 
important early member who helped to get us 
going. The activities of the Working Group 
have been facilitated by continuing support 
from NNEWH. That support, supplemented 
with grants from MRC, the Department of 
Sociology at York, and the Dean of Arts at 
York, allowed us to hold this workshop. We are 
very grateful to all our sponsors. 
genetics for women’s health and their 
sense of research priorities in this realm. 
Building on the feedback from that 
workshop, the Working Group decided to 
try to focus the 2000 workshop’s 
investigation of the implications of the new 
technology for women’s health around the 
three core themes of health, wealth, and 
community. We re-framed our initial 
agenda beyond genetics to the whole 
range of biotechnology in the hope of 
having an impact on the government’s 
current efforts to restructure its approach 
to the biotechnology industry. Our hope 
was that the national strategic workshop 
would provide an opportunity for 
participants to define and begin to address 
a series of fundamental, feminist questions 
about the Canadian Biotechnology 
Strategy (CBS) in relation to women and 
health. 
 
It is our view that that there are basic 
questions of values related to the genetic 
modifications of humans and other 
organisms that must be identified and 
addressed. These questions cannot be 
resolved internally through state 
bureaucratic processes, since they involve 
questions of society’s value commitments. 
Such decisions must be pursued through 
democratic processes. Indeed, recognition 
of the importance of public debate was a 
major factor behind the federal 
government’s 1998 efforts to solicit public 
input on these matters through a round of 
policy consultations. Many of us 
participated in some of those sessions and 
were confirmed in our sense that the level 
of critical cultural knowledge and public 
understanding of biotechnology is weak. 
The development of socially accountable 
strategic frameworks for state 
biotechnology policy suffers from this 
dilemma. We are particularly troubled by 
the lack of attention directed at the 
question of what these policies mean for 
women. A distinctly feminist perspective 
must be brought to bear on the 
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identification and investigation of the 
values underlying biotech policy. 
 
We use the term 'women and health' quite 
expansively to refer to three processes: 
the impact of policy and technology on 
women's health; women's relationship to 
medicine and health systems; and 
women's 'interests' in health – health as 
women's business – personally, culturally, 
socially. We asked Workshop participants 
to focus on the following: What are the key 
questions to ask so that we might best 
understand the impact the CBS will have 
on women and health? What kinds of 
research and action need to be 
undertaken to answer these questions? 
 
In deciding on participants for the 
workshop, we sought out individuals 
engaged in developing new knowledge or 
in carrying out advocacy work. We tried to 
structure the workshop to facilitate the 
exchange of existing knowledge, and also 
to produce new questions and to incite the 
development of new knowledge and 
advocacy. We intended the workshop to 
be a forum for the design of future 
research projects and activities, where 
resources could be identified and networks 
formed of individuals and groups 
committed to taking the issues further. The 
aim of the workshop was not to produce 
consensus. We meant to stimulate and 
facilitate rather than conclude. We hoped 
to leave with a clearer sense of what 
questions should be asked, what research 
undertaken and what advocacy pursued to 
deal with the Canadian Biotechnology 
Strategy from the perspectives of women 
and health. The collection of papers in this 
Proceedings suggests that we 
accomplished our goals. 
 
I have the privilege of leading things off. 
Let me do that by situating my own 
research interests in the context of our 
agenda. I work in the field of ethics, more 
specifically feminist health care ethics. It is 
very clear that there is need for sustained 
feminist research directed at clarifying the 
many vague suggestions found within the 
government documents about the values 
that should be guiding Canada’s 
biotechnology strategy. We can begin by 
documenting the incoherence in the 
values expressed in the government’s own 
statements of the values that form the 
basis for policy directions. For example, 
the expressed commitment to advancing 
the health and well-being of Canadians is 
often incompatible with the strongly 
endorsed value of supporting industry. 
Just making clear the competing and 
incommensurate value frameworks that 
are being proposed allows us to insist that 
government be explicit about the priorities 
it attaches to the various value systems at 
work. Toward this end, it is particularly 
important that we ask the familiar feminist 
questions as to who is likely to benefit 
from the various types of biotechnology 
and who is likely to suffer from them. Let 
me try to be a bit more specific. 
 
It is essential that Canadians understand 
the different forms of freedom and choice 
that are proposed as a central value for 
emerging policy. The terminology of 
freedom and choice is often used to 
represent quite different value systems. 
Not surprisingly, industry is particularly 
enthusiastic about market models in which 
freedom is reduced to the ideal of 
unrestricted consumer choice. In this 
conception, government is assigned a role 
of regulating trade to ensure accuracy of 
information and adequate opportunities to 
acquire the information necessary to make 
a rational choice. This is especially tricky 
terrain for feminists for we often hear our 
own slogans about the importance of 
“choice” and personal control over 
decisions regarding our bodies invoked to 
support industry’s right to market any 
“health” or “reproduction” related product 
or service directly to consumers.  
 
We must, therefore, be very clear about 
the type of personal freedom we 
understand to be central to feminist 
values. Specifically, feminists need to 
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insist that the personal control we demand 
is not a matter of being granted 
unrestricted access to problematic 
technologies. Rather, we seek access to 
opportunities that can support women’s 
overall autonomy, and not increase their 
oppression. We cannot decide whether 
any particular consumer option meets this 
criterion by examining it in isolation and 
seeing if it meets some particular person’s 
current desires or needs. To determine a 
technology’s impact on personal autonomy 
we need to investigate it in the context of 
what opportunities are created or lost by 
its introduction.  
 
Elsewhere, I have proposed that we try to 
understand the ideal in question through a 
concept I call “relational autonomy” 
(Sherwin, 1998) The idea of relational 
autonomy is that we must critically 
examine not only the decision-making 
capacity of the agent to make rational 
choices free of direct coercion, but also 
the nature of the set of options from which 
she must choose. Emphasis on the 
relational dimension of autonomy (which 
literally means self-government) is meant 
to counter the familiar over-simplification 
by which autonomy is equated with the 
exercise of preferences without 
interference. Relational autonomy 
demands moral evaluation of the context 
in which the person is being asked to 
choose. In particular, agents should be 
free of the “double binds” of oppression 
that tend to reduce an individual’s options 
to a set of harmful choices where the best 
she can do is to select that option most 
likely to minimize the resulting damage. 
 
Relational autonomy is also distinguished 
from consumer freedom in its appreciation 
of the processes that are essential 
elements of becoming autonomous. It 
rejects the common assumption that being 
autonomous is achieved merely by virtue 
of reaching adulthood and being free of 
explicit coercion. Under the consumer 
choice model of freedom the self is 
expected to approach important decisions 
fully formed and self-transparent; but 
selves are never fully formed, coherent, 
consistent, and clear. When individuals 
are faced with difficult personal decisions 
they often surprise themselves with the 
decisions they make. Real autonomy 
comes not from entering such 
circumstances with our values settled, 
such that all we need is respect for our 
well-articulated preferences, but from 
having the opportunity to discover what 
our values really are and how they apply 
to the situation at hand. We need to 
wrestle with the implications of serious 
options to know what we stand for and 
how we want to be treated. Thus, to 
respect autonomy for individuals it is not 
sufficient to leave them free to exercise 
their preferences; rather we must provide 
them with the resources necessary for 
discovering what they truly value and what 
sort of person they wish to be. It is our 
reflective, considered values that demand 
respect, not our current inclinations. Self-
discovery and self-definition are relational 
activities that are essential pre-conditions 
of genuine self-direction. 
 
Therefore, a consumer model of choice 
with respect to various sorts of 
biotechnologies cannot be equated with 
the moral ideal of autonomy. The fact that 
people are willing, perhaps even eager, to 
purchase some form of biotechnology is 
not evidence that this technology should 
be brought to market. Individuals are often 
in no position to resist technologies on 
their own. If some form of technology is 
normalized, the option of refusing it may 
disappear. For instance, it is already 
difficult for many women to resist prenatal 
testing of their fetuses even if they are 
committed to carrying the pregnancy to 
term and the information available from 
prenatal testing will be of no benefit to 
them. Similarly, if the crops produced by 
genetically modified seeds prove invasive 
to other crops, or if they allow production 
at vastly reduced rates for a few years, 
independent farmers may be unable to 
continue to plant traditional seeds in an 
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economically viable way. The fact that 
women choose prenatal testing under the 
mistaken belief that it will improve the 
health of their fetus or that farmers choose 
to buy seeds from the major distributors is 
not evidence that the individuals 
concerned are acting autonomously. Only 
if their decisions reflect their deepest 
values can we consider their actions fully 
autonomous.  
 
We need to do more than clarify and order 
the values underlying the Canadian 
Biotechnology Strategy, of course. We 
also need to explore structures that can 
ensure that the values selected will be 
reflected in the policies our government 
adopts. This project is especially 
challenging, since it is difficult to see how 
Canadians might actually go about limiting 
the development of any potentially 
profitable biotechnology industry. While 
government is well positioned to foster the 
development of favoured industries, it is 
not as well equipped to restrict the 
undesirable ones. Biotechnology 
industries are particularly resistant to 
government restrictions, for the companies 
involved are typically engaged in a global, 
not a national, marketplace. In fact, many 
belong to that most postmodern of 
phenomena: multi-national corporations 
that are situated both everywhere and 
nowhere. Producers effectively resist 
national regulations on the grounds that 
local restrictions would put them at an 
unfair economic disadvantage in a 
competitive global marketplace. Typically, 
they are able to make credible threats that 
they will move production to a different 
jurisdiction if their interests are ignored. 
Governments are understandably reluctant 
to introduce policies that inhibit the growth 
of industries when the jobs in question can 
be easily moved off-shore. Indeed, 
governments are far more inclined to 
support than to restrict these new 
industrial initiatives. For example, Health 
Canada was very explicit in its recent 
announcement that it would shorten the 
waiting time needed before initiating phase 
one drug trials from 60 days to two days 
because it hoped such a move would 
attract more pharmaceutical research to 
Canada. 
 
Moreover, it is not only the producers who 
may resist national restrictions. In an era 
where free trade has become a mantra of 
politicians and economists, it is difficult for 
nations to develop policies that effectively 
protect their citizens from the potential 
hazards of products originating elsewhere. 
While consumers may welcome 
government’s role in setting minimal safety 
standards and promoting truth in 
advertising, they tend to be rather 
intolerant of government restrictions on the 
availability of goods they personally 
desire. In fact, many Canadians have 
become quite adept at “cross border 
shopping.” This means that if our 
government ever does manage to finally 
introduce its long-promised legislation to 
regulate reproductive technologies, we 
can anticipate that some Canadians will 
side-step restrictions on reproductive 
services (e.g., sex selection) through 
travel to U.S. clinics. Similar action will be 
taken for access to home-testing kits for 
genetic traits, anti-aging potions, and even 
organs for transplant if such products are 
restricted in Canada but available for 
purchase in other jurisdictions. 
 
Nonetheless, I believe that Canada must 
develop a national policy on 
biotechnology. We need to do this in order 
to protect and promote the personal 
autonomy of our citizens, because 
individuals cannot control the social and 
material conditions that structure the 
options they face; many of the 
preconditions for relational autonomy can 
only be achieved through political action. 
In order to make certain that the options 
facing Canadians in the realm of 
biotechnology will promote and not limit 
personal relational autonomy, it is 
necessary for the government to develop 
policies that reflect our national autonomy. 
That is, they must be policies that reflect 
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and help to realize the deepest values of 
Canadians.2  
 
In order to develop such policies, we must 
conduct exercises in collective self-
discovery and self-definition about the 
sorts of activities well informed citizens 
wish to permit and the sorts of threats they 
wish government to protect them from. It is 
only through a complex exercise of 
communication and debate that we can 
decide what might constitute “Canadian 
values” in the diverse, multi-cultural, 
heterogeneous society we inhabit. In fact, 
the federal government has recognized 
that potential transformations of 
fundamental values and understandings 
are inherent in many forms of 
biotechnology. It has undertaken efforts to 
promote the conversations Canadians 
must undertake in pursuing the activities of 
self-discovery and self-definition that are 
essential for genuine autonomy. For 
example, more than ten years ago it 
established the Royal Commission on 
New Reproductive Technologies to advise 
on policies in the realm of reproduction. 
The Royal Commission conducted 
extensive consultations with Canadians 
and determined that we are united in not 
wanting to be a society that treats children 
or women’s reproductive capacities as 
commodities to be bought and sold. By 
exploring the meaning of this commitment, 
the Commission learned that Canadians 
did not think it appropriate to treat 
reproductive activities, including the 
contribution of embryos, eggs, and sperm 
as commodities to be auctioned off to the 
highest bidder.  
 
In 1998, the federal government initiated 
conversations central to self-discovery and 
self-definition in the sphere of 
biotechnology broadly defined. It held a 
series of public consultations regarding 
                                               
2 I do not believe that oppression of minorities 
reflects national autonomy at all, but rather the 
co-optation of ethical language in the service 
of immoral abuses of local power. 
development of a biotechnology strategy 
which would “enhance the quality of life of 
Canadians in terms of health, safety, the 
environment and social and economic 
development by positioning Canada as a 
responsible world leader in biotechnology.” 
(CBS, 1998). Ethical analysis was 
understood to be a central element of 
these deliberations. But as several papers 
noted, the motivation for discussion was 
couched in language aimed at facilitating 
the development and promotion of 
biotechnology industries and did not really 
leave room for alternative strategies to 
emerge. It is, therefore, essential that we 
make clear the inherent contradiction 
between a commitment to explore 
Canadian values regarding biotechnology 
and an assumption that the outcome of 
such analysis will be a shared commitment 
to support most biotechnology industries.  
 
Last fall, the federal government took the 
next step in its biotechnology strategy 
process and appointed a 20 member 
Biotechnology Advisory Committee 
(CBAC). According to the Minister of 
Industry “CBAC is an expert, arm's-length 
committee created under the renewed 
Canadian Biotechnology Strategy (CBS) to 
advise Ministers, raise public awareness 
and engage Canadians in an open and 
transparent dialogue on biotechnology 
matters. . . . CBAC will advise government 
on broad policy issues associated with the 
ethical, social, regulatory, economic, 
scientific, environmental and health 
aspects of biotechnology.” (CBAC, 1999). 
Its express purpose is to facilitate 
continued dialogue of self-direction and 
self-definition in the pursuit of national 
autonomy in the realm of biotechnology. 
There is, however, plenty of reason to 
worry about its effectiveness in achieving 
this task. It is arguable that the advisory 
panel of distinguished Canadians is not 
representative of all concerned citizens; 
certainly, there are many groups that fear 
their views will not be represented nor 
their voices heard. Health activists seem 
to have been deliberately excluded and I 
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know of only one member who is explicitly 
committed to a woman’s health agenda. 
CBAC will need to find ways to promote 
trust in its ability to fully engage Canadians 
in self-discovery and self-definition and to 
report accurately the outcomes of these 
conversations if its advice is to carry the 
necessary authority. One thing we can do, 
here and in the future, is to begin to 
formulate a substantive list of questions 
regarding the impact on women’s health 
that CBAC should attend to in its 
deliberations. We might also propose 
procedural ways that can facilitate 
meaningful input from citizens who are 
concerned with, and knowledgeable about, 
women’s health. 
 
Of course, self-discovery and self-
definition are not the only elements of 
autonomy. Self-direction is also required. 
So far, the Canadian government has 
been unwilling or unable to engage in the 
final step of exercising national autonomy 
in the realm of biotechnology. Despite the 
thoroughness of its public consultations 
and of its research and analysis, none of 
the 293 recommendations of the Royal 
Commission on New Reproductive 
Technologies has yet been implemented. 
It is still too early to determine whether 
CBAC will be able to contribute effectively 
to self-direction on biotechnology policy. It 
is clear, however, that there are likely to 
be structural impediments to its capacity to 
influence policy, that is, to see its moral 
analysis translated into national self-
direction. The panel reports to an inter-
governmental agency in which the 
Department of Industry plays a leading 
role; the principal responsibility of this 
ministry is to promote industrial 
development. Such an arrangement does 
not seem to be particularly conducive to 
generating policy that may require 
imposing restrictions or prohibitions on 
certain industries. 
 
So far, then, the biotechnology strategy 
espouses interest in identifying and 
reflecting the values of Canadians but the 
processes that have been put in place 
make it difficult for the government to hear, 
let alone adopt, values other than those of 
industry. We need to identify strategic 
ways to demand more accountability from 
government in: 
 
1. identifying the appropriate values to 
guide biotech policy; and 
2. ensuring that the values agreed upon 
do in fact structure both national and 
international policies. 
 
Protecting and promoting women’s health 
must surely be fundamental to that 
agenda. Our hope for the workshop was 
that it would help to provide direction to 
the research and political activities that are 
essential elements of translating this 
commitment into practice. Clearly, there is 
much work for feminists to do in promoting 
biotechnology policies that truly support 
women’s health. The following papers 
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Journalist and community activist Sharon Batt has written extensively about breast 
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About the Article 
For many women’s health advocates, the challenge of genetics in relation to breast 
cancer is the challenge posed by a new breed of genetic tests. In this piece, Sharon Batt 
suggests that there are other challenges to consider. Batt introduces readers to a new 
treatment protocol for breast cancer, involving a genetically engineered antibody which 
targets a malfunction that is genetically associated − Herceptin (or Trastuzumab). As 
Batt discusses it, the new drug Herceptin poses both new and familiar challenges. On 
the familiar side of the ledger, and despite the hype to the contrary, this new genetic 
therapy is no miracle cure; moreover, like the better known therapeutic protocol of 
chemotherapy, Herceptin has dangerous adverse effects. On the less familiar side of the 
ledger, this drug is exorbitantly expensive, and herein lies the new challenge. While this 
drug and others like it that are coming down the pipe may provide new tools for fighting 
cancer, they may also prove unaffordable. Batt argues that if the new era of biotech 
medicine provides some medical assistance for the few, while contributing to the demise 






Breast cancer is the number one killer of 
mid-life women and has been for decades. 
Treatments are harsh and have limited 
benefits. An effective new treatment would 
be welcome indeed, and one that worked 
and had few or no adverse side effects 
would transform the experience of breast 
cancer beyond recognition. Enter the 
Human Genome Project, promoted as 
precisely the Aladdin’s lamp we’ve been 
waiting for. Research mapping genes to 
diseases will lead us into a world of just 
such therapies, miraculously effective 
because they are based on a true 
understanding of how genes work. At least 
that’s the hype. Women’s health 
advocates need to weigh these claims, 
balancing our scepticism of this project 
against the desperate need of sick women 
for more enlightened therapeutic 
approaches to cancer. 
 
Feminist discourse about breast cancer 
and genetics has concentrated on the 
issues related to genetic testing for breast 
cancer susceptibility, especially the BRCA 
1 and 2 genes, and on the reductionist 
emphasis on genetics − to the exclusion of 
environmental triggers – as the basis of 
cancer. While these are critical issues, we 
can’t neglect the questions arising from 
genetic treatments that are now coming 
onstream. Health Canada approved 
Herceptin, the first novel gene therapy for 
breast cancer, in August, 1999. 
 
In the rest of this paper, I look at what we 
know so far about what Herceptin does for 
women with breast cancer, its side-effects, 
its cost, how advocates are responding to 
this new therapy, and the dilemmas the 
drug presents for those of us concerned 
about Canada’s biotechnology strategy. 
 
 
What is Herceptin? 
 
Herceptin is the first therapy of its kind 
ever approved for the treatment of breast 
cancer. Unlike cytotoxic chemos which 
simply aim to kill the misfunctioning cell, 
Herceptin aims to re-balance the process 
that is misfunctioning. In this case, the 
therapy is designed to correct an over-
production of the protein produced by a 
certain oncogene (i.e., cancer gene), 
which the defective gene uses to make the 
cell cancerous.1 This gene has been 
named “HER-2 neu,” a clever moniker for 
a drug designed for women. HER-2 refers 
to the protein, “Human Epidermal-growth-
factor Receptor-2,” and neu is the name a 
different scientist, who discovered the 
gene first, decided to call it. Geneticists 
refer to the production of excess protein as 
"overexpression". Herceptin is intended to 
correct the overexpression of the Her-2 
protein.2 
 
Because the Her-2/neu gene produces an 
excess of the Her- 2/neu protein, 
researchers developed what is called a 
"monoclonal antibody" to attack the protein 
and shut it down. (The body produces 
millions of different antibodies − which 
themselves are proteins −to attack 
invading viruses and infections. A 
"monoclonal" antibody is laboratory 
manufactured, using genetic engineering.) 
 
Researchers working on this problem in 
the late 1980s were amazed and delighted 
when they added the monoclonal antibody 
to a petri dish containing breast cancer 
cells that overexpressed Her-2/neu: the 
cancerous cells stopped growing and 
dividing. When they injected the antibody 
into mice into which breast cancer cells 
had been implanted, the tumours shrank. 
                                               
1 NB. This genetic change is part of the cancer 
process; it is not inherited. 
2 Again, the language reverberates for 
feminists: women have long been chastised as 
overexpressing our emotions; now we have a 




Over the next decade, the antibody was 
adapted for use in humans and then 
tested in clinical trials using women who 
had breast cancer tumours that tested 
positive for Her-2/neu. (Bazell, 1998:42-3) 
 
This modus operandi is very different from 
traditional cancer chemotherapies, which 
are systemic, and which are designed to 
kill cancer cells. In theory, herceptin is a 
huge therapeutic advance. As everyone 
knows, conventional chemotherapy drugs 
have horrible side-effects, because they 
kill any rapidly dividing cell, healthy or 
cancerous. What's more, they have not 
been very successful in treating breast 
cancer, especially in patients with 
advanced disease − in fact, they often kill 
the patient before the disease does. While 
Herceptin was in development, the drug 
was touted as a treatment that would work 
better than cell-kill chemo and which 
would have no side-effects at all. A 
patient’s dream drug. 
 
 
Does Herceptin Work? 
 
Does Herceptin Work? The answer is 
sometimes and sort of. 
 
Like most new cancer therapies, Herceptin 
is being tested in patients with advanced 
cancer, that is, in women whose condition 
is very likely to be fatal. Twenty-five to 
thirty percent of women whose cancer has 
reached this stage have been found to 
overexpress HER-2 − and they are women 
whose disease is typically unusually 
aggressive, or fast-spreading.  
 
Clinical trial data for Herceptin have been 
coming out since 1998. The original study, 
which convinced regulators to approve the 
drug, comprised 469 women with 
metastatic breast cancer. Women treated 
with a Herceptin-chemotherapy 
combination lived longer than women 
treated only with chemotherapy by a 
median time of 5 months. Those who had 
standard chemo lived a median time of 
20.3 months from the beginning of 
treatment; those who had chemo plus 
Herceptin lived a median time of 25.4 
months from the beginning of treatment. 
(Slamon et al 1998). After two years of the 
trial, researchers were announcing that the 
addition of Herceptin to chemotherapy 
increased patient survival by 22% (Zoler, 
1999). 
 
In the world of breast cancer treatments, 
this was considered remarkable. Very few 
chemotherapy trials have ever shown a 
survival difference between two 
treatments. On the other hand, this is far 
from the miracle women with breast 
cancer hope for. 
 
The drug has been disappointing on a 
number of other counts. First of all, it 
benefits only a subset of women with 
advanced disease. To see if she qualifies 
for Herceptin, a woman is given a test to 
see if she is one of the cancer patients 
who are Her-2 positive; that is, one of the 
25-30% of women with advanced breast 
cancer who overexpresses the Her-2 
protein. 
 
But even a positive Her2 test result is no 
guarantee that Herceptin will benefit 
women who take it. In the clinical trials 
data, 32 percent who were treated with 
chemotherapy alone showed tumour 
shrinkage compared to 49 per cent of 
Her2 positive women under the Herceptin 
+ chemotherapy regimen. Even with the 
combined treatment, 51 per cent of Her2 
positive women did not respond to 
Herceptin. 
 
Other trials have suggested that 
Herceptin-alone may be a useful treatment 
for metastatic breast cancer. Because it 
was considered unethical to deny 
chemotherapy to women with cancer, 
these trials have involved women who 
have already had a course or more of 
chemo, but whose cancer has returned. In 
the largest trial of this kind, involving 222 
women, the results were considered 
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significant. Herceptin produced a 15% 
“response rate” (in other words, 15% of 
these women had at least a 50% reduction 
in the size of their tumours), for a median 





Though potentially a useful addition to the 
treatment protocol for metastatic breast 
cancer, Herceptin has not lived up to its 
advance billing. As one American activist 
summed it up, "While Herceptin may 
represent an important new direction for 
cancer therapy, the oncology community's 
excitement about a 5.1 month median 
survival benefit also shows how little has 
been achieved since the war on cancer 
began in 1971." (Schiff, 2000:23) 
 
But more surprising for its proponents than 
its limited efficacy, has been the extent to 
which this drug is associated with adverse 
effects. On the one hand, Herceptin is 
generally given in combination with 
chemotherapy drugs. The researchers' 
thinking was that the antibody would hold 
the cancer in check, while chemotherapy 
attacked it (Bazell, 1998:137). If a selling 
point for genetic treatments is that they are 
more targeted and less toxic than cell-kill 
chemotherapy, this advantage is 
somewhat academic if the drug is given in 
combination with a cell-kill regimen. 
Another problem is that Herceptin can't 
cross the blood/ brain barrier. Some 
women whose metastases disappeared in 
their liver, lung or bones eventually died of 
brain metastases. (Bazell, 1998:170) 
 
But most important is the apparent toxicity 
of Herceptin for heart tissue. The cell-kill 
chemotherapy regimen which is used is 
already quite toxic − especially to heart 
tissue. To everyone's surprise, Herceptin 
actually increased the heart toxicity by 
25%. This was the case even for those 
women who had Herceptin-alone; in the 
trial of 222 women noted above, 4.7% 
experienced what’s known as “cardiac 
dysfunction.” 
 
In May 2000, Genentech, the 
biotechnology company that developed 
the drug, sent out an alert to providers, 
warning them to pay special attention to 
heart function when prescribing this drug. 
Genentech reported 62 serious adverse 
events related to the use of Herceptin; 15 
of these women died. The company noted 
that while some of these events had been 
observed in the clinical trials of the drug, 
some were more severe, or new: 
specifically, “adult respiratory distress 
syndrome, anaphylaxis and death within 
24 hours of a HERCEPTIN infusion.” 
(Genentech, 2000) 
 
Such extreme and fatal outcomes 
prompted heart specialists to speak out 
about the drug. They note that “heart 
failure, like many cancers, is a progressive 
disease, “and they argue that physicians 
should take care that “patients do not 
trade one lethal disease for another.” 
(Feldman et al, 2000:272). Fear of cancer, 
and particularly fear of breast cancer, is 
clouding clinical judgement, in the view of 
cardiovascular specialist Arthur Feldman 
of the University of Pittsburgh Medical 
Centre. “…if someone were to go to the 
FDA with a new drug for heart failure or 
cholesterol or high blood pressure – all of 
which are leading killers of people – and 
that drug was associated with even a 1% 
incidence of cancer, it would never be 
approved by the FDA,” said Dr. Feldman. 
“No manufacturer would take the drug to 
the FDA. Yet here is an anticancer drug 
that is associated with a 28% incidence of 
heart failure and it is approved.” (Gottleib, 
2000) BMJ 2000; 321:259 (29 July)] 
 
Given these results, the future of 
Herceptin is not certain. What is certain, 
however, is that other genetically 
engineered drugs are on the way, and 
some of the issues that Herceptin raised 





The Price of Herceptin 
 
No one involved in Herceptin’s 
development ever expected the world’s 
first designer breast cancer drug to be 
cheap. A book about HER-2’s 
development, by TV journalist Robert 
Bazell, culminates at an oncology 
conference in Los Angeles at which the 
results of the clinical trials are presented to 
an audience of 18 thousand delegates. 
That evening, Genentech held a party for 
its researchers, for the clinical trial 
investigators, and for activists who had 
helped promote the trial. "Everyone at the 
party could celebrate an enormous 
success,” Bazell (1998) writes. “Women's 
lives would be saved and a huge fortune 
would be made.”(186) 
 
Drug pricing hasn't been an issue in breast 
cancer until recently. The pricing of two 
earlier drugs, tamoxifen and taxol made 
some waves, but the cost of Herceptin is a 
big issue. To give away the punch line, if 
this drug were made available to all the 
women with breast cancer who test HER-2 
positive it, and the imitators sure to follow, 
could bankrupt our health care system. 
 
In the US, the FDA approved Herceptin in 
October 1998; health Canada approved 
the drug in August 1999. In the US, 
Herceptin costs about US$2,000 a month; 
the Canadian price is about $Can $16,000 
for a 6-month course (Sibbald, 1999). This 
is unprecedented for a breast cancer drug. 
 
Insurance-wise, US patients fall into 3 
categories: 
•  those covered by a private medical 
plan, usually via their employers; 
•  those who qualify for MedicAid; 
•  and the "working poor, the 40 million 
who have no medical coverage. 
 
Genentech has agreed to provide 
American women in this latter category 
with HER-2 free of charge, although I 
know of no figures showing how many 
women actually take advantage of this 
possibility. 
 
Hoffman-La Roche, which took over 
Genentech in 1990 (Bazell, 1998:54-55), 
made it clear the company intended to cut 
no deals to increase women’s access to 
the drug in Canada. In a June 1999 letter 
to a woman seeking access to the then-
unapproved drug, Medical Director Dr Len 
Walt wrote:  
 
It is important to note that the 
responsibility of providing new 
therapies to patients is a shared one. 
There are three critical sectors, each 
with definitive accountabilities, 
responsible for bringing new therapies 
to Canadian patients. 
 
• the pharmaceutical industry develops 
and manufactures new products; 
•Health Canada reviews the scientific 
evidence in support of new products 
and gives the manufacturer the 
authority to distribute new products in 
Canada; 
•provincial and other funding 
agencies ensure that adequate funds 
are set aside to cover the costs of 
new products introduced into the 
health care system. 
 
Each of these sectors should be held 
accountable for delivering on their 
responsibilities. The pharmaceutical 
industry cannot make up for the 
deficiencies in Health Canada or the 




In Canada, each of the provinces have 
had to decide how to deal with the drug. 
When it looked like Herceptin was a 
benign cure, Ontario and BC decided to 
cover the drug under medicare; it is not 
clear what some other jurisdictions will do, 





Our Patented Medicine Prices Review 
Board sets the price of drugs like 
Herceptin by comparing the prices in 
seven other countries: the US, the UK, 
Germany, France, Italy, Switzerland and 
Sweden. The Canadian price can't be 
higher than the median international price. 
When Canada approved Herceptin, the 
only other country the drug was available 
in was the US, so the price was set 
relative to the US price − and the US is the 
only country in the world that has no 
system of price controls on drugs. 
 
Herceptin is being heralded as the 
harbinger of a new era. In her introduction 
to Bazell's book on Her2, geneticist Mary 
Claire King, harkened back to Churchill's 
declaration at the battle of El Alamein, in 
1942: "Now this is not the end. It is not 
even the beginning of the end. But it is, 
perhaps, the end of the beginning."(Bazell, 
1998:xi) 
 
Herceptin is expected to be the first in a 
long line of such treatment options. And to 
a dying woman, the chance of being one 
of the few patients for whom a drug like 
this means a long-term remission, is 
invaluable − especially when the 
alternative is a median life expectancy of 
20 months. But Genentech never intended 
that this drug be reserved for dying 
women. Cancer drugs are always tested 
first on the terminally ill. Genentech hoped 
to move Her-2 quickly to the status of a 
front-line treatment, that is, a drug that is 
prescribed immediately after breast 
surgery (Bazell, 1998:175). Because of 
cardiac toxicity, this is unlikely to happen 
with Herceptin, but that will certainly be the 
goal for other such drugs. And such a 
strategy, while increasing the market for 
manufacturers, poses additional 
challenges for those who pay for health 
care. 
 
If the main goal of the Canadian 
Biotechnology Strategy is to generate jobs 
and goose the economy by encouraging 
the manufacture and sale of profitable new 
treatments, Herceptin sets a positive 
precedent for gene therapies to come. 
From the standpoint of provincial 
treasuries, however, the high cost of 





From an advocacy standpoint, Herceptin is 
an interesting test case of the two 
competing philosophies described in 
several of the papers included in this 
volume.3 
 
One can look at Herceptin as a possible 
breakthrough that provides sick women 
with a new choice, and stimulates the 
economy at the same time. Or one can 
look at Herceptin as the latest chapter in 
an old story, the focus on downstream 
solutions to cancer, while the upstream, 
causal factors are ignored. One can 
question the ethics of a system designed 
to spin enormous private profits from the 
genetic information provided by dying 
women praying for a few extra months of 
life. 
 
Already, the cancer drug pricing issue has 
fostered some strategic alliances. In 
October, McGill medical ethicist Margaret 
Somerville (1999) published a paper called 
"The Ethics and law of Access to New 
Treatments for Cancer." The paper was 
financed by an educational grant from 
Bristol-Myers Squibb, the maker of taxol, 
another expensive cancer treatment with 
modest benefits for patients. Somerville 
argues that physicians have a primary 
obligation of personal care to patients, and 
that provinces must provide medically 
necessary treatments as a condition of 
receiving federal transfer payments. She 
                                               
3 Herceptin brought other advocacy issues to 
the fore, including the questions of 
compassionate access, advocates’ 
involvement in clinical trial recruitment, and 
fast-tracking of drug approval. These issues 
are outside the scope of the present paper. 
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suggests that cancer patients would be on 
firm ground in suing a provincial 
government that denied potentially life-
saving care. Acknowledging the difficulty 
this presents for a universal system, she 
suggests that a parallel, private system in 
Canada may emerge. “This would change 
the locus of, but certainly not eliminate, the 
difficult ethical and legal issues raised by 
decisions on access to new or emerging 
treatments for cancer,” she concludes. 
 
Somerville also refers to a group of 
"patients and advocates", "concerned 
about timely access to new cancer 
treatments in Canada" who conducted a 
survey of provincial governments to find 
out how decisions about access to drugs 
are made in each province. This group has 
issued press statements under a number 
of names, including ACT (Access to 
Cancer Treatments) and the Cancer 
Advocacy Coalition of Canada, and its 
activities are funded by major 
pharmaceutical companies, including 
Bristol Myers Squibb. In November, 1999, 
the group convened a meeting of cancer 
patients, oncologists, and representatives 
from cancer agencies, to discuss 
questions raised in Dr Somerville's report 
and by their inquiry. 
 
Interestingly, neither Dr. Somerville's 
paper nor the advocacy group raise the 
issue of drug pricing although the cost of 
drugs is clearly the nub of the access 
problem. Nor are the larger contexts of 
overall medical care and the 
environmental and social determinants of 
health part of their discussions. 
 
Yet surely an ethical analysis must take up 
the cause of access for all needy patients, 
not only the privileged. And in considering 
the ethics of drug access, we also need to 
address the broader implications of 






Even though Herceptin is beginning to 
seem like a false start for the new era of 
genetic therapies, we cannot expect this to 
always be the case. If the high cost of 
treatments like Herceptin have the 
potential to split our universal system into 
two tiers, it's fair to assume women will be 
over-represented in the bottom tier. It 
would be ironic indeed if the very women 
who come out in such numbers to “run for 
the cure” and who volunteered for clinical 
trials, were unable to access not only new 
genetic therapies, but the hospital beds, 
nursing care and other health services we 
take for granted. 
 
As an activist, I see Herceptin as a test 
case for advocacy in biotech therapy. I am 
concerned when I see women with breast 
cancer, funded by industry and describing 
themselves as advocates, promoting 
access to new therapies as a right, in 
isolation from its likely consequences. The 
environmental movement calls industry-
funded groups that present themselves as 
green lobby groups as “Astro-turf groups”. 
What should we call their counterparts in 
the health field? I suggest we call them 
“placebo health groups” − for sugar-coated 
advocacy. 
 
We need to be clear about the issue, 
values and vested interests behind various 
lobbies. Despite the novel language of 
biotechnology, the central political 
questions raised by the herceptin story are 
familiar to feminists. Drugs have been 
over-promoted to women before; the 
issues of rising drug prices and corporate 
influence on health policy are among the 
galvanising issues of our age. 
 
 
What can we do? 
 
The anti-consumerist organisation 
Adbusters has developed strategies to 
disrupt the consumer culture, a process its 
founders call "culture jamming". An 
example is Buy Nothing Day, their day of 
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“consumer fasting”. Canada’s 
biotechnology strategy has been honed to 
serve a consumerist economy, with no 
public discussion of the consequences: 




What might genome-jammers do? 
 
We could oppose private ownership of 
genetic material for therapies; these 
therapies are developed from specimens 
donated by − or taken from − patients who 
hope to see treatments developed for the 
benefit of other cancer suffering 
individuals, if not themselves. 
 
We could boycott clinical trials by 
companies that won't agree to price 
controls, and which maintain secrecy 
about their true R & D costs. 
 
We could boycott Runs for the Cure, 
unless sponsoring agencies agree that the 
money raised be used to finance 
treatments that would be reasonably 
priced, and unless the funds are 
distributed equally to “upstream” disease 
prevention work. 
 
“Choice” is an illusion if genetic treatments 
are the only options on the menu; that is, if 
prevention is excluded from serious 
discourse; if lower-cost interventions are 
not even tested; if treatment prices bear 
no relationship to the true benefit of the 
intervention for patients.  
 
Treatment choice is also a moot 
advantage if we fail to provide adequately 
for the needs of the dying, if our society 
remains intolerant of people living with 
disease and its consequences, and if our 
worldview rejects the inevitability of death.
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While preparing what to say at this 
workshop, I read the papers that the 
conference organisers had loaded into my 
e-mail. A diverse, marvelously exciting 
collection – a series of bright lights shone 
into the ‘black box’ of biotechnology. They 
forced me into constantly scrapping what I 
had written and starting over because a 
paper, or a combination of papers, had 
sparked a new idea, suggested a new 
theme. What I finally wrote was not so 
much a paper as a series of reflections. 
 
The background papers for the workshop 
covered the spectrum from micro to 
macro, from the individual to the 
community, from society writ large through 
to microscopy of the individual cell, from 
biotechnology in medicine to 
biotechnology in agriculture. Reading them 
as a package, one switches from the micro 
level (the women reflecting on the risk of 
breast cancer in Anne Robertson’s paper) 
to the meso (Ken Basset’s discussion of 
the policy issues faced by provincial 
governments) and then forward to the 
macro level (the role of the multi-nationals 
in the agricultural and pharmaceutical 
industries as discussed by Margaret 
Eichler and Pat Armstrong). 
 
Trained in different disciplines, the people 
who wrote these papers brought insights 
from ethics, history, anthropology, law, the 
biological sciences, sociology and 
medicine into their discussion of the new 
genetics. The challenge for the workshop 
was to find the connections between these 
different voices and themes. Yet, the 
critical importance of the workshop lay 
also in its representation of so many 
different perspectives on the new genetics 
and so many different ways of collecting 
and collating information and doing 
research. 
 
I agree very much with Abby Lippman that 
we need a new language in which to talk 
about genetics, but we also need a new 
form of research. Although there are 
important exceptions, the primary focus of 
the social science literature on the new 
genetics has been on the meaning of 
genetic testing for the individual tested. 
Some part of this choice may be dictated 
by access to research funding, but it also 
reflects a deep commitment to grounding 
research on biotechnology in the 
experience of the individual, particularly 
the individual woman (Franklin and 
Ragone 1998). While essential that this 
type of focused, in depth work continue, 
there are also many questions about the 
new genetics, relevant to women, that this 
type of research cannot answer. 
 
Rayna Rapp recently wrote about the 
need for research at the place “where the 
cutting edges of genetic research 
converge with social policy.” The problem 
is that this “place” is one of relative chaos, 
packed with a very disparate array of 
actors, each with a particular perspective 
on the new genetics. As a rough list, they 
include the federal and provincial 
governments, researchers, family 
practitioners, geneticists and genetic 
counselors, research funding agencies, 
family practitioners, priests and ethicists, 
families and multinational companies, 
lawyers and providers of venture capital, 
Myriad Genetics of Utah, Inc., and public 
health departments. If we are to capture 
some element of this rapidly changing, 
chaotic world we also need an approach 
more akin to collage, allowing for the 
constant addition of new pieces of 
information, new actors, new technologies. 
 
In putting this paper together, I used the 
background papers, but also drew on a 
study with Margaret Lock in which we are 
looking at the process by which a genetic 
test moves out of the laboratory and into 
the clinic. In addition, I made use of the 
bric-a-brac of news and information picked 
up from the media or the internet, as well 
as small pieces of academic gossip, books 
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read, conferences and meetings attended 
and conversations held. I also drew on my 
own background and experience in 
different areas of research on women’s 
health, although the result is best 
described as idiosyncratic rather than self-
reflexive. This is a collage rather than a 
structured academic paper. It provides 
very little by way of answers, but raises a 
lot of questions. 
 
 
Cassandra(s) and the Information Age 
 
The first of these questions is the product 
of a sleepless night, the result of talking 
with Madeline Boscoe and then going 
back to re-read what Abby Lippman had 
written. At four o’clock in the morning, I 
asked myself: “Can we stop it?” “It” being 
roughly everything that sits under the label 
‘biotechnology’; “we” being the doubters, 
the luddites, those sceptical of the 
promises of the new genetics, the critics 
and questioners. Reluctantly, my answer 
had to be “No”. Less optimistic of the 
possibility of revolution than Abby 
(particularly at four o’clock in the morning), 
I see the momentum as too advanced, the 
forces as too strong; the motivators – 
particularly fear and money – as too 
powerful. Where does this leave us? 
Possibly in the role of Cassandra; a set of 
truth tellers, crying doom, but condemned 
never to be believed. 
 
Yet, while pessimistic, I do not think that 
things are altogether dark. There is 
evidence, admittedly scattered, that some 
people in some places are making some 
choices. Companies have ‘chosen’ not to 
use genetically modified foods. A number 
of European countries chose to oppose 
Canada and the US over the importation 
of ‘Franken’ foods. Offered the 
opportunity, some individuals have 
‘chosen’ not to be screened for genetic 
diseases. Women are very key to this 
process as the implementation of many of 
the new technologies depends on their 
compliance, whether a willingness to 
buy/not-buy genetically modified foods, or 
to be screened/not screened, or to have 
their fetus screened/not screened. To 
make decisions about the new genetics 
within the terms of their own lives, women 
need information and they need 
information of many different sorts in many 
different forms. 
 
In the sense of being put together from 
bits and pieces, patched together into a 
whole fabric, we need research by 
bricolage. As a brief illustration of what this 
might mean, I have taken a single topic 
and pursued it across different disciplines 
and up and down different levels of 
analysis from micro to meso to macro and 
back again. There was time and space 
only to raise questions rather than find 
answers, but finding answers is not the 
purpose of the exercise. It is rather to 
show how the questions change with 
every boundary crossed, but also how a 
single question may have multiple 
answers at many different levels. 
 
 
Micro: the woman and the prophylactic 
oophorectomy 
 
My starting point is a prophylactic 
oophorectomy. Attending a meeting of 
oncologists, geneticists and genetic 
counselors last year, I heard some one 
discuss the advisability of a woman, tested 
positive for BRCA1, having a prophylactic 
oophorectomy. Looking back, I am not 
sure why this shocked me as much as it 
did, for I was already familiar with the 
literature on the increased risk of ovarian 
cancer among women testing positive for 
BRCA1 and BRCA2. Possibly it was 
because discussion was about a real 
body, a real person, rather than part of an 
academic debate. 
 
Yet, my reaction was partly a product of 
my work on menopause and my 
knowledge of that clinical literature. The 
bilateral oophorectomy, included in that 
literature as a surgical form of menopause, 
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is recognized in this literature as having a 
more severe impact on the body and as 
producing more severe symptoms than 
natural menopause. The orthodox clinical 
response is to put a woman on immediate 
and long term hormone therapy to control 
her symptoms, protect her heart and the 
density of her bones. As a quasi-
epidemiologist, the key question for me 
was whether or not the routine prescription 
of estrogen therapy would be advisable for 
a young woman with a genetic pre-
disposition to breast cancer. Yet even as 
the question was framed in my mind, I 
knew that not only is no information 
immediately available, but that it is unlikely 
to be in the future. For given the current 
inability to closely monitor the ovaries for 
the first signs of cancer, it would be 
unethical to set up a controlled trial in 
which healthy women with the same 
genetic test results and the same surgery 
are randomized to take or not take 
estrogen. Unfortunately, this is only one of 
the many questions within the new 
genetics for which there is no absolute 
answer. 
 
Still thinking as a quasi-epidemiologist. I 
wondered also what was the quality of the 
evidence being used to advise a test-
positive woman to have a bilateral 
oophorectomy? A MEDLINE search 
produced a small but very recent collection 
of papers including one on the costs of 
screening Ashkanazi Jewish women for 
BRCA1 and BRCA2. Its authors claimed 
an economic benefit, but only if women 
who tested positive underwent 
prophylactic surgery. Reviewing their 
evidence, this conclusion represented an 
enormous leap of faith even for a health 
economist. More cautiously, the Cancer 
Genetics Study Consortium advised that 
there was “insufficient evidence to 
recommend for or against prophylactic 
oophorectomy as a measure for reducing 
ovarian cancer risk”, but added that: 
“Women with BRCA1 mutations should be 
counseled that this is an option open to 
them (Burke et al. 1997). The European 
Familial Breast Cancer Collaborative 
Groups came to a very similar conclusion. 
While conceding that the data were 
insufficient, they also advised that the 
prophylactic oophorectomy was “a 
reasonable option in high risk women”. A 
third review of essentially the same 
literature concluded that prophylactic 
oophorectomy resulted in, at most, small 
gains in life expectancy (Schrag et 
al.1997). 
 
Why would the members of these different 
study groups and consortia – largely 
geneticists and oncologists – recommend 
something for which the epidemiological 
evidence was weak by their own 
admission. Broadening the initial 
MEDLINE search by dropping ‘genetics’ 
as a key word produced several papers on 
the use of prophylactic oophorectomy in 
healthy women with healthy, but 
postmenopausal, ovaries. Two of the 
studies in the search reported on reviews 
of the medical records of women with 
ovarian cancer to determine if there had 
been an earlier, but missed, surgical 
‘opportunity’ to save them. (The 
opportunity being the body opened, the 
uterus removed, the ovaries left in place, 
but subsequently becoming cancerous.) 
Another paper, a survey of Irish surgeons, 
reported that 88% of the participants 
would remove the post-menopausal ovary. 
A third paper based on a 1996 survey of 
gynecological surgeons in Alaska, found 
that 98% said that their usual practice was 
to remove apparently normal ovaries in 
postmenopausal women; 86% said they 
would perform a prophylactic 
hysterectomy in women with a strong 
family history of ovarian cancer regardless 
of age; 71% would be influenced by a 
family history of breast cancer. 
 
My naïve assumption that prophylactic 
oophorectomy had gone out of style was 
misplaced; it was clearly normative for the 
majority of the surgeons in the two 
surveys. Even more interestingly from my 
perspective, the design of the two medical 
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record reviews implied that failure to 
remove was blameworthy. In all of these 
studies, the underlying model is that the 
ovaries, seen as likely to go bad, are best 
removed before they can damage or 
destroy the whole body. These few papers 
were also a reminder that the “new” 
genetics comes into being in the context of 
“old” medical practice, which includes 
existing beliefs about heredity and danger, 
but also this very particular fear of the 
cancer-prone ovary. The very new 
contribution of the new genetics lies in 
being able to test closely related women 
and determine which ones are vulnerable 
and which not. The problem is, however, 
that this information is somewhat in 
advance of the technological capacity to 
determine when a predisposition turns into 
an actual cancer, leaving the prophylactic 
oophorectomy as still the primary 
response. 
 
Another part of my reaction, however, was 
as an anthropologist rather than an 
epidemiologist and owed something to 
Terri Kapasalis’ (1997) account of the 
history of the bilateral oophorectomy. 
Once known as “Battey’s operation”, 
practiced on slaves in the American South, 
it became fashionable in the late 
nineteenth century as treatment for 
insanity in women. Although losing favor 
among psychiatrists, the use of 
oophorectomy was revived in the 1930s 
and 1940s by gynecological surgeons, 
who saw all ovaries as potentially 
diseased and took pride in removing them 
whenever possible. The temptation was to 
write off the incorporation of this surgery 
into the genetics discourse as another 
example of the medicalisation of the 
female body. My problem with this 
interpretation was that it both cuts off 
further discussion and turns women into 
passive victims rather than active figures 
in the increasingly complex dance that 
decision making has become in heredity 
cancer clinics across North America. 
 
In population terms, ovarian cancer is 
relatively rare, but for the geneticist or 
oncologist working in the heredity cancer 
clinic, or for a woman from a family with a 
history of heredity cancer, it is a common 
and known risk. They have experiential 
knowledge, based on actual women with 
ovarian cancer, patients or family 
members. Relative to this knowledge, 
statistical knowledge questioning the 
quality of the epidemiological evidence in 
support of a prophylactic oophorectomy 
will probably seem a relatively 
meaningless component in the decision 
making process. Yet, if one moves up a 
level, from the micro to the meso, to the 
level of provincial governments and 
provincial cancer agencies, then this 
information takes on a new relevance as 
necessary evidence in health policy 
decision making. Social scientists, but also 
bioethicists although in a more abstract 
sense, have tended to focus at the micro 
level, the level of the woman and those 
who meet with her in the clinical 
encounter, namely the geneticist, the 
oncologist, the genetic counselor. In the 
next section, I want to shift to the meso 
level, focusing initially on just one of these 
figures, the genetic counselor. 
 
 
The Clinic, the Government and the 
Breast Cancer Gene 
 
Seen through the eyes of a woman waiting 
for her test results, a counselor should be 
empathic, supportive and able to provide 
her with the information she needs in 
language she can understand. Most 
Canadian women testing positive for 
BRCA1 or BRCA2 within Canada will have 
seen a genetic counselor, as their need for 
counseling is still one of the most taken-
for-granted assumptions of the Canadian 
programs. Some Canadian women have 
traveled to the United States for testing; 
their number is unknown and so also is the 
quality of their counseling care. Women go 
to the United States usually because they 
do not meet the strict criteria for testing set 
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by Canadian centres, or they do not want 
to wait. When this paper was written 
(February, 2000), the waiting period to see 
a genetic counselor in my own province of 
Manitoba was approximately one year. 
 
The implications of waiting can be studied 
at the micro-level by talking to the women 
waiting and their families as was done by 
Lodder et al. (1999). Alternatively, the 
analysis can be moved to the meso level 
and questions formulated at the level of 
the clinic, the research agency, the 
provincial ministry of health, and a local 
cancer foundation or breast cancer 
support groups. At this level, many of the 
key questions are framed in terms of 
traditional health policy issues, such as 
training, funding, access, cost 
effectiveness and evidence based 
decision-making. Other questions, 
however, have to do with the politics (but 
also the ethics) of health care delivery. 
 
There is, for example, an international 
shortage of clinical geneticists and genetic 
counselors, a reflection of the gap 
between the rapid expansion in genetic 
testing and the time needed to train those 
capable of doing the diagnostic work-up 
and the counseling. Around the time that 
testing for BRCA1 was just getting started 
in 1995, there were only two medical 
geneticists per million population in the UK 
and only about a 1000 board-certified 
genetic counselors in the United States 
(Reilly 1995). Many of these counselors 
and geneticists will have trained when the 
expectation was that they would work 
within a prenatal screening clinic with very 
different clients to those seen at a 
hereditary cancer clinic, a different set of 
diseases, and very different data on risk 
and probabilities. How should training 
change given a rapidly changing 
knowledge base? How should the 
numbers in training be increased? Who 
should pay for this expansion? Counseling 
has increasingly become the responsibility 
of obstetricians and family practitioners; 
most of whom had very little 
undergraduate training in genetics and 
systematic postgraduate training in 
genetics is even more rare (Harris and 
Harris 1999). Should the problem of 
access to counseling be met by ‘retro-
fitting’ other health professionals, not only 
the family practitioners, obstetricians and 
oncologists, but also nurses and social 
workers? Who should pay for further 
training for these groups? Is one-on-one 
counseling the best or only way? Would 
an interactive video serve as a substitute, 
or supplement to a live counselor as 
Pershkin and Lerman suggest (1999)? 
 
The issues and the questions are also 
political. Access to genetic testing and 
genetic counseling has rarely been evenly 
distributed across geographical or social 
space, favoring the white, the urban and 
the middle class. As discussed in Ken 
Bassett’s paper, so long as the scale has 
been small and largely invisible outside 
the amniocentesis or genetics clinics, 
there has been little concern or protest. Is 
this likely to change with the expansion of 
genetic testing into high profile diseases 
such as breast and ovarian cancer? 
Already there are rumors of pressures on 
ministers of health to increase the number 
of counselors and to expand the number 
of clinics testing for hereditary cancers. 
 
The list of questions is long, although by 
no means exhaustive. They are left 
without answers, as their purpose is to 
suggest that the questions about the 
genetic counselor to be asked at the 
health policy level have a quite different 
resonance than if asked within the clinic of 
the woman waiting. Yet, the length of her 
wait is determined by how these questions 
are answered. Possibly part of our 
obligation as latter day Cassandra’s is to 
keep women informed on how health 
policy in this area is made and 
implemented. 
 
An equally long, if different set of 
questions could be generated about the 
test itself and looking towards the future. 
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At present, most testing for BRCA1 and 
BRCA2 in Canada is done in major 
research laboratories. Who will own the 
laboratory in which the test is done, pay 
for its staff and its equipment, as testing 
becomes a routine clinical service? Will it 
be the government or the private sector? If 
genetic testing becomes part of routine 
clinical service, will it have to be shifted to 
laboratories licensed by a foreign patent 
holder? Will government still retain the 
right to regulate all laboratories in the 
province, or will the patent holder set 
standards? Who will set the price of the 
test and who will pay? Does genetic 
testing, as some health bureaucrats in 
some provincial ministries might argue, fall 
outside the scope of the Canada Health 
Act? Would making the woman pay fall 
inside or outside her entitlements under 
that act? Should we urge women that this 
is an occasion for political protest and 
lobbying the politicians for equitable 
access to testing? 
 
Genetic testing up until mid-1990s has 
been a cottage industry, a small item on 
the overall medicare budget line, often part 
of block grants to departments of 
pediatrics. Suddenly all this is changing 
and very rapidly. The ‘old’ system is still in 
place for the very rare genetic diseases 
and for prenatal testing, but the money 
used in genetic testing for BRCA1 or 
BRCA2 is more likely to have come out of 
a research budget, or a line item in the 
budget of a cancer foundation. This 
situation clearly cannot last, but how 
important is it that women understand their 
options? 
 
What are these options? Answers, self-
obvious at the micro-level of the woman 
being tested, are less clear at the level of 
government or advocates for women’s 
health? Will the demand for access to 
genetic testing and counseling for breast 
and ovarian cancer not only increase, but 
become a woman’s health issue or at least 
an issue for the breast cancer movement? 
Yet, health bureaucrats might say that the 
evidence of benefit from prophylactic 
oophorectomy is too weak to justify the 
use of public monies. While some health 
activists might question what place genetic 
testing for ovarian cancer should occupy 
on a priority list of women’s health needs 
given that current thinking suggests that 




Macro: Global Companies and Global 
Politics 
 
Moving from meso to macro, the questions 
shift from cost to money and profits. This 
level is occupied by a vast array of 
speculators, venture capitalists, 
multinational pharmaceutical companies, 
universities, biotechnology companies, 
and different levels of government, all 
hoping to grow rich or at least financially 
benefit. Even we benefit, doing research, 
attending workshop such as this. 
 
The sums involved are quite large; for 
example, a quick scan of the Breast 
Cancer Bulletin (Summer, 2000) published 
by the Canadian Breast Cancer Initiative 
suggests that well over half the award 
made out of a total of $14.4 million was 
spent on some form of genetic research. 
 
Research The connections between 
the different institutions are also quite 
tight. Myriad Genetics, the company 
holding the patent for the BRCA1 and 
BRCA2 breast and ovarian cancer 
susceptibility genes, recently made a 
deal with the National Cancer Institute 
in the US to do full BRCA testing at a 
cost of $1,200 per person, “less than 
half the commercial costs”, but only for 
researchers funded by NIH. Myriad’s 
own Web site notes that the company 
has formed strategic alliances with a 
remarkable list of multinational 
pharmaceutical companies, including 
Bayer, Eli Lilly, Hitachi, Pharmacia, 





Research A small item of news late 
last year noted that Myriad was trying 
to move forward its patent claims in the 
European market. British scientists 
were furious over Myriad claims to 
exclusive patent rights to what they saw 
see as their own, British discovered, 
genetic property, the BRCA2 gene. 
Myriad countered by questioning the 
quality of British testing. 
 
An awareness of the history of our health 
care has perhaps made women more 
skeptical than men of the bright promises 
of science. They also have somewhat 
greater awareness than men that their 
sicknesses may be profitable to others, but 
mainly in the form of physician incomes 
being increased by a little extra surgery, a 
few more visits. The money to be made in 
the new genetics is of a quite different 
order and the mechanics of its making 





As the latter-day daughters of Cassandra, 
our task may be less one of crying doom, 
but rather one of collecting, sorting, 
analyzing, critiquing and disseminating 
information to women. To do this 
effectively will require a degree of 
openness to different types of knowledge, 
a willingness to collaborate across 
disciplinary boundaries, and the capacity 
to seek out information from many 
different sources. It will also require being 
able to say when a question cannot be 
answered, because there is no information 
or the information is inaccessible. The 
consequences of informing women as 
health consumers may be as unexpected 
and radical as learning to read the bible 
proved to be for the making of the English 
working class. 
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The production of genomic/ genetic 
knowledge occurs within political, 
economic, and cultural contexts, and in 
turn reshapes those contexts (Brunger and 
Bassett,1998). As the lines between 
science, industry, and government (as well 
as patients, subjects, and consumers) are 
becoming increasingly blurred, it becomes 
more and more difficult to devise a 
research strategy that will promote public 
reflection on the range of effects that 
seemingly beneficent technologies may 
have on individuals, communities, and 
society. How can we best ensure that 
typically silenced voices are actively 
engaged in debate in ways that promote 
accountability and transparency of 
science/ industry to the public? 
 
Political, economic and cultural contexts 
not only shape the production of 
biotechnology knowledge and its 
application; they also shape how critiques 
of biotechnology are produced and 
applied. The beliefs, values, and norms of 
academic critics, no less than industry/ 
science, necessarily advance specific 
perspectives, valorizing some voices and 
not others. Given that research funding 
within the social sciences is increasingly 
linked to industry- and/ or community- 
alliances, we must be absolutely vigilant 
about transparency, conflict of interest and 
perceptions of conflict of interest. In other 
words, deciding on strategies and setting 
research agendas is a situated activity and 
it is therefore not a value-neutral activity. 
There is an ”agenda” just as the word 
suggests. Thus it also follows that we 
ought to make explicit the values, 
economic incentives, and relations of 
power which shape and guide our 
priorization of particular research areas or 
‘agendas’. 
 
If we reject the notion that genetics has 
one correct model of risk and reality that 
the lay people are deficient in, then we 
must also reject the notion that academics 
have a privileged way of understanding 
the potential effects of biotechnology on 
the lives of individuals and communities. 
Lay knowledge and understanding is a 
legitimate and specialized means of 
making sense of the world; it is in this 
sense never incorrect. It may be 
inconsistent with other forms of knowledge 
but it is never “wrong”. For example, 
women asking for increased access to 
genetic testing for breast cancer may 
promote geneticization in a way that is 
counter to prevailing feminist critiques of 
biotechnology, but the perspectives and 
experiences of such women should inform 
our understanding of geneticization, and 
not be dismissed as naïve or the effects of 
false consciousness. Following from this, 
we recognize that as academics whose 
research focuses on the ethical and social 
effects of new health technologies, we 
have a moral obligation to be explicit about 
the values and contexts that shape our 
research; to engage the public in debate 
around our research and its conclusions; 
and to ensure that our research agendas 
do not inadvertently silence important 
voices. 
 
What follows is a description of the 
research ‘agendas’ that we have been and 
wish to continue advancing. These 
agendas involve collaborating with 
communities to strategize for change in a 
way that privileges the knowledge of 
individuals in the everyday context. 
 
 
1. Engaging with patients/ 
“consumers”1 
                                               
1The following is based on issues raised in a 
research project on “Ethical and Moral 
Dimensions of Genetic Risk: Huntington 
Disease and Breast/Ovarian Cancer 
Experiences" (Burgess, Cox, and D’agincourt-
Canning); and in a project on "The Social 
Construction and Clinical Management of the 
Hereditary Aspects of Autosomal Dominant 




It is crucial for feminists and activists 
critiquing the biotech industry to continue 
to focus on the political, economic and 
social contexts shaping the production, 
application and distribution of genomic/ 
genetic knowledge. However, it is equally 
important to not lose sight of how the 
understanding and use of genomic/ 
genetic knowledge both shapes and is 
(re)shaped by individual fear and suffering 
within families and communities (Cox and 
McKellin 1999; Cox 1999). This entails 
learning how genetic information is 
understood, used, resisted, and reshaped 
by patients/ consumers and moreover, 
how this in turn shapes and transforms our 
understandings of the process of 
geneticization. Research must therefore 
include examinations of the moral issues 
and experiences most salient to 
individuals and families who are the 
potential or actual patients/ consumers of 
genetic services. This includes learning 
how the everyday meanings and 
experiences of those at risk shape their 
decisions to be or not be tested; and how 
their experiences and decisions work to 
promote or reshape geneticization. 
 
An emphasis on everyday meanings and 
experiences around the use or non-use of 
genetic services by potential or actual 
consumers continues to provide an 
important counter to clinically-based 
studies which typically employ a battery of 
psychosocial questionnaires; it also offsets 
bioethics' traditional concern with assisting 
clinicians in determining their ethical 
responsibilities vis a vis other patients. 
Research to date has almost exclusively 
studied the social and familial effects of 
genetic testing as a clinical medical event, 
emphasising ethical issues that raise 
problems for the delivery of services to 
individual participants in genetic testing. 
We direct attention toward the non-clinical 
understandings of, and effects of, genetic 
testing in relation to everyday ideas about 
                                                                    
and Cameron). 
heredity and familial or ethnic identity in 
the community setting.  
 
 
2. Engaging with communities/ 
“subjects” 2 
 
Genomic/ genetic research poses complex 
issues of consent, banking, sharing of 
data, recruitment, negotiating with specific 
communities, and intellectual property 
arrangements. Some of the ethical 
concerns biotechnology raises for 
communities, such as biopiracy in relation 
to community DNA banking, insurance 
discrimination related to ethnicity-based 
genetic testing, and concerns about the 
use of linked data bases to identify social 
risk factors such as sexual preference or 
workplace environment, fall outside of the 
scope of the traditional ethics review 
process. These broader concerns involve 
risks to non-participants in the research. 
The effects of genomic/ genetic research 
on groups, that is, on those who do not 
participate in research but are affected by 
it, requires an assessment of whether 
harms to non-participants are justified. 
 
Traditionally in research ethics, individual 
consent suffices. Informed consent is the 
cornerstone of contemporary research 
ethics with its historical roots in Western 
scientific medicine and liberal theory 
(Beauchamp and Faden 1986). In this 
tradition, the collective good that is likely to 
follow medical research cannot alone 
justify the risks to individual participants. 
Rather, individual participants must 
knowingly accept the risks to them of 
participation in specific research projects. 
 
Informed consent does not work for 
authorizing the effects of research on 
groups. Some have suggested expanding 
the notion of consent to include group 
                                               
2The following is based on issues raised in a 
research project on “Culture, ethnicity, and 
genetic testing” (Brunger, Burgess) and in 
Burgess and Brunger, in press. 
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“consent” (e.g. Weijer et al 1999). That 
approach, however, raises complex issues 
around representation and relations of 
power: Who represents the group? 
Paternalism – which is explicitly rejected 
and avoided through the mechanism of 
individual consent – is inevitable when 
authorizing the effects of research on 
groups, since someone has to speak for 
the group. 
 
Understanding the effects of research on a 
group, and decisions about whether 
research is acceptable to a group, must be 
based on a carefully negotiated 
understanding of diverse values and 
beliefs within the group; and this 
information must be understood in the 
context of relations of power within and 
between groups (Burgess and Brunger in 
press). This negotiation, to be genuine, 
must be conducted in ways that do not 
overextend the authority of researchers, 
group leaders, or ethics review boards. 
Where possible, community-based 
research should be conducted with, rather 
than "on", community members, to enable 
community members to help direct 
research objectives and goals, to shape 
research design and implementation, and 
to participate in the dissemination of 





Our research strategy for identifying and 
managing ethical issues raised by 
biotechnology is to begin by learning how 
individuals as “subjects” and “consumers” 
are being shaped by, and also shaping, 
geneticization. This entails emphasizing 
the values and beliefs which shape the 
production of genomic/ genetic knowledge 
(e.g., the relationships between science, 
industry, and government); and how this 
“culture” of science affects, and is affected 
by, the experiences of families and 
communities. This background 
understanding of the everyday meanings 
around biotechnology within the context of 
family and community life is, for us, an 
important step to knowing what kind of 
research agenda to set. 
 
Our goal is to not arrive at answers to 
questions about the effects that the 
biotech industry may have on families or 
communities. It is, rather to come up with 
a strategy for widening the space of public 
debate in a way that: 
 
(1) provides the public with information 
about the production, distribution and 
application of genetic knowledge; 
 
(2) legitimizes lay knowledge; 
 
(3) attends to a multiplicity of voices; 
 
(4) welcomes dissent as a sign that all 
voices are being attended to; 
 
(5) allows the debate to be transparent 
and public; and 
 
(6) promotes the accountability of 
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About the Article 
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The Canadian Biotechnology Strategy is 
an expression of what I have called the 
process/ideology of geneticization 
(Lippman 1991).1 The CBS, in the name of 
health and health care, and with the goal 
of national economic growth, is geared to 
support the “translation” of basic genetic 
research into such "choices" as genetic 
testing, genetically engineered drug 
design (e.g., "pharming" and "designer" 
drugs), genetically engineered animal 
organs for human transplantation, and 
gene "therapy." In fact, the CBS is 
rationalized, in large part, on the promise 
of increasing women's choices with 
respect to health and health care. In what 
follows, I will focus on the issues of 
"choice" and geneticization, making some 
general remarks about each and 
proposing how some of the dangers to 




Marketing (multiple) choice(s). 
 
With health and economic policies 
merging in the politics of neoliberalism, 
and with health (care) seen as a source of 
economic development, increasing the 
choices women have is becoming a major 
way to stimulate the economy. As a 
consequence, feminist objectives for 
                                               
1. Geneticization refers to the increasing 
tendencies to make distinctions between 
people on the basis of what one believes are 
genetic differences, to view most disorders, 
behaviors and physiological variations as 
determined (wholly or in part) by genes, and as 
I have defined and use the term, comprises 
ways both of thinking and of doing, applying 
genetic technologies to diagnose, treat and 
categorize conditions previously identified in 
other ways. 
2 More detailed examinations of choice and of 
geneticization can be found in a recently 
published paper, from which sections of this 
text have borrowed heavily: Lippman A. 1999. 
health, and the principle of choice that 
women introduced into the health care 
arena as essential for our well-being, are 
being appropriated by politicians and 
industry and turned into an array of 
biomedical options for us to use or 
undergo. Industry is encouraged (even 
subsidized with public funds) to develop, 
market and sell us choices in the form of 
new drugs, new technologies and new 
programs which, among other things, can 
not only identify our health risks, but also 
provide ways to manage them. And, with 
risk increasingly the lens through which 
choice is filtered – "you are at risk for...; 
you can choose to do/undergo/... to 
manage it" – a dangerous synergy 
between a "tyranny of risk” (Lupton 1995) 
and what has become a "tyranny of 
choice" is catalyzed. 
 
Clearly, this market-driven approach to 
health (care) co-opts and manipulates 
concepts of choice to rationalize industry-
driven health goals. It also enables the 
accelerating transfer of health financing 
and services (in Canada and elsewhere) 
from the public to the private sector in the 
search for cost-containment 
(governments) and profit (industry). 
 
More and more, women's demands for 
choice in how our health is promoted/ 
protected, and in how (and what) care is 
available when we need it, are being 
answered in the form of various (multiple 
choice) biotech-based menus. These list 
options from which individuals are 
supposed to make selections for personal 
curative medical care and preventive risk 
management (with the selections often 
unattractive – and almost certainly not 
equally accessible to all women). 
 
For instance, in response to demands for 
healthy pregnancies and healthy babies, 
women are offered a gamut of prenatal 
tests. In response to demands for safer, 
cleaner environments from which 
carcinogenic materials are removed to 
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protect our health, we are offered costly 
procedures that will screen us for DNA 
patterns thought to be associated with an 
increased risk of developing breast 
cancer, as well as with "prophylactic" 
mastectomies, or expensive drugs (of 
unproven safety) alleged to prevent breast 
cancer (Batt 1994). The huge growth of 
the commercial, for-profit health 
information industry (Minkler 1989), which 
produces books, magazines, websites and 
packaged exercise programs to educate 
us, as well as the boom in computer/ 
informatics technologies to identify 
"manageable" risks and monitor our health 
and health care (for example, algorithms 
to assess a woman's risk of breast 
cancer), result in still further options for us. 
But the choices thereby manufactured do 
not promote our health, ensure social 
justice, and support a holistic view of 
women's health. Rather, these “choices” 
are evidence of the marketability of 
women's health issues and concerns, 
produced primarily for political/ economic 
reasons and private profit. 
 
This commercial – and downstream – 
response to women's demands (for 
choices), articulated both implicitly and 
explicitly in the CBS, fails to address the 
kind of choice in health care women have 
fought for, and certainly does not meet our 
demands for the powers we need to 
choose and to protect our health. With 
industry increasingly portraying itself as 
responding to women’s needs when it 
offers multiple choices for our self-
improvement, health promotion becomes 
more of a product (i.e., objects, programs, 
devices, etc. we can buy) than a goal 
(Milio 1988). Even more, rather than 
supporting structural changes that will lead 
to improved health, the language of health 
promotion is employed to justify the further 
development of more technological and 
pharmaceutical options, more sources of 
information on health and so-called life-
style, and more wellness programs for us 
to purchase. 
 
This market approach reinforces 
libertarian self-reliance without promoting 
true self-determination and choice. Worse, 
it serves to privatize want: what seems to 
be a personal choice (e.g., to have 
prenatal testing; to take tamoxifen) may 
really be merely a substitute for societal 
failures to provide what women truly need. 
These include the resources (financial, 
social, supportive) that would allow a 
woman to mother a child with Down 
syndrome; the guarantees that the water 
we drink is not polluted with harmful 
chemicals or bacteria. Downstream 
choices (menus) of biologically-tailored 
drugs are insufficient; the upstream 
availability of safe jobs, clean 
environments, safe contraceptives and 
women-friendly work schedules are 
needed for avoiding known risks to health 
and preventing the disorders the drugs are 
created to treat. 
 
The manufacture and manipulation of 
“choice” as a tool to commercialize and 
further privatize health (care) presents 
special risks for women insofar as options 
are construed as gender related. Thus, the 
commercial value in the (belated) 
recognition by researchers and industry 
that "women are not small men" is vast. It 
is, perhaps, but a further stage in the 
"corporatization of medicine" that Starr 
(1982) described almost 20 years ago, 
wherein health problems are seen as good 
for business and economic growth. Today, 
specific attention to women and their 
medical risks and alleged needs for 
medication creates a niche market with 
lucrative potential; new commercial 
projects to develop female-specific product 
lines in health businesses turn chronic 
conditions into investment opportunities 
(Fuller 1998), with women's health 
problems (e.g., osteoporosis, menopause, 
depression, fertility/ infertility in particular) 
among those likely to have the best return 
on their investments (into research and 
production of new drugs, new diagnostic 
technologies, DNA markers of 




This commercial application of “gender 
awareness” to justify female-specific 
health product development for the 
marketplace is a dangerously reductive 
view of women's health needs. It helps to 
hide, if not perpetuate, the many 
differences between women and the 
origins of health problems in inequitable 
social/ political/ economic arrangements, 
with this most recently exemplified, in 
Canada, with the newly begun marketing 
of women-specific cancer insurance 
policies. 
 
In co-opting women's demands for 
empowerment, for choice, and for gender-
based care, research and policy, 
governments (as in the CBS) and the 
private sector are playing on our 
reasonable fears of paternalism, 
overmedicalization and exclusion. 
Furthermore, the current dominance of 
economic conceptions of health and health 
care displace/ manipulate feminists' 
perceptions of these as having primarily 
social, political, and economic 
determinants. This makes it imperative to 
be wary whenever "choice" is offered to us 
as a solution to women's health concerns. 
To re-establish choice in women’s terms, 
to put choice in women's hands, means 
not to focus on how to give women 
responsibility for their health, through the 
creation of multiple options, as the CBS 
would have it, but on how to ensure all 
women can be "response-able."3 
 
To see how this might be operationalized, 
how women could become able to make 
the responses and choices they want for 
themselves, consider, for an example, 
prenatal screening and testing. Why not 
require that for every government dollar 
spent for these programs, $10, $100, 
                                               
3. Insofar as “response-able” refers to what a 
person is enabled to do, it embodies feminist 
principles and avoids the potential for victim-
blaming contained within the sound-alike term, 
“responsible.” 
$1000 or more must be spent for the 
children and their families living with the 
condition for which testing is offered? This 
might help make refusing prenatal testing 
as much a choice as accepting it appears 
to be. As well, it might give community 
groups and disability activists the 
resources they need to develop material 
about the conditions for which genetic 
testing is offered, to counter the stories 
coming from the biomedical world, thereby 
helping to ensure that women's choices 
can be truly informed. 
 
Further, why not insist that companies 
developing screening tests (or expensive 
medicines) for something that ails us apply 
some of the profits from their sales of 
these products towards addressing the 
social determinants of women's ill health. 
A formal "tithing" system, with money 
deposited into a blind trust to be used to 
care for those for whose disease one 
seeks a DNA association, might be 
another approach. And to give such 
policies "clout," companies that contribute 
could perhaps be offered some tax 
advantage, with those refusing heavily 
penalized. 
 
As another policy, why not insist that 
"charitable" status be granted to groups 
and organizations that advocate for 
change rather than allow this privilege only 
for those that "pick up the pieces" of 
harmful government policies. And in place 
of "stakeholders" setting the policy agenda 
for women's health and genetic and other 
biotechnologies, why not insist on more 
participatory democratic approaches (e.g., 
citizen juries, consensus conferences) and 
engage in more discursive processes 
(Davidson et al 1997) to debate and 
decide on the choices we want for 





Geneticization is as much implicit as it is 
explicit in the CBS, and it is at odds with 
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the concepts of health and health 
promotion as understood by the women's 
health movements and other social justice 
seeking groups. Regrettably, however, 
most of the critiques of the "new" genetics 
have concentrated on the potentially 
harmful consequences of using the 
information that genetic (mapping, testing, 
screening) projects will provide, and on 
how the undesirable effects can be (must 
be) controlled. In general, the "problems" 
investigated are sequestered for analysis 
in "ELSI"4 projects that deal with a variety 
of ethical, legal and social issues related 
to human genetics. The existence of these 
projects suggests that by understanding 
these problems, by maintaining specific 
rules and regulations, and by adhering to 
standard ethical principles, we can avoid 
the undesired consequences. But this 
downstream, managerial approach is 
grossly insufficient, and perhaps even 
irrelevant. 
 
To begin, the majority of these critiques 
tend, themselves, to be based on 
reductionist thinking. They also legitimize 
the very assumptions of essentialism and 
determinism that they would otherwise 
fault. Putting aside the need to distinguish, 
when appropriate, between essentialism, 
reductionism and determinism, it 
nevertheless remains insufficient to restrict 
analysis of geneticization to psychological, 
legal and ethical consequences and their 
management, and to base regulatory 
proposals on misconceptions of what 
genes do (see, for comparison, Caulfield 
2000). Though necessary, these critiques 
are not sufficient; they are certainly not 
primary. They appear to take further 
development and use of genetic 
technology, and of geneticization, as faits 
accomplis, and to perpetuate artificial 
distinctions between means and ends, 
between effects and side-effects, between 
use and mis-use. They ignore how 
geneticization is a new way of thinking 
                                               
4. ELSI is the acronym for Ethical, Legal and 
Social Issues.  
even more than a new way of doing. Thus, 
even when the hyperbolic claims made for 
genetics are shown to be unsubstantiated, 
the tendency to see "genes as the answer" 
persists. 
 
Prevalent "ELSI-type" assessments of 
developments in applied genetics continue 
to privilege liberal individualism, and the 
latter, as Susan Wolf (1996) underlines, 
mostly preserves those with power in 
society. These assessments also gloss 
over the importance of group membership, 
isolating processes, techniques, and 
services from societal trends (e.g., 
privatization, commercialization, 
globalization, etc.) in which they are 
embedded. Clearly, more fundamental 
analyses of geneticization – social 
evaluations in particular – are required to 
clarify if "responsible genetics" is an 
oxymoron, or if it can actually be practiced 
(Vandelac, Lippman 1991). And new, 
imaginative ways to assess geneticization, 
fresh metaphors for speaking and writing 
about things genetic, are urgently needed 
if we are to begin these. 
 
There are no detailed recipes for how we 
might do these analyses or reframe our 
thinking, but there are some practical 
things we might consider. To start, if 
health (and not the elimination of disease 
and disability) is our societal goal, 
collective approaches might be better than 
individualized ones. If we want "genetic 
responsibility," might it not be more 
efficient to reverse the usual order of 
subject and object and make society, 
rather than the individual, accountable for 
protecting our genetic "heritage." This kind 
of approach would lead to such things as 
supporting serious efforts to remove 
known mutagens from the workplace, 
renovating substandard housing to remove 
lead-based paint, and demanding limits on 
agribusiness, rather than to screening for 
and then removing or vaccinating 
"susceptible" workers or children. 
Screening for situations "of risk" seems far 
more sensible – and far more equitable as 
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corrective justice – than screening for 
persons "at risk." 
 
Risk situations, even more than genetic 
risks, are not equally distributed. 
Moreover, the likely synergy between 
physical and chemical risks, and the 
unequal distribution of the determinants of 
health, may necessarily increase the 
exposure of some groups of women (e.g., 
underemployment ! work in a bar ! 
exposure to second-hand smoke; poverty 
! decreased resources for organic food 
! increased pesticide exposure; racism ! 
ghetto-ized housing ! increased 
exposure to toxic dump sites). 
 
Geneticization, and the CBS of which it is 
an expression, are pushed not only by 
people claiming to do good, but also by 
those with corporate interests and eugenic 
idea(l)s. Geneticization is advanced by 
people who seek financial gain by doing – 
or underwriting – genetics: governments 
and corporations, and also the media 
which use "human interest" stories, 
supposedly involving genetics, to sell their 
papers and programs. Justifying mapping 
the genome as the way to improve health, 
and to provide medical cures, is doubtless 
productive for molecular geneticists, 
pharmaceutical companies, manufacturers 
of laboratory equipment, insurance 
companies, police forces, genetic 
engineers and health ministers, among 
others. But seeing things this way closes 
the debate, suggesting we need only 
regulate the "costs" (albeit broadly defined 
in ethical, legal and social terms) of 
genetics to obtain all the benefits. It is to 
overlook how costs and benefits are not 
distributed to the same groups, and how 
risk management, as "exposure," is clearly 
gendered. Moreover, more than costs and 
benefits (economic and otherwise) are 
involved in assessing the genetic 
approach. It may be ethical – "cost-
beneficial" in some currency – but still 
dangerous to women's health. The genetic 
perspective itself, and not just its 
consequences, is problematic. 
 
Therefore, we need to change critical 
strategies and go to the source, to 
question the very ways geneticization 
frames our thinking about such things as 
similarities, differences, health, illness, 
social justice and what it takes to have a 
good life. We need not only to understand 
– and underscore – the biological limits of 
what a gene is and can do but, even more, 
to devise ways to approach genetics/ 
geneticization that may help us reclaim our 
rights as citizens for health and health 
promotion. 
 
One way to begin might be to delete the 
word "health," a holistic term, when we 
really mean the absence of disease, and 
to reject the notion that there is something 
usefully called "genetic health." Not only 
are we unlikely ever to reach consensus 
about its meaning, but trying to do so may 
be a distraction. Genes may have 
something to do with disease, but they 
certainly have little if anything of relevance 
to women's health. In a similar vein, we 
could insist on a research agenda in which 
it is assumed that biological conditions 
have social explanations and actively 
search for and invest in these. After all, 
one can as reasonably link housing 
conditions and osteoporosis, racism and 
cardiovascular disease, ageism and hip 
fracture, pet ownership and hypertension, 
as one can link DNA patterns to these 
conditions. Let's make these findings 
media friendly so that they become the 
banner headlines of newspapers. 
 
Next, let's make it a practice to ask, 
whenever we see the word "genetic" used 
as an adjective, "why?" What is gained 
and what is lost, and by whom, by this 
qualification of some test, disease, 
diagnosis. Similarly, let's ask, whenever 
we see "autonomy" advanced as the basis 
for ethical analysis, whether individual 
choice or a richer concept is meant. 
Adopting Sherwin’s (1998) relational 
notion of autonomy would at the least 
remind us that the notion of genetic 
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"response-ability," what a person is 
enabled to do, is at least as important as 
the notion of genetic "responsibility," that 
which those with power must assume. 
 
For some final suggestions, let me invoke 
the concept of justice. If we assume that 
justice is simultaneously intragenerational 
and intergenerational, and not think of it 
merely as the principle for providing equal 
access to some service, we might begin to 
view health as a general (social) benefit, 
not as a commodity to be bought and sold 
in the marketplace. Thus viewed, our 
health policies would, contrary to the CBS, 
focus on such things as income-
redistribution, employment programs, 
neighborhood revitalization, trade 
agreements and global corporations. 
Similarly, we might see social 
determinants of health (poverty, racism, 
illiteracy, etc.) NOT as barriers for an 
individual to overcome but, instead, as 
objectives for social/ societal change. 
Going further, we might recognize a need 
to redistribute health equitably, with the 
consequence that some of us, the more 
privileged today, may have to give up 
some of our alleged benefits (use of high-
tech genetics, for example) to ensure that 
others share equally in the resources 
needed for health, even perhaps requiring 
programs of affirmative action as 
necessary to correct past injustices locally 
and globally. 
 
In this regard, "responsible genetics" 
("responsible biotechnology") might at the 
outset be defined as a policy which 
acknowledges that we can't afford, either 
economically or socially, the most recent 
high-tech approach to disease(s). It would 
favor a long-term sustainable approach 
that gives priority to problems in proportion 
to their importance in causing (or resulting 
from) ill health and disability (see, for 
comparison, the African American 
manifesto about limiting genomic sampling 
until there is improvement in the health 
and education services to the community: 
Jackson 1997). Following this policy (and 
again adopting from Sue Sherwin 1992), 
only technologies which do not, in their 
application, feed into oppressive 
circumstances (for groups without power) 
would be considered for research and 
development, with only those that foster 
the interests of un(der)privileged groups in 
society admissible in practice. Thus, a 
prerequisite for setting up any prenatal 
diagnosis program would be the 
guaranteed provision of adequate, 
sensitive and baseline prenatal care for all. 
No "new" technologies/ programs/ 
services would be introduced for some 
women until a basic level of care was 
assured for all women. Similarly, a new 
technology or a new application of an old 
technology (e.g., prenatal diagnosis) might 
be considered for provisional use, but only 
if it was demonstrably a resource to 
respond to a situation for which no other 
solution was thinkable, for which no other 
way to resolve the particular problem 
could be imagined (e.g., prenatal 
diagnosis for Tay Sachs disease if painful 
death is unavoidable for a child with this 
condition). And, while I once proposed 
doing health impact assessments before 
the introduction of – even before 
supporting the research for – a genetic or 
reproductive technology, I would now 
suggest what Labonte (1999) calls a 
"health inequity impact assessment": will 
use of this technology, will geneticization, 
however defined, decrease health 
inequities, especially those inequities 
between and among women (rich and 
poor, in the North and the South). Instead 
of ELSI analyses, we need “ELSocJusI” 
studies; beyond ethical, legal and social 
issues, we must also consider social 
justice issues. 
 
Geneticization might possibly contribute to 
the solution of some "problems" of 
disease, it might even contribute to the 
decrease of inequities downstream (a 
possible example being the development 
of medications for infectious diseases 
based on knowledge of the DNA of the 
organism), but we can't assess this yet – 
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and seem far from it. But, do we want to 
intervene only downstream? Because I 
don't believe doing so will either conform 
to feminist principles of social justice or 
address the many and varying women's 
health needs and problems, I suggest that 
we look upstream and first unpack the 
problems whose solution is framed 
through the lenses of biotechnology and 
geneticization. Does either the definition of 
a “problem” or the response to it in 
technological terms lead to a better 
solution for everyone than we might devise 
if we asked why there was a problem in 
the first place? Whenever genes (or 
biotechnology) are said to be "the 
answer," we must immediately ask: what is 
the question? And who is talking.
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“Health” constitutes one of the principal 
industrial opportunities under the 
Canadian Biotechnology Strategy (CBS). 
While a range of products are being sold 
under this heading – vaccines, biologics, 
biopharmaceuticals – a key product 
continues to be genetic tests, tests which 
provide information which is predictive, to 
a greater or lesser extent, of specified 
disease outcomes. Indeed, such tests are 
expected to proliferate. Reading through 
current medical and biomedical journals, 
one is struck by the assumption that the 
Human Genome Project heralds an era of 
widespread molecular genetic tests, 
predicting both Mendelian diseases, and 
those diseases in which genetic factors 
may play some ‘pre-disposing’ role (e.g. 
SACGT 1999). Insofar as genetic 
biotechnology promises a revolution in 
medicine, it promises a revolution in the 
availability of genetic information. 
Therapeutic capacity, when discussed, is 
generally acknowledged to lag far behind 
diagnostic capacity (the ‘therapeutic gap’). 
For the foreseeable future, and for most 
people, genetic medicine is principally 
about genetic information. 
 
As an historian, what is especially striking 
to me about expectations for the future of 
genetic medicine is how non-futuristic they 
seem. In this paper, I suggest that the 
recent history of efforts to gather, interpret 
and deal with genetic information 
concerning health, disease and disability – 
a process we can abbreviate by the 
phrase “genetic counselling” – can tell us 
quite a bit about current and future 
practices. At the least, it can shed light on 
what the real “drivers” of change are. For 
while proponents of biotechnology in 
health care would have us believe that a 
revolution is upon us, and that this 
revolution is a direct product of new 
scientific and technical capacity, I would 
argue that there is both more and less to 
the story. 
 
In this paper, I tell four over-lapping 
historical stories about genetic 
counselling. The first history sets out the 
basic chronology since the Second World 
War, the second story adds questions 
about health and medicine to this 
narrative, the third interrogates the 
‘genetic’ status of these practices, and the 
fourth story asks questions about women. 
 
 
Story One: Genetic Counselling 
 
Today, genetic counselling is an 
acknowledged practice – a key 
complement to and justification for genetic 
testing (Task Force 1997). The current 
state of professional genetic counselling 
has been developing since the 1940s, 
when heredity counselling began to take 
institutional shape in the Euro-American 
world, and clinics were established in 
Universities and research hospitals in 
Canada, the US and the UK. 
 
To a considerable extent, the timing of 
early developments was a function of 
shifts within the eugenics movement. As 
Molly Ladd Taylor has argued, genetic 
counselling promised a voluntary and 
individualistic eugenics that dispensed 
with the older strategy of enjoining 
members of the middle classes to observe 
their duty toward the race – a strategy 
which had clearly failed by the late 1930s. 
Instead, heredity counselling worked to 
foster middle class desire. Its chief 
advocates promoted a narrative of large, 
happy families of “normal” children which 
saw little place for divorce, disability or 
childlessness (Ladd Taylor 1999). Into the 
1960s, with the word ‘eugenics’ not yet a 
universal term of opprobrium, genetic 
counselling was frequently discussed as a 
practical form of eugenics (Paul 1998). 
 
Through the 1950s and 1960s the number 
and scope of genetic counselling services 
increased in tandem with the science and 
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profession of human genetics, which 
assumed an institutional identity in North 
America with the founding of the American 
Society of Human Genetics (ASHG) in 
1948. Indeed, genetic counselling should 
be seen as a defining characteristic of the 
emerging discipline of medical genetics 
(then, a sub-field of human genetics), and 
central to professional identity. 
 
The 1970s brought increased visibility to 
genetic counselling through the expanded 
scope made possible by prenatal 
diagnosis using amniocentesis, and the 
expanded visibility of genetic science in a 
decade of highly public efforts at in vitro 
fertilisation, recombinant DNA (cloning 
DNA), and genetic screening among 
specified sub-populations (i.e. Ashkenazi 
Jews for Tay-Sachs disease, African-
Americans for Sickle Cell Anemia). As a 
consequence, this decade witnessed 
professional innovation and consolidation 
in genetic counselling practices and 
practitioners. The post-W.W.II generation 
of medical geneticists who had pioneered 
genetic counselling, and repeatedly 
debated its form and function, set out to 
clarify the definition of the practice. This 
new definition, published in 1975, 
highlighted the centrality of 
communication, non-directiveness, 
voluntarism, and the provision of support 
for decision-making (ASHG 1975). 
 
In many ways, the new definition simply 
codified existing protocols. But it differed in 
one important respect from tradition. 
Where genetic counselling had originally 
been embedded within the research 
routine of a professional medical 
geneticist, the new definition conceived of 
genetic counselling as a self-contained 
practice. This shift reflected the fact that, 
in its success, genetic counselling was 
expanding beyond the purview of that 
small band of researchers who had been 
its pioneers. In fact, the 1970s witnessed 
the emergence of a new practitioner 
category which would devote itself 
exclusively to the now self-contained 
practice of genetic counselling. Originally 
called the ‘genetic associate’ and soon to 
be called the ‘genetic counsellor,’ this new 
semi-profession involved a Master’s level 
education which mixed scientific 
knowledge with more formal training in 
counselling practices (Kenen 1984;1997). 
 
In the 1980s, molecular genetic tests 
began to be added to the complement of 
genetic tests already available for genetic 
counselling. In addition to the predictive or 
diagnostic information that could be 
gleaned from family histories and 
biochemical and cytogenetic 
(chromosomal) tests, some few rare 
diseases could be assessed using 
recombinant DNA technology. It is these 
molecular genetic tests that are expected 
to expand so greatly in number, scope and 
significance in the coming years as a 
direct consequence of the Human 
Genome Project and allied research. 
According to the US Secretary’s Advisory 
Committee on Genetic Testing, which 
conducted “A Public Consultation on 
Oversight of Genetic Tests,” in the 
Summer of 2000, genetic testing is 
clinically available for more than 300 
diseases or conditions in the US, and tests 
are under development for at least 300 
more diseases or conditions (1999:5). 
 
 
Story Two: What’s So Medical About 
Genetic Counselling? 
 
Contemporary discussions of genetic 
counselling presume the obvious clinical 
significance of this practice, and the 
relevance of medical involvement in, and 
management of, its conduct. Yet the 
medical status of genetic counselling is a 
relatively recent and contested 
phenomenon. This peculiar fact about the 
history of genetic counselling is very 
important to the interpretation of its current 
and future incarnations. 
 
The pioneering band of post-W.W.II 
medical geneticists who institutionalised 
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genetic counselling in North America were 
researchers first and foremost. Many were 
trained as PhDs, but those who were MDs 
were (as was not uncommon) working as 
scientists. Genetic counselling should not 
properly be called a ‘clinical’ practice, 
then. It was an applied form of human 
genetics, or eugenics. It piggybacked on 
clinical institutions such as hospitals, and 
benefited from collaboration with clinicians 
with the competence to diagnose disease, 
but was often funded as research, and 
took much of its justification from its 
articulation with research projects. 
 
In addition, genetic counselling, as a 
central component of medical genetics, 
was distanced from the main traditions in 
medicine in other ways in the inter-war 
and early post-W.W.II decades. First, 
genetic counselling proposed a rather 
different modality of care than that 
traditionally advanced by medicine. Rather 
than treatment, genetic counselling offered 
reproductive management in light of 
information about the risk of disease in 
offspring. Second, genetic counselling 
proposed rather different protocols of 
provider-client interaction than medicine: 
emphasising knowledge transmission and 
client decision-making, rather than 
physician decision-making and paternalist 
models of information management. 
Finally, in addition to advancing work on 
Mendelian diseases – diseases that 
observed simple genetic laws – medical 
genetics emphasised chronic and 
congenital conditions with complex 
systems of causation. In these early years, 
medical genetics pressed notions of ‘pre-
disposition’ even to infectious diseases – 
as part of a marginal tradition within 
academic medicine which resisted the 
dominance of the ‘infectious disease 
paradigm’ with its ‘magic bullet,’ antibiotic-
driven approach. At one of its early annual 
meetings in 1952, for example, the 
American Society of Human Genetics 
sponsored a special symposium on the 
genetic aspects of resistance to chronic 
infectious diseases such as pulmonary 
tuberculosis, poliomyelitis and rheumatic 
fever. 
 
The growing acceptance of genetic testing 
and counselling as aspects of ‘health’ care 
since the 1970s can, in part, be attributed 
to the developing congruence between 
genetic counselling and new patterns in 
medicine: the rise of a patients’ rights 
agenda; the emphasis on prevention, 
especially through lifestyle management; 
and, growing interest in chronic and 
congenital disease. But while the success 
of genetic counselling reflects these 
elements of conceptual convergence 
between medical genetics and medicine, it 
has also been hampered at an 
organisational level by the outsider-status 
of genetic counselling within the halls of 
professional medicine. 
 
In the first instance, professional medical 
geneticists have faced significant 
problems in securing funding for, and 
retaining authority over, genetic 
counselling. In particular, since many 
medical geneticists were PhDs rather than 
physicians, much manoeuvring was 
required to avoid the strictures of medical 
specialisation. In Canada, in the 1970s, 
medical geneticists pursued block-funding 
of genetic counselling through regionalised 
centres, rather than a fee-for service 
system, and they established a national 
college in 1975 (Canadian College of 
Medical Geneticists) to provide some 
system of professional accreditation and 
allow PhD-trained medical geneticists to 
provide genetic services. 
 
In the US, medical genetics began the 
formal process of becoming an 
acknowledged medical specialty in the 
early 1990s, with the formation of a 
College and Board. By the latter-half of the 
1990s, this new specialty was able to 
participate in the funding and practice 
negotiations of the medical profession. 
This is an extraordinary medical specialty 
– one that permits PhD-trained workers to 
practice clinically. Moreover, genetic 
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counselling continues to be definitional to 
the identity of the medical geneticist. 
Treatment protocols pertaining to genetic 
disease, or which derive from genetic 
information, are not managed by medical 
geneticists but are dispersed among a 
wide array of medical specialties. The 
medical genetics specialty continues to be 
defined by the ability to diagnose and 
counsel: to procure and manage genetic 
information in the clinical encounter. 
 
Despite this formal success, the 
integration of medical genetics within 
medicine continues to be fraught. PhD 
medical geneticists are a declining 
proportion of medical genetics 
practitioners, as the pioneering pattern of 
blending research with applied practice 
passes into memory. Moreover, those 
medical geneticists who work principally 
as genetic counsellors (rather than running 
laboratories, for example) are devalued 
within the medical profession. Charles 
Bosk (1992), in his ethnographic study of 
medically-trained genetic counsellors in a 
major eastern US city, argued that the 
devaluation of these practitioners is 
attributable to their engagement in “social 
dirty work” (63). In recent decades, then, 
while the enthusiasm for genetic medicine 
has increased, the status of genetic 
counselling has come increasingly into 
question. A reduced status is exemplified 
by the rise of the Master’s level trained 
practitioner, the genetic counsellor. 
Moreover, there is much interest in 
routinizing the genetic counselling 
encounter, and shifting the obligation to 
primary practitioners, with only complex or 
highly risky cases referred to specialist 
practitioners. Specialist genetic 
counsellors, whether trained at the 
doctoral or master’s level, are often 
supportive of such an approach which 
promises to raise their status. Yet this 
tiering of genetic counselling, and the 
successful integration of genetics into 
medicine upon which it is premised, 
implies a loss of control by professional 
medical geneticists over the protocols 
which govern genetic counselling. 
 
The recent medicalization of medical 
genetics – most obvious in calls for 
standardized medical curricula for genetics 
– promises to alter both the practices and 
practitioners of genetic counselling. It is 
likely that increased medicalization will be 
an important force for enhanced and more 
routinized use of genetic information in the 
clinical encounter. Moreover, 
medicalization encourages fee-for-service 
systems of compensation, which are 
themselves drivers of increased use. 
 
 
Story Three: What’s so “Genetic” 
About Genetic Counselling? 
 
Much of the current interest in the 
expansion and routinization of genetic 
counselling rests on the belief that, as 
some enthusiasts put it, “genetic testing 
will soon become a commonly used tool in 
primary care practice.” For this to happen, 
advocates suggest, genetic testing will 
have to expand beyond its current focus 
on diagnosing a range of comparatively 
rare disorders, to test for “genetic 
predispositions” to various common 
diseases (Cho et al 1997:314). Testing for 
such “predispositions” could, at best, 
provide individuals with complex statistical 
risk estimates, and would seem to create 
new dilemmas, as well as new 
opportunities, for genetic counselling. 
 
Many critics have identified problems with 
the predisposition approach. Problems 
stem from the uncertain predictive power 
of such tests, and thus their potential 
relevance to significant proportions of the 
population (Hubbard and Lewontin 1996). 
Moreover, the genetic predisposition 
approach gives primacy to genetic forces 
in systems of multiple causation. Such an 
approach has been christened 
“geneticization” by Abby Lippman (1991) 
and sustains what Dorothy Nelkin and 
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Susan Lindee (1995) call the “DNA 
mystique.” 
 
Though divided on the question of merits, 
both proponents and critics of expanded 
genetic testing are united in their 
conviction that the predisposition 
approach, and the uncertainties involved 
in such diagnoses, are new. But are they? 
I would argue that genetic counselling has 
consistently dealt in uncertain predictions 
and multi-causal conditions. Indeed, it has 
grown by advancing an expansive reading 
of genetic disease. Early genetic 
counselling was premised on a slippage 
between congenital and genetical disease 
– between genetic disease and birth 
‘defect’ – promising to help people “avoid 
the tragedy of a defective child,” as one 
popular periodical put it (Katz 1954:32). 
Moreover, much of the advice provided in 
the genetic counselling encounter involved 
statistical risk estimates for conditions for 
which no obvious Mendelian patterns of 
transmission were known – for example, 
cleft lip or palate. Finally, the development 
and expansion of prenatal diagnosis in the 
1970s entrenched the slippage between 
congenital and genetical. Prenatal 
diagnosis is, after all, principally 
concerned with congenital conditions – 
with problems manifest at birth – however 
clear the genetic mechanisms of causation 
may be. 
 
Social historians of medicine have 
consistently argued that disease identity is 
never obvious. Instead, disease identity is 
a contingent product of professional 
identity, institutional relations, 
technological capacity and patient 
experience. Genetic diseases are no 
different. What gets defined as a genetic 
disease, and managed by medical 
geneticists and genetic counsellors, is not 
pre-determined by technology alone. Over 
the course of their history, genetic 
counsellors have expanded their 
professional standing and medical 
significance through a form of genetic 
imperialism, or geneticization. They have 
claimed to possess interpretive capacity 
with respect to a broad spectrum of 
diseases, and have had to deal in 
statistical risks concerning predisposition. 
The genetic status of genetic medicine is 
contingent and need not be accepted as 
simply true. New molecular tests for 
genetic predispositions, which suggest 
that almost all diseases are genetic 
diseases and can be managed through 
genetic medicine, must be seen, in part, 
as professional claims-making. 
 
 
Story Four: Women and Genetic 
Counselling 
 
Women’s lives, their social roles and 
feminist politics have intertwined in 
complex ways with the histories of genetic 
medicine and genetic counselling. If, as 
I’ve suggested, genetic counselling has a 
contingent relationship with medicine, and 
genetic disease is a malleable concept, 
then making sense of these historical 
contingencies requires a gendered 
analysis. 
 
First, genetic counselling has drawn 
heavily on women workers. In Canada, the 
messy and marginal science of human 
genetics was pioneered in the inter-war 
and war-time years by workers who were 
marginalised by their gender. Indeed, the 
preponderance of women in early human 
genetics research that was a result of 
women’s marginality as scientific workers 
has been influential in ensuring a 
significant presence of women in the field 
today. Moreover, as these women worked 
to promote genetic counselling in Canada 
in the 1940s and 1950s, they often 
defended their place in university and 
hospital communities by suggesting 
women’s inherent capacity to engage in 
such work. Women’s sensitivity and 
communicativeness were advanced as 





The gendered social roles drawn upon by 
pioneering Canadian practitioners, in the 
1940s and 1950s, served as a more 
general resource in the 1960s in the 
creation of a feminised semi-profession to 
aid in the genetic counselling encounter. 
Sarah Lawrence College in the US, 
originally a women’s college, initiated the 
first Master’s level training program for 
what were then called ‘genetic associates’ 
in 1969. In establishing this new semi-
profession, its founders sought to service 
a growing field with scientifically educated 
women who otherwise had restricted 
employment opportunities. Over the 
course of the 1970s, counselling training 
was added to the curriculum and by the 
end of the decade the term ‘genetic 
associate’ was coming to be replaced by 
the term ‘genetic counsellor.’ 
 
Master’s level trained genetic counsellors 
have struggled with the low status and 
constrained authority that is the corollary 
of a female-dominated profession. At the 
same time, this profession has been 
consistently supportive of a feminist ethos 
with respect to reproductive rights, 
voluntarism and decision-making 
autonomy (Wertz 1997). The challenged 
status of genetic counselling within 
medicine is symbolised and sustained by 
the female dominance of this activity. That 
genetic counsellors do what Bosk 
characterises as ‘social dirty work’ 
demands investigation as a gendered 
phenomenon. 
 
In addition to the prevalence of women 
practitioners in genetic counselling, 
women have consistently, if only implicitly, 
been conceived of as the principal objects 
of such activities. In the early years of 
genetic counselling, women were 
positioned as the keepers of family 
records. They were represented as most 
likely to know about family patterns of 
illness and thus were a crucial resource for 
human geneticists as they reconstructed 
pedigrees. Women were also deeply 
implicated by patterns of familial disease, 
being responsible for managing the 
households affected by such ailments. 
Moreover, enduring patterns of maternal 
blame have been reproduced in genetic 
counselling discussions, notably through 
women’s responsibility for disabilities 
associated with ‘late’ maternal age and for 
X-linked diseases. Long before prenatal 
diagnosis situated women at the centre of 
much genetic counselling activity, 
women’s lives and bodies were centrally 
implicated by the reproductive decision-
making, and the gendered constructions of 
genetic risks, that have been constituted 
through genetic counselling. 
 
Finally, women’s politics have been 
implicated in the advance of genetic 
counselling and genetic medicine 
generally. While it would be false to 
suggest that abortion rights were 
advanced solely through demands for 
genetic (or eugenic) abortions, the threat 
of congenital disease has consistently 
been one of the triumvirate of needs, 
including rape and maternal ill-health, that 
women have used to justify abortion to a 
resistant medical profession, and the wider 
public. On the eve of the 1970s in Canada, 
amniocentesis was heralded as a 
technology that might legalise abortion; 
and in the US, one prominent women’s 
magazine opined that prenatal diagnosis 
could serve the career woman who wished 
to postpone childbearing, without 
increasing her risk of bearing a child with 
Down’s syndrome. 
 
Perhaps more importantly, and as has 
been consistently observed, the women’s 
health movement, in its demand for 
choice, access to information, and 
preventive self-care, has articulated a 
politics that seems consonant with the 
demands pressed by genetic counselling 
and advanced through genetic testing. 
Moreover, this liberal feminist ethos is of 
sustained relevance to many women 
today, and is a significant resource for 
proponents of an expanded role for 







The Canadian Biotechnology Strategy 
takes for granted the merits of new genetic 
technologies for use in health care. It 
advocates the development of these 
technologies, and assumes that they 
necessarily herald a new era of biotech 
medicine. The histories that I’ve recounted 
here suggest some ways to critically 
evaluate these assumptions. 
 
First, insofar as biotech medicine involves 
genetic tests, there is much that will not be 
entirely new about this new era. Genetic 
tests pre-date the molecular testing 
promised by the Human Genome Project 
and allied research, and many of the 
dilemmas of genetic tests – their uncertain 
meaning, statistical complexity and de-
coupling from treatment options – are 
decades old. I am not suggesting that 
nothing is new here. Indeed, there are new 
and significant challenges for medicine 
and health care that are posed by biotech 
medicine – such as the high cost of these 
tests, their private ownership and thus the 
difficulty of integrating them into 
conventional lab routines. It is important to 
recognise that what is new here are not 
the technologies alone, but the new social 
arrangements in which they are embedded 
– social arrangements which are the 
product of public policy decisions, such as 
over-extended patent protection for 
biotech “inventions”. 
 
Second and by extension, genetic tests 
have been and will be propelled into use 
by very specific actors in the health care 
system, even while the CBS fails utterly to 
consider such actors. Genetic information 
has been introduced into and managed 
within clinical settings by an evolving mix 
of practitioners who have jockeyed with 
each other and with such institutional 
powers as organised medicine. Who 
provides genetic counselling, and in what 
clinical context, matters. If more medical 
management of genetic information is 
pursued, then we need to address the 
tendency of medical practitioners to be 
more directive than counsellors, and the 
perverse incentives created by fee-for-
service systems of compensation. I am not 
suggesting that more investment in 
Masters-level trained genetic counselling 
is necessarily a better option, however. 
While the feminised status of genetic 
counselling may be responsible for its 
under-resourcing, a feminist response 
would not necessarily be to advocate for 
more access to such services. We might, 
on the contrary, wish to question the 
construction of ‘communication’ as a 
women’s issue, and to question the 
relevance of a woman and health agenda 
in supporting such services. What should 
be understood is that the practice of 
genetic counselling – whoever does it – 
has been and will continue to be 
fundamentally facilitative of genetic 
medicine, and of an expanded use of 
genetic tests. 
 
Third, the extent to which genetic tests are 
necessarily genetic is part and parcel of 
negotiations over the practice of genetic 
counselling and medical genetics. I would 
argue that the commitment of human 
genetics to genetical explanations is 
historically contingent, rather than 
necessary or inevitable. Moreover, I would 
argue that the extent to which a disease is 
understood and managed as genetic is a 
negotiated outcome. The new era of 
biotech medicine, if it is upon us, can be 
managed differently – to emphasize social 
and environmental systems of causation 
and solution, for example. 
 
The CBS would have us believe that we 
are powerless before the advance of 
science and technology. The best 
response is to get on the bandwagon and 
take what profits we can from this new 
direction. Yet it is clear that there is a great 
deal of contingency here – and social 
analysts and activists can and should have 
an impact on future directions. 
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Genetic modification of human embryos or 
fetuses has been proposed for purposes 
of both prevention of disease and 
enhancement of capacity. The 
development of sophisticated in vitro 
fertilization methods, preimplantation DNA 
analysis, improved techniques for gene 
transfer, insertion, or conversion, and 
embryo implantation procedures, have 
made such interventions technically 
feasible. 
 
The hazards of genetic modifications to 
humans have usually been discussed in 
terms of somatic (body cell) modification, 
in which only non-reproductive tissues are 
affected, and germline (egg or sperm cell) 
modification, in which changes to an 
individual’s DNA can be passed down to 
future generations. Indeed, this division 
has led to the general belief that the only, 
or main hazard of developmental 
modification is the potential of 
transmission of undesired alterations in 
the germline. 
 
But genetic modification of early embryos – 
as well as chromosome and nucleus 
transfer techniques, including cloning – 
present hazards to the developing 
individual, and in certain cases to the 
mother, even if there is no germline 
transmission to future generations. Genetic 
manipulation of the human embryo, with or 
without changes to the germline, is referred 
to as developmental modification. 
 
The hazards of germline transmission of 
DNA modifications are obvious from a 
reading of the literature on transgenic 
animals. For example, germline 
introduction of an improperly regulated 
normal gene resulted in progeny with 
unaffected development but enhanced 
tumor incidence during adult life (1). Such 
effects may not be recognized for a 
generation or more. 
 
It is important to recognize that many 
hazards of developmental gene 
modification are not eliminated if there is 
no germline transmission. The biology of 
the developing individual will still be 
profoundly altered by the manipulation on 
his/ her genes at an early stage. 
Laboratory experience shows that 
miscalculations in where genes are 
incorporated into the chromosomes can 
lead to extensive perturbation of 
development. The disruption of a normal 
gene by insertion of foreign DNA in a 
mouse caused lack of eye development, 
lack of development of the semicircular 
canals of the inner ear, and anomalies of 
the olfactory epithelium, the tissue that 
mediates the sense of smell (2) 
 
Interactions among genes and their 
products are highly integrated, having 
been refined over evolutionary time 
scales, and often serve to stabilize 
developmental pathways (the sequence of 
structural and biochemical changes that 
an embryo passes through on the way to 
becoming a fully-formed organism) and 
physiological homeostasis (the normal 
state of dynamical balance among the 
body’s many processes) (3-5). In addition, 
the biochemical pathways used by the 
organism and its cells to achieve this 
stability and balance are overlapping, 
rather than discrete or separable (6) 
ensuring that any developmental genetic 
alteration will have broad, uncontrolled 
ramifications. Through experimental error, 
unanticipated interactions among different 
versions of the same gene, or poorly 
understood regulatory mechanisms such 
as imprinting (the parental source of the 
gene – mother or father – affecting its 
function), developmental genetic 
manipulation risks altering sensitive 
biological equilibria. Disrupting these 
interactive systems is likely to have 
complex and uncertain biological effects, 
including some which only become 
apparent during the development or 




Genetic alterations to the germline are 
possible even where only body (somatic) 
cells are targeted for DNA transfer. This 
represents a hazard in many of the more 
than 200 somatic gene therapy protocols 
now in use. For example, the viruses that 
are used to transfer DNA in some somatic 
gene therapy protocols were able to infect 
isolated mouse eggs in laboratory studies, 
leading to germline transmission of a 
transgene in the progeny (8). Although 
removal of the external “shell” of the egg 
was a prerequisite for infection of the eggs 
in vitro, these “shells” are absent in the 
early development of eggs in the ovaries. 
These experiments thus raise the 
possibility that modification of ova may 
occur in women undergoing somatic gene 
treatments, with unknown and 
uncontrolled consequences to their 
progeny. 
 
In protocols that attempt somatic gene 
therapy for life-threatening illnesses, 
saving the life of the individual patient is a 
value that must be balanced against 
developmental risks, including those to the 
germline of that individual, and indeed, 
such considerations also pertain to 
chemotherapy in cancer patients (9). With 
respect to deliberate developmental 
modifications, the story is quite different. 
Not only is the “patient” (embryo or fetus) 
and its progeny at risk from the procedure, 
but so is the pregnant woman if the genes 
are to be introduced in utero, since such 
genes can also infect her tissues, 
including her own germline, and entail 
other risks to herself, such as cancer. 
Clearly she is not in a position to give 
informed consent on behalf of herself, or 
the developing embryo, for a procedure 
that has not yet been tested in humans, 
and which promises no direct benefits to 
her health (the usual justification for 
experimentation on humans). However, 
she will inevitably be under pressure to 
assume such risks for the sake of her 
baby. 
 
Even if the procedure is to be done in vitro 
rather than in utero, the basis for informed 
consent remains problematic. Here there 
is no existing person whose life is in 
jeopardy, but rather an embryo in a petri 
dish that the egg or sperm donor (or 
whoever else may gain the right to its 
disposition) would like to have turn out 
genetically differently. No truly informed 
consent on the part of the potential 
parents is possible, because no reliable 
information would be available when it is 
first attempted. 
 
It is clear that pressures on women will be 
growing over the coming years to submit 
themselves to experimental genetic 
procedures, first to prevent disease, and 
eventually to enhance the appearance, 
performance, and so forth, of her baby. It 
is no accident that there are increasing 
proposals to use newly obtained genetic 
information to “improve” embryos by 
manipulating the embryo (11, 12), rather 
than for prenatal diagnosis. The new 
genetic research has flourished during a 
period in which there have been 
aggressive attempts to reverse abortion 
rights in the U.S.; consequently, the use of 
prenatal diagnosis as a justification for 
public funding of the science has been 
taboo. This period has also been one in 
which patenting and commercialization of 
genes has been possible for the first time 
(10), and eugenic ideologies, after their 
post-World War II eclipse, have gained 
new respectability among opinion makers 
(13). 
 
In evaluating proposals to use the new 
genetics to remake human biology, 
women should be aware of hazards to 
themselves and their offspring from the 
primitive state of the science and 
technology, as well as the commercial and 
reactionary political agendas behind these 
efforts. Opposition to germline 
engineering, and to other developmental 
manipulations such as cloning, is 
emerging among public interest advocates 
(14-16). This new movement clearly has 
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natural affinities to ongoing efforts to promote women’s rights.
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As more genetic mutations are 
‘discovered’ as being implicated in the 
development of particular diseases, our 
understanding of health risks is becoming 
effectively geneticized (Lippman, 1991). 
The case of breast cancer provides a 
useful example of this geneticization of 
risk. The identification of genes implicated 
in the development of breast cancer (e.g. 
BRCA1, BRCA2), has resulted in the 
proliferation public information about 
genetic risk for breast cancer through the 
mass media. As well, this knowledge has 
been translated into the development of 
genetic testing ‘clinics’ that provide women 
with genetic risk information – that is, 
numerical estimates of their genetic 
susceptibility for breast cancer. 
 
Public and professional discussions of 
genetic testing and genetic risk more 
generally tend to emphasize the benefits 
of these biotechnologies for individual and 
population health. For example, one 
clinical genetics reference book describes 
genetic testing as having “enormous 
implications for prevention and treatment 
(Offit, 1998: ix) by identifying those 
individuals who are genetically ‘at risk’ for 
particular diseases (e.g. breast cancer). 
The potential benefits of genetic testing 
technologies are also highlighted in the 
Canadian Biotechnology Strategy Health 
Sector Consultation document which 
identifies early cancer screening and 
detection (enabled by technologies such 
as genetic testing) as a ‘key surveillance 
area’ to facilitate health protection for the 
population as a whole. 
 
Drawing on my experience conducting 
interviews with individuals at risk for 
familial melanoma, my primary aim in this 
paper is to show how individuals’ 
experiences of genetic testing are related 
to broader political, economic and social 
arrangements. First, I situate genetic 
testing as a neoliberal political technology, 
and thus situate this growing public health 
and medical practice in its broader context 
(social, economic, political). In the second 
section of this paper, I generally describe 
the major themes that emerged from the 
interview data in an effort to situate 
individuals’ experiences of genetic testing 
politically. In particular, I suggest that the 
practice of genetic testing creates 
possibilities for conducting oneself as a 
moral and responsible citizen – citizens 
who acquire knowledge of their genetic 
risk, manage their genetic risk through 
lifestyle modification and greater bodily 
surveillance, and who inform their relatives 
of their genetic susceptibility. In the final 
section, I draw some conclusions and 
identify some areas that deserve further 
attention, debate and analysis. 
 
 
I. Genetic Testing as a Neoliberal 
Biotechnology 
 
What is Neoliberalism? For the purposes 
of this paper, I use the term neoliberalism 
to characterize a particular way of 
governing, or way of problematizing the 
questions of government. In contrast to a 
more straightforward description of 
neoliberalism as a reactivation of market 
principles or laissez-faire politics, this 
conceptualization of neoliberalism directs 
our attention towards thinking about 
“government” as a way of thinking about 
and acting upon problems. In other words, 
neoliberalism is not just a set of political 
ideals, but is a “political rationality” 
(Foucault 1991; Gordon 1991) or “formula 
of rule” (Rose 1996) that informs how 
government is practiced.  
 
From this point of view, questions 
concerning government are not limited to 
questions about the state or political 
process. Rather, acts of governance occur 
in many places and take many forms 
(Dean 1999; Rose 1993). In the case of 
genetic testing, for example, practices of 
governance would include those carried 
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out by the state (e.g. policymaking), the 
practices related to the creation of 
knowledge about genetic risk (e.g. the 
Human Genome Project), the translation 
of such knowledge into clinical practice 
(e.g. the institutionalization of genetic 
testing clinics), the education and training 
of genetic specialists (e.g. medical 
geneticists, genetic counselors) and the 
practices of self-governance by which 
individuals use genetic risk information to 
alter their own behaviours. 
 
Genetic Testing, ‘Right to Know’ and 
‘Informed Choice’: Understood broadly as 
a political rationality, neoliberalism 
involves problematizing the questions of 
government not in terms of top-down state 
intervention, but rather towards the 
development of conditions that facilitate 
autonomous self-regulation (Petersen 
1999). This characterization of 
neoliberalism as a political rationality 
allows for a consideration of how 
individuals are governed through their own 
self-regulation and exercise of choice 
(Miller & Rose 1994). 
 
The practice of genetic testing, and 
discourses on genetic risk more generally, 
are guided by the rhetoric of ‘right to know’ 
and ‘informed choice’ (Petersen 1998). 
Being able to make informed decisions or 
choices about one’s health is typically 
used as a rationale for obtaining genetic 
risk information. Consider the following 
quote from a book on the psychological 
consequences of genetic testing:  
 
The provision of genetic information in 
medical practice has the potential to 
facilitate patients’ informed decision 
making about reproduction and 
personal risk modification. As such, 
these advances have profound 
implications for reducing the 
incidence of genetic disorders and 
for reducing morbidity and mortality 
through early detection of disease in 
individuals at risk. (Croyle & Lerman 
1995:11, emphasis added) 
 
The argument that genetic information 
leads to informed choices which, in turn, 
will lead to reductions in morbidity and 
mortality relies on a conception of the 
individual who not only exercises her ‘right 
to know’ her genetic risk status, but who 
also acts responsibly on the basis of that 
information by modifying her lifestyle 
accordingly (e.g. increasing frequency of 
breast examinations). Indeed, this 
expectation of ‘personal risk modification’ 
is stated explicitly in the above quote. 
 
The importance of making ‘informed 
decisions’ has also been taken up by 
women with a family history of breast 
cancer advocating for more accessible 
genetic testing. For example, a recent 
court ruling that women with a strong 
family history of breast cancer would 
receive provincial medical coverage for 
genetic testing was described as an 
‘important victory’ because it “could allow 
hundreds of women to make informed 
decisions about whether to take drugs or 
have their breasts or ovaries surgically 
removed as precautions against 
developing cancer” (Abraham 1999). 
 
Genetic Testing and Citizenship: Genetic 
testing, as a practice and domain of 
knowledge, constitutes one site for the 
construction and exercise of citizenship 
within neoliberal modes of governance. 
Within neoliberal political arrangements, 
experts (e.g. researchers, genetic 
counselors) act as advisors and define 
norms, yet individuals are called upon to 
take an active role in decision-making 
(Petersen 1999), to exercise their right to 
know so that they can make informed 
choices about their health. This imperative 
is reflected and institutionalized in the 
practice of genetic counseling which 
emphasizes  the importance of counseling 
individuals in a ‘non-directive’ manner. 
Thus, active involvement in decision-
making can be considered as a key 
mechanism by which individuals regulate 
themselves—not through being coerced, 
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but through the exercise of their freedom 
of choice (Petersen 1999; Rose 1993; 
Rose 1999). 
 
As with other kinds of health risks (e.g. 
lifestyle, environmental), the ways in which 
ideas about genetic testing are framed and 
clinically applied are founded on a 
conception of the individual as an 
‘enterprise’ who is required to adopt a 
calculating attitude in terms of how they 
conduct themselves (Lupton 1995; 
Petersen 1997; Robertson 2000). This is 
consistent with neoliberal political 
rationalities in which individuals are 
expected to govern themselves through 
“processes of endless self-examination, 
self-care and self-improvement” (Petersen 
1997: 194). The practice of genetic testing 
is an especially effective tool for activating 
these processes. That is, through their 
participation in genetic testing, individuals 
are able to obtain information about their 
genetic risk status, compare themselves to 
genetic norms established by 
epidemiological research, and receive 
advice from health professionals as to how 
they should regulate their own behaviours 
(in light of their knowledge of a genetic 
risk) to avoid disease onset in the future. 
 
 
II. The Construction of Responsible 
Citizens: Implications of Genetic 
Testing for Subjectivity 
 
In this section I discuss how the practice of 
genetic testing constructs individuals as 
responsible citizens who seek out and act 
on genetic risk information to protect their 
personal health as well as the health of 
their family members. To do this, I have 
included some insights from my 
experiences interviewing individuals who 
had were at various stages in the process 
of undergoing genetic testing for familial 
melanoma risk.  
 
Constructing Women as Agents of Self-
Regulation: The Duty to Manage Personal 
Risk 
 
The previous theoretical discussion 
suggests that genetic testing recruits 
individuals into processes of risk 
management involving self-examination 
and lifestyle modification. At a glance, this 
may not seem different than non-genetic 
forms of medical screening and 
surveillance. However, genetic testing has 
considerable potential to shape how 
individuals understand and practice health 
in the absence of disease or symptoms, 
and thus to blur the distinction between 
health and illness (Gifford 1986). In this 
sense, genetic risk information constructs 
particular body parts as potentially 
dangerous (e.g. ovaries, breasts) prior to 
the onset of symptoms. Thus, the practice 
of genetic testing has serious implications 
for how women experience their bodies 
and construct their identities (Hallowell 
1998; Koenig & Stockdale forthcoming), 
and can encourage a person to 
experience their own body as potentially 
dangerous in everyday life (Kavanagh & 
Broom 1998; Robertson 1998; Robertson 
2000). As Koenig and Stockdale note with 
regard to their work in the area of breast 
cancer: 
 
How will women understand ‘risks’ that 
literally reside within them, in their 
genes, over which they have little 
control, and which they may already 
have passed on to their children? Will 
breasts and ovaries be experienced as 
potential time bombs, harboring the 
early stages of cancer, in need of 
constant surveillance? (Koenig & 
Stockdale forthcoming: 20) 
 
Furthermore, unlike environmental or 
lifestyle-related health risks, genetic risk is 
‘embodied’ (i.e. located within the body) 
and is typically not considered to be 
amenable to therapeutic intervention 
(Kavanagh & Broom 1998). While genetic 
risk is distinct from lifestyle- or 
environment-related risks, I believe it is an 
error to consider different types of risk 
discourses in health (e.g. genetic, lifestyle, 
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environmental) as completely 
independent. This is because such a 
separation neglects a major assumption 
underlying genetic testing – that a 
woman’s knowledge of her genetic risk 
status will enable her to make ‘informed 
choices’ with regard to her health. Rather, 
by constructing new categories of genetic 
normality, and situating particular body 
parts as potentially dangerous, genetic 
testing recruits asymptomatic individuals 
as agents of self-regulation who manage 
their health risks through self-imposed 
lifestyle modifications (e.g. increased 
frequency of breast self-examinations, low 
fat diet). In turn, individual responsibility for 
health through personal risk management 
is emphasized. 
 
The importance of informed decision 
making, and its implications for how 
individuals see and act upon themselves, 
was obvious in my interviews with 
individuals who were considering, 
undergoing, or who had undergone, 
genetic testing for familial melanoma risk. 
In these respondents’ accounts, there was 
a general consensus that “the more 
information one had about one’s 
health, the better” because this allowed 
one to gain a greater “awareness” of 
health risks and of bodily signs of 
normality and abnormality (irregular 
moles). In particular, the process of 
genetic testing influenced how individuals 
recognized ‘healthy’ and ‘unhealthy’ moles 
such that they began to examine their 
bodies through ‘clinician’s eyes’. In this 
sense, genetic risk information was 
seen as part of a plan of prevention 
since it allowed individuals to take 
appropriate and more informed action 
through increased self- and medical 
surveillance. As well, the need to become 
more vigilant in terms of bodily 
surveillance was seen by participants as 
incredibly important since early detection 
is key in avoiding more invasive forms of 
treatment for malignant melanoma. 
 
 
Constructing Women as Carriers of Health 
Information: The Duty to Inform 
 
Genetic risk information, being familial in 
nature, not only has implications for 
individuals undergoing genetic testing, but 
also has implications for their family 
members. While much research has 
focused on the personal implications of 
being identified as a ‘carrier’ of “defective” 
genes, less attention has been paid to the 
familial implications of identifying 
individuals who are identified as 
genetically at risk. 
 
As a family-implicating medical 
technology, genetic testing has specific 
implications for the considerations 
individuals make when deciding to accept 
or defer genetic testing. For example, in 
the interviews I conducted, it was clear 
that decisions to accept testing were often 
rooted in a sense of obligation to inform 
current or future family members of any 
undesirable traits that may have been 
passed on. Information about genetic 
risk was seen as especially useful to 
“pass along to the family” to increase 
familial awareness about potential health 
risks and signs of possible hereditary 
disease (e.g. irregular moles). In 
particular, genetic risk information was 
seen as having preventive benefits for 
children by encouraging parents to 
protect their children from the sun, and by 
encouraging their children to be more 
‘aware’ of their bodies and more vigilant in 
protecting themselves from sun-related 
risk 
 
With respect to women in particular, other 
research has shown that women will 
overlook their own desire to not know their 
genetic risk status for breast or ovarian 
cancer so that they can provide genetic 
risk information to their family members, in 
particular their children (Hallowell 1999). 
This calls into question whether decision-
making is really autonomous, an aspect of 





Thus, genetic testing create opportunities 
for new forms of citizenship based on 
familial obligation wherein individuals are 
constructed as ‘carriers’, not only of 
‘defective’ genes, but also of genetic risk 
information. Within this logic, individuals 
are recruited as agents of ‘health’ doing all 
they can to ensure that their family 
members are ‘armed’ with the information 
necessary to manage and minimize their 
own personal health risks. This ‘duty to 
inform’ family members of potential 
genetic susceptibility may have specific 
implications for women, as they have been 






The previous discussion illustrates how 
individuals are recruited as agents of self- 
and familial regulation, processes that are 
consistent with active citizenship under 
neoliberal forms of governance. It is not 
my intention to propose that genetic 
testing is necessarily oppressive, or to 
suggest that these individuals are suffering 
from false consciousness which is 
masking an underlying ‘truth’ or ‘reality’. 
Certainly, the majority of individuals who I 
interviewed on the familial melanoma 
project experienced genetic testing as 
positive overall, and as providing them 
with information that enabled them to 
make personal health-related decisions, 
and that they could pass on to other family 
members. Still, the discussion presented 
in this paper points to a number of areas 
that are in need of further research, 
analysis and debate. 
 
The construction of individuals as agents 
of self-regulation assumes that individuals 
have the psychological and material 
resources necessary to reduce health 
risks, and, even if these resources are 
available, that personal risk management 
should take precedence over other 
matters concerning everyday life. 
Furthermore, this assumes that personal 
risk management through lifestyle 
modification is a straightforward task, and 
does not acknowledge that there may be 
an overwhelming number of 
recommendations for risk management 
which may contradict one another (e.g. 
conflicting mammography guidelines). 
Finally, the focus on personal risk 
modification reinforces a conception of 
health, and responsibility for health, as an 
individual undertaking, and thus other 
conceptions of the determinants of health 
(e.g. environmental influences on breast 
cancer) and the actions which may be 
taken to improve health (e.g. collective 
action) are overshadowed. 
 
The underlying assumption of one’s duty 
to inform family members of potential 
genetic susceptibility neglects to consider 
personal and familial circumstances (e.g. 
recent death of family member) which may 
influence the amount of anxiety one 
experiences from genetic testing, and how 
individuals understand and communicate 
risk information. Also, this assumption 
does not consider that some individuals 
may want to protect their family members 
(in particular their children) from knowing 
their genetic susceptibility to disease. In a 
similar vein, the potential negative effects 
on individuals and families of having 
knowledge of genetic susceptibility are 
often overlooked. In the interviews I 
conducted, individuals felt that they were 
well informed during genetic counseling 
about the potential psychological effects of 
knowing their genetic risk status yet, for 
some, unexpected concerns emerged only 
after they gave blood for genetic testing. 
As well, more attention should be paid to 
the personal consequences of receiving a 
negative/ indeterminate genetic test result, 
for such a test result may not necessarily 
lead to feelings of relief as it can position 
an individual in a state of greater 
uncertainty regarding their genetic 
susceptibility and the risk adjustments that 
they should make in response to a 
negative test result. In short, while genetic 
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risk information is often framed as 
providing individuals with greater control 
over their health, this claim should be 
systematically evaluated through in-depth 
empirical inquiry of individuals’ 
experiences of genetic testing.  
 
Last, there is a need for research on how 
women perceive and experience genetic 
testing and genetic risk information in the 
context of their everyday lives. While 
research on ‘lay’ perceptions of health 
risks is growing, a substantial amount of 
this research focuses on the ‘accuracy’ of 
lay perceptions of risk (Gabe 1995) – that 
is, on whether lay perceptions are aligned 
with biomedical perspectives. Implicit in 
such research is the conviction that lay 
perceptions are somehow lacking and are 
in need of better and more timely 
information so that individuals can become 
better governors of their genetic fates. 
This perspective on lay perceptions needs 
to be countered with research that focuses 
on how individuals understand risk 
information and create meaning about 
genetic risk in the context of their everyday 
lives. Such an approach to research would 
take into account a woman’s entire ‘stock 
of knowledge’ (Petersen 1999) with regard 
to genetic risk (including mass media, for 
example) and would illuminate how 
women actively construct meanings 
around genetic risk. In particular, the 
specifically gendered way in which women 
experience a sense of familial obligation 
as a result of their participation in genetic 
testing would be a fruitful area of research, 
and would have serious implications for 
both practice and policy. A focus on 
women’s experiences with genetic testing 
would also help provide a more complete 
picture of the ethical implications of such 
practices, as it would shed light on the 
influence of genetic testing on the 
everyday lives of women and their 
families. In this regard, the concept of 
citizenship provides a promising way to 
conceptualize personal experiences of 
genetic testing within larger political 
programmes. A focus on women’s 
everyday knowledge about genetic risk 
and genetic testing not only promises to 
illuminate the links between subjectivity 
and broader political currents, but may 
also “provide the basis for exploring the 
contradictions and tensions around 
genetic knowledge and prevention and for 
contesting the imperatives surrounding 
genetic health.” (Petersen 1999: 137). A 
major challenge will be to create 
mechanisms that allow for input from such 
research into decision making processes 
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The … point is not that everything is 
bad, but that everything is dangerous 
… If everything is dangerous, then we 





The purpose of this discussion paper is to 
explore the personal and political 
implications of current discourses on 
health and risk, and to suggest some of 
the ways in which these discourses are 
produced and shaped, in part, by existing 
and emerging biotechnologies, specifically 
diagnostic and screening technologies. I 
use the term “discourse” in the sense that 
Michel Foucault used it to refer to ways of 
thinking, speaking and writing about a 
particular area of knowledge, as well as 
the actual practices associated with those 
ways of thinking, speaking and writing. 
Biomedicine, for example, continues to be 
one of the major discourses on health, 
tending to dominate over alternative 
perspectives on health and healing such 
as holistic or traditional medicine. This 
paper is based on the premise that 
discourses on health are never just about 
health. Particular discourses on health 
emerge at particular historical moments 
and gain widespread acceptance primarily 
because they are more or less congruent 
with the prevailing social, political and 
economic order within which they are 
produced, maintained and reproduced. 
That is, discourses on health are always 
contingent. Moreover, because they are 
always attached to other interests and 
agendas – professional, economic, 
political, cultural, ideological – discourses 
on health, including discourses on health 
risks, also function as repositories and 
mirrors of our ideas and beliefs about, 
among other things, what it means to be 
human and the kind of society we can 
imagine creating and how best to achieve 
it. In this sense, discourses on health are 
fundamentally prescriptive. 
 
This paper is informed, in part, by 
empirical research that I have conducted 
on women’s accounts of breast cancer 
risks. While the study discussed in this 
paper has a phenomenological focus, in 
focussing on women’s experiences in the 
context of their everyday lives, it also is 
based on the assumption that women’s 
health experiences – specifically, the ways 
in which they talk about their own personal 
risks for breast cancer – are located within 
the broader social, political and cultural 
context which produces and shapes those 
experiences. In other words, a 
“phenomenology of risk” is a situated  
phenomenology. This paper argues that 
diagnostic/screening technologies are not 
only part of the context that shapes 
women’s health experiences, they are also 
produced and implemented within that 
same context. In addition, particular 
diagnostic/screening technologies both 
make possible and are made possible by 
particular discourses on risk, which 
themselves are produced within a 
particular context. In other words, there is 
a dialectical relationship between women’s 
health experiences, prevailing discourses 
on health risks and emerging 
diagnostic/screening technologies. This 
means that they must all be analysed 
within the same social, political, moral, 
cultural and ideological context. 
 
It should be made clear at the outset that 
this paper is not intended as a neo-Luddite 
diatribe against biotechnology in general. 
Some biotechnologies clearly have 
enormous potential to improve health 
overall – and women’s health, in particular. 
However, it was clear from the CBS 
documents that there exists a tension 
between, on the one hand, the 
consideration of social and ethical issues 
related to the development and 
deployment of biotechnology (Canada 
1998a) and, on the other hand, the belief 
that “industrial growth should be the 
primary objective of the CBS renewal, 
along with “provision for ‘unencumbered’ 
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basic research”, (Canada 1998b). As 
noted in the CBS Health Sector 
Consultation Document (Canada 1998c:8), 
“the health sector bears a particular 
responsibility to provide leadership to 
society in imagining creative solutions that 
articulate and balance emerging social 
values with expanding technological 
capabilities within regulatory policy 
development” (emphasis added). This 
paper seeks to contribute to achieving this 
balance. Moreover, I will argue that in 
addition to considering the social and 
ethical implications of biotechnology as the 
CBS documents call for, the dialectical 
relationship between prevailing discourses 
on risk and emerging diagnostic/screening 
technologies also has significant personal 
and political implications which must be 
considered. 
 
This paper consists of three parts: first, a 
brief overview of my empirical study of 
women’s accounts of breast cancer risks; 
second, a discussion more broadly about 
what this study indicates about the 
personal and political implications of 
prevailing discourses on health risks, and 
some speculation about how these results 
relate to current and emerging 
diagnostic/screening technologies; and 
finally, a consideration of questions – 
empirical, policy, moral – which a critical 
social science research agenda might 
address with respect to the social 
management of biotechnology. 
 
 
I. Our Bodies, Our Enemies: Women’s 
Accounts of Breast Cancer Risk 
 
There have been a number of studies, 
recently, specifically investigating women’s 
perceptions of risk for breast cancer 
(Black, et al. 1995; Breast Cancer Bulletin 
1995; National Forum on Breast Cancer 
1993; Hallowell 1999; Kavanagh and 
Broom 1998; Koenig and Stockdale 
forthcoming; Lipkus, et al. 1999; Lloyd, et 
al. 1996; Mannheimer 1992; Potts 1999). 
However, with a few exceptions, most of 
the studies of women’s perceptions of 
breast cancer risk have employed a 
number of psychosocial measurement 
instruments and structured interviews with, 
until recently (Hallowell 1999; Koenig and 
Stockdale forthcoming), very few 
phenomenological investigations of 
women’s accounts of risks for breast 
cancer. 
 
According to Sandra Gifford (1986), one of 
the few researchers who has conducted 
phenomenological research on women’s 
perceptions of risk for breast cancer, risk 
for breast cancer becomes internalised 
and is experienced as a state of being, 
which leads to an ambiguous relationship 
between health and ill-health: "This 
ambiguity results in the creation of a new 
state of being healthy and ill; a state that is 
somewhere between health and disease 
..." (215). As with illness narratives, 
personal narratives of risk may help 
women make sense of breast cancer risk 
by providing an "arena for the negotiation 
of reality" (Early 1982:1491). At the same 
time, by leaving women feeling 
"precariously perched between illness and 
health" (Garro 1994:784), awareness of 
risk "forces an awareness of the body as 
separate from self" (782). As Baines says: 
"For women with breast cancer, it is a 
chronic disease; for women generally, it 
can be a chronic problem" (Baines 
1990:20). 
 
In order to investigate the extent to which 
this was the case, I undertook a study of 
women’s accounts of breast cancer risks. 
Focus groups and in-depth interviews 
were conducted with 20 women recruited 
from a pool of women who had attended a 
Breast Health Clinic at a metropolitan 
teaching hospital and had not been 
diagnosed with breast cancer. Participants 
were divided into 3 clinically-designated 
risk groups – low, medium and high – 
based on certain clinical criteria. Focus 
groups and interviews were tape-recorded 
and transcribed. The transcripts were then 
subjected to a standard qualitative data 
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analysis to elicit common themes that 
emerged from the women’s accounts of 
risks for breast cancer. 
 
The following analysis focuses, in 
particular, on what study participants said 
about two issues with respect to breast 
cancer risk: firstly, their perceptions of 
their own personal vulnerability to breast 
cancer; and, secondly, how much control 
they felt they, personally, and women in 
general have over whether or not they 
ultimately develop breast cancer. For the 
sake of brevity, the three major themes 
which emerged from analysis of the data 
are briefly outlined below. Data, in the 
form of direct quotes from the study 
participants, supporting these themes is 
provided in a longer paper based on this 
study (Robertson 1999) 
 
Breast worry: vulnerable and flawed – All 
the participants expressed varying 
degrees of “breast worry”. This worry had 
three essential components: the 
inevitability of breast cancer, the 
constancy of this worry about breast 
cancer, and the sense of the breasts as 
flawed body parts (employing terms like 
“time bombs” and “Achilles heel”). 
 
Managing uncertainty: numbers and risk 
status – Linked to the constant awareness 
of vulnerability to breast cancer that these 
women felt was the theme of uncertainty. 
For some women this was expressed as 
an awareness that uncertainty was 
something they simply had to live with. For 
others, it was expressed as a desire for 
more certainty. One of the most common 
strategies that women in this study used 
for managing this uncertainty was to figure 
out their own breast cancer risk status. 
Many women appeared to be continually 
adjusting their sense of their own risk 
status over time as a result of 
incorporating additional information or 
making changes in their own health 
behaviour. 
 
Playing the odds: individual 
responsibility/no control – Nearly every 
woman in this study talked about the 
individual responsibility that she and all 
women have for reducing their personal 
risks for breast cancer. This was always 
framed in terms of individual responsibility 
at the level of lifestyle behaviours such as 
diet, smoking and alcohol consumption, 
behaviours which they were well aware of 
as “risk factors” for breast cancer. 
 
While there was a general emphasis on 
this kind of individual responsibility, at the 
same time, many of these same women 
recognised that there were many risks for 
breast cancer that they had no real control 
over. Significantly, even though most 
women spoke about environmental issues 
like polluted air, water and soil and food 
additives, which they all considered to be 
major contributors to increasing risks for 
breast cancer, not one of the women in 
this study talked in terms of collective 
action at the social, political and economic 
levels for reducing breast cancer risks, 
such as lobbying for stricter environmental 
controls or food regulation.  
 
What appeared to happen was that 
women tried to reconcile these two 
conflicting issues – individual responsibility 
in the face of limited or no control – with 
the notion of "playing the odds". One 
participant expressed how going back and 
forth between these two poles of 
responsibility and control kept her poised 
on the edge of uncertainty. The result was 
a fundamental bifurcation of body and self. 
While this is a particularly eloquent and 
poignant expression of this, every woman 
in this study expressed some degree of 
this bifurcation of body and self.  
 
… I think that there's – say there's two 
of me and one of me goes low-fat [diet], 
doesn't drink or has the odd drink, 
doesn't smoke, exercises, and the other 
one smokes and drinks and eats so 
that they're out like this, yeah, I think 
I'm gonna – this one over here 
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[indicating the “healthy lifestyle” self] is 
going to have a lot better chance of not 
developing cancer than this one over 
here [indicating the “unhealthy lifestyle” 
self]. I would say this one over here will 
develop it if she has … the propensity. 
But then the thing is both these two 
people have the genes. They both have 
an eighty-five per cent chance. Yeah, 
and I would say this one over here, the 
fat one, the smoking, alcoholic fat one, 
will develop it. And this one over here, 
the exercising obsessive, maybe she 
won't get it; but there's a good chance 
she will. But she seems to be smart 
enough that she looks after her body 
and she takes care of herself that she'll 
get the proper help to deal with it better 
emotionally, she'll nip it in the bud 
because she's aware of it and she's 
doing things about it, and she won't die; 
whereas this one over here may not 
realise she has it until it's too late. 
(Donna, HR:29 - 31). 
 
Donna, like all the women in this study, 
have literally embodied prevailing 
discourses on breast cancer risk, and 




II. Embodying Risk, Embodying 
Political Rationality 
 
“Risk” has become one of the defining 
cultural characteristics of Western society 
at the end of the twentieth century (Beck 
1992b; Douglas 1994; Douglas and 
Calvez 1990; Douglas and Wildavsky 
1982; Giddens 1991; Nelkin 1985; Renn 
1992; Scott, et al. 1992). Perhaps, most 
significant is that, in the current context, 
the meaning of risk has shifted away from 
being a neutral mathematical probability, 
and has come to signify impending danger 
(Douglas 1990; Lupton 1994b). A common 
theme in much of this literature is that risk 
consciousness reflects a new social, 
political and moral order: “[the] risk 
debates around which much of modern 
politics has been shaped are 
quintessentially tied up with … the search 
for new forms of legitimate order and 
authority” (Wynne 1996:78). 
 
As in other areas of life, “risk” has become 
has become central to discourses related 
to individual health; that is, risk has 
become a common construct around 
which health in Western society is 
described, organised, and practiced, both 
personally and professionally (Bunton 
1992; Hayes 1991; Hayes 1992; Lupton 
1995; Petersen 1996). The results of this 
study demonstrate the extent to which the 
participants embody discourses on risk, in 
general and discourses on breast cancer 
risk, in particular. This embodiment of risk 
is expressed by the women in this study in 
terms of a phenomenological experience 
of “being at-risk” for breast cancer. There 
has been much recent discussion about 
the implications of this “at-risk” 
consciousness (Castel 1991; Crawford 
1994; Greco 1993; Lupton 1994a; 
Petersen 1998; Petersen 1996). 
 
Firstly, and as indicated by the results of 
the present study, such consciousness 
contributes to the emergence of a 
particular form of subjectivity – that is, a 
particular way of thinking about, relating to 
the self in terms of the broader social and 
political context within which the self is 
embedded/located. The particular 
subjectivity made possible by current 
discourses on health and risk and the 
resulting “at-risk” consciousness has been 
described as the “entrepreneurial subject” 
(Petersen 1996; Rose 1990; Rose 1993). 
This captures the notion that “life should 
be an enterprise of oneself” (Petersen 
1996:48), a personal project, to be 
continually and actively assessed, 
managed, worked and improved upon 
(Greco 1993; Lupton 1995; Petersen 
1997; Petersen 1996; Rose 1993; Rose 
1990); in turn, “this requires the individual 
to adopt a calculative and prudent attitude 





For the women in this study, this 
enterprise is essentially an embodied one: 
they manage their anxiety about being “at-
risk” for breast cancer by managing their 
bodies, that is, by adhering to particular 
lifestyle behaviours such as low-fat diets, 
not smoking, controlling their alcohol 
consumption, practising stress 
management strategies and managing of 
their reproductive options in particular 
ways. Where they are not actually 
engaged in such “healthy” lifestyle 
choices, they exhort themselves to 
become so. Other investigators have 
talked about "panic bodies" (Lupton, et al. 
1995b; Lupton, McCarthy et al. 1995), 
"risky bodies" or "risky selves" (Nettleton 
1997), and even "dangerous bodies" 
(Hallowell 1998) and "malignant bodies" 
(Williams and Bendelow 1998). The 
women in the present study appear to 
manage their uncertainty and anxiety 
about breast cancer by negotiating an 
uneasy pact with their "treacherous 
bodies". 
 
The phenomenological experience of the 
women in this study does not, of course, 
occur in a vacuum; such experience is 
always situated and located – socially, 
politically, historically. In analysing the 
portrayal of risks for breast cancer in 
popular media, Deborah Lupton 
(1994a:73) found that the Australian press 
drew upon "dominant cultural metaphors 
and discourses concerning femininity, the 
individual's responsibility for illness, and 
medical and technological dominance”. 
These same themes were reflected in the 
accounts the women in this study give of 
their vulnerability to breast cancer. 
 
Many scholars have written about how the 
role of public health is central to the 
reproduction of this risk consciousness. 
(Bunton, et al. 1994; Bunton 1992; Lupton 
1995; Nettleton 1997; Petersen and 
Lupton 1996). For example, the 
phenomenological consequences of the 
public health practice of “risk assessment” 
for the entrepreneurial subject are clear. 
 
Preventive medicine and statistical 
calculations in the context of 
epidemiology are part of a moral 
technology; by being made aware of 
risks, the individual is told to provide for 
and discipline the future, to calculate 
future actions and dealings. 
(Adelswards and Sachs 1998:207; 
emphasis added) 
 
The scope of public health would appear 
to be almost limitless, for as Castel 
observes, “for what situation is there for 
which one can be certain that it harbours 
no risk, no controllable or unpredictable 
chance feature” (Castel 1991:289). And it 
is diagnostic/screening technologies – 
such as mammography and genetic 
testing for breast cancer – which, in part, 
have provided the means for public health 
and preventive medicine to cast an ever-
widening “clinical gaze” – or more 
specifically, a “technological gaze” – over 
the health and lives of women, such that  
“to be suspected, it is no longer necessary 
to manifest symptoms … it is enough to 
display whatever characteristics the 
specialists responsible for the definition of 
preventive policy have constituted as 
risks” (Castel 1991:287). 
 
Diagnostic/screening technologies are 
instrumental in defining and assessing 
these “characteristics”, resulting in a 
“technologization” of risk. To date, these 
have been largely imaging technologies – 
such as mammography, ultra sound, 
bone-density testing – but with the 
enormous global effort being put into the 
Human Genome Project, these 
“characteristics” are becoming increasingly 
genetic, surely confirming Lippman’s 
(1992) early insights into the 
“geneticization” of risk. With the current 
push to make genes the ultimate “risk 
factors”, the individualization of health, and 
health risks, is complete. Health risks are 
in the very “building blocks” that make up 
 
 70 
the person and not in the social, physical 
or political environment. 
 
Prevailing discourses on risk, and the 
biotechnologies which both make them 
possible and are made possible by them, 
also have implications at a social and 
political level. It could be argued that the 
phenomenological experience of the 
women in this study represents an 
embodiment of a currently prevailing neo-
liberal rationality (Burchell 1993; Castel 
1991; Greco 1993; Petersen 1997; Rose 
1993; Rose 1990). The argument here is 
that neo-liberal notions of individual 
autonomy, the free market and limited 
government are related, in a mutually 
producing and sustaining way, to the 
imperatives to “self-care” (Greco 1993) – 
in the form of self-surveillance and self-
regulation – which themselves are a 
consequence of the phenomenological 
experience of being “at-risk”. Petersen 
makes this link between risk 
consciousness and the prevailing political 
order, characterised, in part, by the rapid 
retreat of the welfare state. 
 
Neo-liberalism calls upon the individual 
to enter into the process of their own 
self-governance through the processes 
of endless self-examination, self-care, 
and self-improvement. Given that the 
care of the self is bound up with the 
project of moderating individual burden 
on society, it is not surprising … that 
since the mid-1970s there has been a 
clear ideological shift away from the 
notion that the state should protect the 
health of individuals to the idea that the 
individuals should take responsibility to 
protect themselves from risk. (Petersen 
1996:48-49) 
 
In other words, the entrepreneurial subject 
is reconceived – and reproduced – as a 
new kind of citizen: a neo-liberal citizen 
who is autonomous, responsible and self-
governing. Within this kind of rationality, 
health and health risks are individualized 
and, thus, depoliticized. It should, 
therefore, not be surprising that the 
women in the study discussed here readily 
took up prevailing discourses on breast 
cancer risk, assigned themselves a “risk 
status” and talked about the management 
of breast cancer risk only at an individual 
level and not at a collective or political 
level.  
 
It is to this extent that it could be argued 
that, for the women in this study, 
embodying risk represents the 
embodiment of a neo-liberal rationality. 
Diagnostic/screening technologies are 
firstly imagined, and then developed and 
deployed, within that same political 
rationality which they, in turn, reinforce 
and reproduce.  
 
 
III. Implications for a Canadian 
Biotechnology Strategy 
 
The preceding discussion is offered as 
some preliminary thoughts about the 
dialectical relationships between prevailing 
discourses on health risks, emerging 
biotechnologies (specifically, 
diagnostic/screening technologies) and the 
prevailing social, political, moral, cultural 
and ideological order (more specifically, 
the current neo-liberal rationality). This 
raises a number of questions at several 
levels – social, political, ethical. What I will 
attempt to do in this final section is to raise 
two fundamental questions, to begin with, 
which a critical social science research 
agenda might address in relation to the 
current Canadian Biotechnology Strategy. 
 
Firstly, at a phenomenological level, I think 
we need to understand more about how 
women take up prevailing discourses on 
health risks. It would appear that women, 
generally, have willingly taken up certain 
practices of self-surveillance and self-
governance (eg. breast self exam, annual 
mammograms, lifestyle management). It is 
poignant to reflect on the extent to which 
the notion of “Our Bodies, Our Selves” 
(reflecting a political intention, on the part 
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of the women’s health movement, for 
women to “re-own” their bodies – i.e. to 
remove them from the clinical gaze) has, 
within 30 years shifted to “Our Bodies, Our 
Enemies” (reflecting a turning back of the 
clinical gaze on oneself). But is this what is 
actually happening? Do women take up 
prevailing discourses on risk – and submit 
themselves to the diagnostic/screening 
technologies – wholly, uncritically? Or are 
there pockets of resistance to these risk 
discourses? What do these discourses of 
resistance look like and, remembering 
Foucault’s injunction to “look to the 
margins”, where are they located?  
 
In this respect, there are clear limitations 
to the study reported here because of the 
selective nature of the study sample. The 
participants were all English-speaking 
women of European – mostly northern 
European – descent, middle-class, mostly 
working and largely professional. More 
significantly, they were all either self-
referred or referred by their family 
physicians to the Breast Health Centre of 
a major downtown teaching hospital in a 
large urban centre. This in itself speaks to 
a certain pre-selection in terms of class, 
education, and other social locations of 
these women. Because of this limitation, 
the investigation of potential differences in 
terms of a variety of social locations – 
class, race/ethnicity, mother tongue, 
sexual orientation – representing different 
experiences of embodiment, was not 
possible. For theoretical reasons, one 
might expect very different results from 
women who attend a Community Health 
Centre in a low-income neighbourhood, 
women who are recent immigrants, 
women who live in rural settings or women 
who have some other racial/ethnic/cultural 
origin besides northern European. Further 
research would illuminate how differently 
embodied subjects take up, interact with 
and transform prevailing discourses on 
health risks in general and breast cancer 
risks in particular.  
 
In addition, remembering that 
phenomenological experience is always 
situated, comparative research would 
indicate what and how different discourses 
on health risks emerge within different 
professional, political, legislative and 
regulatory contexts (e.g., UK, USA and 
Canada). For example, is there now a 
global discourse of breast cancer risks or 
are there jurisdictional variations? And 
how does this impact on women’s health 
experiences within these contexts? 
 
Secondly, and related to the above 
question (in ways which remain to be 
explored) is the question of public 
participation in the setting of the Canadian 
public policy agenda for the development 
and deployment of emerging 
biotechnologies. The CBS documents 
appear to address this issue, but the 
nature of the suggestions and 
recommendations makes it clear that this 
represents a kind of “tokenism”, referring 
to the “information needs” of the public 
and strategies for “increasing public 
awareness and understanding of 
biotechnology products and processes” 
(Canada 1998d:15). The assumption here 
is that the public somehow doesn’t “get it” 
with respect to biotechnology, and that 
public knowledge is somehow a 
“degenerate” form of knowledge. This is 
often reflected in the reference to 
“scientific evidence” and “lay beliefs”, as if 
science, itself, were not a belief system. 
The solution, according to the CBS, is to 
make scientific knowledge more 
“accessible” to the public. 
 
Research points to gaps in consumer 
awareness and understanding of 
biotechnology … The attributes of 
biotechnology applications often are not 
directly evident to citizens. More work is 
needed to determine the best way to 
inform them about such technologies. 
(Canada 1998d:14) 
 
In other words, the suggestion here seems 
to be that the biotechnology sector needs 
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to engage in a public relations campaign. 
Note, also, that not only understanding, 
but also accepting, scientific knowledge 
has become an attribute of citizenship. An 
alternative view is to regard public (or 
“lay”) knowledge as a legitimate, 
competing knowledge system alongside 
scientific knowledge (Brown; Balshem 
1991), albeit less systematically 
articulated. Further research into public 
knowledges about health risks and what 
happens to them as they enter the public 
policy arena would be illuminating. Again, 
comparative research would indicate how 
different jurisdictions have addressed the 
issue of ensuring (or, alternatively, limiting) 
public participation in setting the public 
policy agenda with respect to the 
development and deployment of 
biotechnology. 
 
This Discussion Paper is offered in the 
spirit of David Suzuki’s caution that 
“science is too important to leave to the 
scientists”. What this means for social 
scientists is that, as Foucault said, “we 
always have something to do”.
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About the Article 
Agricultural biotechnology is the focus of Elisabeth Abergel’s paper. In illuminating the 
recent history of GE foods in Canada, she identifies the way that the current prevalence 
of GE crops and GE foods has been hidden from Canadians. The CBS is, for Abergel, 
only the most recent version of a developing policy agenda at the federal level which has 
worked to promote the industry, while obscuring the awareness of Canadians and 
marginalizing ethical and social issues. Abergel’s analysis also highlights tensions for 
feminists. The positioning of women as consumers, she suggests, limits the nature of the 
critique that can be made in the name of women and women’s health. A feminist critique, 
by contrast, needs to advance a broader social justice analysis. How, Abergel asks, will 





The use of genetic engineering (GE) in 
agriculture is highly controversial. The 
ecological and human health impacts of 
this technology for food production are 
uncertain and contested. Throughout the 
world, a growing number of scientists, 
politicians and activists have been 
criticizing the way in which GE has been 
introduced in our fields and our food 
system, pointing to the lack of rigorous 
testing methods and the limited knowledge 
about long-term health and ecological 
consequences. European anti-GMO 
(Genetically Modified Organisms) protest 
has resulted in the adoption of a 
precautionary approach to the regulation 
of GE foods and the blockage of imports of 
North American crops. Canada is a major 
player in agricultural biotechnology; it is 
the third largest producer of GE crops in 
the world. Large public investments have 
helped to foster the Canadian 
biotechnology industry in the last two 
decades. The Canadian government has 
played a conflicting role in biotechnology, 
simultaneously promoting and regulating 
the products of genetic engineering. 
 
North American resistance to GE is 
growing, largely as a result of worldwide 
concern. While the movement to block 
GMOs in food is often associated with a 
new health and environmental risk 
awareness, it also represents a global 
political movement, cutting across issues 
of race and class, linking the struggles of 
women, North and South, against the new 
trade agenda. Feminist opposition to 
agricultural genetic engineering has 
focused on the corporate domination of 
the food system, the ownership and 
control of vital biological resources and the 
marginalization of women’s role in global 
food security. 
 
As this short piece suggests, however, 
health and medical applications of the 
technology divide feminists in much more 
profound ways, highlighting the complexity 
of biopolitical issues facing women today. 
The Canadian Biotechnology Strategy 
(CBS) did not provide a viable forum for 
women’s views to be heard, as no 
opportunities to discuss the wider 
implications of the technology existed.1 
Early discussions about biotechnology 
policy excluded public participation and 
the development of regulations replaced 
any kind of formal technology assessment. 
The Canadian federal government has 
played a contradictory role in the area of 
biotechnology policy, promoting the 
industry while protecting the health of 
Canadians. As a result, the opportunity for 
women’s groups to debate the use of 
genetics for various applications was 
missed. Canadian feminist discourse has 
remained fairly compartmentalized in 
terms of its critiques of biotechnology, 
mostly relating to changes in healthcare 
and the delivery of services for women. 
 
 
Agricultural Biotechnology Policy 
 
The first genetically modified organism to 
be introduced in Canada was herbicide 
tolerant canola in 1995, and there are 
currently over 40 GE crops approved for 
environmental release and commercial 
application. Crops such as herbicide 
tolerant and insect resistant corn, 
soyabeans and potatoes have been 
introduced into the Canadian food system. 
Indeed, it is now estimated that over 60% 
of all processed foods sold in Canada 
contain GE ingredients. 
 
Agricultural biotechnology has, until now, 
targeted industrial applications (food 
production and processing) leaving the 
public wondering how GE might affect 
them. These so-called “first generation” 
                                               
1 This is separate from the Royal Commission 
on New Reproductive Technologies that dealt 
with a wide array of technologies which did not 
exclusively involve genetic engineering. 
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GE crops have opened the way for 
“second generation” products also known 
as “nutriceuticals,” incorporating 
pharmaceutical and/or nutritional 
components such as vitamins and 
minerals considered essential to a 
“healthy” diet. 
 
When it comes to agricultural 
biotechnology, Canada is characterised by 
a lack of public debate and openness in 
decision-making. Although the success of 
GMOs was premised on consumer 
acceptance, the Canadian public has been 
systematically excluded from discussions 
regarding the desirability and safety of 
these products. As a result, these products 
have largely remained hidden from public 




Canadian Regulation of GMOs 
 
The Canadian federal government 
designates all new plant varieties and new 
foods derived from them as ‘Plants with 
Novel Traits’ and ‘Novel Foods’, equating 
biotechnology with traditional techniques 
of genetic modification such as plant 
breeding. In practice then, regulations 
focus solely on the new characteristics of 
GMOs (and foods derived from them) in 
what has been called a reductionist 
approach. New characteristics (genetic 
traits) in themselves are rarely seen to 
pose any new environmental or health 
risks (i.e. herbicide tolerance can be 
achieved through means other than GE 
and herbicide tolerant plants are not new). 
The adoption of a product-based 
regulatory system focuses the approval of 
'novel' organisms independently from their 
method of production. A product or 
commodity focus makes the techniques 
and processes of genetic engineering 
irrelevant as possible sources of hazards. 
This ignores the inherent risks posed by 
the technology, focusing the attention of 
regulators and the public on the outward 
characteristics of the novel plant and away 
from GE. The environmental and health 
approval of GE foods is based on a 
method of analogous reasoning comparing 
the hazards/ safety of modified crops 
against their natural counterparts. Hence, 
the hazards of conventional agriculture 
and current food practices establish the 
normative baseline for the assessment of 
GMOs. As a result, the acceptability of 
risks is a negotiated process occurring 
between regulators and crop developers. 
The scientific data submitted for approval 
of new crops is provided by the applicants 
(mostly industrial interests); the results of 
field and nutritional trials are not peer-
reviewed, nor are they independently 
assessed by scientists; this information 
remains strictly confidential and away from 
public scrutiny.  
 
On a more direct level, there are no public 
information requirements for foods derived 
through biotechnology and foods 
containing GE ingredients. They are not 
labelled. The system in place at the 
moment in Canada is “voluntary labelling,” 
meaning that food producers or 
manufacturers have a choice to keep the 
content of their products from consumers. 
Unfortunately, despite repeated demands 
by the Canadian public for the mandatory 
labelling of all GM foods and ingredients, 
the federal government persists in 
defending the rights of industry to withhold 
that information. Similarly, public 
campaigns requesting the segregation of 
GE from conventional crops have been 
deemed too costly (it is argued that costs 
would be passed on to consumers) and 
too difficult to manage through the food 
handling and processing system. What is 
clear is that in this case, labelling would 
give consumers the choice to knowingly 
not purchase GE products. The results of 
many public polls confirm this statement. 
In any case, it is obvious that by keeping 
GE out of the sight and mind of 





While labelling and segregation are 
important issues in the anti-GMO 
campaign, they also constitute a false 
debate. For GE opponents, the question is 
not simply about labelling or segregating 
but it is about maintaining access to non-
GE foods and products and calling for 
sustainable alternatives.  
 
Now that GE products have been around 
for a while and that people have been 
consuming them, it becomes easier to 
“banalize” the use of GE food. That is 




From NBS to CBS: Twenty Years of 
Biotechnology Policy 
 
Through the various phases of the 
Biotechnology Strategy, first known as the 
National Biotechnology Strategy (NBS) 
and more recently the Canadian 
Biotechnology Strategy2 (CBS), the federal 
government charted the course of 
biotechnology policy. It has provided the 
impetus for the development of a 
Canadian biotechnology industry through 
funding programs and policy formulations. 
The three phases of the CBS have 
mirrored technological developments, from 
R&D to marketing and more recently to 
issues of commercialization and “public 
participation.” The three phases 
proceeded as follows: 
 
1. Research and Development (1983-
1988): funds were allocated to stimulate 
                                               
2 The change in name reflects not only regional 
interests in biotechnology but issues of 
nationalism. Quebec has been a strong 
supporter of biotechnology in the past and 
represents an important player in the 
pharmaceutical industry, however, objections 
were raised about the “national” focus of the 
last strategy. For this reason, the Strategy 
Office at Industry Canada decided to rename 
its latest policy forum the “Canadian 
Biotechnology Strategy.” 
the development of the industry in various 
strategic sectors of the economy; 
 
2. Industrial Development and Regulatory 
Policies (1988-1997): during this period 
the regulatory framework was finalized in 
order to facilitate the commercialization of 
new biotechnology products, and finally; 
 
3. Public Concerns (1998-): this latest 
effort is marked by the formation of a 
Canadian Biotechnology Advisory 
Committee whose primary function is to 
channel public concerns to relevant 
government agencies. 
 
The fact that public concerns formed the 
focus of the most recent biotechnology 
strategy is indicative of the federal 
government's commitment to the success 
of the industry. For many critics of the 
Canadian approach, it appears as though 
the Canadian biotechnology industry is 
largely the product of the federal 
government’s involvement, through 
various policy initiatives and generous 
public investments. This bias is expressed 
in the framework developed for regulating 
GE products which facilitates 
commercialization (treating GE as 
inherently safe) and serves to enforce the 
acceptability of transgenic agriculture. As 
a result, the formation of an arm's length 
advisory body to deal with socio-ethical 
issues reflects the government's lack of 
commitment to ensuring a fair and 
balanced policy process. In addition, the 
choice of an advisory body as the 
preferred mechanism for public 
participation in biotechnology issues after 
GE products have been approved for 
consumption and marketed to Canadians 
without their knowledge seems like 
inverted logic.  
 
The sequence of events of the NBS to the 
CBS has essentially served to remove the 
implicit 'ethics' contained in the current 
regulatory system from public debate. This 
was successfully achieved by the 
exclusion and marginalizing of alternative 
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voices during the development of the 
technology. In other words, biotechnology 
has often been described as an 
autonomous technology, simply because it 
did not originate from public demand but 
instead from scientific advances. As a 
result, it is recognised that this type of 
technology generally neglects the “public 
good,” leaving out important social 
questions about technological change and 
unintended health/ environmental 
consequences. For this reason, the policy 
process has tended to reflect the federal 
government’s enthusiasm for the industry 
at the expense of the public interest.  
 
The social acceptance of biotechnology 
has been tacitly built into government 
promotional and management 
programmes facilitated through the CBS. 
However, It is now apparent that this 
strategy has not been successful at 
silencing critics of the biotechnology 
industry. Clearly, one of the biggest 





The 'biopolitical' issues raised by this 
technology divide women and feminists. 
Debates over GE have largely been 
portrayed as consumer issues. The fact 
that women are the primary purchasers of 
food and pharmaceutical products and are 
often responsible for feeding and 
maintaining the health of their families is 
used to support this view. This implies that 
resistance to these products and 
technologies are defined as being 
essentially 'consumer-based.' However, 
the issues raised by GE go beyond this 
simple analysis. For many women, 
resistance to GE food is linked to wider 
social and ethical questions about the 
collective rights of people to be self-reliant, 
have access to safe and healthy food and 
live sustainably on the land. For many 
activists such as myself, resistance to GE 
in agriculture is one way of reflecting upon 
the broader questions about the use of 
that technology to transform nature and 
ultimately humans. 
 
It has been my personal view, as a 
feminist involved in agricultural and health 
issues, that opposition to GE, although it 
has the potential to express much deeper 
concerns about the social use of 
biotechnology for defining particular 
models of society, raises some difficult 
issues for women. I personally find the 
separation of health from food and from 
environmental issues as a whole artificial 
and somewhat short-sighted. While there 
is widespread agreement among women 
that GE food may not be desirable for a 
variety of reasons, the medical uses of GE 
and the issues they raise are more 
divisive. It appears as though public 
reaction to the use of genetic technologies 
for producing pharmaceuticals and for 
medical interventions, such as gene 
therapy or genetic screening, have been 
mixed. They are generally viewed more 
positively than the production of transgenic 
foods. Unlike opposition to GE foods, 
differences in the level of concern raised 
by these technologies in healthcare often 
emphasise deep disparities among 
women, further polarizing feminists. Unlike 
food issues that stress the collective 
purpose of political action, many of the 
possibilities offered by genetic 
technologies as they relate to women’s 
“health” tend to individualise problems, 
leaving women with difficult if not 
impossible choices. For other women, the 
lack of access to these genetic 
technologies is the issue. However, the 
same “life science” companies are 
appropriating, controlling and manipulating 
genes for food and medical purposes. 
They are, along with compliant 
governmental authorities, precipitating the 
rapid commercialization of new foods, 
drugs and new technologies derived 
through biotechnology without public 
debate and consensus. For critics such as 
Vandana Shiva, corporate and 
technological control over reproduction (in 
plants, animals and humans) represents 
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the ultimate patriarchal project. Opposition 
to a technology such as GE is an 
opportunity to reflect upon the values 
embodied in that science and to consider 




Questions to Consider 
 
While I do not offer any solution to the 
issues raised in this short paper, I propose 
some questions that may provide the basis 
of further discussions: 
 
•  How can feminists concerned about 
biotechnology reconcile these 
differences while respecting the 
diversity of women’s individual 
experiences?  
 
•  How can a conversation about 
women and health incorporate these 
apparent contradictions? 
 
•  Do such differences weaken feminist 
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About the Article 
Given the focus of most papers on the negative role of the state – as key promoter of 
biotechnology – Pat Armstrong’s reasoned and critical defence of the state provides a 
fresh perspective. The state is. she argues, the only agent capable of providing goods 
such as universal health care, and comprehensive social services. Armstrong does not 
adopt a romantic view of the state, however. She notes that the state has been 
principally active in serving the needs of corporations. But this leads her, once again, to 
seek to use the state: “It is precisely because the state is now so activist,” she writes, 
“that we need to make demands on it.” Armstrong’s analysis is especially cogent in an 
era of widespread state-led “reform” of health and social services – reform which can 
seem deceptively attractive in light of past state failings. She cautions feminists to 
ensure that our arguments are not turned against us. The feminist critique of the welfare 
state, for example, is sometimes used to reduce social services; and the feminist critique 
of medical priorities, and their often auxiliary role in generating health, has been used to 
shrink health care services. 
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Feminists have been very critical of both 
the welfare state and of medical practices. 
And feminists have warned against a 
nostalgia for the past, for defending a 
welfare state that did not support women's 
welfare or women's health. In light of these 
legitimate concerns, the state-sponsored 
restructuring of health and social services 
that has been underway in recent years – 
often presented to the public as “reform” – 
can seem very attractive. 
 
With reforms done in the name of 
challenging medical dominance and 
welfare practices, many feminists have 
found it difficult to oppose reforms and 
many even offer support for reforms that 
seem to respond to their issues. Indeed, 
with reformers talking about empowerment 
and community, patient rights and 
continuity of care, evidence-based 
decision-making, efficiency and 
effectiveness, and a focus on primary care 
combined with de-institutionalization and 
the breaking down of the silos that 
separated aspects of care, it is 
understandable why reforms may have 
some appeal. 
 
However, I would argue that these reforms 
are conducted within a context and 
paradigm that result in these processes 
meaning very different things to reformers 
than they do to feminists, meanings that 
are harmful for most women. The new 
paradigm is a business paradigm, where 
the business of government is business 
and the only line is the bottom line. 
Powerful forces – ones that are about 
what Brendan Martin (1993) in his book In 
the Public Interest calls the grubby hands 
hidden behind the so-called free market – 
at the international, national, provincial 
and local levels are shaping reforms so 
that efficiency and effectiveness are 
defined in not only numerical but monetary 
terms, and empowerment is based on 
ability to pay. Continuity is for processes 
not people; community means dumping 
care work and costs on families, and 
within them on women; evidence is 
defined by the powerful in very positivist 
scientific terms; entrance through a 
primary care giver means both restricted 
access and more formulas for care; and 
patients' rights mean individual 
responsibility, rather than collective 
strength and shared risk. 
 
This issue of patient rights can be 
particularly thorny for feminists, even in 
their own paradigms. As Sheryl Burt 
Ruzek (1999:304) points out: 
 
Individualism and choice are deeply 
ingrained concepts in Western 
feminism. They have been critical 
precepts for extending reproductive 
rights, widening options for maternity 
care and giving patients a say in 
decision making, in requiring consent 
for medical care. But as useful as 
individual choice is in these arenas, can 
choice be taken as the first principle on 
which to base a national medical 
system? Are there other and competing 
and conflicting principles that warrant 
equal or greater consideration? Will a 
market-driven consumer model of 
health address pressing issues of 
access and equity? To what extent do 
individualism and choice conflict with 
the need of society to ensure a single, 
affordable standard of care for all? 
 
Ruzek is talking to a US audience and of a 
US system, where universal health care 
has never existed. But her questions do 
have resonance for Canadians, especially 
as we increasingly look to the US for 
models of reform. Her argument leads me 
to another important issue in the feminist 
approach, the problem of class and race 
centred views dominating feminist 
approaches to reform. 
 
Many of these reform processes and 
proposed institutions, as well as the stress 
on individualism and choice, have positive 
meaning for white, middle class feminists 
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living in urban centres, but may be very 
different for women with other locations. 
For the homeless, the movement of care 
"closer to home" may be punishment 
rather than release from oppressive 
institutions, empowerment may mean 
denial of access to institutional care, and 
choice based on finances or physical 
location may mean no care at all. 
 
I would also argue that we have no choice 
but to look to the state for strategies that 
can lead to better health care. Only the 
state can provide universal access, only 
the state can provide the overall planning 
that can make care efficient in people 
terms, only the state can create stability 
and continuity, only the state is subject to 
democratic control. Only the state is 
powerful enough to counter the power of 
the global corporations. This is not to 
argue that the state has served women 
well, or served to reduce inequalities 
among women, or lately, to improve health 
care. Rather, I would argue that the 
current state is very active in serving the 
interests of corporations, in regulating to 
create markets and control populations, 
increasingly directly through households 
and through the privatization of health 
care. It is precisely because the state is 
now so activist that we need to make 
demands on it. It does make a difference, 
and we need to make sure that the 
difference it makes is different, both from 
what the state is doing now and from the 
past. To argue that the state did not create 
equality is a challenge rather than an 
indictment. 
 
A second, and related issue, is the matter 
of health determinants. Originally 
championed by political economists 
stressing the social forces that shape our 
collective lives, health determinants have 
been taken up as the new truth for health 
reformers of every stripe. Indeed, the 
health determinants literature has been 
used as a justification for dramatic 
downsizing within the public health care 
system. However, as is the case with other 
concepts, health determinants have been 
transformed within this new context. 
Unemployment, income, social support, 
etc, have been redefined as individual 
problems rather than as collective ones. 
The risk, and responsibility, is understood 
as individual, with that responsibility 
increasingly enforced in Ontario and 
Alberta by a neo-conservative state. I think 
we have to re-appropriate health 
determinants, initially by insisting that 
states and markets be included in the list 
as major determinants of health status.
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We are writing from our perspectives as 
women who have worked for many years 
in a community-based, women-centred 
health centre, the Women’s Health Clinic. 
In addition to providing health services to 
women, the clinic is committed to health 
education, advocacy and research 
responsive to women’s needs. We have 
participated in a wide range of federal and 
provincial committees and task forces 
related to new reproductive and genetic 
technologies (RGTs); helped to develop 
policy papers; conducted qualitative 
research on women’s experiences with 
RGTs; and have experience with coalitions 
and networks in the women’s health 
movement, locally nationally and 
internationally. We are committed to 
developing critical consumer health 
information resources that locate issues in 
a broader context, capture the nature of 
current debate and discussion, and are 
accessible to women from diverse 
backgrounds. 
 
Like many feminists, our interest in 
biotechnologies has been principally 
focused on the new reproductive and 
genetic technologies, where genetic 
science and women’s bodies meet most 
intimately. Recognising  these points of 
intersect between our individual 
experiences and the wider political and 
social context allows “teachable moments” 
– or crucial learnings to occur. For 
example, we not only ask: “Should I have 
this prenatal test?” and "Do I and my 
family have the capacity to cope with a 
child with particular disabilities and 
challenges?" but also, "Does my 
community provide the supports we will 
need?" and "Should public or private  
money be allocated to making such testing 
available?” 
 
Our contribution takes the form of a series 
of basic questions. Some of these are 
crudely formulated, because it is difficult at 
times even to ask “the right” question. We 
hope they will stimulate discussion and 
contribute to a clearer understanding of 
how to develop broad-based strategies for 
generating knowledge and research and 
for public education and action. Despite 
promises of future benefits and cures, we 
worry that the development of 
commercially-driven biotechnologies 
poses new, unforeseen risks to human 
health and raises profound ethical 
implications which have only begun to be 
considered in  public discourse. 
 
 
How can we contribute to the 
regulation and management of bio-
technologies? 
 
Social research and activism related to 
biotechnologies have focused mostly on 
the development of well articulated 
“critiques”. While some general 
frameworks for regulation have been 
suggested, there are few models proposed 
which would address the specific 
challenges of regulation or other ways of 
managing the technologies. We believe 
this is an area of urgent need. 
 
We can learn from discussions of 
reproductive and genetic technologies by 
women’s health groups. There have been 
strong analyses and critiques, 
documenting the discourse and meaning 
of the technologies, as well as the 
“choices” they provide. In contrast, there 
has been little exploration of models for 
regulation and management. Indeed, there 
is ongoing debate regarding use of federal 
criminal powers to regulate and even 
prohibit certain technologies. Mechanisms 
for management of prenatal genetic 
testing are unresolved. 
 
The development of regulatory 
mechanisms for biotechnologies needs to 
be situated in the context of existing and 
shifting  regulatory mechanisms and the 
challenges these present. Health Canada 
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is engaged in a “Transition Process” which 
may offer opportunities for new linkages 
and integration among departments on 
these issues. A “Risk Management 
Framework” is being developed. This is an 
area for further research, public debate 
and synthesis. This framework will need to 
be reviewed with a cautious eye. The 
language and vague terms do not 
adequately describe what processes or 
specific standards will be put in place. 
There is a need for greater transparency 
and public access to information about 
regulatory decisions. For example, the 
pressure from manufacturers and from 
some consumers to bring drugs to market 
more rapidly has implications for the 
public’s health and safety since shorter 
time frames for clinical trials means we 
know less about long-term effects prior to 
public use. As well, apparent gains in 
public access to information are hard won 
and often limited. For example, the recent 
World Trade Organization decision 
permitting labelling of genetically altered 
foods for export does not in itself address 
issues of safety, research, development 
and corporate control. There is need for a 
more sophisticated analysis of regulatory 




In the context of the regulation and 
management of biotechnologies, how 
will research  be managed? 
 
It appears difficult to clearly separate 
laboratory research, research trials and 
therapeutic or product applications of 
biotechnology research. For example, 
research in biotechnologies in plants, 
animals and particularly humans removes 
the concept of a “safe laboratory” or 
“sealed environment.” As well, in vitro, in 
vivo, clinical trials and clinical therapeutic 
uses of biotechnology products are often 
carried out simultaneously, ensuring 
products are brought to market very 
rapidly. While the use of inadequately 
tested drugs, products and devices is not 
a new phenomenon (e.g. DES; other 
hormones; and blood products), 
biotechnologies seem to raise even 
greater health and environmental 
concerns. As consumers, professionals 
and activists, we feel we are always 
having to play “catch up” with new 
technologies and techniques, asking to 
regulate technologies, the introduction and 
implications of which should have been 
debated at a much earlier research stage. 
 
We ask: how are proposals for 
biotechnology research reviewed and how 
is the resulting research monitored? Are 
there constraints on the transparency of 
such research? What is the impact of 
corporate secrecy in research and 
development? How is increasing 
commercialization of research within 
universities affecting the climate of critique 
concerning research and monitoring? With 
reduced public funding for university-
based research, there is increased 
pressure for corporate-university 
partnerships. How do university based 
ethics review boards function in this 
environment and to what standard? Do we 
need new review processes? 
 
What is the impact of the proliferation of 
private research institutes on the potential 
regulation and management of 
biotechnologies? What will be the impact 
of the restructuring of health research 
within the Canadian Institutes of Health 
Research and the proposed peer review 
process? What mechanisms can be put in 
place to track the impact of this 
restructuring? Can the role and scope of 
Research Ethics Review Boards be 
strengthened, for example, to include the 
use of “citizen panels” and juries in 
reviewing complex ethical questions? 
What effective models are there that could 
be used? How can the public learn about 
biotechnology research in an accessible 
way, exploring the broader  implications? 
 
We look to those involved in the ethical 
review of research proposals to address 
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the wider context within which such 
research is being conducted and the goals 
to which it is directed. Hopefully, there is 
the will and capacity in the independent 
academic / research community to do so. 
The question remains: How will this be 
done to benefit the public and not just the 
individual or corporate sector? 
 
 
Can we think “seven generations 
ahead”? 
 
Can we learn to think beyond the present, 
even “seven generations ahead,” as 
Aboriginal elders teach? How can the 
“precautionary principle” be realistically 
applied to specific situations in the 
present, but envisioning the future? More 
immediate pressures for livelihood often 
overshadow a long-term perspective and 
sound public health practices. For 
example, we have seen communities 
argue that environmental regulations 
should be weakened or ignored because 
of proposed short term benefits, such as 
access to well paying jobs and the influx of 
capital to sustain rural communities.  
 
What does it take to develop broader 
public consciousness in relation to health 
and long term sustainability – to think 
beyond the next paycheck (if there is one) 
to future generations? What are some of 
the personal, social, economic costs/ risks 
of thinking this way? What are the costs/ 
risks in not doing so? How can we get our 
governments, attuned to electoral time 
lines, to apply the "precautionary principle" 
with a vision of the future? 
 
 
Must we always say “No”? 
 
While wary of the possible long term 
hazards of biotechnology, we ask: Are 
there some aspects and applications of 
biotechnology research that offer 
therapeutic value and improved human 
health outcomes to future generations – or 
is that truly impossible to know? For 
example, is there a qualitative difference 
between some genetically modified 
products (e.g. soy products; crops for 
hardier climates) and “terminator 
technology” seeds? Are there important 
directions to research and applications 
that mitigate suffering (e.g. genetic 
screening for Tay-Sachs disease) but that 
do not lead to the denials of human dignity 
and human rights underlying eugenics? 
Should we screen for diseases – or 
susceptibilities to diseases – for which 
there is no known cure, or which may be 
triggered by complex social/ 
environmental/ emotional factors? What 
about germ line research? Is there a 
“continuum” with its inevitable “slippery 
slope” – or are there qualitatively different 
types of research? Is the question solely 
about the capacities of the technologies or 
is it also about who controls the 
knowledge and its application within 
private and public domains? 
 
Further, if we in Canada say “no” to a 
technology (e.g. cloning), what are the 
implications of “leaky borders” – the 
legalization of the same practice in 
another country? How do patents and 
international trade agreements shape 
Canada’s ability to act within its borders? 
In the realities of increasing corporate 
consolidation, global markets and 
commercialization of the products of 




Can we nurture ‘critical 
consciousness’? 
 
Human genome mapping has the public’s 
attention; the almost daily announcement 
of a new gene discovery nurtures an 
ideology of “geneticization” (as Abby 
Lippman so insightfully characterizes it), in 
which genetics is assumed to play a 
determining role in social life. 
Biotechnology research has transformed 
the impossible into the possible. What 
appeared unthinkable several years ago is 
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now considered inevitable: buying and 
selling genetic materials; patenting life 
forms; trans-species genetic transfer; 
cloning; selling Iceland’s “gene pool” for 
research purposes. To our children, and 
increasingly to us, these are ‘normal’ news 
items. 
 
What does ‘normalizing’ these processes 
do to developing a critical evaluation and 
assessment of the new biotechnologies? 
As women hear about new technologies 
and products, they naturally want options 
to maximize their health and the health of 
their families. But personal choices and 
options are necessarily set in a context 
that excludes other possibilities. The 
challenge for policy makers is to direct 
resources to social needs which will have 
a broad impact on population health, while 
also addressing the specific needs of 
particular groups and individuals. How can 
we distinguish in a meaningful way 
between “real risk” and “presumed risk” for 
individuals and ‘populations’ and create a 
clearer lens for analysis? How do we apply 
understandings of gender and social class 
to this analysis? For example, we know 
that in addition to appropriate health care 
services, health is best addressed through 
reduced stress, sound nutrition, exercise, 
healthier work environments and better 
housing – and by reducing poverty and 
violence which affect the overall well-being 
of so many women. Where does/ should 
biotechnology research fit in the context of 
addressing these social determinants of 
health? 
 
Are there creative and effective ways to 
develop critical public consciousness 
about the political, economic and scientific 
"drivers" of biotechnology research and 






How can we make information about 
biotechnology and its implications 
accessible to women and men from a 
variety of backgrounds and 
experiences? 
How do we create spaces for 
discussion and debate? 
 
We have few opportunities to examine the 
issues suggested by biotechnology 
research. In fact, we are often confronted 
with the implications and dilemmas of 
these technologies in our role as 
consumers: Should we purchase 
genetically modified foods? Should we 
consent to genetic screening? Would we 
participate in a clinical trial for a procedure 
using biotechnology? Should we donate 
our embryos or cord blood? These 
dilemmas take place in an environment 
characterized by ‘individual consent’ and 
limited information. Often, the issue is 
raised at an emotionally charged time, 
such as a crucial stage of pregnancy or 
during family illness. The questions are 
narrowly framed. The commercial and 
other interests behind the development of 
many of the technologies are rarely 
considered. 
 
Schools have little time or capacity to 
teach about and discuss these issues to 
prepare students for future dilemmas. 
Ethicists, scientists and health 
professionals may debate these issues but 
the content of the discourse is usually not 
accessible to the public. Sometimes the 
press and other media raise issues and 
initiate debate. Infrequently, public 
discussion is generated through art or film 
(for example, the NFB film, “On the Eighth 
Day” on new reproductive technologies). 
 
There is a lack of time, opportunities and 
resources for most adults to engage in 
constructive debate on these issues. 
Governments, to date, have relied on 
researchers and lobbyists to provide them 
with policy direction. Public opinion is 
measured by the numbers of letters to 
ministers, attention in the public media and 
polling results. Yet, as educators, we know 
that it is in discussion and debate that 
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adults learn best and that we can come to 
a much deeper understanding of the 
broader social context to complex issues. 
Appropriate information in accessible 
formats is essential to help generate such 
debate. Face to face or other types of 
encounters (e.g. internet chat groups) can 
offer settings for listening to others from 
different backgrounds and perspectives. 
Despite conflicting interests and opinions, 
there may be the potential to develop a 
‘working consensus’ or at least define the 
terms of ‘constructive opposition’. 
 
Recently, governments have become 
more overtly committed to the involvement 
of the public in policy development and 
decision making. This change within the 
regulation development processes offers 
opportunities for engagement, but also 
raises concerns. For example, the goal of 
citizen engagement has been adopted 
throughout Health Canada. (An Office of 
Consumer and Public Involvement has 
been created within the Health Products 
and Food Branch). Women’s groups and 
other non-governmental organizations are 
receiving numerous requests for input on 
crucial issues such as transgenic human 
transplantation and regulation of natural 
products – but few have the resources and 
capacity to respond. As well, while some 
processes for public involvement seem to 
be committed to broad and diverse input, 
other consultations appear carefully 
controlled and managed as to content and 
outcome. 
 
We must continue to ask: How will 
women’s groups and organizations, 
particularly those that address the front-
line health needs of women and their 
families, find effective mechanisms for 
education, critical synthesis and debate 
AND for input into the decision making 
processes on research and commercial 
developments in biotechnology? Will there 
be adequate resources for groups to be 
able to respond and engage? At present, 
some NGOs and individuals with interest 
and expertise in these issues are part of 
working groups that communicate online. 
They require financial resources to 
continue to develop well-researched 
information, effective workshops and 
symposia. Can policy and decision-makers 
in government engage with women’s 
groups on these issues in mutually 
respectful, authentic ways? If so, how? 
 
How does an agenda of social change, as 
articulated, for example, in the Beijing 
Action Plan, and in concepts such as 
“Health For All by the Year 2000" move 
forward? What, if any, is the role of social 
protest movements in the year 2000 in 
advancing these agendas? Strong 
opposition has emerged in Europe to 
genetically modified foods and to the 
development and trade policies of the 
major financial institutions. Protests 
(Seattle, Montreal, Prague) show these 
social movements capable of attracting 
media attention and influencing global 
institutions on these issues. 
 
Activists, researchers, independent 
academics and others from the 
environmental, social justice, consumer 
rights, farm and women’s movements, etc 
are raising fundamental questions about 
the course of development in the 21st 
century. Biotechnology and its commercial 
applications are at the centre of their 
concerns. Perhaps the protesters are 
reminding us that answers are being 
proposed  before many of the most basic 
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Separating the issues of health, wealth 
and community in the context of women 
and the new genetics proved a difficult 
exercise, perhaps highlighting their 
appropriateness. I have chosen four main 
issues that are important to RAFI’s work. 
These include: 
 
1. the use of genetic research in the 
pharmaceutical industry, 
2. the corporate concentration in the life 
industries. 
3. the Terminator and Traitor 
technologies, 
4. the threat of genetic biowarfare. 
 
A brief discussion of each issue is followed 
by the key gender equality issues and 
research and action needs. 
 
 
1. Research and use of genetics in the 
pharmaceutical industry. 
 
Human Genetic Diversity Research is 
being conducted and commercialized at 
an alarming rate. Were the commercial 
value of human genetic diversity research 
ever in doubt, those misgivings were 
unambiguously laid to rest when Iceland 
sold its genetic heritage to the genomics 
company deCODE, who, in turn, hawked 
the human data to Hoffman LaRoche of 
Switzerland for US $200 million. The 
spectacular and controversial deal turned 
genomics research overnight from an 
obscure biotech niche industry into a 
mainstream commercial venture. 
Suddenly, almost unheard of genomics 
companies like Millennium (US), Genset 
(France), and Axys (US), are turning 
diversity studies into a multi-billion-dollar 
commercial product strategy aided and 
abetted by researchers at universities and 
even some governments. The extension of 
patentability by the US Patent and 
Trademark Office to single nucleotide 
polymorphisms (SNPs- the smallest unit of 
genetic variability) has further galvanized 
commercial pharmaceutical enthusiasm 
for the new industry. SNPs are the genetic 
basis upon which diversity researchers 
define their investigations and distinguish 
individuals and human populations from 
one another. 
 
Given this full-scale commercial foray into 
diversity research in combination with the 
new methods of sampling and sequencing, 
the pressing question for ethnically unique 
populations and particularly for indigenous 
peoples is no longer "Will we be 
sampled?" but rather "Who will have 
access to human genetic diversity, and will 
it be subject to exclusive monopoly 
control?" The commercial race for diversity 
material is not faceless, but involves the 
lives of particular groups of people in 
increasingly alarming ways. The potential 
violation of basic human rights, particularly 
with respect to research subjects' health 
and social well-being, appears to be 
increasing. Further, in many of the studies 
it seems likely that researchers are not 
obtaining fully informed consent from their 
research subjects. Finally, more general 
ethical questions about the patenting and 
commercial use of this genetic material 
have simply not been adequately 
addressed. 
 
An example of these problems in genetic 
research can be found in studies by 
genetic diversity researchers at Harvard 
University who, in collaboration with a 
number of pharmaceutical companies, 
including Millennium Pharmaceuticals, a 
biotechnology firm based in Cambridge 
Mass., have been conducting large scale 
genetics studies in China. At least 14 
projects are underway in China, 
encompassing as many as 200 million 
Chinese citizens. The projects include 
research on obesity, schizophrenia, 
pulmonary disease, atherosclerosis, 




There is a mounting body of evidence 
suggesting that the rights and protection of 
the research subjects, mostly located in 
Anhui Province in China, are being 
violated. In many cases, the research is 
being conducted under conditions where 
proper informed consent is likely not being 
obtained. The real health risks associated 
with many of the research studies are 
accentuated by a situation where health 
systems, particularly in the rural areas, 
have completely broken down due to the 
changes in the Chinese economy. 
According to many health workers and 
other observers, the blood supply is 
heavily contaminated and syringes and 
needles are re-used and unsterilized. In 
many cases, the research is being 
conducted in China specifically because 
the population does not have access to 
modern medicine. The Harvard 
researchers are not ensuring that their 
research subjects are provided access to 
known therapeutic drugs – a situation that 
would not be tolerated in the US. 
 
In a country where researchers cannot 
guarantee the privacy of their research 
subjects, confidential information may lead 
to prejudiced government authorities 
having full access to the research data. 
Serious ethical questions arise in projects 
that attempt to uncritically capitalize on the 
poor human rights situation in China, for 
example, by using the detailed 
reproductive records of Chinese women. 
Not least, many of the studies will be of 
absolutely no benefit to the people being 




Key Gender Equality Issues: 
 
•  What are the specific threats to 
women of genetic diversity research? 
•  How does gender inequality in health 
care affect the risk posed to women 
from such research? 
•  How can feminist concepts of 
informed consent be used in discussing 
this issue? 
•  How has the notion of "choice" 
advocated by western feminists been 
co-opted by corporate and commercial 
interests (and by the Canadian 
government) in discussions about the 
new genetics and health. 
 
 
Research and Action: 
 
Research. 
•  Monitoring the increasing 
commercialization of genetic diversity: 
who is doing the research, where is it 
conducted, which groups are the 
targets of the research, what are they 
looking for. 
•  Follow-up research focusing on 
individual cases of abuse.  
 
Action. 
•  Life patenting, particularly patenting 
gene sequences, needs to be 
challenged in the courts, the legislature 
and by the public. In particular, there is 
an urgent need for a public debate on 
this issue which is currently being 
decided in the courts rather than 
through a democratic and accountable 
process. The meaning of the CBS in 
the discussion about patenting is clear: 
they mean to ensure that patenting is 
approved in Canada. 
•  Cases of abuse of research subjects 
need to be publicized. Peoples and 
governments should declare a 
moratorium on all human diversity 
collection and commercialization until 
certain agreements are in place. At the 
international level, action must be 
expected from the UN Human Rights 
Commission, from the World Health 
Organization, and from UNESCO’s 
International Bioethics Committee 
(which has woefully neglected the 
intellectual property and commercial 
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issues arising from human DNA 
collection). 
•  Nationally, governments could review 
their medical ethics and research 
protocols to guarantee the rights and 
dignity of their citizens. In particular, 
governments might consider legislation 
that would criminalize the collection or 
removal of human germplasm without 
the prior informed consent of the 
individual, their community, and the 
national government. 
•  The issue of the patentability and 
Human Rights associated with human 
tissues must be discussed by the UN 
General Assembly. An outstanding 
concern is the place of human 
biodiversity within the framework of the 
Biodiversity Convention. Although most 
countries concur that human diversity 
should not be managed by the 1992 
Convention, legal interpretation of the 
Convention suggests that human 
biodiversity is part of the agreement. In 
order to correct this problem and assign 
responsibility more appropriately, the 
General Assembly may seek an 
Advisory Opinion from the International 
Court of Justice (ICJ). The ICJ could be 
asked to determine the position of 
humans within the Biodiversity 
Convention and whether or not 
patenting of human tissue, as required 
by the World Trade Organisation 
(WTO) contravenes Human Rights.  
 
 
2. The corporate concentration in the 
new genetic industry 
 
The intense corporate concentration, and 
the financial incentives which characterize 
the new genetic industry are the clear 
backdrop to much of the Canadian 
Biotechnology Strategy. Any concerted 
feminist response to the CBS requires an 
understanding of just how significant these 
interests are. Important elements of this 
concentration involve the issues of 
intellectual property and ownership of life, 
both of which are important subtexts in the 
Canadian Biotechnology Strategy. 
 
The 'life industry' comprises the giant, 
transnational enterprises that dominate 
commercial products for agribusiness, 
food and pharmacy. Loosely defined, the 
Gene Giants include the transnational 
enterprises that dominate commercial sale 
of pesticides, seeds, pharmaceuticals, and 
food and animal veterinary products. The 
1990s saw a swift and bold concentration 
of power in the life industry – a trend that 
has shown no signs of abating. A steadily 
shrinking number of corporate Gene 
Giants control expanding market share 
over agribusiness, food and pharmacy. 
These are the transnational enterprises 
that aim to manipulate, control, patent and 
profit from life. Market dominance 
combined with monopoly patents gives the 
Gene Giants unprecedented control over 
the products and processes of life – the 
biological basis for commercial food, 
farming and health. 
 
To conclude that transnational 
corporations rival the power of the nation 
state is a gross understatement. Indeed, 
the Economist reported that when 
corporate executives were negotiating the 
merger of Travelers and Citicorp, one of 
the negotiators mused: 'Can anybody stop 
us?' The only response was 'NATO.' 
 
Since 1996, virtually every major seed/ 
agrochemical company has invested in 
plant genomics research. Driven by the 
increased efficiency of genomics 
technology and fierce competition among 
major agbiotechnology firms, investment in 
crop genomics has accelerated 
dramatically. Particularly noteworthy is the 
very minor participation of public sector 
researchers in agricultural genomics. After 
the Gene Giants and their genomics 
partners stake patent claims to molecular 
bits and pieces of commercially important 
plant genomes – what will be left for the 
public sector? With patents in hand, the 
Gene Giants have the legal right to 
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determine who will get access to plant 
genomic material and at what price. 
 
Unchecked corporate power coupled with 
the vanishing role of public sector 
research will affect all areas of global 
health, agriculture and nutrition. Neglect of 
the public good is inevitable when the 
research agenda is determined by the 
private sector in pursuit of corporate 
profits. There is a widening knowledge gap 
between rich and poor, men and women, 
both within and between the industrialized 
North and the impoverished South. Access 
to food, health and nutrition – once 
considered a fundamental human right – is 




Key Gender Equality Issues: 
 
•  With the development of so-called 
'functional foods' and 'nutraceuticals' 
the lines between food and medicine 
are blurring, further enticing food 
processors, agbiotech firms and drug 
companies to merge complementary 
interests in food, biotechnology and 
pharmaceuticals – what are the 
implications of these changes for 
women who are the primary consumers 
of such products? 
•  How does corporate concentration in 
the life industry affect the ability of 
women to resist? 
•  How does this concentration further 
polarize gender inequality in wealth and 
control and access to resources? 
•  How quickly is the gap widening as a 
result of the unchecked corporate 
power?  
•  How has public sector research been 
affected by the increase in corporate 
concentration and what impact has/will 
that have on women's health concerns? 
 
 
Research and Action: 
 
Research. 
•  Continue monitoring the Gene Giants 
to determine what direction the mergers 
are headed in. 
•  Examine the implications of the 
consolidation of the power of the Gene 
Giants on world food security and 
gender equality. 
•  Pay close attention to consolidations 
and mergers, for example, 
pharmaceutical companies are 
"vertically integrating" by taking over 
cancer research centres. In other 
words, who is paying the doctors who 
are prescribing the drugs. 
 
Action. 
•  The concentration of economic power 
in the hands of the Gene Giants, and 
the privatization of science and 
technology is not being systematically 
addressed by intergovernmental 
bodies. These issues should be at the 
top of the list for UNESCO. 
•  The Consultative Group on 
International Agricultural Research 
(CGIAR) – the world's largest 
international agricultural research 
network – runs the risk of irrevocably 
distorting its mandate to serve the 
world's poor farmers if it pursues the 
path of high-tech proprietary science in 
partnership with transnational Gene 
Giants. It must instead strengthen its 
research synergy with national 
programs and small farmers, including 
women farmers. 
•  The Food and Agriculture 
Organization (FAO), which 20 years 
ago held a major conference on 
agrarian reform and rural development, 
urgently needs to revisit and strengthen 




3. Terminator and Traitor Technology  
 
The infamous Terminator technology 
identified by RAFI in March 1998 is a 
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technique for genetically altering a plant so 
that the seeds it produces are sterile. It is 
a threat to agricultural biodiversity and the 
wellbeing of 1.4 billion rural people, most 
of them women, who depend on farm-
saved seed and local plant breeding. In 
January 1999 RAFI revealed that virtually 
all the Gene Giants (Monsanto, Novartis, 
Astra/Zeneca, DuPont, BASF, Rhone 
Poulenc) are working on their own genetic 
seed sterility patent claims. Over two 
dozen new patents reveal that engineered 
seed sterility is not an isolated research 
agenda, it's the Holy Grail of the 
agricultural biotechnology industry. As a 
result of public pressure, Monsanto has 
backed down from its position on the 
Terminator, however, the US government 
still holds the patent and refuses to agree 
not to use it. In fact, both the corporation, 
Delta and Pineland, and the USDA which 
jointly hold the patent are planning on 
going full speed ahead with this 
technology. The corporations which 
rejected Terminator, including Monsanto, 
have since morphed and spun off parts of 
their company, indicating how flimsy 
corporate promises can be in a climate of 
increased mergers and consolidations.  
 
The new generation of Terminator patents 
goes beyond the genetic neutering of 
crops. The patents reveal that companies 
are developing suicide seeds whose 
genetic traits can be turned on and off by 
an external chemical 'inducer' – mixed with 
the company's patented agrochemicals. In 
the not-so-distant future, we may see 
farmers planting seeds that will develop 
into productive (but sterile) crops only if 
sprayed with a carefully prescribed 
regimen that includes the company's 
proprietary pesticide, fertilizer or herbicide. 
The latest version of Monsanto's suicide 
seeds won't even germinate unless 
exposed to a special chemical, while 
Astra/ Zeneca's technologies outline how 
to engineer crops to become stunted or 
otherwise impaired if not regularly 
exposed to the company's chemicals. A 
Novartis patent (US 5,789,214) describes 
a process for chemically regulating a 
number of developmental processes in 
plants – such as germination, sprouting, 
flowering, fruit ripening, etc. The patent 
specifically mentions that the chemical 
regulator can be applied to plants in 
combination with a fertilizer or herbicide. 
RAFI calls it 'Traitor Technology.' (For 
more information and in-depth analysis, 
see RAFI Communiqué’s and press 
releases on Terminator and 'Traitor Tech,’ 
at http://www.rafi.org/ ).  
 
If companies can genetically program 
suicide seeds to perform only with the 
application of proprietary pesticide or 
fertilizer, it means they will dramatically 
increase sales of their patented 
agrochemicals and other proprietary 
inputs. Chemically-dependent suicide 
seeds are a dazzling technological 
achievement and a brilliant marketing 
strategy, but it's grim news for farmers, the 
environment and global food security.  
 
 
Key Gender Equality Issues 
 
•  Given that the majority of the world's 
farmers are women, and that the majority 
of the world's seed savers are also 
women, the issue is dramatically important 
to the well-being of women. The seeds are 
cultivated and exchanged in accordance 
with local needs and traditions. The loss of 
the potential characteristics of traditional 
varieties is a matter of survival for women 
who anyway cannot afford agricultural 
inputs. Most of the genetically modified 
varieties are for herbicide resistance, 
however, women in most of the world, 
particularly in the south perform the 
weeding activities, therefore the impacts 
on women of these varieties may be 
different in terms of labour. 
 
 





•  Further research to monitor 
Terminator and Traitor patents. 
•  Research on the potential socio-
economic and health effects of 
Terminator and Traitor on women. 
 
Action. 
•  The USDA must be pressured to 
reject the Terminator. 
•  Other national governments should 
take action at the WTO and elsewhere 
to reject Terminator and Traitor 
technologies on the basis of public 
morality. 
•  The Ad Hoc Working Group revising 
the Biological and Toxic Weapons 
convention should challenge the US 
research as a violation of Article One of 
the Protocol. 
•  The Convention on Biological 
Diversity must reverse its earlier 
decision allowing commercialization of 




4. A Related Risk: The Specter of 
Biological Warfare: 
 
Those of us who monitor biotechnology 
have paid too little attention to its military 
applications or its impact on democratic 
institutions. It is almost impossible to 
distinguish between peaceful, 
humanitarian uses of genetic research and 
the development of genetic weaponry. 
According to Dr. Pauline Lane of the 
University of East London, 'The line 
between medical research and warfare is 
often difficult to distinguish and [it] is a 
difficult area to monitor.' (Lane, 1999). A 
report released in January 1999 by the 
British Medical Association warns that 
biomedical research could be perverted to 
develop 'weapons which may become a 
major threat to the existence of Homo 
sapiens, and a development of 
biotechnology which perverts the 
humanitarian nature of biomedical 
science.' (Boseley, 1999. The report is 
entitled “Biotechnology, Weapons and 
Humanity,” by Prof. Malcolm Dando). 
 
Although RAFI first expressed concern 
over the likelihood of crop-targeted 
biological warfare at Bogève in 1987, our 
warnings elicited little interest until the 
Terminator patent was granted on March 
3rd, 1998. Suddenly, the potential to 
switch a suicide sequence in the seed on 
or off with a chemical promoter posed real 
concerns about economic sabotage – the 
real "eco"-terrorism. Would it be possible 
to insert the Terminator into seed exports 
and "bury" the trait for several generations 
of planting – or activate the trait through 
some remote command, chemical, or 
atmospheric condition? Such speculation 
seemed paranoid to many. However, the 
basis for concern was provided exactly 
one year to the day before the Terminator 
patent was allowed. On March 3rd, 1997, 
the South African Government, having 
admitted that the former apartheid regime 
had undertaken biowarfare research on 
both crops and ethnic populations, tabled 
a list of twenty crop pathogens it had 
investigated for possible weaponization. 
South Africa’s study was presented in 
Geneva to the ad hoc group of countries 
considering ways to strengthen biological 
warfare treaties. Then, in June, 1999, 
Scientific American published a stunning 
report by researchers at the University of 
Bradford in the UK that chronicled crop 
and livestock biowarfare research not only 
in South Africa but also in the USA, the 
UK, Russia, and Iraq. While some of the 
history dates back to World War II or the 
Vietnam War, the Iraqi work took place in 
the 1990s and included bioengineering of 
wheat pathogens that could have 
devastated food security in the Middle 
East. 
 
In November 1998, the London Sunday 
Times reported that scientists are 
attempting to engineer deadly biological 
organisms to produce 'ethno-bombs' that 
are capable of targeting human victims by 
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ethnic origin (Mahnaimi and. Colvin, 
1998). 
 
In early January 1999, Craig Venter of 
Celera Genomics told the American 
Association for the Advancement of 
Science that his company was on the 
threshold of constructing the world's first 
simple artificial life form, based on 300+ 
genes borrowed from a simple microbe. 
But Venter's team announced that it would 
halt further work because artificial 
organisms could be misused and become 
a template for deadly biological weapons 
in the hands of bioterrorists (Cohen, 
1999). 
 
In a world in which a handful of 
transnational enterprises dominate 
agricultural biotechnology; in a world 
where the Terminator is the platform 
technology upon which all new biotech 
breeding is undertaken; it is not difficult to 
believe that corporations or governments 
would use the technology to impose their 
will. A textiles trade dispute with South 
Asia, for example, could lead to the denial 
of a modified Roundup herbicide needed 
to ensure the rejuvenation of Monsanto’s 
cotton seeds containing the Terminator 
sequence. An agricultural dispute with 
France could lead to the same threat to 
France’s BT maize crop. Brazil’s soybean 
harvest – a major export competitor with 
U.S. farmers – would be rendered 
defenseless if the U.S. soybean breeder – 
or the US government – withheld the 
critical chemical protector. Eco-terrorism 
could prove to be far cheaper and much 
faster as a means of resolving trade 
disputes than WTO arbitration processes 
that are both lengthy and uncertain. In the 
1970s, a U.S. Secretary of Agriculture 
appointed by the same U.S. president who 
unilaterally dismantled biowarfare 
stockpiles nevertheless felt entitled to 
acknowledge that food is a political 
weapon. The policy continues. 
 
During the World Food Summit of 1996, 
the United States argued that the Right to 
Food should not become part of the final 
declaration. They eventually lost. 
However, the USA won its argument that 
sovereign states need not strive to be food 
self-sufficient as long as they were food 
self-reliant – that they could afford to buy 
the difference between national need and 
national production. Now, with Terminator 
Technology, food deficit countries are 
faced with the possibility that their national 
production will be wholly dependent upon 




Key Gender Equality Issues: 
 
•  How can women, particularly in 
developing countries, resist the danger 
of economic bio-terrorism? 
•  What are the differential impacts on 
women from such biological disasters? 
•  Women are less likely to grow cash 
crops than men in the developing 
world, how would this affect the impact 
on women of bioterrorism? Could there 
be a "feminist bomb?" (maybe there are 
characteristics that all feminists 
share??!?!) 
•  How might the right to be food self-
reliant rather than food self-sufficient 
have a differential impact on women? 
 
 
Research and Action: 
 
Research. 
•  Research on the questions identified 
above. 
•  Monitoring new traitor technologies. 
•  The connection between the military 
and the human diversity collections 
must also be monitored.  
 
Action. 
•  Action could be taken at the level of 
the 1972 Biological and Toxic Weapon 
Convention (BTWC), signed by 141 
countries, which bans the development 
and production of biological weapons. 
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The Convention is currently impossible 
to enforce because it lacks 
mechanisms for oversight and 
enforcement. In 1998 negotiators met 
in Geneva to strengthen the BTWC, but 
efforts to develop a legally-binding 
compliance protocol were stalled 
because pharmaceutical and biotech 
representatives voiced concern about 
industrial espionage and the theft of 
intellectual property (Anonymous, 
1998). A conference to review the 1972 
Convention is due in 2001, which might 
be an opportunity to raise the issues of 
the use of terminator and traitor 
technologies as biological weapons.
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About the Article 
Margrit Eichler takes the Canadian Biotechnology Strategy to task for its claim to support 
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products, and by the environmental and social relations of their production. “The 
problems that genetically modified foods are supposed to solve,” Eichler argues “are all 
due to a combination of economic, social, cultural and government factors, and need to 





In its CBS documents, the government 
repeatedly commits itself to sustainable 
development within the framework of its 
biotechnology strategy. For instance, it 
identifies advancing the principle of 
sustainable development as one of its 
roles (Canada 1998a:6, 8-11) and 
presents it as one of the prominent guiding 
ethical principles and values identified in 
other countries for biotechnologies (12). 
 
Sustainable development is defined as "a 
commitment to consider the needs of both 
present and future generations" (12). In 
the following, I will provide a short critique 
of this definition and propose an 
alternative one, and then apply it to the 
issue of biotechnology and food. 
 
 
Critique of the CBS definition of 
sustainable development 
 
A commitment "to consider" the needs of 
future generations is no guarantee that 
these needs will be respected. To be 
meaningful, there needs to a firm 
prohibition against engaging in practices 
that are likely to harm future generations 
or that would lead to passing on fewer 
natural resources than are available to this 
generation. 
 
An undifferentiated statement concerning 
"generations" makes no acknowledgement 
of different access to various resources 
within a generation (present or future). At 
present, the world has ample resources to 
satisfy the needs (although not the wants) 
of all humans on earth. Canada, in 
particular, has ample resources to satisfy 
the needs of all Canadians. Nevertheless, 
a larger number than ever before lack the 
necessities of life at present. This is 
relevant at two levels: for one, unless 
there is perceived social justice at present, 
people will be unwilling to give up anything 
for future generations. For the other, a 
society that fails to distribute resources 
equitably for people who are currently 
alive will have no yardsticks with which to 
determine what is equitable between 
generations. Indeed, our reckless 
utilization of non-renewable resources 
demonstrates that we are incapable of 
preserving these resources, and our 
utilization of theoretically renewable 
resources (fish, forests, water, high quality 
farm land, etc.) demonstrates that we 
deplete them not only for future 
generations but even for those alive now. 
 
 
Alternative definition of sustainable 
development 
 
Sustainable development can be 
defined as a condition in which all 
human imperatives, and particularly the 
economic, social, cultural and 
governance imperatives, are met –
subject to the constraints imposed by 
the ecological imperative to remain 
within the planetary bio-physical 
carrying capacity. 
 
We can understand: 
 
•  the economic imperative as securing an 
adequate material standard of living for all; 
 
•  the social imperative as the creation or 
maintenance of social structures that are 
beneficial to all those involved; 
 
•  the cultural imperative as a cultural and 
spiritual base that acknowledges our 
dependence on the ecosystem, our 
interdependence with other humans, 
transcendence of material accumulation 
as the road to human fulfillment and 
commitment to non-violence; and 
 
•  the governing or decision-making 
imperative as an effective and legitimate 
decision-making structure capable of 
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implementing policies to fulfill the other 
imperatives (see Eichler 1999). 
 
We now have a set of criteria that we can 
apply to biotechnology. If a particular 
policy moves us closer to meeting these 
imperatives, while remaining within the 
bio-physical carrying capacity of the earth, 
these technologies are either sustainable, 
or at least more sustainable than present 
alternatives. Either condition must be seen 
as positive. If a policy fails to move us 




Applying the sustainability criterion to 
bioengineered food 
 
Bioengineered food is put forward in the 
CBS as a means to protect health and 
prevent disease. The following benefits 
are detailed (Canada 1998b:6-7): 
 
• it will enable us to produce more 
healthful food with higher 
nutritional quality; 
 
• it can produce novel, desirable 
nutrient and medicinal contents in 
food that will virtually eliminate 
human and animal nutritional 
deficiencies; 
 
• it will improve the availability of 
therapeutic products; 
 
• it will provide an inexpensive and 
abundant supply of compounds 
with potential health benefits, such 
as fructans, which are good for 
digestion and can be used as low-
calorie fat substitutes; 
 
• it will prevent diseases by 
enhancing the levels of those 
compounds in food that are known 
to have beneficial physiological 
effects, such as carotenoids in 
tomatoes and peppers that have 
anti-cancer properties or onions 
with elevated levels of quercetin-a 
(a compound that can prevent 
stomach cancer); 
 
• it facilitates the development of 
new foods for Canadians who 
suffer from food intolerance 
disorders, e.g. new plants or 
cereals that are similar to wheat 
but non-toxic to persons with 
coeliac disease. 
 
There are apparently no negative effects 
that merit mention. 
 
Let us compare this list of benefits with the 
statements made in a recent World Health 
Organization report (Daar and Mattei 
1999:89-96). Here we find some 
discussion of potential problems with 
bioengineered food. Such problems 
include: 
 
• bioengineered food may result in 
unpredictable allergies to proteins 
not usually found in food products, 
but now present as a result of 
inserted genes; 
• many food products are being 
introduced stealthily. "For example 
60% of consumer food products 
(margarine, chocolate bars, baby 
food) contains soybean material, 
much of which is now sold, 
sometimes without labeling, as a 
mixture of unmodified and 
genetically modified soybeans” 
(94); 
 
• there are reports of lapses in 
observing guidelines/ laws 
regarding agricultural release into 
the environment; 
 
• there are potential dangers of 
conflict between nations in the future 
with respect to issues of patents, "bio-
piracy" and the sharing of the fruits of 
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research. "Thus, it seems, there are 
enormous potential, perceived, and 
unquantifiable risks." (94) 
 
In other words, the World Health 
Organization identifies both potential 
health risks, as well as other problems, 
with genetically modified foods. 
 
Taking a step backward, we need to ask 
ourselves whether the problems that bio-
engineered foods are supposed to 
address are identified appropriately. In 
general, the most healthful food is locally 
produced, and fresh. There is enough food 
available in the world (although it is not 
clear whether in Canada) to feed all. 
Canada imports a lot of food, but that is 
tied up with the demise of local food 
production, and the desire for exotic foods, 
rather than an incapacity, in principle, to 
feed ourselves. Canada’s – as well as the 
world’s – food needs are thus an 
economic, social and political (and partially 
cultural) problem, rather than a 
technological one. 
 
While the rhetoric employed often sounds 
noble – e.g. to alleviate or even eradicate 
hunger in the world – the driving force 
behind all of these efforts is profit. Hence 
the major effort is not directed towards 
developing healthier foods for consumers, 
but in genetically engineering crops to 
make them pesticide tolerant, improve 
appearance, allow for longer shelf life and 
allow for long distance transportation. All 
of these are practices which directly 
increase our already very high level of 
unsustainability, by increasing pesticides – 
a poison in nature – over organic methods 
of farming, by favouring agribusiness over 
local production. 
 
Such practices are at least partially 
responsible for creating some of the 
problems bioengineered foods are 
proposed to solve. This is particularly the 
case for food intolerance. We have 
witnessed a huge increase in immune 
system deficiencies in the last two 
decades, of which food allergies are only 
one. One might argue that the pollution in 
our environment, which includes large use 
of pesticides, is a cause of such 
breakdowns. It seems ironic, then, to 
propose as a cure more of the same. 
 
I would argue that the problems that 
genetically modified foods are supposed to 
solve are all due to a combination of 
economic, social, cultural and government 
factors, and need to be solved at that 
level. 
 
Looking briefly at the four imperatives in 
my definition of sustainable development, 
there is a great likelihood that genetically 
modified crops will worsen the situation 
both for family farms in Canada and for 
third world farmers. GM crops will make 
Canada even more dependent on large-
scale agribusiness and further reduce 
local autonomy over our food supply. 
Agricultural biotechnology therefore runs 
counter to the economic imperative as well 
as the social imperative. With respect to 
the cultural imperative, open-air planting 
(of GM crops) is disrespectful, in a 
multitude of ways, toward the ecosystem – 
denying our ultimate dependence upon it. 
There are already documented cases of 
unintended cross-pollination between 
genetically modified and non-GM crops 
under open-air planting conditions. 
Several species of insects are threatened 
by the genetically modified crops (the 
Monarch butterfly has received some 
public attention recently). There is no long-
term, cautious testing of the potential long-
term impact of GM crops on the 
ecosystem, as would certainly be 
appropriate, given the potentially very 
serious consequences (cf. Weizacker 
1995). Just as antibiotics resulted in so-
called "superbugs" which do not respond 
to these same antibiotics, so the profligate 
use of pesticides may result in super-pests 
as well as weeds which are hardier than 
other crops – to name just one of the 
many dangers. With respect to the 
government imperative, our governments 
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are giving up more and more of their 
decision-making to corporate entities as 
they push biotechnology as a prime 
industrial growth strategy. 
 
Looking at this selection of factors, then, 
we must conclude that contrary to the 
claims made in the CBS documents 
genetically altered food may have potential 
health hazards, and that it moves us in a 
direction of even greater unsustainability.
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The link between genetics and 
privatization is not intuitively obvious. 
Genetics is a branch of biology that deals 
with the heredity and variation of 
organisms, and understands such 
variation to be located in one’s genes.1 
Privatization refers to the process of state 
restructuring attendant on the economic 
and political forces set off by 
globalization.2 Contrasted in this way, 
genetics is aligned with the realm of the 
natural, the empirically verifiable and the 
material essence of the individual 
organism. Privatization stands on the 
opposite side of the nature/culture divide. 
It is a politically inspired project; the 
creation of human design. However, as I 
suggest in this paper, there is a significant 
affinity between the new genetics and the 
recent projects of privatization and neo-
liberalism. 
 
Privatization is largely a political and 
economic phenomenon – entailing a shift 
in state form from Keynesianism to neo-
                                               
1.Victor McKusick (1993:2351), whose 
catalogue of human genetic conditions is a 
classic in the field, defines “genetics” in the 
following way: 
[T]he science of biological variation; human 
genetics: the science of biological variation 
in humans; medical genetics: the science of 
biological variation as it relates to health 
and disease; and clinical genetics: the part 
of medical genetics concerned with health 
and disease in individuals and their families 
or the science and practice (art) of 
diagnosis, prevention, and management of 
genetic disorders. 
2 For the past three years I have been part of a 
SSHRC funded collaborative research project 
– based at Osgoode Hall Law School – on 
Women, Law and the Challenge of 
Privatization. This paper emanates from my 
part in that project – a study of genetics in a 
post-Keynesian era – and is adapted from a 
presentation made before the Feminist Legal 
Analysis Section of the Canadian Bar 
Association, March 25, 2000. 
liberalism, as well as a shift in governing 
practices. It derives its economic 
momentum from the notion that the 
Canadian state must reduce the fiscal 
burden of social welfare programmes 
which have become too costly in the 
globalized market economy, while 
simultaneously creating the conditions for 
capital accumulation. In one sense, 
privatization refers to the effort to reduce 
public debt and alleviate the pressures on 
public finance by eliminating, scaling back 
or transferring to the private realm of the 
market or the family, services that were 
formerly provided by the welfare state. 
Privatization also refers to a more far-
reaching restructuring of social and 
economic institutions, and aims at the 
actual promotion of private sector interests 
in the economy as a means of meeting 
global competition. In this sense, 
privatization refers to an active and 
conscious restructuring of state institutions 
to favour the market and private 
investment. Increasingly, the public sphere 
embraces as its governing logic market 
rationales and practices. As Janine Brodie 
(1995:6) suggests: “governments are 
effectively acting as the midwives of 
globalization, transforming the state 
apparatus, development strategies and 
regulations to respond to the ‘perceived 
exigencies’ of a global economy.” 
 
At a discursive level, privatization is also 
about privacy, individual choice and self-
reliance. One of its core ideas is that the 
preferred mode of social arrangement is 
one that allows individuals to control their 
lives as they see fit, without interference 
by others and government. It is a view 
about economic arrangements and 
normative social relations that distrusts 
collective solutions to problems, indeed 
imagines problems as individualized and, 
therefore, outside the purview of collective 
response. Thus, within neo-liberalism, the 
best form of regulation is one which is self-
governing, where the governance of 
individual subjects promotes processes of 
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self-regulation and provides the 
circumstances under which people may 
effectively govern themselves. 
 
My original entry into thinking about 
privatization and state re-structuring in the 
context of globalization was through the 
doorway of genetic and reproductive 
technologies – but, primarily genetic 
technologies. When I first began thinking 
about this issue, I was principally 
interested in examining how genetic 
technologies and therapies – the 
anticipated fruits of the much celebrated 
and publicly-funded international effort to 
map and sequence the human genome – 
were going to be configured in the post-
Keynesian, restructured, neo-liberal state. 
If genetic services were truly the public 
goods they were promised to be, how 
would they be allocated/ accessible in a 
health care context where evidence-based 
medicine, cost containment, 
individual/consumer choice and 
restructuring were the mantras of the day? 
At the same time, I was also concerned 
about, and interested in, how the 
information that is the product of genetic 
testing and screening was going to be 
used in the context of the leaner, meaner 
state. If genetic diagnostics are capable of 
producing information about the health 
risks and genetic characteristics or 
capacities of the individual tested – or their 
biological family members, fetus or 
possible progeny – will this information be 
used in invidious ways to mark certain 
citizens or prospective citizens, or their 
characteristics, as deviant, abnormal, 
socially undesirable or risky? Is there a 
sense in which the new genetic 
technologies are being used, or are 
capable of being used, as a means of 
literally creating the responsible, 
autonomous, citizen of neo-liberalism – 
that citizen who makes no legitimate 
claims on the state but rather, who freely 
exercises their capacity for choice and 
manages their own self care? 
 
The ways in which specific genetic 
technologies serve to restructure, and 
privatize the relationship between the 
citizen and her/his health have been the 
subject of considerable feminist 
scholarship in recent years. These are 
certainly areas of concern. Yet, more is at 
work at the level of state practices and 
legislation in relation to the new genetics. 
In Canada, genetic technology as a whole 
is being actively promoted by some 
branches of the state, in particular, 
Industry Canada. At the same time, Health 
Canada, the branch of government which 
indeed has the mandate to regulate the 
social, legal and health consequences of 
the new genetic technologies, lags further 
and further behind. The Canadian 
Biotechnology Strategy and the 
reorganization of the federal Health 
Protection Branch point to a shift in state 
policy from social protection to the 
encouragement of capital accumulation. 
This form of privatization is paralleled by a 
move to the individual as the site of 
governance through the self regulation of 
genetic risk. 
 
The advent of the new genetic 
technologies and the policies of 
privatization corresponding to globalization 
are not independent of one another. The 
pattern emerges of an interdependent 
process whereby biotechnology is at once 
promoted by the state as the high 
technology answer to the hollowing-out 
effects of globalization, and justified on the 
basis of its contribution to health. The 
changing understanding of health and 
health care brought about by genetic 
technologies in the post-Keynesian state 
connects the fostering of biotechnology as 
a form of industrial production, and the 
privileging of individual responsibility and 
risk management in the realm of health. In 
this sense, the role of biological 
technologies may be seen as both 
symptomatic and as an important 
constitutive factor in the transformation of 





The Canadian Biotechnology Strategy 
 
The development of the Canadian 
Biotechnology Strategy (CBS) is a key 
component of an industrial strategy aimed 
at reaping the benefits of a “knowledge 
based economy” to meet the challenges of 
globalization. It is a way of capitalizing on 
genetic information. It is worth noting that 
the Organization of Economic Cooperation 
and Development (OECD) defines 
“knowledge” in the “knowledge based 
economy” as, “the acquisition of 
intellectual property through learning or 
research” (OECD 1989). It is important to 
recognize that the appropriation of genetic 
information as intellectual property is an 
integral aspect of the knowledge based 
economy in general and the Canadian 
Biotechnology Strategy in particular. 
 
The “vision statement” of the CBS was 
formulated as,  
 
To enhance the quality of life of 
Canadians in terms of health, safety, 
the environment, and social and 
economic development by positioning 
Canada as a responsible world leader 
in biotechnology (CBS 1998a:8). 
 
 
The CBS and Health 
 
According to the federal government, 
“[B]iotechnology’s greatest impact both in 
Canada and world wide has been in the 
health field. More than 90 percent of the 
advanced biotechnology products on the 
world market are related to health” (CBS 
1998b:1) Projections are that health 
products will continue to dominate the 
biotechnology arena. It is significant that 
the lead Department for the co-ordination 
and development of the Canadian 
Biotechnology Strategy is Industry Canada 
with the involvement of six other 
departments, including Health. Moreover, 
the strategy seems to be one designed to 
accommodate the ethos of the 
marketplace and not that of the health 
care system. While the CBS is promoted 
as a strategy to develop the tools to 
improve the health and well being of 
Canadians through “more reliable health 
surveillance, disease diagnoses and 
therapies,”(CBS 1998b:3) its principal goal 
is to promote industrial activity and 
economic returns “to position Canada as a 
responsible world leader in the 
development and sale of biotechnology 
products and services” (CBS 1998c:2). 
 
 
Genetics and Changing Definitions of 
Health 
 
There cannot be an industrial strategy 
without a market. In the new biotech age, 
that market is intended to be primarily in 
health products and processes. However, 
in the creation of that market, our very 
definition and understanding of health is 
transformed. In adopting a new genetic 
understanding of health, we are changing 
our definitions of health and disease and 
creating entirely new categories of 
embodied individual health risk. Genetic 
technologies constitute a significant 
departure from conventional medical 
technologies in that these new 
technologies do not, for the most part, 
treat an existing condition or diagnose a 
disease in progress. Genetic testing often 
has the effect of identifying individuals with 
genetic susceptibilities to particular 
diseases, but who are otherwise well, as 
unhealthy, or at least, to mark their health 
as suspect. Thus, the alleged predictive 
ability of genetic testing is problematic as it 
takes for granted that awareness of one’s 
personal risk status, as defined by genetic 
testing, is important to the individual, and 
that awareness will encourage behavioural 
changes such as to prevent the future 
development of the predicted condition. By 
creating the category and increasing 
awareness of genetic risk, the 
biotechnology industry creates a market 
for its products – genetic tests – which the 
responsible health care consumer feels 
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compelled to use in order to determine 
their own risk status or that of their future 
offspring. A prime example of this dynamic 
was at work in the case of BRCA1&2 
testing with the attendant controversy and 
litigation about public funding for private 
testing in Ontario. 
 
 
The Health Protection Branch of Health 
Canada and its “Transition” Program 
 
Nowhere has the shift in governmental 
roles been so apparent as in the recently 
proposed transformations of the Health 
Protection Branch within Health Canada. It 
is this branch which is responsible for, 
among other things, regulating the safety 
of drugs and devices including those 
related to the new genetic technologies. 
Arguing that the new reproductive, and 
especially the new genetic, technologies 
do not correspond physically or 
conceptually to the medical devices and 
pharmaceuticals traditionally licensed and 
regulated by the Health Protection Branch, 
Health Canada has suggested that its 
regulatory and legislative framework is 
inadequate, and launched a so-called 
“transition” program. This initiative to 
renew Health Canada’s mandate of health 
protection corresponds to the restructuring 
of the Canadian state in a climate of 
privatization. Not surprisingly, the 
transition program includes strategies to 
externalize the costs of regulation by 
enhancing cost-recovery and the 
development of stronger relations with 
industry. The effort to externalize the costs 
of regulation corresponds with a reduction 
of in-house research and scientific activity. 
One of the central safeguards proposed 
under the HPB Transition Program is to 
pass legislation making it illegal for a 
manufacturer to place a dangerous 
product on the marketplace. Such 
legislation is expected to force 
manufacturers to be more explicitly 
responsible for ensuring product safety 
due to enhanced and more rigorous 
liability. As the law now stands however, it 
is the Federal government, and ultimately 
the Minister of Health, who is responsible 
for ensuring product safety before 
approving a product for release onto the 
market. Currently, the government is 
primarily accountable to the public for 
safety and the protection of public health. 
The proposed legislation alters this 
situation by shifting responsibility from the 
government to private industry. Moreover, 
it creates a situation where instead of 
Health Canada being primarily responsible 
for ensuring product safety prior to public 
exposure, industry carries this 
responsibility. Health Canada’s 
interventions are activated after a danger 
has been detected through market use 
(i.e. protection through the threat of a 
harsh punishment, instead of protection by 
preventing product entry onto the market 
in the first place). 
 
Health Canada acknowledges that its 
regulatory system is shifting away from a 
model where assessments are made in-
house towards one, which it calls a 
“networked” model, including universities 
and industry. This new model is defended 
as more consistent with access to the best 
scientific knowledge and expertise, 
although the Health Protection Branch 
transition team is apparently still grappling 
with the problems of accountability raised 
by this model. I suggest that this new 
model is consistent with the relativized 
position of the post-Keynesian state, 
testifying to the contradictions of the 
state’s role in health protection versus 
industrial promotion. To illustrate, one of 
the goals of the transition process is to 
promote “efficiency” in speeding up 
regulatory approvals. Speedier 
introduction of new pharmaceuticals is 
obviously in the interests of industry, but 
glosses over the potential tradeoffs 
between accelerated introduction of new 
products and the assessment of possible 
risks. The changing emphasis in health 
protection is consistent with the goals 
articulated in the Canadian Biotechnology 
Strategy. Increasingly, the Health 
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Protection branch will depend on its clients 
to achieve the regulatory purpose of its 
mandate. Diffusion of accountability and 
responsibility forms its own kind of 
“privatization”. 
 
There is no evidence that Health Canada 
or the federal government seeks to 
abandon its mandate in health protection, 
or that it is blind to the ethical concerns 
which have been raised. Instead, the 
renewal of the mandate for health 
protection occurs in a context where the 
role and meaning of the state is shifting, 
and where the autonomy of the Canadian 
state in relation to international trade 
agreements, and the demands of 
multinational corporations, is shrinking. 
The implementation of the privatization 
agenda is not therefore bringing about the 
deregulation of health, rather the manner 
in which health is being regulated is 
changing. Health is increasingly being 
regulated as a commodity rather than as a 
public good, and health care as a business 
rather than as a public service. In this 
context, it is interesting to note that one of 
the proposed name changes of the Health 
Protection Branch was to call it the 
“Management of Risks to Health” branch. 
No longer is the federal government to be 
involved in protecting the health of society 
from unsafe pharmaceuticals and medical 
devices, but it is positioning itself to 
manage the risk inherent in such 
commodities and mediate between the 
interests of industry and the citizen public. 
From a central concern with health care 
provision and public safety, the state has 
now shifted to a principle concern with the 




The Regulation of Genetic and 
Reproductive Technologies 
 
Despite the fact that the Royal 
Commission on New Reproductive 
Technologies reported more than seven 
years ago (1993), no new legislation has 
been passed regulating the health and 
social implications of these technologies 
despite a significant amount of public 
support for such regulation. The federal 
government did introduce one piece of 
legislation, Bill C47, which died on the 
order paper of the last Parliament, and 
one discussion paper with legislation 
promised before the Fall of 2000. The 
important fact, for my purposes here, is 
not what is in the proposed legislation but 
the discrepancy between the urgency with 
which the Canadian Biotechnology 
Strategy and the restructuring of the 
Health Protection Branch have been 
pursued, and the hesitancy and caution 
with respect to the introduction of 
legislation to regulate the health effects of 
the new reproductive and genetic 
technologies. In the climate of state 
restructuring and privatization, study of the 
new genetics reveals how the priorities of 
the state in relation to health have shifted 
from protecting the public good to 
promoting the interests of industry, and 
creating the conditions for health to be a 




Conclusion: About New Biotechnology, 
Accumulation, The Discursive Shift 
around Health, The Role of the State 
and Law. 
 
I have arrived at two major conclusions 
with respect to the introduction of genetic 
technologies and the ways in which these 
are regulated in Canada. The first 
conclusion – little discussed in this paper, 
but discussed more widely in feminist 
monographs3 – concerns the ways in 
which the market for genetic technology 
shapes our understanding of health and 
                                               
3 Both areas of privatization are discussed and 
analysed, in depth, within my book chapter, 
“Private Bodies, Public Parts: Genetics in a 
Post-Keynesian Era,” in the forthcoming book 
edited by Brenda Cossman and Judy Fudge. 
(Toronto: University of Toronto Press, 2001). 
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risks to health. With genetic tests 
marketed as a kind of health-risk kit, 
individuals are being called upon to 
undertake self-surveillance in the name of 
reducing the burden of disease on 
themselves and on society as a whole. 
Thus, genetic testing and genetic 
understandings of health, are seen as a 
means to create the ideal citizen of the 
post-Keynesian order – one vigilant about 
her/his economic burden or contribution to 
society and willing to discipline themselves 
or their procreative activity in the name of 
maintaining healthy and productive 
citizens. It is particularly through the 
genetic surveillance of potential offspring 
that women become the gatekeepers of 
the new social order, with genetic 
technology introducing a new gendered 
division of labour with respect to 
maintaining a disciplined order of 
productive citizens. 
 
The second conclusion has to do with the 
nature of regulation and law in the post-
Keynesian era of the new genetics. Here, 
the problem or phenomenon we witness is 
not simply “deregulation” in the service of 
the market, but rather a different kind of 
regulation and a shift in the legal paradigm 
of regulation. Instead of deregulation, we 
find a re-regulation intended to make 
possible the greater appropriation of 
intellectual property and its capitalization. 
What the Canadian Biotechnology 
Strategy, the restructuring of the Health 
Protection Branch and the paralysis with 
respect to legislation on reproductive and 
genetic technologies illustrate is not just 
the promotion of the biotechnology 
industry, but a redefinition of the public 
interest. The state no longer sees itself as 
defending the public interest against the 
private interest of private actors, but sees 
itself as promoting the interests of private 
actors as the potential benefactors of the 
public through the production of health 
commodities. In so doing, however, the 
state is also changing the nature of 
regulation. In moving away from defining 
and representing the public interest, and 
towards a model of product liability and 
intellectual property, the state is shifting 
the arena of adjudication into the area of 
commercial law and away from public and 
constitutional law. This entails not only a 
different set of concerns, expertise and 
evidentiary rules but also a shift into a 
social arena with its own gendered 
hierarchy. 
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In the document, The 1998 Canadian 
Biotechnology Strategy: An Ongoing 
Renewal Process, the Canadian 
government outlines how best to market 
biotechnologies. Indeed, this is the major 
aim of this report. This becomes clear 
through a number of statements, such as 
“The Government of Canada has 
consistently expressed its support for 
biotechnology as a priority” or the 
government’s position that biotechnologies 
“offer significant economic benefits, 
particularly in exports and job creation” 
and to “safeguard the environment.” 
 
Nowhere in this document are the 
concerns expressed by independent 
women, farmers, scientists and other 
concerned groups. Instead, the 
government presents its public relations 
strategy designed to pacify people in 
Canada into accepting the legitimacy of 
the biotechnology industries’ plan to 
expand and make greater profits. Although 
the biotechnology industry is engaged in a 
wide array of initiatives in further 
technology development, including 
reproductive and genetic technologies, 
pharmaceutical products and a number of 
key areas in agriculture, it is the latter that 
I will concentrate on. Indeed, the 
biotechnology industries’ incursion into 
agriculture has been one of the main 
rallying points upon which groups in the 
global South and North have galvanized 
people’s opposition. This is not a 
coincidence. 
 
It may be difficult for those of us in the 
North who, when we think of farming, 
picture the gigantic mono-cropped fields of 
the North American prairies, but 80% of 
the world’s farmers continue to be 
engaged in small-scale farming. Nowhere 
in the world have industrial agricultural 
methods become more entrenched than in 
North America. There are still small-scale 
farmers left in Europe. And, of course, 
most of the farmers of the global South 
continue to be small-scale farmers. Thus, 
it is no coincidence that the greatest 
struggles against the biotechnology 
industries have occurred in the South and, 
to a lesser extent, in Europe, and most of 
them have been organized by or through 
small-scale farmers and organizations run 
by them or working with them in solidarity. 
Nor is it a coincidence that here, in North 
America, we are just beginning to organize 
ourselves effectively on the issue of 
biotechnologies and agriculture. 
 
The furor over the “life sciences” foray into 
agriculture rests on the basic fact that the 
biotechnology corporations have arrived at 
new technologies of colonialism. That is, 
they have devised new means by which to 
continue to dispossess people of their 
ability to live outside of a capitalist political 
economy – new processes by which to 
enslave them. Let us not forget that the 
social process by which people are 
transformed into workers continues to 
mark the expansion of capitalism. The 
wide-scale destruction of the rural 
economy in the South can be said to be 
the major effect of this latest period of 
“globalization.” It is the movement of 
women and men from a devastated and 
privatized countryside into the “free export 
zones” throughout the South (and 
increasingly the North) that has allowed for 
the creation of a “global assembly line.” 
 
One of the key technologies of colonialism 
today is the patenting of life forms. 
Through this process, biotechnology 
corporations are engaged in a wide-scale 
appropriation of common property. As 
Vandana Shiva rightly points out, 
patenting is the late 20th century form of 
“enclosing the commons” (1997). As in the 
past, this theft is ideologically concealed 
through claims of the sanctity of private 
property. This argument is apparently 
legitimate for those whose consciousness 
has been wholly shaped through 
acceptance of white, capitalist 
patriarchies. In the global South, at least, it 
is women who produce the majority of 
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their own, their family’s and their 
community’s everyday needs. It is women 
who, year after year, save the seeds 
necessary for survival. Indeed, women 
everywhere have created elaborate, 
community-strengthening, ways to honour 
their productivity and the productivity of 
nature. By patenting their very means of 
survival and saying that it is the private 
property of the owners of some 
transnational corporation that is usually 
located half-way around the world, the 
biotechnology corporations – and the 
governments and international governing 
institutions supporting them – are ensuring 
the destruction of the rural economy and 
its replacement with industrial agriculture 
on farms owned by fewer and fewer 
people. This is the goal. It achieves two 
things: the replacement of small-scale, 
ecologically-sound agriculture with 
industrial agriculture and, two, the creation 
of a working class dependent solely on 
capitalists for their livelihood. This goal is 
currently being achieved in many ways. 
 
The main goal of the promoters of 
industrial agriculture has always been to 
prevent farmers from saving their seeds. 
This is now possible through 
biotechnologies, such as the “Terminator” 
technology, the “Traitor” technology and, 
ultimately (and even without these), the 
patenting of life forms. Of course, it is not 
the technologies alone that are 
responsible. They are only the mechanism 
of ruling, not the rulers themselves. What 
makes these technologies possible and 
perhaps more importantly, actionable 
today, are social relations based on 
unequal exchange between the North and 
the South, racism, sexism and capitalist 
political economies. 
 
Thus, it comes as no surprise that one of 
the major selling points of the new “life 
sciences” in regard to the “advantages” of 
biotechnologies is its promise to “feed the 
growing world’s population.” In this one 
statement is condensed the entire gambit 
of white, capitalist patriarchy. In this one 
statement it is assumed that 
 
a) population growth results from ‘Third 
World’ women having “too many” 
babies; 
b) people starve because of this and; 
c) ‘Third World’ peoples need the help 
of ‘First World’ people and their and 
“advanced” technologies. 
 
Of course, embedded within this discourse 
is the notion that it is ‘backwards’ to be a 
small-scale farmer, that the destruction of 
the rural economy is a “good” thing and 
that finding an industrial job is the goal of 
the world’s people. Indeed, this is the 
textbook definition of a “modern” person in 
the “development” literature. These 
ideological notions contribute to the 
expansion of white, capitalist patriarchies 
that make women the dependents of men, 
make people the dependents of capitalists 
and make the South dependent on the 
North. Also hidden from view is that in 
reality it is men who exploit the wealth of 
women’s labour, it is the capitalists who 
steal the fruits of workers’ labour and it is 
the North whose ravenous consumption 
practices are dependent on the theft of 
Southern wealth. 
 
The Canadian state is a wholesale 
supporter of continuing to base social 
relations throughout the world on this 
exploitative model. Indeed, this 
government is acting according to a script 
that reads as if it was written by people in 
biotechnology industries. For example, the 
government says that “biotechnology has 
the potential to increase…sustainable 
development” (Canada, 1998:5). Contrary 
to growing evidence, but in a repetition of 
the company line, the government says 
that genetically engineered (GE) crops 
allow farmers to apply fewer chemical 
pesticides and herbicides. 
 
This government also wants Canada to 
“have a prominent role in the emerging 
science of genomics, including genome 
 
 116 
mapping and gene sequence 
technologies” (Canada, 1998:19). They 
further add that they want to make 
“Canada’s international development 
assistance policies and programs” fit into 
the CBS vision and goals, “particularly with 
regard to the developing countries to 
which Canada exports or is likely to 
export” (Canada, 1998:16). And, the 
government states that “modernizing 
Canada’s intellectual property laws and 
ensuring their effective administration 
would significantly improve the domestic 
investment climate in biotechnology” 
(Canada, 1998:16). In other words, they 
want to make sure that current patent laws 
in Canada are in line with WTO (World 
Trade Organization) guidelines that 
sanction life patents. 
 
Importantly, throughout this document is 
the government’s concern that people (re-
defined as consumers) accept and be 
confident in and comfortable with new 
genetic technologies. In particular, the 
government is concerned with people’s 
fears of eating genetically engineered 
foods. For instance the government’s own 
polls show that a majority want to see 
labeling of such foods so they can 
distinguish between them and untampered 
foods. Thus, they stress that “the public 
wants assurance that biotechnology 
products and services are safe for 
humans, animals and the environment” 
(p.14). Not coincidentally, the Canadian 
government has gone into a 
communications venture with the 
biotechnology industry in a new media 
institution designed to convince people 
that there are indeed benefits to the 
consumption of genetically engineered 
foods and that this is safe. I, like many of 
you, have been subjected to corporate 
propaganda being voiced as if it was a 
public health message (e.g. GE is nothing 
new. Organically making cheese is a form 
of GE. So is the process of making yeast, 
beer, etcetera. Genetically adding alien 
nutrients is sound science and good public 
health policy, ad nauseum). 
 
While the government recognizes that a 
much more effective sell job is needed 
before people will happily eat genetically 
engineered foods, it argues that the best 
way to sell biotechnologies is to link them 
with community health concerns. In the 
Canadian Biotechnology Strategy 
document, then, the government states 
that “people are more likely to accept 
applications such as new drug therapies 
that clearly address health needs, and are 
less likely to accept applications that offer 
less obvious benefits.” Is it a coincidence, 
then, that we have been seeing huge 
spreads within the Globe and Mail (just to 
use one example) on the health benefits of 
patenting and biotechnologies? 
 
Another one of the ways the government 
wants to secure public approval for 
biotechnologies is to have so-called public 
consultations on what are called the “core 
values” of an ethics framework. This is 
especially troublesome since the 
government makes it very clear that they 
wish to “enhance the quality of life of 
Canadians in terms of health, safety, the 
environment and social and economic 
development by positioning Canada as a 
responsible world leader in biotechnology” 
(Canada, 1998:8). Obviously, this set up 
already precludes a real debate since it 
takes the application of biotechnologies for 
granted. 
 
I believe that we need to take a very 
strong position against attempts to co-opt 
the women’s movement into participating 
in the establishment of the so-called 
ethical “core values” on the use 
biotechnologies. It is simply impossible to 
simultaneously act ethically while working 
to enclose people’s common spaces, 
destroy people’s ability to be self-
determinant, concentrate the world food 
supply in a small number of hands, cross-
pollinate GE crops with organic ones, etc. 
It is the practices of the biotechnology 
corporations that are unethical. We cannot 
allow ourselves to separate their actions 
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from an abstract, philosophical statement 
on the “ethical” standards of 
biotechnologies. 
 
First, this method of securing “approval” is 
manipulative as it only gets to the lowest 
common denominator. We have seen this 
occur through other government 
consultations, namely “public 
consultations” on immigration policy, 
citizenship policy, social welfare policy, 
poverty, etc. whereby the concerns of 
feminists have been pitted against the 
concerns of neo-Nazis, corporate lobbyists 
and anti-feminists and the government has 
been able to slide up the middle (which 
itself has shifted much to the Right) and 
act as the reasonable arbitrator of “public” 
interests. 
 
Secondly, the government has provided a 
built in role for biotech corps by saying that 
one of their key goals is commercialization 
of biotech and then stating that it is the 
private sector that has the “lead 
responsibility” for this (Canada, 1998:10). 
Moreover, would any of us seriously 
consider that the Canadian government is 
going to uphold whatever “ethical” 
standards we might like to see given that 
commercialization of new biotechnologies 
is the government’s biggest priority? 
 
I believe that we need to radicalize our 
message in total opposition to the 
biotechnology industries. In this regard, let 
me repeat the position of the Basmati 
Action Group (of which I’m a founding 
member). We support the outright banning 
of GE crops being grown and sold in 
Canada. This is the only ethical response 
by those living in a country that is a major 
producer and exporter of GE foods. 
 
We believe that by simply labeling GE 
foods, we fail to act in solidarity with those 
people who have little choice in what they 
eat, those people whose main source of 
food is not from the grocery store and 
those farmers around the world who are 
trying to maintain GE-free crops. By 
saying that we will settle for labeling of GE 
foods, we are buying into the liberal-choice 
model that tells us that those who eat 
chemically-infested foods are “choosing” 
to do so, that those who eat food that is 
GE (after it has been labeled as such) are 
also “choosing” to do so. This takes the 
heat off the people who are supplying us 
with toxic food. 
 
By settling for labeling of GE foods, we are 
saying that we don’t value the 
Precautionary Principle. We say that by 
allowing consumers the “choice” to buy 
GE foods or not, that we are ready to 
leave it to the market to determine whether 
this food is safe or not. Finally, the issue 
for most of the world’s people is not what 
is being sold on the shelf but what is being 
grown in the field. Only by banning GE 
crops can we ensure that natural 
biodiversity will not be destroyed. 
 
Following the mass, direct action in 
opposition to the WTO in Seattle in 
November, 1999, I can attest to the fact 
that radicalizing our message and 
mobilizing people in total opposition to 
processes that unleash oppressive and 
exploitative practices is more effective 
than trying to make reforms. 
 
For me, my involvement in the protests in 
Seattle was a turning point. It was in 
Seattle where I saw our power as a 
grassroots movement against capitalist 
globalization being strengthened, 
consolidated and radicalized. This is partly 
because our direct actions showed the 
moral and strategic bankruptcy of the 
small minority who would have us co-
operate with the WTO instead of shutting it 
down. These are the people who allow 
themselves to be co-opted by national 
governments in desperate need of a 
legitimacy fix. These are the people who 
have allowed themselves to be portrayed 
as the “reasonable protestors” in contrast 
to “the violent rabble” on the street. 
Indeed, after the grassroots’ power that 
people demonstrated in Seattle, it is more 
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distressing than ever to see a small 
number of NGO “leaders” selling the WTO 
as “fixable,” as “reformable,” as “open to 
democratization” when it is clear to most 
that the only good WTO is no WTO.1 
 
What we need to do is figure out how to 
re-shape people’s consciousness to 
recognize the benefits of overthrowing the 
current ways of organizing our world. The 
best way to do this is to provide 
alternatives. One thing that is really 
inspiring is the knowledge that in 
agriculture (as in safe, effective 
reproductive health), women already know 
how to realize an alternative to white, 
capitalist, patriarchal forms of organizing 
our relationship to our food and with each 
other. In agriculture, there are women who 
know how to grow food organically, in 
small-scale, with community help. This is 
the only kind of agriculture that we can 
support ethically. Eating the fruits of this 
kind of labour should not be a luxury-
commodity available only to a small 
number of relatively well off people in the 
world. We need to keep in mind that just 
40 years ago, most of world was able to 
grow and eat organic foods. It was the 
values of the so-called ‘Green Revolution’ 
that was sponsored by industrial 
agricultural and petrochemical industries, 
promoted by national governments and 
enforced by the World Bank and the 
International Monetary Fund, and the 
                                               
1 It should come as no surprise that those who 
led the most effective protest seen in North 
America for the last thirty years were those of 
us who did not see much, if any, benefit from 
the supposed “golden days” of the 1950s and 
60s. We were the ones who never saw any 
good come from “negotiating” with the beast. 
We, Indigenous activists, street-identified 
young people, women of colour, working-class 
women and men who were never included in 
the labour aristocracy, Gen X’ers (who 
perhaps knew better than many in North 
America that the beast had no loyalties to 
them) and more – all of us, together, refused to 
compromise. Here, in the belly of the beast, we 
became indigestible. 
incredible proliferation of chemicals into 
the world’s food supply, that resulted in the 
loss of organic food for life forms on the 
planet. This is what we must reclaim. 
 
A radical position on biotechnologies is the 
message we ought to be sending to the 
recently established Canadian 
Biotechnology Advisory Committee that 
reports to the new Biotechnology 
Ministerial Coordinating Committee, 
responsible for overseeing the 
implementation of the government’s 
strategy. We in the Basmati Action Group 
have been circulating a flyer pointing out 
the government’s position on 
biotechnologies and giving people the 
address and e-mail of the CBS taskforce 
so they can directly send this message to 
these guys. Much more grassroots work 
needs to be done by all of us. The only 
hope we collectively have for the 
continued life of this planet and for the 
struggle for social and ecological justice is 
to mobilize a mass movement in 
opposition to the biotechnology industries 
and the people whose sexism, racism and 
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After a recent trip to Laos (Lao PDR) in 
January 2000, as a member of a team 
which introduced food security and gender 
into a project on natural resource 
management, I find that I view genetically 
engineered (GE) foods and biotechnology 
strategies in a different light. Here I want 
to raise points from a personal and 




Lao Stories - January 2000 
 
On the plane, on the way to Vientiane, the 
capital of Lao PDR, I overhear Asian-
Canadian businessmen discussing new 
crops introduced into Vietnam through the 
Canadian International Development 
Agency's (CIDA’s) joint ventures. They 
discuss the opportunity for field trials in 
Lao PDR. Settled in my hotel room in 
Vientiane, I am hooked up to CNN and 
between news of the Montreal meetings 
on the Protocol on Biosafety are 
interspersed commercials for "Life 
Industries" and the wealth they will bring to 
Asian entrepreneurs and their western 
business partners. The next day I travel 40 
kilometres in 3 hours over non-existent 
roads to the village of Ban Hai Tai where I 
speak with women about food security. 
Food security to them is the ability to feed 
their children, access to land to grow local 
varieties of glutinous (sticky) rice, and 
access to forests for wild products 
(providing food diversity and medicines). 
There has been little incentive to introduce 
HYV (high yielding varieties) of glutinous 
rice to Lao PDR, because there is no 
commercial market and farmers prefer the 
taste of their local varieties. 
                                               
1 I have written in a more academic manner on 
issues of infant feeding, food security and 
development in: Van Esterik, Penny, and 
Carole Counihan. Eds. 1997; Van Esterik, 
1999a, 1999b, 1997, 1996a, 1996b, 1996c. 
 
In spite of extreme poverty, exceptionally 
high maternal mortality rates 
(656/100,000) and high infant and child 
mortality rates (142/100,000), the 
community is sustained by two interaction 
cycles: 
 
1. the production of breastmilk and its 
delivery to a newborn, and the transfer 
of knowledge about breastfeeding from 
grandmother to mother to daughter; 
 
2. the production of food from seed to 
plant to seed to plant and the transfer 
of knowledge about how to grow and 
prepare food in different localities, 
seasons and circumstances. 
 
Just as these women know how to 
preserve their own seeds for future 
harvests, so breastfeeding women 
preserve and transmit knowledge of 
breastfeeding. In contrast, North American 
women came close to losing knowledge 
about breastfeeding, so that there was 
nearly a lost generation who did not value 
breastfeeding or know how to manage 
lactation. Seeds and children both have to 
be nurtured to grow and reproduce. 
Nothing should break these self-reliant 
cycles of nurture. Yet both cycles are 
under threat by some of the same 
processes – even the same corporations. 
 
Consider the research on genetically 
engineered human proteins which were 
bred into Herman, the first transgenic dairy 
bull, bioengineered to carry a human gene 
for producing milk with human proteins, 
lysozyme and lactoferrin. Lactoferrin has 
natural anti-oxidant, anti-bacterial, anti-
viral, and immune stimulating properties 
and is present in human milk. When added 
to infant formulas, this "wellness 
ingredient" was said to simulate the 
composition of breastmilk. Herman's 
female offspring were to produce these 
proteins at a lower cost for commercial 
uses such as in infant formula. The 
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products were to be launched in 1996. For 
some reason, the bioengineering of 
human milk proteins was considered 
"ethically safe." That is, manufacturers did 
not expect resistance. However, after 
protests from several groups (including the 
Rural Advancement Foundation 
International, RAFI and International Baby 
Food Action, IBFAN), the transgenic 
product was redefined as containing 
modified lactoferrin and was sold as a 
product to cure AIDS. 
 
Infant formula made from human protein 
bioengineered in the milk of transgenic 
dairy cattle is certainly not human milk, 
and is far removed from breastfeeding. But 
the GE ingredients would provide an 
opportunity for the development of new 
marketing strategies: "just like mother's 
milk" would have a new appeal. New infant 
feeding products with ingredients such as 
nutritional oils providing two essential 
acids DHA and ARA, present in breastmilk 
but until recently absent from all breastmilk 
substitutes, are targeted for fullterm and 
preterm infants – a marketing strategy 
which may be used with GE foods. The 
proliferation of soy-based infant formulas 
is particularly disturbing, since GE soy is a 
key ingredient, and the health effects on 
premature and fullterm infants is as yet 
unknown. 
 
In March, 1998, the Delta and Pine 
Company patented the terminator 
technology, a biotechnology invention that 
will permit its owners to create and market 
sterile seeds by programming plant DNA 
to kill its own embryos, irretrievably 
breaking the plant to seed to plant cycle 
on which human life depends. The 
purpose of this technology is to increase 
the value of seed owned by American 
companies and open up new markets in 
third world countries. In 1999, these 
companies vowed not to commercialize 
terminator seeds. But according to RAFI, 
Delta and Pine Land Seed Company is 
moving aggressively to commercialize 
these “suicide seeds.” Monsanto bought 
the company that developed and patented 
this terminator technology in May, 1998 
and in June, 1998 American Home 
Products (AHP), home of Wyeth along 
with many agro chemical products, 
attempted to buy Monsanto. AHP would 
have become the largest agro/ chemical/ 
pharmaceutical/ "Life Industries" company 
in the world, if the merger had not fallen 
through over disagreements over who 
would be "boss". And as agrotoxins 
bioaccumulate in the food chain and begin 
to appear in mother's milk, we would have 
come full circle, as Wyeth also produces 
infant formula. 
 
And so I think back to these Lao women, 
managing to feed their families with so few 
resources, and wonder what the future will 
bring, with a new bridge to Thailand, and 
new roads to Vietnam bringing in tins of 
"old" infant formula without the "new" 
ingredients already present in their own 
milk, and the possibility of our oversees 
development assistance programs funding 
field trials for "new" seeds to improve on 
their "old" seeds. 
 
 
Women and Food 
 
At the World Food Summit in 1996, Maria 
Meiss and Vandana Shiva organized a 
Women's Food Day to highlight how the 
policies being decided largely by men in 
the formal FAO summit were likely to 
affect women. They asked why women 
were not consulted and why the concerns 
of women farmers, entrepreneurs and 
consumers were not being heard. Perhaps 
it is because what many women know 
about food is used to nurture others; this 
knowledge is hard to protect, easily shared 
through communal cooking, food and 
recipe exchanges and "potluck" meals. 
Women's influence on the food system is 
greatest in households and communities. 
What many men know about food 
becomes property, commodity, with 
access protected through intellectual 
property rights, copyrights and patents. 
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The faces of men are particularly visible at 
national and international food forums 
where they represent industry and trade 
concerns. In a world where everyone was 
dependent on multinational corporations – 
or worse, one giant corporation – for their 
seeds, medicines and food, whose views 
would prevail? Consider the inducements 
that companies would offer to end such 
self-sufficient practices as planting a 
garden with your own seeds or 
breastfeeding your baby. To share food 
and seed is normal practice for women; 
will it become a crime to share ideas or 
seeds according to the new regimes run 
by companies like Cargill and Monsanto? 
 
Currently, I am introducing this topic to my 
nutritional anthropology class, using 
Nottingham's (1998) Eat Your Genes as a 
text. The book has no entry for women, 
feminism, gender, reproduction or any 
suggestion that GE foods are of special 
concern to women. However, what women 
are putting in their bodies has implications 
for their own health and that of the next 
generation. 
 
As family food managers on a daily basis, 
women are targets for industry messages 
designed to promote acceptance of GE 
foods. Messages will appeal to women's 
sense of fairness, to give the new products 
and companies a fair hearing, and to think 
of those who do not have access to 
sufficient food. Industry knows the appeal 
of the argument that GE foods are the 
answer to hunger and food insecurity. And 
they will no doubt stress the ‘right to 
choose’, a phrase that has a special 
meaning for many women activists, yet 
should flash warning lights when used by 
government and industry. 
 
Women have been in the forefront of 
protests against the speed and extent of 
the introduction of GE foods. In matters of 
family food, women are cautious, 
suspicious of changes, for whoever cooks 






Food security means having enough food 
to maintain a healthy and productive life 
today – and in the future. Communities 
enjoy food security when all individuals in 
all households have access to food – 
adequate in quantity and quality, 
affordable, acceptable, appropriate and 
readily available from local sources on a 
continuing basis. 
 
In the fall of 1999, an article in the Toronto 
Star featured a number of male chefs 
banding together to protest the use of GE 
foods; they planned to use only organic 
foods in their expensive restaurants. In 
this city of food boutiques and food banks, 
where will the foods containing GE foods 
be located? As consumer protests against 
GE foods increase, will poor women make 
ends meet with discount produce, 
cardboard tomatoes, and processed foods 
that last longer on the shelves, but that 
have been rejected by others with more 
resources – both knowledge and money? 
 
What will GE foods do to ease the burden 
of hunger and food insecurity in Canada 
and elsewhere? What assurances do we 
have that future generations will not be 
affected by what they were fed before and 
after birth? Monsanto, Cargill and Nestle, 
among the largest corporations in the 
world, are exercising increasing control 
over what we eat and feed our children, 
and even the governments we elect, but 
they are not contributing to food security. 
In our advocacy work, it is important to 
examine how corporate power is exerted 
in places in the world where Canadian 
technology has spread, often through 
CIDA's development assistance programs. 
 
GE foods are presented by industry as 
"nothing new" but a result of our 
increasing control over the domestication 
of plants and animals over the past 10,000 
years. My position is that GE foods are a 
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radical break in the evolution of food 
production, not a continuity. Why? 
Because of the speed with which changes 
are occurring, and corporate control over 
the process. Thus, we are in need of 
totally new policy, research and advocacy 
approaches to address problems raised by 
GE foods.
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The Canadian Biotechnology Strategy is 
about wealth – simply put. The 
government documents are filled with 
phrases such as 'economic potential,' 
'worldwide market,' 'generate revenue,' 
'future jobs,' 'increase … international 
competitiveness.' 
 
The Working Group on Women, Health 
and the New Genetics and the rest of the 
Workshop participants constitute a sample 
from the wealthiest 10% of North 
Americans – the wealthiest 2% of the 
world's citizens. From wealth, can we step 
aside and analyze wealth? 
 
For some 10 years now I've done feminist 
technology assessment using a system of 
queries I've devised. From that system, I 
shall select one query: For whom are the 
benefits? To whom fall the costs/ risks? In 
this situation we can look at wealth as one 
benefit and poverty as one risk. 
 
Let's look at a semi-hypothetical example: 
Suppose we bioengineer a wheat plant 
minus the gene that gives people wheat 
allergies. Who benefits, besides the 
biotech companies? People with wheat 
allergy who also have enough money to 
buy it. To whom fall the costs? Many 
people: workers in and near the fields and 
other consumers, who develop allergic 
reactions to the much more potent 
allergens in the pesticides and herbicides 
necessary to allow that new plant to grow. 
Wealth and health go hand-in-hand in this 
example: wealth with health versus 
indigence with illness. It would be cheaper 
to devise and manufacture delicious 
breads from ordinary corn and rice, which 
almost everyone could afford to eat. 
 
Now for the Canadian Biotechnology 
Strategy, who is to get wealthy? 
Multinational corporations? In most of the 
submitted papers the answer is a strong 
'yes.' These corporations are driven to 
accumulate wealth not only for their CEOs 
and Board members, but also for their 
stockholders. Stockholders! I'll come back 
to these later. 
 
Who else is to get wealthy? Will the 
Canadian government coffers expand 
through taxes on corporations? And then, 
will the government use those monies to 
improve the health determinants (see Pat 
Armstrong's essay, this volume) for 
Canadians? Theoretically this could 
couple health for citizens with wealth for 
tax coffers. But, note in the CBS’s Health 
Sector Consultation Document that 
Canada claims to have the most generous 
research tax credits in the world. The 
policy priority then, appears to be ensuring 
private profit rather than wealth 
distribution. 
 
Who else is to get wealthy? Will it be many 
citizens of Canada, as individuals, who 
gain employment in those biotech firms? 
Although a very small percentage of the 
population may acquire job opportunities, 
many of the technician-level jobs may be 
hazardous, healthwise. In any countdown, 
however, one must offset such gains by 
jobs lost in agriculture. 
 
Let's turn from the benefits list to the costs. 
Some costs will accrue to farmers, 
especially women-as-farmers, as Margrit 
Eichler makes abundantly clear. Some 
costs will accrue to women-as-food-
shoppers, women-as-cooks, and women-
as-unpaid-home-nurses. Some costs will 
accrue to women-as-health-care-
consumers, since their health may be 
jeopardized both by the food they eat and 
by their encounters with the medical 
system. A very few may have improved 
health due to some high-tech treatment, 
with ancillary cutback in health care for the 
majority of Canadians. A biotech emphasis 
may indirectly (and possibly directly) 
maintain the diversion of monies from 
improving health determinants and 
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increase the gap between the haves and 
the have-nots. 
 
Let's look at Penny Van Esterik's excellent 
example: the chefs of Toronto protest GE 
foods and do not use them in their haute 
cuisine, while the poor and homeless eat 
them in food pantries and soup kitchens. 
 
Let me put out, however, two examples 
that seem to uncouple the health-with-
wealth partnership. One is the drug 
herceptin, as discussed by Sharon Batt. 
Women who can purchase or can 
persuade their health insurers to purchase 
for them (in both cases, 'wealthy') might 
find themselves taking a drug that may be 
a hoax or has serious side effects. 
 
My second example is the use of the drug 
DES in Chicago in the 1950s. In hospitals 
there, white women who threatened 
miscarriage got the drug, but it was never 
offered to black women, obviously 
because of racial prejudice. The result is 
that clear cell cancer of the cervix is 
extremely rare in black women. 
 
 
Papers in the “Wealth” Session 
 
Now I turn to a few comments on specific 
papers in the collection for this session. I 
commend and praise these authors for 
their perception and their ability to hit nails 
on their heads. I shall emphasize and 
expand a few of their points and be a bit 
skeptical about some proposed solutions. 
 
First let me underscore Julie Delahanty's 
and RAFI’s concern about Human 
Genome diversity research – research to 
sample populations all over the globe to 
see how little bits of their DNA differ. 
Humans have 98% of the same DNA as 
chimpanzees, and each one of us in this 
room has 99.999% of the same DNA as 
each other. A tremendous amount of 
wealth is passing among corporations over 
finding those teeny 0.001% differences. 
Shares of their stocks rise on the stock 
market. RAFI’s term 'Gene Giants’ puts it 
very well. Yet there's no 'product.' The rich 
are getting richer, and they can afford it 
when the bubble bursts. 
 
Iceland is a clear example. Samples of 
DNA of 261,000 of the 270,000 citizens of 
Iceland are now in the freezers of Hoffman 
LaRoche in Switzerland. I believe they 
plan to follow each citizen until he or she 
dies. And then try to find the differences in 
DNA between the stroke victim and the 
diabetic, between the fisherman who fell 
through the ice and the drunkard. Wealth, 
real wealth, enters the picture here. But 
scientists are divided as to whether 
citizens of Iceland will benefit in any way 
(Lewis, 1999). 
 
Jumping from Iceland to Canada, I 
endorse Nandita Sharma's point that the 
main aim of the Canadian Biotechnology 
Strategy is to market biotechnologies. As 
she says, “throughout this document is the 
government's concern that people accept 
and be confident in and comfortable with 
new genetic technologies.” “The media,” 
she continues, “are being used to promote 
the benefits and safety of genetically 
engineered food.” Finally, she notes, 
"corporate propaganda [is] being voiced as 
if it was a public health message." 
 
It happens that allaying the public's fears, 
and promotion of its project, also were and 
still are the unwritten goals of the U.S. 
Center for Human Genome Research’s 
ELSI program (Ethical, Legal, and Social 
Implications) (Andrews 1999:206). For 
instance, many grants are awarded for so-
called 'education' projects, although that 
word is not in their title. (The word 
'education' here simply means 
propaganda or indoctrination.) ELSI has 
never awarded a grant to any project 
suspected of being critical of the basic 
premise: the very existence of the Human 
Genome Project. 
 
Now let me turn about and ponder one of 
Elisabeth Abergel's concerns. She admits 
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the fact of "governmental promotional 
programmes," but feels that although most 
women would agree about opposing GE 
food, the medical uses are, as she puts it 
'more divisive' among women. This is an 
important point. For we cannot, must not, 
forget women who are not in our midst, for 
example, the mothers of children with 
genetic disabilities. Many of them believe 
that biotechnology is on the verge of 
finding a genetically engineered cure for 
the disease in their families. My own view 
is that such beliefs result from 
propaganda, but should feminists quench 
their faith and dreams? If so, how? 
 
Similarly, Madeline Boscoe and Sari 
Tudiver ask, "Must we always say NO?" 
And then flush out this question 
wondering, “Are there some aspects … of 
biotechnology … that reflect careful 
evaluation, promising therapeutic … 
outcomes in the long term … not 
necessarily dependent on corporate 
monopoly control for their development 
and marketing?" 
 
By 1992 in the United States there were 
over 130 'genetic support groups,' each 
one focused on a particular genetic trait in 
their members' kindreds. Eighty percent of 
these had women CEOs or presidents. 
These leaders are very knowledgeable 
about how close the search is for finding 
'their' gene, who is searching, and what, if 
any, attempts at treatment are going on. 
To be sure, they are middle class and 
educated, so the 'wealth' issue surfaces 
here again. And here again are faith and 
dreams, but among some very well-
informed women. 
 
This leads into Pat Armstrong's concern 
about a "market-driven consumer model of 
health." We need reforms in medicine and 
welfare, she says, but the new focus is 
harmful to most women, simply because 
the paradigm is business, and efficiency is 
measured in monetary terms. The women 
who are empowered are those with the 
ability to pay. Look again at the women 
CEOs I just mentioned. Most of the 
genetic conditions in their kindreds are 
rare diseases, ones that occur so 
infrequently in the population that it would 
never lead to corporate profits to develop 
a test to detect that gene – the so-called 
orphan diseases. Therefore, these women 
pressure foundations for grants; some of 
them lobby Congress to develop such 
tests or to subsidize corporations to do it. 
In recommending policy we need to know 
that such women exist. 
 
Now, to return to Hoffman LaRoche in 
Switzerland and its ilk. Rare diseases are 
not profitable. So they turn to the big killers 
of the wealthy. Most wealthy people in this 
world do not die of rare genetic diseases, 
but of heart attacks, strokes, diabetes, 
AIDS, Alzheimers, and various cancers. 
And let's add in murder and suicide so we 
can invent a violence gene and a suicide 
gene. The ultimate in genetic reductionism 
is to find in human DNA the 
predispositions to such conditions as 
these. Just exactly how is my personal 
Grim Reaper going to stalk me? The Gene 
Giants can make big bucks saying that 
they've found the codes for a given 
Reaper. What happens then? Their clients 
can do little but worry. Yes, they can abort 
a fetus or impose a 'life-style change' on 
their kids or themselves. But when the 




Solutions: Band-Aid Approaches 
 
Band-aid approaches are what Industry 
Canada hopes, I think, will satisfy any 
public clamor, measures that can allay the 
public's worries so that biotech can go full 
steam ahead. Two of these that worry me 
are: 
 
A) Labeling of all GE food. The basic 
drawback to labeling is that it accepts 
the existence of GE food – labelling 
implies approval and acceptance of 
GE foods, as Sharma explains. 
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Another drawback is that it forces 
woman-as-shopper to make choices. A 
woman simply trying to feed her family 
should not have to do an ethical 
evaluation of each specific engineered 
food: has the introduced gene escaped 
into weeds, does it require specific 
pesticides and fertilizers sold at high 
cost, does it produce sterile seeds, 
etc.? 
B)  Putting regulations in place and 
announcing this to the public. In her 
opening comments Sue Sherwin 
describes the 20-member advisory 
committee (the Canadian 
Biotechnology Advisory Committee, 
CBAC) as not representative and 
including no health activists. Thus, the 
first problem with band-aid approach B 
is how to get the government to form 
an appropriate regulatory body. 
Because of current love affairs 
between governments and global 
corporations, any regulatory body most 




Two weeks ago I was witness to a good 
example of governmental fear of genuine 
regulation. I attended a 'public 
consultation' in Baltimore on 'supervision 
of genetic testing.' An excellent committee, 
more than half of them women (and some 
of those, feminists-in-spite-of-themselves), 
had prepared the document we were to 
critique (SACGT, 1999). But it was clear 
that this blue-ribbon committee was under 
the strong constraint of not impeding any 
biotech firms from devising more and more 
genetic tests. Their document avoided the 
word 'regulation' and used instead 
'guidelines.' I found myself in a miserable 
little discussion group with several 
representatives from biotech companies. 
"Too much regulation already," they said. 
 
 
Most of you have heard that in January 
2000 the U.S. National Institutes of Health 
(NIH) halted gene therapy trials at the 
University of Pennsylvania (Barbour, 2000: 
384; Horton, 2000: 329). After one death 
came to light, it was eventually discovered 
that there had been 691 deaths or serious 
incidents in other clinical trials of gene 
therapy (Nelson and Weiss, 2000: A01). 
For some two years the U.S. Food and 
Drug Administration (FDA) has been in 
charge of genetic engineering 
experiments; it keeps confidential any 
reports it gets (Smaglik, 2000: 5). Adverse 
events are also supposed to be reported 
to the NIH, but many researchers said 
they did not know about that requirement 
(ibid.). Some scientists claim that the 
deceased patients would have died 
anyway from their condition, since most of 
them were terminally ill with cancer (Ibid.). 
 
Here I tease out several points: 
(1) it's obvious that we have to be vigilant 
that regulations do not backfire – so 
that they end up not benefiting the 
public because they have stirred up a 
backlash; we have to be ready to deal 
with the complaint that regulations hold 
back the progress of science; 
(2) corporations may protest regulations 
by going where there are no 
regulations in place, for example, in 
the U.S. where government-funded 
experiments on embryos are 
forbidden, preimplantation diagnosis 
and other fiddling with human embryos 
simply goes on in the private sector or 
in countries without regulations;  
(3) any regulations should define 'adverse 
events' and include a specific place 
and method to report these. Let us all 
dream that any such events in genetic 
experimentation (plants, animals, 
humans) must be reported to the 
Women's Health Movement. 
 
 
Solutions: Possible Effective 
Approaches 
 
Use the media. Several commentators 
noted that the media are part of the 
problem. Yes, they are mesmerized by 
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biotechnology. If a scandal breaks out, 
they'll zero in on that temporarily, but then 
go back to being mesmerized. For 
example, although the 'gay gene' is only a 
hypothesis based on equivocal evidence, 
the media often now blithely mention 'the 
gay gene.' 
 
One problem in the U.S. is that the major 
commercial networks and newspapers are 
parts of huge conglomerates that include 
pharmaceutical houses and 
agribusinesses. Television documentaries 
are definitely censored. It's hard to believe 
– when you seem to be getting both sides 
of a question in investigative reporting – 
but any TV documentary that appears has 
already passed corporate censorship. Yet 
as individuals, most journalists are 
ethically committed to the truth, even if 
their stories get suppressed. 
 
Because of this basic personal integrity, 
one way to use the media is to go first 
through the alternative press, which will 
welcome reports we write. The February 
2000 issue of Mother Jones published 
"Pandora's Pantry," an article on GE 
foods. Such pieces may then be seen by 
reporters from the mainstream media, and 
from time to time critical articles have 
appeared in the New York Times. 
 
Go through stockholders. Can we get 
biotech stockholders to take a stand? We 
all know the example of South Africa. Big 
stockholders, usually institutional 
investors, such as universities and labor 
unions egged on by their constituencies 
(students, workers, alumni), divested 
stocks from firms that were doing business 
in South Africa. Or, they chose not to 
divest when companies were following the 
'Sullivan Principles' of human rights with 
their employees. This led to the fall of 
apartheid. Now, can we invent principles 
under another name and try the same 
thing with genetic engineering? How about 
the 'Sherwin Principles'? 
 
Global Activism. We can join global 
actions or create and recruit globally to our 
own actions. Fritolay, a subsidiary of 
Pepsico, has told its suppliers that it won't 
buy genetically engineered corn. 
Apparently this did not come from 
stockholder pressure, but Fritolay realized 
that consumers were getting wary. (As far 
as I know, they still use bt potatoes for 
their potato chips.) And after the country of 
Brazil forbad the planting of GE soybeans, 
more and more countries switched to 
buying their soybeans from Brazil 
(Passoff, 2000). 
 
Help from the state. Despite its poor track 
record with women, the Canadian 
government can protect its citizens. Pat 
Armstrong says, "Only the state is 
powerful enough to counter the power of 
the global corporations . . . precisely 
because the state is now so activist [in 
serving the interests of corporations] we 
need to make demands on it." Nandita 
Sharma has far less faith as she describes 
a government in league with corporations 
broadcasting propaganda as if it were a 
public health message. Yet – and it really 
has nothing to do with GE – it's ethically 
right for the state to take responsibility for 
health determinants. 
 
Hold fast on not patenting life forms. I want 
to urge Canadians to hold fast to your 
current patent laws, and not succumb to 
the argument to "modernize Canada's 
intellectual property laws," i.e., not to put 






I have a strong affection for Canada 
having spent at least 35 summers 
camping or traveling in many of your 
provinces, dating back to the fifties when a 
picture of the Queen was in every parlor. 
And Canada produces some remarkable 
feminists, many of whom have 
intellectually and spiritually enriched my 
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life. So – my pro-Canada sentiment wants 
Canada to be wealthy or, better 
expressed, wants no one in Canada to be 
poor. 
 
I am not alone in these positive feelings 
about Canada. Canada has an 
international reputation of high moral 
standards, of being a moral leader. Many 
Canadians scoff at such an interpretation, 
because you know only too well about so 
many specific instances of immoral 
actions, especially against your aboriginal 
peoples. But I am speaking of the global 
perception of your country, whether or not 
this can withstand close scrutiny. Thus I 
urge you to make use of that moral 
argument, the argument that Canada 
should do what is morally right and be 
proud of an international stance that holds 
morality above expediency. 
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In international policy circles it is 
increasingly recognized that the 
conservation of biological diversity (or 
biodiversity) is integrally related to the 
preservation of cultural diversity and that 
indigenous peoples and local communities 
hold traditional ecological knowledge of 
great potential value and importance in 
global efforts to achieve sustainable 
development objectives. Such peoples 
and their knowledges are endangered. 
This paper will consider global efforts to 
value and preserve traditional ecological 
knowledges, the use and significance of 
digital technologies in facilitating the 
preservation of this cultural diversity, and 
point to issues that require further 
research.  
 
After introducing the policy issues, the 
paper will consider the obligations of 
Austria, Belgium, Bulgaria, Canada, 
Luxembourg, Switzerland, and the United 
Kingdom (hereinafter the Council Parties) 
under the Convention on Biological 
Diversity (hereinafter the CBD), and 
initiatives taken by the Council Parties to 
protect traditional ecological knowledge 
both domestically and internationally; it 
also addresses some important regional 
initiatives and provides examples of 
academic and non-governmental 
organization (NGO) activities. Given the 
importance that the CBD attaches to 
intellectual property rights (IPRs) and the 
enormous body of literature that 
addresses the propriety of IPRs as a 
means of protecting traditional 
environmental knowledge, the paper then 
considers the role of IPRs with respect to 
the preservation of cultural diversity1 and 
                                               
1. A recent survey of important works may be 
found in King and Eyzaguirre. An enormous 
bibliography is maintained by Graham Dutfield 
and is operated from Oxford University at the 
website for the Working Group on Traditional 
proposals to amend IPRs to make them 
less conducive to the misappropriation of 
cultural knowledge. The paper next 
addresses indigenous uses of the Internet, 
with particular attention to cultural 
revitalization efforts. More general usages 
of digital technology to assist in the 
protection of biodiversity and indigenous 
knowledge are then surveyed with 
emphasis upon the potential cultural 
impacts of these activities on indigenous 
peoples and local communities. Areas of 
recommended research are identified at 
the end of each section. 
 
 
The Relationship Between Cultural  
Diversity and Biodiversity 
 
Human cultural diversity, it is believed, is 
threatened on an unprecedented scale 
(Posey 3). Languages are generally seen 
as major indicators of cultural diversity—
the codifications, heritages, and 
frameworks which constitute a society’s 
unique understanding of the natural and 
social world. An estimated half of these 
will disappear within the next century 
(UNESCO). Since 4,000 to 5,000 of the 
6,000 languages in the world are spoken 
by indigenous peoples, and these are the 
most endangered of languages, the loss of 
cultural diversity will affect these peoples 
disproportionately. The countries which 
contain peoples speaking the largest 
numbers of languages are also those that 
house the greatest biological diversity in 
terms of species and variations in 
interspecies, and include the greatest 
numbers of indigenous and communities 
with traditional, near-subsistence 
livelihoods. Although no universally 
accepted definition of indigenous peoples 
or of traditional communities exists, the 
majority of the world’s rural populations 
live in direct dependence upon their 
knowledge of and use of local ecosystem 





resources. These resources are also 
disappearing at an alarming rate with dire 
consequences for those peoples whose 
livelihoods depend upon them.2 
 
The world’s poor rely upon biological 
products from local sources for 85% of 
their needs (e.g., for food, fuel, shelter, 
medicine, etc.), over 1.4 billion rural 
people rely upon farm-saved seeds and 
local plant breeding for their subsistence, 
more than three quarters of the world’s 
population relies on the knowledge of local 
health practitioners and traditional 
medicines for their primary medical needs, 
and over half of the world’s drugs are 
derived from plants (Crucible II Group 1:1). 
New plant genetic resources are needed 
in the pharmaceutical, agricultural, and 
biotechnological industries on a regular 
basis, yet the social and cultural conditions 
that nurture their ongoing development 
and ensure their continuing variation are 
threatened.  
 
Plant genetic diversity is considered a 
human legacy but it is one that is 
sustained largely by the uncompensated 
                                               
2. According to an Australian report on 
biodiversity, “[t]he loss of rich, biologically 
diverse environments (such as the Amazonian 
forests) through activities such as logging, land 
clearance and mining and development has 
profound consequences in its impact on the 
culturally diverse groups of indigenous peoples 
whose livelihoods depend on these 
environments. There is in this sense a direct 
relationship between biological diversity and 
cultural diversity; maintenance of the former 
can help preserve the latter. The reverse is 
also true, since indigenous peoples are often 
the custodians and stewards of biological 
diversity, the maintenance of cultural diversity 
is an important factor in the conservation of 
biological diversity.” Commonwealth of 
Australia, Biological Diversity and Indigenous 
Knowledge, Research Paper 17 (1997-8). 
Available at 
<http://www.aph.gov.au/library/pubs/rp/1997-9
8/98rp17.htm.>. See Muhlhausler for further 
discussion of the relationship between 
language, culture, and biodiversity. 
work of culturally diverse, politically 
vulnerable, and impoverished peoples.3  
Only to the extent that such practices are 
supported, encouraged, and maintained by 
in situ conservation measures will 
biodiversity be maintained.4 Hence, the 
CBD Preamble recognizes the “close and 
traditional dependence of many indigenous 
and local communities embodying 
traditional lifestyles on biological resources, 
and the desirability of sharing equitably 
benefits arising from the use of traditional 
                                               
3. As Swaminathan and Castillo write: “Tribal 
and rural farming communities have a long 
tradition of serving as custodians of genetic 
wealth, particularly landraces often carrying 
rare and valuable genes for traits like 
resistance to biotic and abiotic stresses, 
adaptability, and nutritional quality. Several 
land types that carry valuable genes are 
preserved by farmers for religious functions 
and they constitute valuable material for 
conservation and sustainable use. Women in 
particular have been the principal seed 
selectors and savers” (Swaminathan and 
Castillo xii). 
4. According to the Crucible II Group: 
 
Local and indigenous peoples who speak 
ancestral languages are severely 
threatened by loss of sovereignty over land, 
resources, and cultural traditions and the 
promotion of linguistic assimilation. As they 
become increasingly marginalised local 
people lose local scientific knowledge, 
innovative capacity, and wisdom about 
species and ecosystem management. As 
one scholar concludes: “Any reduction of 
language diversity diminishes the 
adaptational strength of our species 
because it lowers the pool of knowledge 
from which we can draw.” The loss of 
traditional farm communities, languages, 
and indigenous cultures all represent the 
erosion of human intellectual capital on a 
massive scale. It is tantamount to losing a 
road map for survival, the key to food 
security, environmental stability and 
improving the human condition. Thus, it is 
increasingly difficult to talk about the 
conservation and sustainable use of genes, 
species and ecosystems separate from 
human cultures (Crucible II Group 1: 9-10 
citing R. Bernard).  
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knowledge, innovations and practices 
relevant to the conservation of biological 
diversity and the sustainable use of its 
components.” This is indicative of a global 
recognition that biodiversity preservation is 
an inherently multicultural process.  
 
Indigenous knowledges may be understood 
as the cultural knowledges of local peoples 
concerning the everyday realities of living 
that are the product of a direct experience 
with nature and a particular, local 
ecosystem.5 Indigenous knowledge, “the 
unique, traditional, local knowledge existing 
within and developed around the specific 
conditions of women and men indigenous 
to a particular geographic area” (Grenier 
1998), is collectively held and, until 
recently, was also predominantly 
communicated orally and from generation 
to generation. Such knowledge is dynamic 
and adaptive, socially shared and 
communicated, and usually recognizes an 
equilibrium among natural forms 
understood to form elements of a cosmos. 
It embraces knowledge of location, 
movements, spatial relationships and 
temporal cycles, and is not restricted to 
knowledge of entities and their parts. 
“Nature” is less likely to be understood as 
something to be conserved and more likely 
to be understood as an extension of society 
and an integral part of human 
interdependence. 
 
Just as indigenous peoples and local 
communities are increasingly under siege 
by forces of urbanisation, 
proletarianisation, linguistic assimilation, 
logging, mining, and large-scale 
development projects, they find that the 
genetic resources they manage and 
develop using their knowledges and 
technologies are of increasing value to 
others. “Biopiracy” of genetic resources 
                                               
5. For a discussion of the various definitions of 
indigenous knowledge and how these are 
situated in relation to conventional, formal, or 
scientific knowledges, see Dei, Hall and 
Goldin-Rosenberg. 
and traditional knowledge is believed to be 
on the rise.6 For example, a survey 
conducted by the Indian Drug 
Manufacturers’ Association found that of 
the 668 pharmaceutical patents filed in 
1997, the vast majority included the use of 
ayurvedic knowledge (traditional Indian 
medicinal systems) with minor 
modifications in methods of extraction and 
processing.7 Research to ascertain the 
use of indigenous and traditional 
knowledge innovations and practices 
(hereinafter ITKIP) in the intellectual 
properties granted to others is both difficult 
and expensive to accomplish given the 
limited information that most states 
provide to the public and the limited forms 
of disclosure required of most patent 
applicants. States concerned with the 
preservation of cultural diversity should 
consider amending their intellectual 
property regimes to enable such research.  
 
Although claims concerning the biopiracy 
of traditional knowledge abound, it is not 
always clear precisely how traditional 
knowledge practitioners are or will be 
precluded from continuing to engage in 
applying and developing such knowledge 
as a consequence of these appropriations. 
Moreover, it is not at all evident that 
patents based upon ITKIP are, in fact, 
valid given that they generally involve an 
“obvious” technology applied to ITKIP that 
lacks the quality of novelty. Nonetheless, it 
is manifestly inappropriate for state 
regimes to put the onerous and expensive 
burden of challenging the validity of such 
                                               
6. As Graham Dutfield explains, “[a]lthough 
outsiders have collected knowledge and 
biological resources from traditional peoples 
for centuries, ‘bioprospecting’ (the search for 
and collection of biological material and 
traditional knowledge for commercial ends, 
with particular reference to the pharmaceutical, 
biotechnological and agricultural industries) 
has intensified in recent years.” Dutfield, 
Rights (505). 
7. Cecilia Oh citing Vandana Shiva, “India: 
Granting MNCs Absolute Monopolies.” Third 
World Network Features. 1999. 
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IPRs upon the impoverished and 
vulnerable holders of such knowledge (or 




IT IS RECOMMENDED THAT COUNCIL 
PARTIES UNDERTAKE FURTHER 
RESEARCH TO CONSIDER: 
 
•Means to amend intellectual property 
regimes to enable interested parties to 
ascertain when and if intellectual 
property rights are being granted for 
works and innovations that appropriate 
indigenous and traditional knowledge, 
innovations, and practices and are 
thereby invalid to the extent that such 
knowledge, innovations and practices 
are not novel and the uses made of 
them are obvious amongst those 
peoples or in those communities. 
 
 
The Convention of Biological Diversity 
and the Recognition of Traditional 
Knowledge 
 
States who are party to the CBD are 
obliged : 1) to respect, preserve and 
maintain knowledge, innovations and 
practices (KIP) of indigenous and local 
communities embodying traditional 
lifestyles relevant for the conservation and 
sustainable use of biological diversity 
(Article 8(j)); 2) to develop and use 
traditional and indigenous technologies 
(Article 18(4)); 3) to promote the wider 
application of such knowledge with the 
approval and involvement of the holders of 
such KIP; 4) to encourage the equitable 
sharing of benefits arising from the use 
thereof; and, 5) to ensure that their 
intellectual property regimes support 
rather than undermine these objectives 
(Article 16(5)). Technology transfer to less-
developed countries is encouraged in 
exchange for the provision of such 
knowledge. For some advocates, “the 
cumulative effect of these provisions is to 
make it mandatory for governments to 
enact a law recognizing indigenous and 
local community knowledge systems. In 
any event they are entitled to enact such a 
law to fulfil their obligations under the 
CBD” (Nijar, Perspectives). With very few 
exceptions,8 states that are party to the 
CBD have yet to introduce legislation 
explicitly protecting ITKIP, or to consider 
what the interaction between a system of 
collective rights and a traditional IPR 
regime would involve. 
 
Existing international trade and intellectual 
property agreements do not pose any 
obstacles to undertaking such an initiative. 
Indeed, to the extent that Article 8 of the 
Trade Related Aspects of Intellectual 
Properties Agreement (hereinafter TRIPs) 
under the World Trade Organization 
(WTO) allows states to take measures to 
protect public health and nutrition and to 
promote the public interest in sectors of 
                                               
8. Exceptions include laws in the Philippines 
and Peru. In the Philippines, the Indigenous 
Peoples’ Rights Act of 1997 recognizes that 
indigenous cultural communities and 
indigenous peoples have, as part of their rights 
to cultural integrity, rights to control bio-genetic 
resources, indigenous knowledge systems, in 
addition to rights to control, develop, and 
protect vital resources, health practices, 
resource management systems, and 
agricultural technologies. For a critical 
discussion of the legislation see Rovillos, 
Indigenous Peoples. The Ley de Biodiversidad 
or Biodiversity Law passed in Costa Rica in 
1998 initiated the process of developing a sui 
generis regime for protecting the KIP of 
indigenous and local communities but also 
explicitly established the juridical recognition of 
these rights without any requirement of 
registration or prior declaration. The 
parameters of these community intellectual 
rights will be determined in consultation with 
indigenous peoples and peasants. See 
discussion in Dutfield, Intellectual Property 
110-3. In Thailand, a draft bill recognizing the 
collective rights of traditional healers and 
benefit sharing for the commercial use of 
traditional knowledge provoked an almost 
immediate challenge by the United States in 
1997. See Correa. 
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vital importance to their socio-economic 
and technological development, it can be 
argued that measures taken for the 
protection of ITKIP fulfills these objectives. 
After all, more than 80% of the world’s 
peoples depend upon such knowledge for 
their health care, ongoing pharmaceutical 
development depends upon it, and the 
continued viability of local agricultures 
ensures global food security.9 
 
The Council Parties have all signed and 
ratified the CBD. Most of the Council 
Parties are funding research into ITKIP 
relevant to the maintenance of biological 
diversity. Other Council Parties (for 
example, Belgium, Luxembourg, and 
Bulgaria) have not linked their 
commitments to preserve biodiversity with 
considerations of cultural diversity and 
have approached biodiversity largely as if 
it pertained entirely to natural 
environments untouched by human 
interaction.10 This, however, is rarely the 
case. 
                                               
9. Indeed, according to Gurdial Singh Nijar, “[a] 
law to protect and further the knowledge 
systems of indigenous peoples and local 
communities would clearly contribute to the 
promotion of technological innovation in 
furtherance of the social and economic welfare 
of large segments of the Third World’s 
populace” (Nijar, Perspectives). 
10. Bulgaria, for example, ranks amongst the 
most biologically diverse countries in Europe 
with huge numbers of endemic species and is 
home to many traditional and rare cultivars. 
Not surprisingly, given its accessiblity to 
Western researchers, it has also been subject 
to exploitation including the illegal gathering 
(and export) of edible fungi, medicinal plants, 
snails, and reptiles (Bulgaria 6). Bulgaria is a 
rich source for botanical drug species within 
Europe and is eighth in the leading export 
countries in the botanical drugs trade. Wild 
botanical drugs continue to be collected by 
villagers who have traditional knowledge of 
their usages (Lange and Mladenova 135-46). 
Although, restrictions on collecting, trading, 
and exporting species have been established, 
legislative initiatives have been oriented 
towards the preservation of biological 
 
Traditional knowledge held within the 
European Council Parties includes KIP in 
relation to hedgerow maintenance, animal 
husbandry, forestry, fish-pond and bog 
management, orchard fruit growing, herbal 
medicines and traditional knowledge of 
phytonutrients. To a limited degree, the 
cultural dimensions of these practices are 
recognized in domestic legislation and 
regional regulation. Austria has passed 
legislation to document, protect, conserve 
natural and cultural landscapes. 
Switzerland defines the preservation of 
biological diversity so as to imply the 
“protection and maintenance of rare 
habitats of great value, including traditional 
and cultural landscapes” (Swiss Agency 
25). The European Council Parties are 
also subject to European Union (EU) 
regulations with respect to the 
conservation, description, collection and 
use of genetic resources in the agricultural 
sector (Council of the European Union, 
Reg. No 1467/94) and European 
Community (EC) objectives to maintain 
agricultural and forestry sectors that 
manage resources so as to preserve 
cultural landscapes. Cultural landscapes 
can only be preserved to the extent that 
the traditional KIP which developed them 
is simultaneously safeguarded. 
 
Surveys of domestic biodiversity in Council 
Parties are ongoing and, in some cases, 
the cataloguing activity has been 
accompanied by a corresponding digital 
database network with international 
linkups (e.g., Austria 21). Inventories of 
the biogenetic reserves of the Council of 
Europe are currently in preparation and 
most of the Council Parties are still in the 
process of documenting autochthonous 
animal and plant species. Council Parties 
understand that the homogenization of 
modes of cultivation threatens the 
existence of certain species and that 
                                                                    
resources rather than the continued cultivation 




species will likely decline to the extent that 
heterogenous cultivation activities are 
abandoned.11 Therefore, although few 
specific measures to protect domestic 
traditional KIP have been taken, the 
importance of the relationship between the 
presence of particular species and 
particular forms of cultivation—many of 
which are likely to vanish unless 
recognized, recorded, and supported—is 
widely acknowledged. Council Parties 
have implemented a number of measures 
as incentives to preserve the in situ 
preservation of biodiversity.12 
                                               
11. For this reason, Austria has committed itself 
to the objective of sustainable agriculture 
which “couples an ecological, site-specific 
adaptation of production methods to a highly 
structured and diverse cultural landscape” 
(Austria 14). Agricultural policy in Switzerland 
aims “to sustain forms of traditional 
exploitation, particularly those which have 
contributed to the formation of landscapes and 
to increase the diversity of ecosystems” (Swiss 
Agency 33), whereas the United Kingdom 
recognizes “the importance of those traditional 
skills and practices upon which many valued 
habitats depend” (United Kingdom 28). 
Switzerland has long had legislation designed 
“to preserve indigenous animal and plant 
species, biotopes and landscapes”(The 
Federal Law on the Protection of Nature and 
Landscape (1966) in Swiss Agency 15), a land 
planning law that allows for the protection of 
areas “of great ecological or cultural 
importance” (The Federal Law on Land-Use 
Planning (1979) in Swiss Agency 16) and, 
most recently, a fund of Sfr. 50 million was 
established “to contribute to the conservation 
of traditional rural landscapes, and to 
safeguard ancient methods of exploitation, 
cultural heritage, and natural landscapes” 
(Swiss Agency 17). 
12. Commitments to traditional cultivation 
methods may be matched by “compensation 
payments for disadvantaged areas” (Austria 
26) that serve to encourage farmers in 
marginal areas, such as montane farming 
zones, from abandoning agriculture and 
thereby help to ensure the continuing 
cultivation of local biodiversity. More generally, 
agro-environmental grants and “ecological 
compensation” programmes have been 
 
Ex situ collections of genetic resources—
including genebanks, seedbanks, 
herbariums and microbial culture 
collections—exist in most of the Council 
Parties.13 As the United Kingdom’s 
National Report on Biological Diversity 
                                                                    
established by Council Parties to remunerate 
farmers for conservation activities, cultivation 
of traditional varieties, sowing indigenous wild 
plants in fallow lands and gardens, engaging in 
organic and integrated agriculture, 
safeguarding biotopes, and as compensation 
for lost income caused by the abandoning the 
practice of more intensive resource use. More 
still could be done. It is estimated that Europe 
has lost 75% of its plant genetic diversity within 
the last century and that the revitalization of 
genetic and cultural diversity will depend upon 
support for organic plant breeding, the 
development of organically produced seeds 
and in situ management of a “diversity of 
cultural plants [which have] evolved from 
generation to generation, in the hands of many 
farmers and in many different landscapes” 
(Wyss and Wiethaler, 37). On these points, 
see Eric Wyss and Cornelia Wiethaler eds., 
Final Report on the International Conference 
on Biodiversity and Organic Plant Breeding, 
2nd and 3rd December 1999 in Frick 
Switzerland. The Report provides information 
on the organic breeding sector in all of the 
European Council Parties except Bulgaria. A 
database of available organic seeds and a 
bulletin board for exchange of information on 
organic breeding and propagation will be 
created at <http://www.biogene.org>. For a 
series of studies on the importance of 
preserving agricultural genetic diversity in situ, 
see Brush, ed. 
13. The Swiss Federal Office of Agriculture, 
following upon the Food and Agricultural 
Organization’s World Plan of Action, 
emphasised preserving the adaptive potential 
of cultivated plants. To this end, the Swiss 
Commission for the Conservation of Cultivated 
Plants (CPC) has attempted to inventory all 
concerned institutions and the genetic material 
that they safeguard. The Millennium Seedbank 
Project at the Royal Botanic Gardens in the 
United Kingdom both banks and supports the 
reintroduction of plant species and the 
Commonwealth Potato Collection is also an 
important repository.  
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acknowledged, however, much 
“biodiversity information remains scattered 
across the country in many different and 
incompatible forms” (United Kingdom 26). 
Only to the extent that information 
networks are created that are accessible, 
regardless of where the information is 
held, will the potential of information 
technology to promote biodiversity begin 
to be realized. 
 
Most Council Parties house or are party to 
the network of international genebanks 
established under the Food and 
Agriculture Organization (FAO) and the 
FAO promotes widespread access to 
these resources. Currently the network 
includes 12 genebanks but 31 additional 
countries have declared an intention to 
join their genebanks to this network. If 
accomplished, this amalgamation would 
incorporate into one network 46% of all of 
the planet’s plant genetic resources 
(Austria 46). The vast majority of crop 
germplasm held in these banks was 
collected from farming communities in the 
developing world (Crucible II Group 1: 20-
22). However, the rights of providers of 
this material to have a stake in any profits 
made in the successful commercial 
application of it is still under dispute. A 
related area of controversy requiring 
further research is the propriety of IPRs in 
genetic resources held in trust by the 
Consultative Group on International 
Agricultural Research (CGIAR) in the 
sixteen international agricultural research 
centres it supports. In 1996, the CGIAR 
endorsed the principle that its centres 
would not claim legal ownership or apply 
IPRs to the germplasm held in trust and 
would require recipients to abide by the 
same principles. What remains disputed is 
the propriety of claiming IPRs in varieties 
and technologies developed from CGIAR 
germplasm to the extent that this 
germplasm was developed by indigenous 
peoples and local communities. 
Mechanisms to provide compensation to 
the farmers’ communities from which such 
germplasm was taken may need to be 
developed. 
 
Many of the European Council Parties 
have participated in and contribute to the 
ministerial process, “Environment for 
Europe,” which is intended to implement 
the “Pan-European Biological and 
Landscape Diversity Strategy” that, in turn, 
provides the European framework of the 
CBD. Within Europe, the location of 
biological diversity in economically 
underdeveloped regions has been 
recognized and more developed Council 
Parties have devoted resources to the 
preservation of biodiversity in these less 
developed regions.14 The degree to which 
development initiatives in Eastern Europe 
could be linked to efforts to document and 
preserve traditional KIP needs to be 
further investigated.  
 
Amongst the Council Parties, the United 
Kingdom is unique in having Dependent 
Territories with both biological and cultural 
diversity that are considered endangered. 
The British Virgin Islands (BVI), the 
Cayman Islands, Gibralter, Jersey and St. 
Helena are included in the UK’s ratification 
of the CBD. However, at least seven other 
territories are not included. In all of these 
territories, older members of the local 
populations are likely to have significant 
traditional knowledge about local 
biospheres that is undocumented and, 
without recognition or support, is not likely 
to be passed onto successive generations. 
A biodiversity database is being developed 
in the BVI, but no recognition of ITKIP 
appears to accompany this initiative. 
 
                                               
14. Switzerland, for instance, has supported 
projects to conserve biological and cultural 
diversity in the region of Lake Onrid, between 
Albania and Macedonia, in addition to other 
ecosystem management projects in Estonia, 
Hungary, Bulgaria and Russia. The UK Darwin 
Initiative has supported the development of 
local expertise in peatland management in 
Eastern Europe.  
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Development priorities in many Council 
Parties have focussed upon environmental 
issues in less-developed countries, but 
such commitments to sustainable 
development are not always coupled with 
any evident concern for the relationship 
between natural resource management 
and cultural diversity.15 This is an area that 
requires considerable research if 
‘sustainable development’ initiatives are to 
support the preservation of cultural 
diversity.16 
 
In Canada, indigenous and traditional 
knowledge has been the subject of several 
commissioned research reports and 
traditional knowledge is now considered a 
source for consultation in environmental 
impact assessments. However, the 
                                               
15. The Belgian government, for example, has 
invested in regional environmental 
management and database projects in West 
and Central Africa (as well as in China and 
Eastern Europe) but the cultural dimensions of 
these initiatives are underdeveloped. The 
Swiss Agency for Development and 
Cooperation, on the other hand, has a portfolio 
of 36 projects devoted to biodiversity in Latin 
America, Asia, and Africa, several of which 
have the conservation of indigenous 
knowledge of cultivation as a priority (Swiss 
Agency 50). The Darwin Initiative funds UK 
biodiversity experts in projects that will help 
developing countries meet their obligations 
under the CBD. The EU funds the Central 
Cordillera Agricultural Program in the 
Philippines, a project which has attempted to 
integrate indigenous peoples’ resource 
management knowledge and practices as well 
as traditional health methods into its 
community development programmes. 
Tragically, a lack of understanding on the part 
of development authorities and government 
environmental officials about the effect of 
introducing new species alongside indigenous 
varieties led to the extinction of traditional 
varieties of great significance to local cultural 
practices (Rovillos, Interphasing).  
16. In recognition of this, the Canadian 
International Development Agency supports 
the work of Cultural Survival in compiling an 
international directory of indigenous 
conservation projects in the Americas. 
Northwest Territories is the only provincial 
government to have developed a policy 
pertaining to traditional knowledge. 
Acknowledging that aboriginal knowledge 
is a valid and essential source of 
information about the natural environment 
and its resources, this policy recognizes 
that traditional knowledge is best 
preserved through continued use and 
practical application, expresses a 
commitment to incorporate traditional 
knowledge into government decisions and 
actions where appropriate, and also 
commits to provide in kind support to 
aboriginal cultural organizations studying 
traditional knowledge.17 Indigenous 
peoples have been on the Canadian 
delegations to the CBD and Canada has 
funded off-delegation indigenous NGOs to 
participate in CBD discussions of 
traditional and indigenous knowledge 
protection. A World Intellectual Property 
Organization (WIPO) fact-finding mission 
in November 1998 involved consultations 
with indigenous groups across Canada to 
consider the viability of IPRs for protecting 
ITKIP.18 
 
NGOs based in the Council Parties have 
been active participants in international 
fora focussing upon these issues and in 
specific projects in developing countries 
that are documenting and preserving 
                                               
17. See 
<http://www.gov.nt.ca/Publications/Policies/52-
06_6.htm>.The Dene Cultural Institute, for 
example, is providing guidelines for use and 
access to traditional knowledge for 
government and industry planning projects and 
environmental impact assessments. See 
<http://www.deneculture.org/tradknow.htm>. 
18 The Union of British Columbia Indian Chiefs 
hosted an international conference on the 
protection of indigenous knowledge in 
February 2000 entitled “Protecting Knowledge: 
Traditional Resource Rights in the New 
Millennium” (February 24-26, 2000 at 
Vancouver, British Columbia, Canada). For 




ITKIP.19 European NGOs, however, have 
been critical of the EC’s draft Biodiversity 
Action Plan, noting that the discussion 
paper circulated in January 2000 made no 
reference to issues of food security, 
TRIPs, bioprospecting, or biopiracy.20 One 
reason for this was the failure of the EC to 
involve NGOs in the early stages of the 
discussion process.21 NGOs with global 
                                               
19. In Austria, the Austrian Rainforest Program 
is involved in projects in cooperation with 
indigenous peoples in Brazil and Costa Rica, 
while the Vienna Institute for Development and 
Cooperation has been working with the 
Embera peoples in Panama to reactivate their 
traditional knowledge about tree species so as 
to conserve and revitalize these varieties. The 
International Development Research Council 
(with offices in Canada and Switzerland) has 
funded the Crucible II Group project, and funds 
projects for preserving indigenous knowledge 
and digital networking in India, Peru, the 
Philippines, Vietnam, Nepal and Papua New 
Guinea (PNG). Rural Advancement 
Foundation International (RAFI) in Canada, 
has been instrumental in bringing the issue of 
biopiracy to international attention and in 
researching and challenging intellectual 
properties that are based upon indigenous 
knowledge of plant genetic resources.See the 
following materials from Rural Advancement 
Foundation International (RAFI): Captain 
Hook, the Cattle Rustlers, and the Plant 
Privateers: Biopiracy of Marine, Plant, and 
Livestock Continues. 11 May 2000; and, Plant 
Breeder’s Wrongs: An Inquiry into Potential for 
Plant Piracy through International Intellectual 
Property Conventions. 26 August 1998. 
<http://www.rafi.org/web/publications.shtml>. 
20. These European NGOs include: Fern, 
Greenpeace European Policy Unit, Birdlife 
International, Royal Society for the Protection 
of Birds, Swedish Society for Nature 
Preservation Arbeitsgemeinschaft für 
Regenwald und Artenschutz, Friends of the 
Earth England Wales and Northern Ireland, 
World Wide Fund for Nature. See Joint NGO 
Comments on the draft EC’s Biodiversity Plan 
(Version 12/1/2000) at 
<http://www.gn.apc.org/fern/NGO%20stateme
nts/biodiversity%20action%20planhtm.htm.> 
Posted February 13, 2000, 3. 
21. These European NGOs point EC member 
states to Articles 5 and 6 of the Council 
links to indigenous peoples are often the 
most significant source for information 
about ITKIP and the threats posed to 
indigenous peoples’ cultural survival. 
 
Finally university research institutes and 
independent researchers in most Council 
Parties are engaged in biodiversity 
research related to ITKIP in both domestic 
and foreign arenas.22 Overseas projects 
are often undertaken in conjunction with 
developing countries’ governments and 
researchers with the aim of improving 
international cooperation on biodiversity 
and cultural landscapes. In many of the 
regions that these researchers visit, local 
peoples are engaged in the task of 
recording traditional knowledge.23 Such 
researchers do not always share their 
                                                                    
Resolution on Indigenous Peoples which notes 
“the key role played by indigenous peoples in 
the conservation and sustainable use of 
natural resources, the positive contribution of 
indigenous peoples in the development 
process, the vulnerability of indigenous 
peoples” and the need for development 
projects that contribute to enhancing 
indigenous self-development. Articles 5 and 6 
of the Council Resolution on Indigenous 
Peoples are annexed to the Joint NGO 
Comments. See note 20, 6-7. 
22. The Swiss Academy of Sciences project, 
The Swiss Biodiversity Forum, for instance, is 
supporting a research project on “Local 
Ecological Knowledge of Swiss Farmers and 
its Influence on Actual Landuse Behaviour”. 
For information on this research project, see 
the homepage at 
<http://www.unibas.ch/mco/research_mueller.h
tm>.  
23. For example, local researchers are 
attempting to archive the over 814 distinct 
cultures in PNG in order to ensure the survival 
of forms of indigenous knowledge. This 
knowledge will be put on the Internet to make it 
more widely available. With one of the largest 
concentrations of biodiversity in the world, 
coupled with its cultural diversity, PNG attracts 
researchers from around the world. For more 
information on this archival project, see 





information with people within the country, 
however, and local peoples are often 
unaware of even published information 
pertaining to their own cultural ancestry 
and ITKIP. Research into the feasibility 
and consequences of making government 
research funding and publication 
subventions contingent upon the 
repatriation of research information to local 
informants and host governments is 
needed. This might be one means by 
which Council Parties could contribute to 




IT IS RECOMMENDED THAT COUNCIL 
PARTIES UNDERTAKE FURTHER 
RESEARCH TO CONSIDER: 
 
•How states can link their commitments 
to preserve biodiversity with 
considerations of cultural diversity and 
the cultural dimensions of ITKIP in both 
domestic legislation and regional 
regulation. 
 
•How the relationship between natural 
resource management and cultural 
diversity can be recognised in all 
environmental protection measures 
such that the preservation of cultural 
landscapes serves to preserve the 
ongoing development of cultural 
diversity. 
 
•How a system of collective rights that 
recognizes ITKIP, encourages its use, 
and facilitate the equitable sharing of 
benefits derived therefrom would be 
integrated with or recognized by 
domestic intellectual property regimes. 
 
•How surveys of domestic biodiversity 
which aim to protect domestic 
traditional knowledge could involve the 
participation of older members of the 
local populations in order to obtain and 
incorporate undocumented traditional 
knowledge about local biospheres and 
involve younger generations so as to 
increase their appreciation for such 
knowledge. 
 
•What type of support is needed for 
organic plant breeding, the 
development of organically produced 
seed, and in situ management of a 
plant diversity amongst different 
farmers and in different landscapes. 
 
•The propriety of claiming IPRs in 
varieties and technologies developed 
from CGIAR germplasm developed by 
indigenous peoples and local 
communities as well as compensatory 
mechanisms for farmers’ communities 
of origination. 
 
•The degree to which development 
initiatives in Eastern Europe could be 
linked to efforts to document and 
preserve ITKIP. 
 
•How the relationship between natural 
resource management and ITKIP can 
be recognized to develop sustainable 
development initiatives that support the 
preservation of cultural diversity. 
 
•The desirability of making government 
research funding and publication 
subventions contingent upon the 
repatriation of research information to 
local informants and host governments 
and how this could be funded by 
Council Parties as one way of assisting 
developing countries in joint efforts to 
preserve cultural diversity. 
 
 
The Contested Role of Intellectual 
Property Protections 
 
Obligations under the CBD that serve to 
protect cultural diversity by preserving 
ITKIP relevant to biological diversity are 
congruent with the Council Parties’ 
obligations pursuant to international 
environmental commitments and human 
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rights covenants as well as domestic 
foreign aid policies oriented towards 
sustainable development. They are also in 
accord with the current agenda of the 
WIPO which has made the protection of 
traditional knowledge a priority. WIPO’s 
1998 fact-finding missions on traditional 
knowledge, innovations, and culture 
involved holders of ITKIP in consultations 
regarding the dimensions of regional 
ITKIP, the development of research 
protocols to govern scholarly and research 
access to ITKIP, the need to distinguish 
between sacred and secular dimensions of 
ITKIP when considering dissemination and 
reproduction, and the need for recognition 
of traditional knowledge in policy-making 
processes for sustainable resource 
management.24 The lack of any such fact-
finding mission to European countries was 
unfortunate as these missions have raised 
consciousness about the significance of 
ITKIP around the world and have helped 
to mobilize traditional communities and 
indigenous peoples to document and 
protect such knowledge and to consider 
the appropriate means for its valuation and 
exchange. 
 
The active role of WIPO in raising public 
awareness of the significance of ITKIP 
does not, however, indicate any broad 
consensus that the intellectual property 
framework is appropriate for recognizing, 
valuing, and compensating ITKIP. Indeed, 
many indigenous peoples and NGOs 
representing traditional farmers and those 
practising subsistence agriculture have 
denounced attempts to impose intellectual 
property protections on third world 
countries.25 These are not isolated 
                                               
24. For example, see World Intellectual 
Property Organization, Fact Finding Mission on 
Traditional Knowledge, Innovations, and 
Culture to North America. November 16-30, 
1998. Doc. No. WIPO/ FFM N-AM/IMR/98/4. 
11 November 1999. 
<http://www.wipo.org/eng/main.htm>. 
25. In its Programme for the Protection and 
Promotion of Biodiversity and Community 
Rights, for example, the Third World Network 
opinions. The resistance to patents in the 
area of food and agriculture has provoked 
street riots involving over a half million 
farmers in India, various indigenous 
refusals to permit researchers to enter 
ancestral areas, and dozens of 
declarations by indigenous peoples, 
including The Seattle Declaration of 
Indigenous Peoples at the WTO meetings 
in 1999 (which continues to make the 
rounds on the Internet and to attract the 
signatures of more and more indigenous 
peoples and NGOs).26 The Seattle 
Declaration opposes the patenting of 
lifeforms, micro-organisms, plants animals 
and all of their parts and natural processes 
and insists upon the principle of prior 
informed consent and the right of veto by 
indigenous peoples with respect to the 
appropriation of indigenous seeds, 
medicinal plants, and related knowledge 
                                                                    
(TWN) has commissioned a series of papers 
on the ways developing country governments 
should implement their Trade-Related Aspects 
of Intellectual Properties Agreement (TRIPs) 
obligations while taking into account the need 
to protect and preserve biodiversity and 
community knowledge, innovation and 
practices (CKIP) and the means to ensure that 
traditional and indigenous knowledge is given 
a vital role in scientific and technological 
policies relating to the sustainable use of 
biodiversity. In nearly all of the papers 
commissioned for the second year of the 
programme, the patenting of lifeforms is 
rejected and the intellectual property system 
itself is denounced for undermining indigenous 
peoples’ rights, knowledge, and livelihoods. 
See, for example, Egziabher; Ho and Traavik; 
and, Tauli-Corpuz.  
26. One of the many websites where this 
document can be found is: 
<http://www.wtowatch.org/library/admin/upload
edFiles/Indigenous_Peoples_Seattle_Declarati
on.htm>. Ultimately, it suggests that the 
cultures of indigenous peoples, their 
knowledges, cosmologies and values provide 
the most viable alternatives to dominant 
models of economic growth and export-
oriented development and that the imposition 
of IPRs forecloses the capacity of indigenous 




about these lifeforms. It is increasingly 
unlikely that existing IPR regimes will be 
used as the primary means for protecting 
ITKIP.27 However, there is still further 
                                               
27. For various legal and administrative reform 
proposals see Dutfield, Rights; Australian 
Institute; and Simpson. Although Volume One 
of The Crucible II Group provides an excellent 
coverage of the policy framework and the 
opportunities and constraints that it provides, 
Volume Two (forthcoming) promises to provide 
more precise options for legal reform. 
 
As Victoria Tauli-Corpuz (Director of Tebtebba 
Foundation, Inc., the Indigenous Peoples’ 
International Center for Policy Research and 
Education) writes in “TRIPs and Indigenous 
Peoples”: 
Intellectual property rights are monopoly 
rights given to individuals or legal persons 
(such as transnational corporations) who 
can prove that the inventions of innovations 
they made are novel, involved an 
innovative step, and are capable of 
industrial application. Indigenous 
knowledge and cultural heritage are usually 
collectively evolved and owned. If 
indigenous peoples have to use Western 
IPRs to protect their own knowledge and 
innovations, they will have to identify 
individual inventors. This will push 
unscrupulous indigenous individuals to 
claim ownership over potentially profitable 
indigenous knowledge which will cause the 
further disintegration of communal values 
and practices. It can also cause infighting 
between indigenous communities over who 
has ownership over particular knowledge or 
innovation. 
 
The concept of exclusive ownership and 
alienability which is inherent in TRIPs will 
have to be internalized and imbibed by 
indigenous peoples even if it goes against 
their usual practice of making available 
such knowledge for the common good. The 
identity and survival of indigenous peoples 
as distinct peoples depends to a large 
extent on the age-old practice of common 
sharing of some resources, knowledge and 
skills which are not alienable. With TRIPs, 
indigenous peoples will now have to think 
of how their knowledge will be protected 
against so-called ‘biopirates.’ Sharing of 
research to be done to determine how IPR 
regimes can be improved so as not to 
undermine forms of cultural diversity. 
 
Despite a fairly overwhelming consensus 
that IPRs will not serve the range of 
relevant indigenous needs, it is widely 
recognized that membership in the WTO 
creates state obligations which will require 
the introduction of some new legal rights 
and the need to legally justify the refusal to 
introduce other forms of intellectual 
property protection. Current legal regimes, 
it is argued, sanction the usurpation of 
farmers’ traditional knowledge.28 Only if 
                                                                    
knowledge becomes a dangerous 
proposition because it might be 
appropriated by those who have the 
capacity to use the system to claim 
exclusive ownership over such knowledge 
and commercialize it. 
 
Although typical, the assertion that 
corporations may claim exclusive ownership 
over knowledge appropriated from indigenous 
peoples is inaccurate. Only the particular 
application of such knowledge, providing that it 
is itself novel and involves an innovative step 
(or in patent parlance, is not obvious to a 
person of ordinary skill in the art) will be 
protected. The patent holder does not gain 
thereby an exclusive rights to the common 
knowledge that underlies the particular 
technology, nor does the commercial 
application preclude the continuance of prior 
noncommercial usages of such knowledge. 
Nonetheless, patents are being granted that 
should not be granted based upon a proper 
application of these legal principles, and 
threats to enjoin alternative usages are often 
made by intellectual property holders even 
when they do not legally have rights of the 
scope that they assert. The assumption by 
indigenous peoples that the legal claims made 
by intellectual property holders are valid ones 
that the Western legal system supports is, 
however, part of the problem that needs to be 
addressed. 
28. This form of creativity, it is argued, is likely 
to continue to be usurped, marginalised and 
eventually extinguished by plant breeders’ 




states are prepared to independently 
protect ITKIP and to limit plant breeders’ 
rights will ITKIP, and the cultural diversity 
it manifests, survive.  
 
Given the TRIPs obligation to protect plant 
varieties, it is asserted that any new 
breeders’ right introduced should be 
subject to a public interest proviso that 
precludes the granting of such a right 
when the public interest so requires. This, 
it is suggested, will be the case “where 
biodiversity is adversely effected, where 
the variety poses a possible hazard to the 
agricultural system and to human, animal 
and plant life, based on the precautionary 
principle, where the introduction of the 
variety might affect the innovative capacity 
and indigenous technologies of farmers, 
healers, indigenous peoples, and local 
communities”(Nijar, Perspectives). 
Moreover, it is suggested that states pass 
laws to protect and respect the knowledge 
of indigenous peoples and farming 
communities with respect to plant varieties 
that would provide for a proprietary right of 
such peoples to any variety developed by, 
or essentially derived from, the knowledge 
of indigenous peoples or traditional 
farming communities, recognizing co-
                                                                    
 
The Union for the Protection of Plant 
Varieties (UPOV) allows for breeders’ rights 
in respect of plant varieties that are 
‘improved’ modifications of farmers’ 
germplasms. UPOV 1991 extends the gap 
between source materials and improved 
varieties in terms of value and ownership 
rights attached to them. This revised 
instrument allows for both breeders’ rights 
and patents for plant varieties. Finally, the 
TRIPs Agreement under the WTO allows 
for patents over life forms and requires that 
plant varieties be protected by patents or a 
sui generis system. In all of these 
instruments, the definitional constructs 
preclude recognition of innovations that are 
inter-generational, collective and for the 
social good—hallmarks of the way 
indigenous people create and innovate 
(Nijar, Perspectives). 
ownership among communities if 
necessary (Nijar, Sui Generis).  
 
All of the Council Parties (with the 
exception of Luxembourg) currently 
adhere to the Union for the Protection of 
Plant Varieties (UPOV). Research is 
needed to determine if the introduction of 
a public interest provision would be 
congruent with UPOV obligations and 
whether recognition of communally-
developed varieties could coexist with a 
plant breeders’ rights regime based upon 
UPOV principles. If Council Parties were 
to refuse to grant patents upon plant 
varieties and to incorporate this definition 
of the public interest in their national plant 
breeders’ rights legislation (putting the 
onus of proof upon the applicant for the 
exclusive right, perhaps supplemented 
with a right of standing for indigenous 
peoples or NGOs with a history of activism 
in this area), then the perceived tendency 
of the intellectual property system to 
sanction biopiracy and to promote 
biotechnology of dubious safety and 
harmful cultural consequences would be 
greatly alleviated. Considerable research 
needs to be done, however, to ascertain 
how and when the introduction of 
genetically modified varieties affects local 
plant life and in what ways the introduction 
of new varieties affects innovation 
activities in indigenous and local 
communities. Such assertions are often 
made, but are seldom adequately 
documented.  
 
A strong case can be made that more 
information about intellectual properties 
being applied for and granted should be 
made available digitally and in a form 
accessible to more of the world’s peoples. 
Indigenous peoples and holders of 
traditional knowledge should be able to 
use digital technologies to ascertain if 
patents, for example, are being granted on 
technologies which are based on 
traditional knowledge, involve an “obvious” 
step in technological development, and/or 
for subject matter that lacks the necessary 
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quality of novelty given publication 
activities known to them. Unfortunately, 
very few patent regimes enable patents to 
be challenged on these legitimate legal 
grounds before a patent is issued. More 
and more information about patents has 
been recently made available on the 
Internet and some of these services are 
free.29 However, the availability of this 
information may be of only limited value to 
indigenous peoples and the NGOs that 
support them. Patent information is 
opaque (even to lawyers) and patent 
claims are often written to obscure rather 
than reveal the scope of the subject matter 
claimed to deter competitors or to 
encourage them to license the technology 
rather than risk infringing it. Even 
assuming that patent and plant breeders’ 
rights documentation was so clear, 
adequate, and accessible that indigenous 
peoples, third world farming communities, 
and interested NGOs could assess their 
validity, the cost of challenging these 
rights is enormous. Further research 
needs to be done into the benefits and 
savings of a patent prosecution process 
that would enable indigenous peoples 
(and market competitors who might be 
inclined to support indigenous challenges 
to monopolies in their fields) to challenge 
pending patent applications on 




IT IS RECOMMENDED THAT COUNCIL 
PARTIES UNDERTAKE FURTHER 
RESEARCH TO CONSIDER: 
 
•How IPR systems can be improved so 
as not to undermine forms of cultural 
diversity. 
 
•The possibility of introducing a public 
                                               
29. For a list of patent sites, see Newton, How 
to Find Information. The British Library also 
offers access to this information at 
<http://www.bl.uk/services/bsds/pxp/overview.
html>. 
interest proviso that precludes the 
granting of plant breeders’ rights when 
the public interest so requires.  
 
•Whether the introduction of a public 
interest provision would be congruent 
with UPOV obligations and whether 
recognition of communally authored 
varieties could coexist with a plant 
breeders’ rights regime based upon 
UPOV principles. 
 
•Means to provide for a proprietary 
right of indigenous peoples and farming 
communities to any variety developed 
by or essentially derived from the 
knowledge of indigenous peoples or 
traditional farming communities, 
recognizing co-ownership among 
communities if necessary. 
 
•How and when the introduction of 
genetically modified varieties affects 
local species and ecosystems. 
 
•How the introduction of new varieties 
is likely to affect innovation activities in 
indigenous and local communities. 
 
•How information about intellectual 
properties being applied for (or granted) 
may be made digitally available in a 
form accessible to more of the world’s 
peoples. 
 
•The benefits and savings of a patent 
prosecution process that would enable 
indigenous peoples (and market 
competitors who might be inclined to 
support indigenous challenges to 
monopolies in their fields) to challenge 
pending patent applications on 
conventional legal grounds and for 
public interest purposes, and/or before 
a patent is issued. 
 
 
Indigenous Peoples, Cultural Diversity, 




Indigenous peoples have been active 
users of the Internet, using it to 
communicate amongst themselves and to 
others, to gain access to resources, to 
publish and access databases, and to 
provide alternative perspectives on issues 
that are not covered in mainstream media 
(Cisler 1998). Apple Computer’s Library of 
Tomorrow project, for example, funded 
several library, networking, and language 
preservation projects with American Indian 
tribes and similar initiatives are now 
underway around the globe.30 
 
In some indigenous communities, elders 
have rejected new information 
technologies, but others see the Internet 
as a tool for cultural survival. 
Unfortunately, in many areas of the world, 
electronic communications systems tend 
to reinforce traditional hierarchical social 
structures which isolate and marginalise 
many indigenous peoples (Donaghy 
1998). Whereas in the U.S. and Canada, 
indigenous networks have received 
extensive technical support from 
universities, in areas like Latin America 
such collaboration is rare (Donaghy 1998). 
European states and regional 
governments can assist in these efforts.31 
                                               
30. As Delgado and Becker write: “Computer 
technology has been taught in a manner which 
makes indigenous peoples recall the way their 
languages work. Most of these languages work 
on an ‘agglutinative’ principle; a root word 
provides the base and an infinite number of 
suffixes are added according to the situation. 
Computer technology, listservs, newsgroups, 
and web sites work in this way as well” (1998). 
31. The “Inkarri” information centre on 
indigenous issues, sponsored by the Basque 
county of Vitoria-Gasteiz, illustrates this 
possibility (Inkarri Site). Similarly, a web site 
functioning from Geneva has enabled a team 
of indigenous peoples to concentrate on 
Andean issues (Pueblo Indio Site). Within 
Europe, EU funds created for cultural and 
economic development in sparsely populated 
areas have been used by the Sami to adopt 
digital technology to further the marketing of 
traditional crafts. However, the failure of the 
Swedish government to recognize Sami other 
Although many sites on the World Wide 
Web are effective in advocating on behalf 
of international reforms and mobilizing 
support amongst Northern activists unless 
these sites broadcast simultaneously in 
indigenous languages they not serve as 
organizing tools for indigenous peoples in 
the South. For many indigenous 
languages, however, new fonts must be 
developed for use in digital 
environments.32 This is a first and 
fundamental step in the drive to realize the 
potential of new information technologies 
for preserving cultural diversity. The 
maintenance, use, sharing, and 
recognition of ITKIP is also dependent 
upon the revitalization and revaluation of 
indigenous languages. 
 
Media experts in Canada’s Northwest 
Territories are optimistic that the Internet 
will help to preserve Dene, Inuit, and Métis 
identities and prevent the further erosion 
of aboriginal languages. Contemporary 
research indicates that language 
maintenance and revival tend to be 
accompanied by a reaffirmation of cultural 
traditions, a revitalization of ITKIP, and a 
renewal of traditional relationships with the 
environment (Maffi 2000). The isolation of 
many indigenous communities may be 
overcome by the Internet because it 
                                                                    
than those engaged in reindeer husbandry as 
having indigenous identity, has limited the 
extent of computer and Internet education. 
Only one Sami language has digital type fonts, 
moreover, and without support for font 
development, the potential of the Internet to 
assist in the survival of these endangered 
languages will not be realized (Forsgren 1998).  
32. For instance, even though most people in 
Burma are not permitted to use the Internet, 
Burmese in exile have taken advantage of it to 
spread information about repression in Burma 
and to organize resistance activities. Members 
of an indigenous human rights and 
environmental organization have traveled 
through border areas to teach computer skills 
to Mon and Karen peoples who have now 
developed digital fonts for use in 




arguably provides an ideal medium for 
aboriginal communications.33 
                                               
33. Northern News Services copy editor, James 
Hrynyshyn, believes that “the Internet is an 
ideal match for Aboriginal tribes, providing the 
necessary economy of scale to support 
electronic publishing for such small 
constituencies...because the Internet can 
support an admixture of audio, video, and text, 
transcending the print medium, it is ideally 
suited to the oral story-telling traditions of the 
Aboriginal Community” (Zellen 1998). Indeed, 
the small town of Inuvik has one of the fastest 
public Internet connections and the Gwich’in 
and Inuvialit globally market traditional art from 
their home pages. The Oneida Nation had a 
web page before the White House did and 
through it has educated an entire Chinese high 
school on Oneida culture, attracted visitors 
from Europe to its cultural centre, and created 
interest in the Middle East in the dissemination 
of Oneida design (Polly 1998). In the South, 
interactive electronic conferencing has enabled 
indigenous peoples living in remote areas to 
share common concerns and exchange 
information about their shared problems in 
relation to nation states. The Zapatista uprising 
against the Mexican government upon the 
ratification of NAFTA marked the beginning of 
the political use of Internet technology by 
indigenous groups. The Maya in Guatemala 
are attempting to electronically retrieve any 
and all information pertaining to their cultures 
to revive their traditional languages and to 
legitimate their claims to their ancient 
territories. The Kuna in Panama have become 
international advocates of indigenous peoples’ 
stewardship over biodiversity and its 
relationship to indigenous rights of self-
determination. 
 
Digital video camcorders will enable 
indigenous peoples to share cultural 
performances and practices, making ITKIP 
globally available, or at least available to other 
indigenous peoples if that is the more 
desirable end. Stories told by elders and 
traditional practices can both be filmed and 
recorded so that they can ‘speak’ to their 
descendants for eternity. This is only valuable, 
however, insofar as their descendants can 
speak their languages and have viable 
opportunities to use these practices in a 
context where they are respected and 
supported. 
 
Indigenous peoples who no longer reside 
on ancestral lands have used the Internet 
to revitalize their indigenous identities 
while those who did not formally belong to 
indigenous groups have rediscovered their 
ethnic heritage through Usenet group. The 
Internet has afforded them opportunities to 
trace their own histories.34 The Hawaiian 
indigenous language, long outlawed and 
facing extinction, has been reintroduced in 
the school system through the use of 
computer technology, the development of 
fonts, the Internet linkage of peoples 
learning the language, and the 
authorization of Microsoft to create a 
Hawaiian language version of the Internet 
Explorer programme (Donaghy 1998). 
This example suggests some inherent 
limitations on the potential of new 
information technologies to aid in the 
preservation of cultural diversity. To the 
extent that most Internet browsers, email 
programmes, web page designs, existing 
fonts, html authoring programmes, and 
Internet multimedia applications are 
proprietary technologies, indigenous 
peoples are put at a profound 
disadvantage when attempting to adapt 
them for indigenous language use. 
Intellectual property holders are under no 
obligation to license these technologies, or 
even to license them at less than market 
rates, regardless of whether these new 
language versions are being put 
exclusively to nonprofit usages that further 
international legal norms and human rights 
commitments. The possibility and 
feasibility of introducing new exemptions 
                                               
34. Indigenous Assyrians, forbidden to teach 
their own language, develop their cultural 
identity, or refer to themselves as a people in 
many Middle Eastern countries, have used the 
Internet to reconnect with Assyrians in exile all 
over the world and to educate the global 
community about their culture, persecution, 
and aspirations (Gabrial 1998). Continued and 
renewed usage of the Syriac or Aramaic 
language through the World Wide Web, 
however, will only be possible if compatible 
fonts are developed. 
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into domestic copyright, trademark, and 
patent regimes to further indigenous use 
of such technologies is a topic that 
requires further research.  
 
The lack of women’s involvement in 
indigenous digital culture is a serious 
shortcoming and, given that indigenous 
women are often custodians of language 
and tradition as well as major holders of 
ITKIP (particularly with respect to 
traditional medicine and agricultural 
techniques), this remains a significant 
obstacle to realizing the full potential of 
Internet technology for preserving cultural 
diversity. Further research needs to be 
done exploring effective means for 
involving more indigenous and rural 
community women in indigenous use of 
digital technology for biodiversity and 
cultural preservation purposes. 
 
When asked whether he had any advice 
for “those who would follow in your 
footsteps and try to preserve their culture 
using a web page,” the Oneida Indian 
Nation’s Internet coordinator, Dan 
Umstead, advocated caution in sharing 
cultural knowledge: “Remember, if you put 
it up, people will use it. So carefully plan it 
all out beforehand” (Polly 1998). To the 
extent that there are cultural precautions 
and prohibitions concerning the use and 
reproduction of particular knowledge, 
imagery, stories, or texts, these are 
unlikely to be known or respected in 
cyberspace. The Internet could become a 
means of educating others about such 
indigenous systems of intellectual property 
and online license agreements based 
upon indigenous cultural principles could 
also be devised. Further research on the 
prospects for recognizing and enforcing 
indigenous customary law in cyberspace is 
needed. 
 
IT IS RECOMMENDED THAT COUNCIL 
PARTIES UNDERTAKE FURTHER 
RESEARCH TO CONSIDER: 
 
•Developing fonts for indigenous 
languages to maximize use of new 
information technologies for preserving 
cultural diversity and the maintenance, 
use, and compensation for ITKIP upon 
which global biological diversity 
depends.  
 
•The feasibility of devising online 
licensing agreements based on 
indigenous cultural principles. 
 
•The possibility and feasibility of 
introducing new exemptions into 
domestic copyright, trademark, and 
patent regimes to further indigenous 
use of digital technologies for cultural 
preservation and revitalization 
purposes.  
 
•New and effective means for involving 
more indigenous and rural community 
women in the use of digital technology 
for biodiversity and cultural 
preservation purposes. 
 
•Prospects and opportunities for 
recognizing and enforcing indigenous 
customary law in cyberspace. 
 
 
Digital Technology, Biodiversity 
Preservation, and the Protection of 
Indigenous Knowledge 
 
Digital technology is widely used for 
biodiversity preservation purposes and 
many state and NGO initiatives are 
underway to develop electronic storage 
and communications media to meet CBD 
objectives. National contacts exist in each 
of the Council Parties for the ‘clearing 
house’ mechanism being established 
under the CBD to promote and facilitate 
technical and scientific cooperation (Article 
18.3) with respect to the sustainable use 
of biodiversity (Article 10), the sharing of 
benefits derived from the use of 
biodiversity (Article 19.2), and the 
involvement and equitable sharing of 
benefits with indigenous and local 
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communities (Article 8(j)). Many of these 
clearing houses are in their infancy and 
currently operate more as catalogues or 
inventories. Most have been launched on 
the Internet.35  
 
Work is underway to create a single 
international facility for information on 
biodiversity—the Global Biodiversity 
Information Facility or GBIF—that will link 
the clearing house mechanisms with other 
“databases on the distribution of plants, 
animals, and microbes around the globe, 
detailed genome maps, compilations of 
the physiological functions of organisms, 
and information about the behaviour and 
function of species within ecosystems” 
(Environment News Service). Such 
international maps, however, are not 
necessarily conducive to the goal of 
preserving cultural diversity to the extent 
they presuppose a singular knowledge of 
                                               
35. The Belgian Institute of Natural Sciences, 
for example, launched the web site of the 
Belgian Clearing House on October 7, 1996. It 
was the second to be added to the official list 
of National Focal Point Clearing-Houses on the 
Internet and provides several options for 
searching for information on biological diversity 
in Belgium and elsewhere. Like other such 
sites, it provides hyperlinks to other national, 
regional, and thematic clearing houses as well 
as linking to the CBD, and the United Nations 
Environmental Programme. The site also 
houses the CBD clearing houses for Niger, the 
Congo, Chad, Mauritania, and Burkina Faso. 
Within the framework of the Belgian Research 
Network (BELNET), the Workgroup on 
Biodiversity has launched a two-part initiative. 
The first part is an inventory of biodiversity 
resources in Belgium—not limited to 
biodiversity in Belgian territory—that refers to 
universities, research institutes, botanical 
gardens, zoos and aquaria, museums, nature 
education centres, associations, libraries and 
nature reserves. The second part of the 
initiative will create an inventory of the content 
of the databases on biodiversity kept in 
Belgium. The linkage between biodiversity and 
cultural diversity could be made more explicit 
in such projects. 
<http://www.naturalsciences.net/bch-
cbd/homepage.htm>. 
the properties of biodiversity that might be 
universally shared. For instance, a key 
feature of the GBIF will be a database 
containing the names of all known 
organisms which, it is envisioned, will 
“ensure a single global nomenclature for 
all named living organisms” (Environment 
News Service). It is, however, precisely 
the continued existence of multiple 
systems of knowledge about natural 
organisms and their culturally specific 
classification systems, nomenclatures, and 
linguistic relations to ecosystems that is 
key to maintaining the cultural diversity 
upon which biodiversity depends.36 
 
Other government departments may also 
use the World Wide Web for public 
education purposes with respect to ITKIP. 
The federal environmental ministry in 
Canada, for instance, posts commissioned 
reports on indigenous and traditional 
knowledge to its web site (Lambrou 1997; 
Mann 1997; Brockman 1997) as well as 
more general examples of the Canadian 
government’s acknowledgment of the 
value of ITKIP in environmental policies 
(Blanchet-Cohen 1996). The government 
of India is producing CD-ROMs of its 
traditional medicinal plant knowledge 
                                               
36. Most of the world’s linguistic diversity is 
carried by small communities of indigenous 
and minority peoples. Indigenous and minority 
languages encode distinct forms of knowledge 
and cognitive maps of local ecosystems that 
cannot simply be translated into dominant 
languages. Nor can such diversity be reduced 
to nomenclature. Ethnobiologists now 
recognize that traditional ecological knowledge 
is not about entities per se, such as natural 
kinds, but about natural processes and 
relations among entities, such as the 
relationships among plant and animal species 
or between humans and the ecosystem. 
Moreover, this knowledge is not carried simply 
in linguistic terms but in grammar and speech 
formulas and culturally conventionalized ways 
of expressing spatial, temporal and causal 
relations. The relationship between landscapes 
and languages is in many cases mutually 




which will be distributed to patent offices 
worldwide to provide a database of prior 
art. This database may serve to prevent 
the issuing of patents such as U.S. Patent 
5,401,504 which claimed the use of 
turmeric for promoting wound healing 
when the practice had been known for 
centuries and published in India for over 
thirty years. Few developing countries 
have the resources to document and 
digitally disseminate ITKIP in this fashion. 
For many indigenous peoples facing 
pressures of assimilation and territorial 
encroachment, the governments of the 
states in which they are resident are not 
bodies that can or will be entrusted with 
such knowledge. There is a need then, to 
support indigenous peoples’ own efforts 
and those of supportive NGOs to develop 
and provide such databases as well as 
protocols for access to data and benefit 
sharing. Research is necessary, however, 
to ascertain the extent to which some 
forms of knowledge should be kept 
confidential and for what purposes. 
Indeed, a concern with confidentiality has 
resulted in the deployment of a trade 
secret model in one Ecuadoran project 
(Bodeker 12). In this project, local and 
indigenous communities are invited to 
participate in depositing and cataloguing 
traditional knowledge in a restricted 
access database, a determination of the 
public domain status of the knowledge will 
be made by the database administrators 
and, to the extent that more than one 
community shares potentially proprietary 
knowledge, a cartel of communities will be 
established to negotiate Material Transfer 
Agreements with the CBD state 
government and those interested in 
exploiting the knowledge for commercial 
use. Further research needs to be done to 
ascertain the viability of similar trade 
secret models in other regions, the degree 
to which violations of database 
confidentiality give rise to legal recourse, 
the extent to which such agreements 
should be respected and recognized in 
national and regional patent regimes, and 
the desirability of amending patent law to 
do so. 
 
The Sociedad Peruana de Derecho 
Ambiental has proposed that all patent 
applications in the future should include a 
sworn statement as to the genetic 
resources, as well as the associated 
knowledge, innovations and practices of 
indigenous peoples and local communities 
utilized directly or indirectly in the research 
and development of the subject matter of 
the patent application. This proposal could 
also be extended to plant breeders’ rights 
applications (Bodeker 12) and would entail 
the submission of evidence of prior 
informed consent from the country of 
origin and the local community.37 Further 
research needs to be done to determine if 
such a requirement is compatible with the 
TRIPs Agreement (and preliminary 
research indicates that it is, if 
characterized as an aspect of the novelty 
requirement) but such an amendment is 
widely urged. In 1997 the Indian 
government submitted a paper to the 
WTO’s Committee on Trade and 
Environment that criticized TRIPs on the 
basis that patent applicants were not 
asked to make such disclosure. 
Facilitators of both the People’s 
Biodiversity Registers38 and the Local 
Innovations Database39 initiatives in India 
argue that the documentation of 
community knowledge will only be 
                                               
37. For a longer discussion of making prior 
informed consent a condition precedent for 
receiving a patent see Coombe. 
38. This project is sponsored by the World 
Wildlife Federation India and is co-ordinated 
with the Centre for Ecological Sciences of the 
Indian Institute of Science and the Foundation 
for Revitalization of Local Health Traditions in 
Bangalore. For more information on People’s 
Biodiversity Registers, see Gadgil et al. 
39. This project has been developed by the 
Society for Research and Initiatives for 
Sustainable Technologies and Institutions in 
Ahmedabad and is managed by Professor Anil 
Gupta of the Indian Institute of Management. 
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successful if intellectual property regimes 
are so modified.  
 
Other electronic databases and digital 
networks are being established in 
developing countries with support by 
Council Parties and Council Party NGOs.40 
                                               
40. For example, the Swiss Agency for 
Development and Cooperation supports The 
Farmer’s Rights Information Service (FRIS) 
developed by the M.S. Swaminathan Research 
Foundation to educate the public about India’s 
heritage of biodiversity and current issues of 
significance in the preservation of agro-
biodiversity, including the need for incentives 
to support ongoing activities of genetic 
stewardship. As the founder’s introduction 
explains, “exchange of information, technical 
and scientific cooperation, research and 
training, public education and identification of 
suitable financial resources are all important 
for arresting the loss of agro-biodiversity”(FRIS 
Website).The web site operates as part of an 
emerging network that links local and 
indigenous communities in conservation 
efforts: 
 
With the emergence of democratic systems 
of governance worldwide and with the 
onset of the information superhighway, the 
widespread involvement of grassroots level 
peoples' organizations in the conservation 
movement is becoming feasible. In addition 
to information dissemination through 
printed and electronic media, ‘awareness 
through action’ programmes will have to be 
fostered in schools and colleges 
(Introduction, FRIS Website). 
 
The website’s founder believes that “the 
information age has provided tools such as the 
Internet and GIS mapping to promote a 
learning revolution in agriculture” and uses the 
site to participate in this revolution. The site 
operates as a tutorial and teaches that: 
entitlements, asset reform and technological 
empowerment of the poor will be essential in 
ensuring economic access; and, that gender 
perspectives must be integrated into the 
development of appropriate technology 
transfers and the information dissemination 
process if agriculture is to serve as an 
instrument of income and livelihood 
opportunity. The site is linked to videos of 
                                                                    
“experts” espousing the importance of 
traditional and tribal peoples and their 
knowledge in preserving biodiversity and to a 
set of “field videos” that take web visitors to 
sacred groves whose genetic diversity is 
maintained by tribal peoples as places of 
worship, to an interview with a local farmer, 
and to local peoples engaged in traditional 
methods of seed storage.  
 
From the site, web surfers may “visit” tribal 
communities in the Indian states of Tamil 
Nadu, Kerala, and Andhra Pradesh, where 
they will gain information on the social 
customs, agricultural practices, and knowledge 
of medicinal and other useful plants held by 
tribal peoples. Such information, however, is 
described in general rather than disclosed in 
specificity.  
 
More specific information is provided for 
Orissa, a centre of origin for traditionally 
cultivated varieties (landraces) of rice assumed 
to contain many valuable genes particularly for 
resistance/ tolerance to various biotic and 
abiotic stresses and thus to hold promise for 
utilization in future plant-breeding 
programmes. The multimedia database 
contains details on the morphological and 
agronomical characters of the rice variety, the 
donor farmers’ name and the community, and 
location and date of collection for landraces 
from five areas inhabited by tribal peoples who 
continue to grow these varieties. Visitors will 
find pictures of the individual who cultivated 
the variety, his or her tribal affiliation, and the 
location of the gene bank in which the landrace 
has been deposited. 
 
More problematic, from the perspective of 
preserving cultural diversity, are the Orissa 
site’s detailed descriptions of the sacred 
groves located in tribal areas. Not only does 
the site name and locate these, it describes 
the species found there, and the particular 
taboos that local peoples observe. To what 
extent does such a practice operate as an 
invitation to those who would appropriate local 
knowledge about species which, by virtue, of 
local cultural prohibitions, are likely to have 
unique genetic properties? What protection 
has been afforded to these peoples against 
biopiracy? Is cultural diversity maintained by 
practices that expose local belief systems to 
such international and indiscriminate scrutiny?  
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Such databases may have consequences 
for the future potential of peoples to 
benefit from this cultivation activity. To the 
extent that such publication does create a 
record in the public domain, it may operate 
so as to prevent the appropriation of such 
knowledge and resources in patent claims 
and plant breeders’ rights asserted by 
others. Again, this will depend upon the 
willingness of patent offices to recognize 
this as “prior art”. However, the option of 
local peoples’ profiting from such 
knowledge as a trade secret may also be 
foreclosed by such publications. Further 
research needs to be done on the likely 
legal and cultural consequences of such 
publications before knowledge of a 
sensitive, sacred, or potentially proprietary 
character is posted on the Internet. 
Protocols for local peoples’ prior informed 
consent to govern such postings need to 
be established. 
 
Traditional systems of medicine and local 
knowledge of plant genetic resources are 
especially diverse in India. In order to 
counter the general public devaluation of 
the traditional knowledge of those in 
marginalised communities and to ensure 
compensation to communities and 
individuals for the commercialization of 
such knowledge, community knowledge 
databases are being created. Such 
decentralized databases may serve a 
number of local cultural and ecological 
purposes and are networked to a national 
database that promotes the use of such 
knowledge for the benefit of local 
communities. Access to the contents of 
such registers is therefore restricted to 
communities of origin who, it is 
anticipated, will be able to charge fees to 
others, create tariffs, and negotiate 
contractual arrangements. Further 
research on the implications of various 
forms of confidentiality for local peoples 
needs to be carried out. On the one hand, 
access restrictions no doubt lessen 
misappropriations. On the other hand, to 
the extent that such knowledge is acquired 
and used, the fact that such information 
was not in the public domain could make 
any patent based upon it difficult to 
challenge because prior art in many 
jurisdictions does not encompass private 
databases (Dutfield, Protecting, 122). 
Ultimately, a global linkage of such 
databases might enable individual and 
collective innovators to receive both 
acknowledgment and compensation for 
commercial applications of their KIP while 
enabling small investors, entrepreneurs, 
and local innovators and communities to 
locate each other for the purposes of 
business development. Such a system 
could maintain linkages with regional and 
national patent offices which would 
universalize prior art so that traditional 
knowledge is respected and 
acknowledged. 
 
In terms of their capacity to preserve 
cultural diversity, however, it is important 
to remember that ITKIP thrives to the 
extent that it is used in ongoing human 
practices to meet new challenges, not to 
the extent that it is archived. As Agrawal 
argues, “divorced in archives from their 
cultural context, no knowledge can 
maintain its vitality or vigour”(Agrawal 
429). The danger of the archival approach 
is that it “may deflect attention from the far 
more important priority of protecting 
traditional knowledge in situ which of 
course requires that attention be given to 
the cultural, spiritual, and physical well-
being of the knowledge holders and their 
communities” (Dutfield, Protecting, 109). 
Some indigenous peoples are concerned 
that the effort to document traditional 
knowledge indicates that outsiders value 
traditional knowledge much more than 
they respect those who generate it. Many 
indigenous peoples have made it clear 
that concern for the protection of IKP 
should be subsidiary to the recognition of 
indigenous peoples’ rights to self-
determination and territorial rights. 
 
Linked database initiatives—like the 
Honeybee Network which documents and 
puts onto the Internet actual video 
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demonstrations of sustainable agricultural 
technologies in several languages—
provide a means for local and indigenous 
communities around the world to share 
traditional knowledge; they may be 
considered a form of technology transfer. 
Again, such postings pose particular 
problems to the extent that they may be 
legally deemed to be anticipations that will 
preclude the issuance of patents for such 
technologies in the future.41 To the extent 
that the sharing of ITKIP helps to meet the 
health and food needs of other local 
communities, it seems inequitable that 
such disclosures should preclude 
innovating communities from later 
                                               
41. As I have argued previously: “because the 
law [of patents] encourages secrecy and the 
privatization of knowledge until its potential 
commercial application becomes clear, third 
world innovators cannot share knowledge with 
others who may desperately need it, nor can 
they seek to attract investors who may be able 
to transform it into a better source of revenue 
for local communities. A group like the 
Honeybee Network is therefore in a difficult 
position. Prior to the publication of knowledge 
in the newsletter, the network must attempt to 
aid either the community or the individual in 
establishing a legal right. In most cases, 
however, the innovation will not have reached 
the point of patentability because the capacity 
for industrial application remains to be 
ascertained, and there is little investment 
capital available to explore the possibility. In 
the meantime, the knowledge may be valuable 
in alleviating poverty amongst other indigenous 
and local peoples and enriching their 
livelihoods. Third World networks and 
networks of indigenous peoples face an 
untenable choice between not publishing in 
order to maintain the potential for future patent 
benefits, in which case they withhold useful 
information from those in dire need of it, or 
publishing it with the knowledge that in 
assisting others, one risks forfeiting the fruit of 
one’s labors. Such a choice violates human 
rights norms that encourage the sharing of 
benefits, the flow of information, the right to 
share in progress in the arts and sciences, 
cross cultural exchange, and the right to 
sustainable development and a healthy 
environment” (Coombe 113). 
benefitting from its commercial 
exploitation. Further research needs to be 
done on the potential for distinguishing 
between kinds and forums of publication 
as modes of “anticipation” and the viability 
of introducing exemptions for indigenous 
knowledge registers and database 
linkages in current patent regimes. 
 
It is imperative that local cultural norms 
with respect to distinctions between 
sacred, secular and sensitive knowledge 
are respected in any and all digital use of 
traditional knowledges. The Indigenous 
Peoples’ Biodiversity Information Network 
(IPBIN), which was developed as a 
mechanism to help indigenous peoples to 
communicate and build capacity in 
implementing the indigenous and 
traditional knowledge provisions of the 
CBD, advises against the posting of any 
ITKIP on the Internet, keeps several of its 
online discussion forums closed to the 
general public, monitors links to ensure 
ethical relationships to posted material, 
and is developing protocols to govern 
clearinghouse mechanisms to ensure that 
these do not operate to the detriment of 
indigenous peoples’ cultures. Further 
research into the protocols developed by 
indigenous peoples and respect for such 
protocols in all Internet activities supported 
by Council Parties would assist efforts to 
preserve cultural diversity. 
 
IT IS RECOMMENDED THAT COUNCIL 
PARTIES UNDERTAKE FURTHER 
RESEARCH TO CONSIDER: 
 
•The viability of trade secret models for 
protecting ITKIP in digital 
environments, the degree to which 
violations of database confidentiality 
give rise to legal recourse, the extent to 
which such agreements will be 
respected and recognized in national 
and regional patent regimes, and the 
desirability of amending patent law to 
respect the norms and agreements of 
confidentiality developed by indigenous 




•The compatibility of the TRIPs 
Agreement with the suggested 
requirements that: 1) all patent 
applications include a sworn statement 
as to the origins of genetic resources, 
as well as any associated knowledge, 
innovations and practices of indigenous 
peoples and local communities utilized 
directly or indirectly in the research and 
development of the subject matter of 
the patent application; 2) evidence of 
prior informed consent from the country 
of origin and the local community be 
submitted with patent and plant 
breeders’ rights applications that 
involve genetic resources and ITKIP. 
 
•The legal and cultural consequences 
of Internet postings before ITKIP of a 
sensitive, sacred, or potentially 
proprietary character is posted. 
 
•The emergence and development of 
protocols for indigenous peoples’ and 
local communities’ prior informed 
consent for Internet postings of ITKIP 
and means of respecting such 
protocols in all Internet activities directly 
or indirectly supported by Council 
Parties. 
 
• Implications of various forms of 
confidentiality for local communities 
and indigenous peoples’ biodiversity 
and cultural diversity preservation 
needs. 
 
•The potential for distinguishing 
between kinds and fora of publication in 
ascertaining whether patentable subject 
matter has been “anticipated” and the 
viability of introducing exemptions for 
restricted access indigenous 
knowledge registers and database 
linkages between local communities as 
permissible forms of technology 





In conclusion, Council Parties’ 
international legal obligations under 
environmental and human rights regimes 
provide opportunities to ensure that digital 
technologies are utilised in a way that 
serves to preserve biological diversity in a 
fashion that simultaneously preserves and 
revitalizes the world’s cultural diversity. 
The recommendations for future research 
contained herein are designed to ensure 
that these efforts are undertaken with full 
awareness of the complexities posed by 
the need to balance intellectual property, 
trade, and environmental considerations 
with cultural diversity objectives.  
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Appendix – Acronyms 
 
CBD Convention on Biological Diversity 
CGIAR Consultative Group on International Agricultural Research  
Council Parties  Austria, Belgium, Bulgaria, Canada, Luxembourg, Switzerland, 
 United Kingdom 
EC European Community 
EU  European Union 
FAO Food and Agriculture Organization 
GBIF Global Biodiversity Information Facility 
IPBIN Indigenous Peoples’ Biodiversity Information Network 
IPRs Intellectual property rights 
ITKIP Indigenous and traditional knowledge, innovations and practices 
KIP Knowledge, innovations and practices 
NGOs Non-governmental organizations 
TRIPs Trade Related Aspects of Intellectual Properties Agreement 
UPOV Union for the Protection of Plant Varieties 
WIPO World Intellectual Property Organization 
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of Health Technology Assessment, and the Chair of the Drug Assessment Working 
Group of the Therapeutics Initiative for the province of BC. Bassett’s central academic 
interest is the relationship between scientific evidence and public policy as these relate 
to gender, class, ethnicity and geography. Currently, Bassett’s primary concern is the 




About the Article 
From his perspective as an academic active on the ‘front line’ of health-care policy in 
BC, Ken Bassett describes the opportunities which are available in the province to 
challenge corporate influence on health-care. According to Bassett, if the Canadian 
Biotechnology Strategy (CBS) is left uncontested, provincial health services are likely to 
be overwhelmed by the activities of the pharmaceutical and device industries, whose 
agendas place profits ahead of need, promoting remedies that are usually expensive, 
often useless, and sometimes dangerous. Bassett’s paper offers direction for provincial 
payment agencies and university research review committees on how to fill what he 






Science has made magnificent 
achievements across several centuries in 
the understanding of nature, in controlling 
it and sometimes even overcoming it. The 
very power of science has enabled its use 
as a tool for society to challenge dogma, 
particularly religious doctrines designed to 
maintain political and economic 
dominance of church over state. 
 
In the modern age, however, the 
seemingly dominant power of science has 
itself become a resource for the corporate 
agenda. In as much as commercial 
interests appropriate science to advance 
their political and economic programs, 
science risks losing its independence and 
becoming co-opted as part of the new 
dogma in the theology of corporate 
profiteering. 
 
Using the language and the very 
institutions of science, manufacturers have 
adopted a liturgy of product promotion in 
which effectiveness claims are 
exaggerated and safety concerns 
minimised. For scientists, academics and 
researchers who cherish the neutrality of 
science, it is of the greatest importance 
that this developing pattern of ‘belief’ 
should be challenged. 
 
My primary activist work is in two formal 
roles. I am Senior Medical Consultant at 
the BC Office of Health Technology 
Assessment (BCOHTA). Health 
technology assessment is a discipline 
which conducts systematic reviews of 
clinical efficacy and effectiveness 
evidence. I am also Chair of the Drug 
Assessment Working Group of the 
Therapeutics Initiative. The Working 
Group is responsible for systematic 
reviews of all new drugs submitted to 
Pharmacare, the Ministry of Health 
Department responsible for the Provincial 
Drug Benefit Plans in BC. 
 
From these evaluative perspectives, I 
have been able to recognise that the 
problem areas faced by women and 
society as a whole in relation to the CBS 
do not differ in substance from a long list 
of health-related initiatives directed at 
women throughout the second half of the 
20th century. 
 
I begin by looking at reciprocal federal and 
provincial responsibilities in health: as the 
federal role diminishes, the provincial role 
grows. Then I describe two provincial 
strategies which have proved more or less 
successful in countering commercial 
interests, by promoting social interests in 
health. I cite almost exclusively our 
(BCOHTA’s) reports, not because they are 
either unique or definitive in these areas, 
but because they provide additional details 
of our provincial social advocacy. I end 
with a description of the osteoporosis 
‘disease management model’, a disturbing 




1. Federal De-regulation 
 
Federal regulation of food and drugs 
developed in the wake of the thalidomide 
disaster in order to restrict market access 
until safety was proven and, in the case of 
drugs, efficacy established. Manufacturers 
explicitly bore the burden of proof. More 
recently, however, Canadian federal policy 
has favoured Industry Canada over 
Health/ Agriculture/ Environment Canada, 
primarily through de-regulation of most 
sectors of the economy. In the case of the 
Health Protection Branch (HPB), de-
regulation has meant non-enforcement of 
current regulations and the introduction of 
new, less-stringent legislation. In keeping 
with this less stringent legislation, the 
burden of proof in product licensing is 
gradually reversing. Manufacturers need 
to meet lower and lower standards of proof 
of safety and efficacy. Researchers, 
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publicly or privately-funded, more and 
more, must prove harm. 
 
The CBS reflects these federal de-
regulatory, pro-industry trends. The CBS is 
strong on supporting an internationally 
competitive industrial strategy, but weak 
on making the case for safety 
requirements. In this sense, I see the 
position of the CBS as not just indicating 
the future direction, but as showing the 
current realities of federal policy. 
 
Others know much more than I do about 
the potential costs and benefits of 
providing input to federal policy-making 
processes such as the CBS. My 
suggestions, therefore, are limited to the 
provincial level: how best to support social 




2. Provincial Mandate 
 
Diminishing HPB regulation could not have 
occurred at a worse time. The past decade 
has seen phenomenal growth in the 
economic power, and with it the political 
influence, of the drug and device industry. 
In addition, during the same time period, 
the drug and device industry has sought a 
more insidious mechanism to control the 
health-care sector: by influencing how 
people and professionals think and 
behave in relation to health, and to what 
are termed healthy and un-healthy 
lifestyles. 
 
This industry now has the power and 
capability to create its own need. It can 
promote certain tests (predictive and 
diagnostic); therapeutic strategies (which 
may include genetically-engineered drugs) 
and massive ‘educational’ strategies for 
administrators, medical professionals, and 
patients. As I shall later describe in 
relation to the management of 
osteoporosis, the marketing strategy forms 
a package, including a ‘disease 
management model’ that supports an 
immensely profitable market structure. 
This package is readily – in fact 
specifically – suited both to a population 
primed to accept pharmaceutical 
‘solutions’ to social problems, and to 
physicians trapped in busy, fee-for-service 
clinical care settings. 
 
Without federal policy to effectively limit 
the market’s access to the health sector, 
provincial purchasers and regulators of 
health services, devices, and drugs take 
on an increasingly important role. They 
must mediate between individuals seeking 
health care, and manufacturers seeking to 
provide goods for the marketplace. They 
must select which services to fund, for 
whom, and to what extent, all within 
capped, global budgets. This task is not 
just difficult, it is all but impossible, 
requiring meaningful prioritisation among 
items as diverse as housing for people 
with disabilities, life-saving techniques, 
sophisticated diagnostic imaging-
technology, and numerous other 
interventions demanded by an increasingly 
‘informed’ population. All this within a 
‘capped’ or finite budget. 
 
To add to their burdens, diminishing HPB 
standards for proof of effectiveness and 
safety have greatly increased the 
responsibilities of provincial purchasers. 
They, rather than Health Canada, must 
now determine the scientific validity of 
effectiveness and safety data, and 




3. Provincial Strategy 
 
The strategy we have used to balance 
commercial with social interests at the 
provincial level is based on one principle: 
focus upstream on key decision-makers. 
 
‘Upstream’ means early attention to the 
purchasing-funding process where 
decisions are made about what is to be 
made available to communities, hospitals 
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and clinics. The corollary is ‘Downstream’, 
the points where these programs, tests or 
technologies are used. 
 
‘Upstream’ or province-wide decisions 
regarding funding and regulation are 
preferred because they involve fewer 
individuals, usually in senior management 
or executive positions, and acting 
according to relatively strict rules of 
conduct within standing committees 
having explicit mandates. They can 
therefore be identified and reached by 
independent researchers, publicly-funded 
assessment institutes, and by social 
activists working with limited budgets and 
small staff. 
 
Downstream utilisation in local medical 
clinics, by contrast, involves diverse 
settings and numerous individuals with 
different values and expectations. Clinical 
settings are the areas most strongly 
influenced by the drug and device industry 
through clinical practice guidelines and 
direct-to-consumer advertising. Similarly, 
downstream utilisation in local hospitals 
varies widely and is equally vulnerable to 
direct commercial control. 
 
For example, in BC, only one hospital has 
a Technology Assessment process able to 
consider the medical necessity of new 
technology. Instead, most hospitals 
encourage new technology because it is 
an important source of prestige and, in the 
case of diagnostic technology, 
desperately-needed funds. Hospitals in BC 
can use diagnostic technology as a 
funding source because they are able to 
bill the provincial payment plans for 
services provided to ‘out-patients’ visiting 
their facility. Meanwhile, all ‘in-patient 
costs, including diagnostic tests, must be 
paid from the global hospital budget. 
 
Given this situation, concerns over a given 
technology, however legitimate, are 
unlikely to be most effectively presented 
downstream. In consequence, “Focus 
Upstream” is the best strategy. 
 
Two upstream provincial opportunities that 
we have used to counter the commercial 
dominance of health (defined broadly) are: 
 
1) University and Hospital Ethical 
Review Committees, under a duty to 
ask not only if research meets ethical 
standards, but also if it is valid science 
and serves public interests; 
 
2) provincial and regional committees 
charged with purchasing tests or drugs. 
 
 
1) University and Hospital Research/ 
Ethics Committees 
 
Most drug and device research in Canada 
requires approval by a research ethics 
committee, usually associated with a 
university or health-care institution or 
program. Strengthening these committees 
and expanding their mandates to review 
scientific validity as well as ethics could 
provide a significant opportunity to counter 
the CBS, at the provincial and community 
levels. 
 
Although these committees have not 
customarily considered issues of scientific 
validity or social relevance of research, 
this role is gaining increasing importance 
in the absence of alternative forums to 
raise these issues. Moreover, assessing 
scientific validity fits with the Helsinki 
Agreement which states that research 
must have "a reasonable likelihood that 
the populations in which the research is 
carried out stand to benefit from the 
results of the research." Our Technology 
Assessment Office has helped some 
committees in the effort to examine 
whether proposed research is scientifically 
valid or a marketing tool. 
 
A scientifically-valid study would enrol a 
sufficient number of reasonably 
representative patients to answer a 
question regarding benefit or harm. 
Marketing studies, by contrast, enrol 
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relatively few patients from as many 
settings as possible, and measure short-
term changes in body parameters such as 
blood pressure or cholesterol, known to 
favour the proposed test or clinical 
intervention. 
 
The strategy of focussing on study validity 
has had some success in slowing the 
introduction of new, virtually unstudied 
treatment technology in the province 
(Bassett et al 1998). 
 
We have also worked with the larger 
Health Regions in BC to strengthen their 
research and ethical review processes. 
Device manufacturers often target regional 
hospital systems to familiarise a medical 
community with their equipment and 
service personnel.  
 
For example, manufacturers interested in 
introducing a new laser treatment in 
urology approached several regional 
hospitals for participation in a clinical study 
(Bassett and Kazanjian 1996). The laser 
technology was rejected when the 
research review committee noted that the 
study, although ethical, was too small and 
too poorly designed to result in 
scientifically-valid findings. A different 
region in the province accepted the 
research study because the manufacturer 
offered the technology at reduced cost at 
the end of the study period. 
 
 
2) Provincial Purchasers and Regulators 
 
A second opportunity to support social as 
opposed to commercial interests occurs 
with provincial regulation and purchase. 
Since 1995, the Drug Assessment 
Working Group of the Therapeutics 
Initiative has produced approximately 200 
reports assessing the effectiveness and 
safety of new drugs submitted to the 
Provincial Drug Benefit Plans for payment. 
The reports have influence public drug 
plan funding policy in BC. 
 
Our Health Technology Assessment Office 
has also had some success at influencing 
diffusion of diagnostic imaging technology 
into the province. Diagnostic technology 
can only be provided in an accredited 
facility which must obtain a specific licence 
to bill the provincial fee-for-service plan. 
 
Licensing is the jurisdiction of a joint BC 
Medical Association-BC Ministry of Health 
committee, where government 
representatives have shown themselves 
prepared to challenge assumptions 
regarding patient benefit from a new 
technology. Working with these 
government individuals, one-on-one, we 
have been able to successfully support 
their challenges on the state of scientific 
knowledge. In the case of bone mineral-
density testing, for example, a moratorium 
on licensing in BC effectively blocked 
diffusion of this unproven technology for 3 
years (Green et al 1997). 
 
Laboratory tests, similar to diagnostic 
devices, need a ‘fee code’ within the 
provincial health insurance payment plan. 
Establishing a fee code and payment 
conditions can take several years alone, 
because fee codes are fought over in a 
very competitive environment within the 
BC Medical Association itself. The BCMA 
is dealing with a capped global budget. 
The fee code must also be approved by 
the provincial government which again 
provides an opportunity for raising issues 
of social concern. Our work on prostate 
specific antigen screening is an example 
of the successful use of this approach. We 
argued effectively that the scientific 
evidence did not support mass screening 
as providing greater benefit than harm 
(Green et al 1993). 
 
 
4. Disease Management Models: The 
Ultimate Public Advocacy Challenge 
 
Disease management models promoted 
by drug and device manufacturers are 
crafted with great sophistication, and 
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aimed at the long-term medical 
management of health issues across the 
life-span. They develop measurements, 
and propose specific drug therapies 
designed to alter those measurements. 
The goal of the disease management 
model is to have drug prescription based 
on and assessed in terms of the 
measurements. 
 
Disease management models have seen 
phenomenal marketing success: blood 
pressure testing and treatment (Kawachi 
and Conrad 1996), cholesterol testing and 
treatment (Savoie et al 2000), glucose 
testing and treatment for adult onset 
diabetes (Management 1998). In all 
instances, the issue is not whether the 
drug alters the test result; it may do so 
unequivocally. Nor is the issue whether 
the test can identify a risk factor for an 
actual clinical event such as a heart attack 
or stroke. All these indicators are accepted 
as population-based risk factors for clinical 
events. The issue with disease 
management models is that they 
exaggerate the treatment benefit both to 
individuals who achieve some benefit and 
to others, by extrapolating findings beyond 
those people in whom a benefit has been 
found. In other words, for individuals, 
disease management models focus 
attention away from problems of diet, 
exercise, lifestyle, poverty, unsafe 
environments, and onto specific 
measurable, alterable physiological 
components. For populations, disease 
management models divert limited funds 
from alternative, often more cost-effective 
programs. 
 
Genetic disease management models are 
not yet as sophisticated as other disease 
management models. While genetically-
manufactured drugs and hormone and 
enzyme replacement products are in 
current use, there is not as yet an example 
of a treatment that alters a test result for a 
genetic disease parameter. Genetic 
disease management models are 
proceeding, however, with treatments 
such as ‘herceptin’ (see Batt, this volume). 
Herceptin does not itself alter the original 
genetic characteristics. It is, however, 
dependent on genetic tests to determine a 
woman’s suitability. 
 
Nevertheless, whether considered a 
genetic or non-genetic disease, the 
problem remains the same for provincial 
policy-makers and regulators. The drug 
and device industry presents disease 
management models within a carefully-
orchestrated marketing strategy. The 
ability of provincial governments to 
respond effectively has been diminished 
by fragmentation over different 




5. The Osteoporosis Disease 
Management Model: Upstream 
Success, Downstream Failure 
 
We believe the upstream focus is both 
necessary and appropriate for our limited 
resources. However, we recognise that it 
is the downstream activity which 
determines who is the ultimate winner, 
public or corporate. 
 
The most recent and dramatic example of 
an upstream success, but downstream 
failure is provided by the osteoporosis 
disease management model. Destined to 
become the most successful disease 
management model to date, it is designed 
to medically manage bones and bone 
health across the life-span. The model 
brings together bone mineral density 
(BMD) measurements with specific drug-
therapy designed to alter those 
measurements. 
 
BMD testing is an x-ray technique used to 
assess bone structure and to predict future 
fracture risk. The problem is that BMD is a 
very poor test for predicting which women 
will and will not suffer future fractures 
(Green et al 1997). Nevertheless, low 
BMD is very actively promoted to well 
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women. This despite the fact that drug 
treatment of low BMD (necessarily offered 
for long-term use) has not been shown to 
reduce the fracture rate of well women, the 
group targeted for BMD testing (Kazanjian 
et al 1999). 
 
From the early 1990s, numerous 
researchers, women’s activist groups and 
the provincial Women’s Health Bureau 
argued that the osteoporosis disease 
management model diverts attention away 
from problems of diet, exercise, lifestyle, 
unsafe walking, shopping environments, 
and focuses instead on the specific, 
measurable, alterable component of bone 
structure - which is not necessarily 
connected to disease outcome. 
 
Our technology assessment office showed 
provincial policy makers that this disease 
management model diverts funds from 
effective programs shown to reduce 
fracture rates (NHS 1996). The 
Therapeutics Initiative argued that 
available hormone and bisphosophonate 
(Fosomax) therapy was of very limited, 
and likely transient, benefit. The latter 
drugs remained as restricted drug benefits 
in the province. As mentioned above, 
support for individuals in the Ministry of 
Health resulted in a 3 year moratorium on 
BMD diffusion in the province (Bassett 
1999). 
 
In the end, however, no one person and 
no committee could adequately argue for 
social needs or consequences, nor solicit 
sufficient public or expert opinion to 
counter the disease management models 
being rolled out by the drug and device 
industry. In short, once BMD technology 
became available to clinical care, it was 
‘game over’. Unsubstantiated clinical 
guidelines and protocols in the use of the 
technology were rolled out as part of drug 
and device industry sponsored 
‘educational’ strategies. 
 
The failure to control the osteoporosis 
disease management model was 
facilitated by providing it a fee code within 
the provincial health insurance payment 
plan, albeit an old code not using the x-ray 
technique. Furthermore, with a fee code in 
place, individual hospitals exercised no 
control over utilisation. For example, when 
BMD was considered by the Greater 
Victoria Hospital Society, Technology 
Assessment Committee, they did not 
consider the medical necessity of new 
technology. 
 
BMD remains as a dark moment in the 
history of the Greater Victoria Hospital 
Society TAC. It is a clear example of the 
inducement mentioned earlier, the 
opportunity to bill for hospital services 
provided to ‘out-patients’ outside the 
global budget. The committee could not 
bring itself to adequately evaluate BMD 
because it was such an important source 
of sorely-needed funds. 
 
 
6. Genetic Testing and Treatment 
 
Decoding the human genome and 
understanding the role of genes in health 
and disease holds great promise and 
challenge for the future. Genetic research 
promises to provide greater understanding 
of the origin and mechanism of disease, 
possibly treatment and, at times, cure. 
Genetic research also promises very 
significant financial reward for a rapidly 
growing, national and international, bio-
technology industry. The challenges faced 
by society include maintaining privacy, 
ensuring access of individuals to health 
insurance, and countering discrimination 
based on disability and eugenics. 
 
Public purchase of genetic tests and 
treatments and the ethical review of 
genetic research provide important 
opportunities to weigh costs and social 
consequences against potential health 
benefits. My recommendation is that 
decision making regarding public purchase 
and ethical review should include very 
clear and unbiased assessments of the 
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scientific validity of effectiveness and 
safety claims. With unbiased 
assessments, science remains a very 
powerful social tool. With biased 
assessments, science risks further 





I have described what provincial 
opportunities exist to provide social 
direction to the federal, pro-industry CBS 
policy, at the points of purchasing and 
research review. Few objective observers 
will doubt the need for strategies of this 
kind to combat the re-modelling of health-
care into a commercial market place. 
 
With the advent of genetics-based 
medicine, these strategies may serve to 
help individuals and committees at the 
provincial level who are soon to face the 
incoming tide of genetic testing and 
treatment options. 
 
Social interests could also be greatly 
furthered by co-ordinating ethical and 
research review committees with one 
another, and with provincial purchasers 
and regulators.
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As an academic geneticist interested in 
the arcane mechanisms of development, I 
spend my days trying to understand how a 
fruit fly's genes determine whether it will 
have a leg or an antenna growing from its 
head. The vocabulary and techniques I 
use daily are often poorly understood by 
colleagues in other biological disciplines, 
let alone most lay people. Nevertheless, 
the motivation for doing this research, and 
my particular approach, should be 
accessible to anyone. Unfortunately, the 
lack of comprehension of science goes far 
beyond problems of communicating the 
essence of one's research to a broader 
community. 
 
My concerns in the area of women/ health/ 
genetics stem from the conviction that for 
citizens to be empowered to make 
decisions with respect to their health, and 
that of their families, they should 
understand the issues involved. As an 
instructor in 1st year seminar courses 
serving as the only science course that 
many Arts students will encounter, I have 
been startled by the inability of these 
students to read newspaper and magazine 
articles on genetics with comprehension. 
This inability extends to recreational media 
like the movies Jurassic Park and 
GATTACA. Part of the problem is that the 
vocabulary, and some of the concepts, are 
not part of their knowledge base. 
 
Another part of the problem is an antipathy 
to "science as a way of knowing". When 
asked what kinds of information they 
would like to have before they decided to 
use a new type of medical treatment, it 
was astonishing to hear that if a relative 
recommended it, that would be good 
enough. These are bright, articulate 
students for whom risk-benefit analyses 
hold no charm and double-blind 
experiments no hope. It would not be 
surprising, therefore, that a few years 
later, if issues of new reproductive 
technologies or genetically modified foods 
became important to them, they would be 
incapable of doing more than putting their 
trust in someone else’s analysis. 
 
I do not understand the cultural dynamics 
responsible for the disaffection with 
science among many of our educated 
citizens. It occurs to me, however, that 
scientists may be looked upon as 
belonging to a priesthood which has 
access to information stored in Temples 
(libraries) which is incomprehensible to the 
lay public. This is not true for many 
aspects of the science-based issues in the 
health/ genetics areas, since a 1st year 
university student with a grade 10 science 
education can search out articles on 
specific, technical subjects and 
understand their key points. Web based 
tools have the power to remove barriers to 
such technical information because the 
cyber library is open to the increasing 
number of people with Internet access. 
 
Yet the Web represents a double-edged 
sword since one has to be able to evaluate 
the information one is getting. The 
challenge for the educational system at 
both the high school and university level is 
to integrate science into curricula as part 
of our culture much as music, drama, 
dance and the graphic arts. This will only 
happen if the demand for such integration 
exists in the community so that science as 
a way of exploring our world and 
understanding technology replaces the 
notion of science as the province of the 
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As Canada enters the 21st century, many 
DNA1-based biotechnologies are 
developing rapidly. Among these are the 
collection, analysis, storage and use of 
DNA for the purposes of forensic evidence 
in the legal system. Indeed there is almost 
daily media coverage about the 
significance of forensic DNA.2 Yet there 
has been little analysis of the potential 
negative consequences and effects of 
collected forensic evidence on Canadian 
society. Also missing is a thorough gender 
critique.3 
 
Forensic evidence is commonly derived 
from the DNA in human fluids and tissues 
– blood, semen, saliva, skin cells, hair, nail 
clippings, finger prints, deposits found in 
bodily orifices. This evidence is generally 
substantiated with photographic or 
diagrammatic and textual descriptions of 
attack sites, bodily wounds and the 
instruments of assault. Such evidence is 
generally found in and on the bodies of 
women. 
 
It is becoming commonplace for police 
investigators to obtain as much 
information as possible from a crime 
                                               
1 DNA is the acronym for deoxyribonucleic 
acid, the genetic composition of all higher 
living organisms. 
2 The terms “DNA evidence”, “forensic DNA”, 
“forensic evidence” all apply to the physical 
collection of bodily, usually human, tissues and 
substances, the analysis of the DNA contained 
therein, and the subsequent storage of the 
physical record and/or the reports based on 
that evidence, and the use by the police and 
courts of that information. The human 
materials are called forensic because they are 
specifically collected for legal purposes in the 
pursuit of social justice. Otherwise they are 
medical evidence collected expressly for 
diagnostic and treatment purposes. 
3 In the mid-1990s two strongly feminist 
commentaries were published on this topic by 
Kubanek 1997 and Miller 1996. 
scene in order to reconstruct the crime 
and to identify a known assailant, or 
archive information that could lead to 
identification of the unknown attacker at a 
future time. Forensic DNA analysis, 
sometimes referred to as “fingerprinting” 
technology, is commonly performed in 
cases of violent physical assault, including 
sexual assault, homicides, and hit-and-run 
accidents. By checking the suspect’s DNA 
against DNA samples found at a crime 
site, usually in the form of semen, saliva, 
skin cells or hair follicles, charges can be 
laid, court proceeding initiated and 
convictions made. 
 
While these potential case-solving aspects 
of DNA forensics have been widely 
publicized, the ways in which the evidence 
is used once it is available have received 
virtually no public attention. I argue that, 
before we allow wholesale use of this 
expensive and time-consuming DNA 
biotechnology we ensure that women’s 
rights4 to privacy, security and 
confidentiality, and their proprietary 
interests in their bodily parts, are 
protected. Furthermore, women victims of 
violent crime must have their right to 
consent to their DNA being stored 
enshrined, and enforced with medical, 
ethical and legal standards of disclosure. If 
this is not ensured, tracing the genetic 
material once alienated from the body may 
be impossible. Some would argue that this 
happens all the time when one gives a 
blood or tissue sample, and hospitals do 
retain the samples for later reference.5 
However, the concern with alienated DNA 
resides in its potential use for surveillance 
                                               
4 I would include under this umbrella the rights 
of children and other vulnerable minorities. 
This discussion paper focuses specifically on 
women’s interests. 
5 Recall the case of Moore v. Regents of the 
University of California, where a man (John 
Moore) being treated for cancer had his cell 




– purposes other than medical diagnosis 
and treatment. 
 
DNA Forensics in Canada 
 
In 1995 DNA warrant legislation made it 
possible for Canadian police to seize DNA 
samples for a wide range of offences 
included under thirty sections of the 
Criminal Code. The expectation at the 
Department of Justice was that this 
legislation would diminish violent assaults 
through deterrence and enhance 
convictions (Canada, Solicitor General 
1996). Consequently, it has become 
routine for a finger prick blood sample to 
be taken from a crime suspect, whose 
DNA is typed in at least nine identifiable 
ways, then checked against DNA found at 
the crime site6, or filed for future reference. 
As this practice has increased, a central 
place to store DNA has become vital. 
 
In 1996 a bill was introduced by the 
Federal Government to establish a 
National DNA Databank. Presently, under 
federal government legislation a bank is 
being set up in Ottawa housed on RCMP 
premises. DNA samples along with crime 
scene data will be stored for future 
reference. Over time it is expected that 
large numbers of Canadians will have their 
DNA profile and a biological sample on file 
in this costly bank. 
 
The RCMP in 1996 projected that the cost 
for DNA studies would be $6 million per 
annum, plus $5.8 million to build the new 
facility (Miller 1996:2). These estimates 
pale in contrast to those of similar banks 
already in existence in Britain, Australia 
and the U.S. In Britain, the reported cost of 
                                               
6 Site may include not only a place, but also a 
human body, usually female, living or dead. 
The Vancouver Police Department is 
accelerating now their systematic search for 
possibly in excess of 30 women missing 
without trace from the Downtown Eastside. 
Mitochondrial DNA evidence is beginning to be 
used in the case of human remains found in 
remote parts of the Province. 
their data bank in the first five years of 
operation for the storage portion alone 
was $300 million Canadian. The British 
government introduced databanking as 
part of a move to increase police and state 
power, particularly in response to curtailing 
terrorism from the IRA (Kubanek 1997:3). 
Its motive was less about the issue of 
public safety. 
 
The perceived focus of DNA collection and 
storage for the Canadian public has been 
the identification of criminals, 
predominantly male perpetrators, who are 
responsible for the greatest proportion of 
crimes (common assault, sexual assault 
and hit and run road accidents). However, 
there has been little discussion of the 
repercussions of DNA evidence collection, 
storage and analysis on Canadian 
women’s experiences, or for marginalized/ 
minority populations in Canada. There is 
minimal awareness of how pervasive and 
extensive is the state’s surveillance 
capacity in the analysis of individual and 




DNA Surveillance: Implications for 
Immigrants and First Nations 
 
There has been some preliminary 
research on the use of genetic information 
in the immigration and refugee context in 
Canada. Critics argue that the use of 
genetic tests to establish or confirm 
familial ties is premised on the assumption 
that consanguineous links, as opposed to 
culturally determined social relations, are 
paramount in determining which significant 
“family” members may be sponsored for 
immigrant status. Therefore using genetic 
testing as the standard tool to determine 
legal residency in Canada compromises 
the rights of applicants whose families are 
based on non-genetic kinship models. 
 
Moreover, the storage and use of the DNA 
information from applicants, either within 
Canada or in countries of origin, could 
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have serious consequences. Employing 
genetics as a gatekeeper strategy to enter 
Canada has sinister reminiscences of 
socio-biological techniques to preclude 
entry into Canada and the United States in 
the early part of the twentieth century. At 
that time new immigrant hopefuls were 
subjected to physical and psychological 
examination in order to assess their 
worthiness for residency. Determinants 
such as low IQ, small head size, diseases 
such as tuberculosis, or being a member 
of certain minorities (gypsies, Jews) 
resulted in many travellers arriving 
exhausted and sick from long journeys on 
the immigrant ships from Europe only to 
be sent back to their homelands.  
 
Currently, DNA technology is being used 
in the international context to analyze, 
store and make available the genetic 
blueprints of specified ethnic groups. This 
data will be available in perpetuity, should 
certain peoples become extinct. The 
Human Genome Diversity Project (HGDP) 
originally aimed to bank the DNA of 722 
indigenous peoples globally. Despite the 
fact that the Indigenous Women’s Caucus 
at the UN Fourth World Conference on 
Women unanimously declared the project 
unacceptable, the project’s sponsors have 
continued their efforts with the approval of 
the international scientific community 
(Kubanek 1997:4). The HGDP proper has 
never actually started, largely because of 
these protests. Yet bio-prospecting 
continues. Canada has not been immune 
to this investigation, as isolated 
communities in the Canadian north, 
composed of First Nations and Inuit 
people have been the objects of 
commercial and intellectual property 
interests. Recently, the Icelandic 
government agreed to collect and submit 
the profiles of all their nationals to HGDP. 
 




DNA Surveillance: Implications for 
Women Survivors of Sexual Assault 
 
The remainder of this discussion focuses 
on a narrower spectrum of DNA use in 
Canada. It addresses some of the ways in 
which the growth of medico-legal 
examinations resulting in the collection 
DNA evidence may affect women 
adversely in their dealings with law 
enforcement agencies and the courts. It 
challenges the prevailing assumption that 
identifying an assailant based on DNA will 
help protect women in general against 
assault, and ensure that the courts rightly 
identify and convict known offenders. I 
question whether DNA databanking is any 
more than a new genetically based form of 
state surveillance, where ethnicity, 
disability and deviance are labelled and 
manipulated by state practices which 
evoke memories of past eugenic policies. 
New areas of research are suggested 
which can begin to address some of these 
issues. 
 
From the hospital setting, through to the 
courts and extending into the realm of 
federal policy, women’s health, safety and 
well-being may be affected in unforeseen 
ways by the perceived need to collect and 
store evidentiary materials and release 
pertinent information in sexual assault 
trials. While I do not dispute that in certain 
instances forensic evidence has great 
value for bringing assailants to trial, 
convicting them of heinous crimes and 
compensating to some degree the 
innocent victim, the discussion that follows 
takes a cautionary approach. It questions 
the degree to which the exponential 
growth and concomitant validation of DNA 
evidence serves the best interests of 
specifically identified women, and by 
extension, all women. 
 
The first point I address concerns privacy, 
confidentiality and the ethics surrounding 
informed choice in the collection of 
forensic evidence. At issue is whether 
women realize that when they submit to a 
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forensic examination following a sexual 
assault that their own DNA will also be 
identified and documented, and potentially 
may end up in the National DNA 
Databank. The second point involves 
inappropriate stereotyping. Although 
sexual assault (not to be confused with 
domestic violence) is indiscriminate 
throughout society, there is a misplaced 
assumption that certain types of women 
are the targets of sexual assault and thus 
they deserve what they get. The third 
point, which follows on from the second, is 
that there is very little research as yet 
about the relationship between 
admissibility of forensic evidence in the 
courts and women’s experience in court. 
 
 
Privacy, confidentiality and the ethics 
of informed consent in the collection of 
forensic evidence 
 
Patient autonomy (or self-direction or self-
determination) is a central value in all 
approaches to health care ethics as Sue 
Sherwin has pointed out. Yet her concept 
of relational autonomy also calls attention 
to the context within which decisions are 
made, the situational ethics. Protection of 
autonomy is particularly difficult in health 
care settings because sick patients are 
dependent on the care and goodwill of 
their caregivers. The tendency towards 
paternalism in medical care “reduces 
patients’ power to exercise autonomy and 
it also makes them vulnerable to 
manipulation, and even to outright 
coercion, by those who provide them with 
needed health services” (Sherwin 
1998:20).  
 
In the situation where medical/forensic 
evidence is collected, it is particularly 
important that patient autonomy is 
respected and that the patient/victim’s 
care is in the context of experienced, 
sensitive assistance from trained sexual 
assault examiners, counsellors and victims 
service workers. BC Women’s Sexual 
Assault Service (SAS), for example, 
actively promotes a woman-centred 
approach, which ensures that a 
patient/victim will be given all the time and 
information necessary to understand 
precisely what she is consenting to. SAS 
has a clear mandate that the physical, 
psychological, emotional and security 
needs of the woman following a sexual 
assault are primary. The forensic 
examination, while available on consent, 
takes second place to health services and 
then only following stringent rules and 
safeguards at every stage of consent. 
 
Allied with the issue of consent is the 
obligation for patient confidentiality and 
privacy. Lack of consent to engage in 
sexual activity, as occurs in sexual 
assault, and limited understanding of the 
consequences of the invasive medical 
procedures which occur in a forensic 
examination both relate to extreme abuse 
of power. They are associated with the 
violation of bodily integrity and acts of dis-
empowerment which undermine the 
dignity and control that women need for 
self-determination, agency and autonomy. 
A patient/victim’s right to confidentiality, 
like consent, is a cornerstone of medical 
ethics. Unfortunately if women fear that 
evidence taken from their bodies may be 
misappropriated by the law enforcement 
and court systems, then their confidence is 
shaken with respect to frontline health 
care. Consequently, some women, who 
are often the most vulnerable, are unlikely 
to seek the medical and psychological 
help they require for the effects of sexual 
assault. 
 
Although legal reform and other social 
changes have brought about greater 
efforts to eradicate biases that confront 
those who press complaints of sexual 
assault (Johnson 1996:36), it is well 
documented that most women who are 
sexually assaulted never involve the police 
or seek medical care. It is estimated that 
about 70% of women utilizing sexual 
assault services do not report to the 
police. In fact, only 1 in 10 women who are 
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sexually assaulted report the incident to 
the police, and in the case of date rape, 
the number rises to 1 in 100. According to 
the Statistics Canada victimization survey 
(1993) more than one in three adult 
women have been sexually assaulted 
since the age of sixteen, and 94% of these 
cases never come before the criminal 
justice system. Moreover, when SAS 
tracked service records they found that 
only 10 out of 100 cases where evidence 
had been collected for the police had led 
subsequently to a trial with a conviction 
(personal communication). 
 
Many women have valid concerns about 
disclosure of an assault for fear of 
repercussions from an abuser if they 
report. Other women, as documented by 
victim services workers, have legitimate 
concerns about how they will be treated in 
court. This rightful wariness of the medical, 
law enforcement and judicial systems 
raises the question: Will DNA collection 
and storage become a further reason for 
victims to remain silent about their 
assaults? Therefore at the outset 
assurances of confidentiality and non-
disclosure are critical for victims who do 
seek victims services or medical supports. 
 
 
Recommendations for research 
 
While issues of consent, confidentiality 
and disclosure of personal records in 
sexual assault cases7 are beginning to be 
recognized and addressed in the health 
care context unexamined to date are 
proprietary rights to DNA in the broader 
context. Should women be concerning 
themselves with what happens to their 
own DNA profile that is collected as part of 
the forensic evidence following a sexual 
assault? One way to investigate this would 
be to evaluate studies conducted at DNA 
databanks that have been operational for 
                                               
7 See papers by Addison, Busby, Robinson 
and Sampson in Metrac publication 1998. Also 
unpublished confidential paper by Lee 1999. 
a number of years. What kinds of 
analyses, if any, have been conducted on 
those records? What is the demographic 
profile of those who have their DNA stored 
in these banks? Furthermore, what kinds 
of safeguards are in place to protect the 
privacy and proprietary interests of any 
given individual? In the short term it is 
important to track the development of the 
DNA databank as it is implemented in 
Canada and the legislation surrounding 
both its own internal operations and its 
linkages with DNA forensic laboratories 
under various police jurisdictions across 




Inappropriate stereotyping of sexual 
assault victims. 
 
DNA banking has the potential to feed into 
the hierarchies and inequities already in 
existence in the prosecution process. 
There is an unfounded assumption that 
certain men’s and women’s accounts have 
more credence than others. Recall how 
white, well-groomed, educated rapist and 
murderer Paul Bernardo evaded 
prosecution for sometime, and did not 
have his DNA collected, while other men, 
such as those who are poor, Native and/or 
substance abusers are more likely to be 
targetted immediately.  
 
This section will discuss how certain types 
of women are stereotyped as more likely 
to be sexually assaulted, for example poor 
women, sex trade workers, substance 
abusers and certain ethnic groups e.g. 
First Nations women. In Vancouver, this 
assumption is based partly on the 
backgrounds of women living in the 
Downtown Eastside who tend to fall into 
these categories and are identified as 
being subject to frequent abuse. Women 
who agree to evidence collection after a 
sexual assault could unwittingly be 
providing evidence that may be used 





The Downtown Eastside scenario exists in 
other inner cities in Canada, where the 
destitute congregate and crime is rampant. 
There is national evidence that native 
men, men of colour and poor men are 
jailed in Canada at a rate disproportionate 
to the Canadian demographic profile. 
Therefore the DNA of marginalized groups 
is more likely to be retained in the National 
Databank. The logical consequence is that 
the DNA of sexually assaulted women, 
who become labelled as “bad girls”, will fall 
into the same categories as their male 
counterparts and thus are more likely to 
show up in this bank. We now know that 
there is greater discrimination and a higher 
incidence of physical and sexual abuse 
among women “whose lives are 
compounded by oppression, including 
aboriginal women, women of colour, 
lesbians, and disabled women. Race, 
ability, age, class and their intersections 
are known to impact on the quality of 
health care service [and legal services] a 
woman received” (Rodgers 1995:164). 
There is much to be learned from the 
critical insights of women of colour about 
the perpetuation of hierarchies of power 
within the medical institution, and the 
forms of resistance that are transforming 
medical ethics and health care systems 
(Roberts 1996:117). These socio-
economic lessons also apply to law 
enforcement and legal institutions.  
 
In the near future, readily accessible 
genetic data such as that retained by the 
DNA Databank may well become a rich 
resource for studies which seek to identify 
certain genetic traits e.g. the propensity for 
substance abuse, or violence, the inability 
to become and remain employed, 
homosexuality etc. There are alarming 
privacy issues wrapped up in this type of 
surveillance through the one-way mirror of 
scientific observation. The institutionalized 
deviant is seen in passive isolation, 
leaving no recourse for the latter to act in 
her/his own interests. 
 
Legislation must ensure that a person 
retains rights over future research and 
statistical use of her/his banked DNA. It is 
unlikely that women, traumatized or not, 
would be aware of the long term 
consequences of the medical/forensic 
examination. The immediate and 
subsequent trauma for women who have 
been sexually assaulted (including date 
rape) makes them particularly vulnerable 
to often well meaning health care workers 
and police investigators, who encourage 
them to submit to evidentiary examination 
in order to aid the justice system or legal 
proceedings.  
 
Recommendations for research 
 
It is important to assess and develop 
strategies that provide all women with 
adequate information about a range of 
aspects relating to sexual assault. This is 
particularly critical for victims faced with 
the collection of forensic evidence. 
Additionally, research needs to be done to 
educate police officers and the courts 
concerning the misplaced myths about 
who gets sexually assaulted, and about 
how women fare in the justice system. 
Woman-centred approaches, particularly 
feminist oriented work (where possible 
conducted in conjunction with police 
departments and various offices of the 
Attorney General) is vital to ensure that 
there are safeguards written into police 
protocols and public policies such that 
victims’ DNA will never become available 




The imperative to collect DNA samples 
and its arbitrary use in sexual assault 
trials 
 
Paradoxically, despite increased pressure 
on Sexual Assault Services and medical 
examiners to collect forensic evidence for 
the police, there is relatively little use of 
that evidence in the courts. Examination of 
court practices reveals that defense 
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lawyers often focus on negative 
stereotyping of victims, on the meaning of 
consent and the significance of the 
complainant’s past sexual history, rather 
than the difficult to dispute facts of the 
forensic evidence.8 The assailant is 
constructed as the maligned victim, while 
the victim is re-victimized by being 
characterized as unstable, unreliable and 
a seductress of innocent men. 
 
Research in British Columbia on court 
proceedings demonstrate both the limited 
number of sexual assault cases that 
actually gain a court hearing, and the 
limited percentage of these for which DNA 
evidence was available, or useful, in 
obtaining convictions.9 Kee’s (1996) report 
for the B.C. Ministry of the Attorney 
General verifies the minimal use of 
collected evidentiary data in court, while 
Herbert and Wiebe’s (1989) earlier study 
for the BC Women’s Sexual Assault 
Service found that more than half the 
cases for which DNA evidence was 
available did not proceed to trial. Recently, 
McGregor et al (1999) conclude that “It is 
important to have good evidence that the 
time spent on the forensic part of the 
examination does indeed influence the 
legal outcome of the case” (1568-9). In 
other words good documentation of 
                                               
8 Contamination of forensic evidence samples 
is now being given as a reason for its 
inadmissibility in the courts. Since 1985 
survival of DNA in evidence samples in 
sufficient quantity and quality has made it 
possible for genetic analysis directly at the 
gene level. In relation to sexual assault, 
specimens in the vagina may last up to seven 
days, in the mouth for several hours and in the 
anal canal for twenty four hours (Sensabaugh 
and Blake 1994:417). In August 1999 for the 
first time in a Canadian criminal trial, 
mitochondrial DNA evidence, which makes 
identification of older remains possible, was 
used to implicate Shannon Murrin in the Mindy 
Tran murder trial. 
9 See research by Herbert and Wiebe 1989, 
Kee 1996, McGregor et al 1999; also a recent 
Ontario publication by DuMont and Parniss 
1999. 
moderate and severe physical injuries 
which can be made available at the time of 
charge laying may outweigh relying on the 
often delayed laboratory report of DNA 
typing to identify an assailant. The 
McGregor report also identified the need 
for more research into other variables that 
predict laying of charges and even more 
importantly the securing of convictions. 
These variables included socio-economic 
factors, and the possible bias of the justice 
system towards certain characteristics of 
victims, who are poor, sex trade workers, 
substance abusers and uncooperative with 
the police.  
 
In spite of more cases of sexual assault 
coming before the courts since the reform 
legislation of 1983, when Parliament 
reviewed the Criminal Code revision 
related to assault, and R. v Chase (1987) 
provided guidelines as to what constituted 
sexual assault, the courts remain hostile 
places for women pressing sexual assault 
charges. Throughout the 1980s and 
1990s, the courts have been a minefield 
for female sexual assault victims. Some 
judges continue to enforce old patriarchal 
practices, legislation enforces production 
of a complainant’s prior sexual history 
records,10 while defense counsellors 
strategize to discredit complainants by 
producing discriminatory stereotypes of 
women as fabricating allegations of rape 
and as sufferers from “false memory 
syndrome”. 
 
Efforts by feminists to create a more 
hospitable climate through legislation11 
protecting women from in-trial exposure of 
past sexual histories has been only 
sporadically successful. So the scales of 
justice continue to teeter, a balancing act 
which leaves women unsure about their 
                                               
10 See decisions in Seaboyer (1991), O’Connor 
(1996) and the ongoing challenges to the 
constitutionality of Bill C-46 in two Alberta 
cases, Mills and Ewanchuk. 




survival in the courts. This distrust is well 
voiced by victims’ service workers who 
frequently attend court with victims. 
 
Recommendations for research 
 
Further research to follow up on the few 
feminist studies which have started to 
track some aspects of the collection, 
admissibility and lack of use of DNA 
evidence in the courts would be valuable. 
If it is found that forensic evidence is not 
consistently considered beneficial 
information in sexual assault trials, then 
the time of sexual assault examiners 
would be better spent on medical and 
psychological services to victims rather 
than on legally based medical services. 
Studies focussing on the various ways in 
which women resist collection of forensic 
evidence, and their experiences with 
police investigators and defense counsels 
in sexual assault trials would also serve to 
illuminate women’s responses to a 
biotechnology which seems to have 






The above discussion encompasses the 
ethical, social and cultural context within 
which certain categories of women are 
often served poorly by the very institutions 
which purport to assist them. In both the 
health care context and the courtroom, as 
well as on the streets, women continue to 
be vulnerable to oppression and control by 
dominant hierarchies. This critique also 
moves into the speculative realm of 
whether women can trust what happens to 
their genetic material if it is captured 
through DNA banking. Here other forms of 
surveillance and analysis may construct 
and re-construct stereotypes of the types 
of women who are sexually assaulted. As 
Canadian society advances into a new 
deterministic genetic age in which the 
genetic blueprint of each person may be 
investigated, it is important to examine the 
new loci of power and control that are 
emerging currently, which are sanctioned 
by federal policies and regulations. At the 
very heart of the matter is the need for 
voiceless, violated women who are the 
targets of sexual assault to be protected 
from further violations by institutions that 
do not always and fully respect 
fundamental rights to confidentiality, 
privacy and proprietary ownership of 
personal bodily tissues and substances. 
These rights underpin basic ethical 
standards of health care, and in the case 
of collection of forensic evidence, what 
happens to the data after it has been 
acquired. Within the Canadian 
Biotechnology Strategy, there is urgent 
need to ensure that those ethical, social 
and cultural values principally affecting 
women be given priority over the 
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About the Article 
Priscilla Settee outlines the work of Aboriginal peoples around the world to mobilise 
against biopiracy – the appropriation of Indigenous knowledge, and Indigenous bodies. 
The focus of much of this mobilising has been the Human Genome Diversity Project – a 
DNA sequencing project proposed as a complement to the international Human Genome 
Project. The HGDP is distinct in being intended as a way to gather the DNA of ‘diverse’ 
or ‘endangered’ peoples and thereby to ‘map the migration history of humankind.’ While 
the official HGDP has been derailed by the protests of its many critics, biopiracy is alive 
and well and commercially lucrative. As Settee here explains, Indigenous peoples have 
organised around the HGDP to articulate their own priorities, and to formulate agendas 




The Human DNA of identified Indigenous 
groups is the focus of curiosity and activity 
among an international consortium of 
scientists, universities, governments, and 
other interests in North America and 
Europe.1 
 
Over 700 Indigenous groups world-wide 
have been identified to have samples 
collected from them. Indigenous 
communities targeted for DNA collection 
include Africa (165), Asia (212), South 
America (114), Oceania (101) North 
America (107 tribes) and Europe (23). 
Established in 1992, the Human Genome 
Diversity Project (HGDP) will take blood, 
tissue samples (cheek scrapings or 
saliva), and hair roots from hundreds of 
Indigenous communities throughout the 
world. Through the Human Genome 
Organization (HUGO) the project is 
mandated to map the entire genetic 
structure of the human race  
 
HUGO seeks to sequence the DNA 
information in all 100,000 genes in the 
human body and is expected to cost 3 
billion dollars over the span of the fifteen 
year project; HUGO is now nearing 
completion significantly ahead of 
schedule; a ‘rough draft’ has already been 
completed. While HUGO intends to 
uncover the norm of the human genome 
as a composite model, the Human 
Genome Diversity Project seeks to map 
and sequence genetic diversity. The 
project is specifically mandated to take 
blood, tissue, and hair samples from 
                                               
1  This article draws on the following source 
material: Indigenous Women Address the 
World. Indigenous Woman Magazine. Special 
Beijing Edition, Rapid City, South Dakota, 
U.S.A. 1996; Indigenous Woman Magazine, 
Rapid City, South Dakota, U.S.A., Vol, 2, No. 
3, 1996; Dukepoo, F., & Harry, D. Indigenous 
Peoples Coalition on Biopiracy, 1998; “Voice of 
Native Grassroots for Environmental Justice.” 
Indigenous Environmental Network News. 
Vol.3 No. 2, 1997; Western Shoshone Defense 
Project Newsletter, 1997. 
"endangered" indigenous communities 
around the world. 
 
The HGD project was formally adopted in 
1994 by the Human Genome 
Organization. It has sought massive 
funding. This multi-billion dollar initiative by 
scientists has plans to sequence the DNA 
in the entire human genetic structure. The 
HGDP seeks to map the genetic difference 
of groups from the monotype genome that 
will be identified by the HUGO effort. 
 
Scientists believe that many of the world's 
Indigenous people are in danger of 
becoming extinct and refer to them as 
‘isolates of historic interest’. Scientists 
hope to gather DNA samples from the 
living before they disappear forever, and 
so avoid the irreversible loss of precious 
genetic information. Indigenous peoples 
find it reprehensible that scientists' interest 
is purely to document scientific genetic 
information rather than to preserve tribal 
groups. In effect, the scientists are asking 
endangered tribal groups to submit 
personal samples before their group 
disappears. The scientists' actions revive 
out-dated and oppressive attitudes, and 
their actions instil self-fulfilling pessimism. 
Such actions are simply unethical. 
 
Blood samples taken from Indigenous 
peoples will become immortalized for 
future study. A technique called "cell 
conservation" will keep certain cells of an 
organism alive and capable of multiplying. 
Unlimited amounts of the organism's DNA 
will be stored at various gene banks, 
mostly in the United States. 
 
Indigenous peoples have many concerns 
with the HGDP. One is the issue of 
informed consent. Although the HDGP 
claims that it will seek the consent of the 
individuals and populations concerned, 
many people doubt whether this will, in 





•  Can tribal leaders give consent for the 
whole tribe? 
 
•  Can one person give consent while 
others don't? 
 
•  How can some of these concepts be 
explained in ways and languages for 
people who have no concept or words 
for these confusing terms? 
 
•  What are the benefits for the local 
communities? 
 




The HGDP North American Committee 
secured a grant to develop a model 
protocol or rules for the collection of 
samples from Indigenous groups. It is felt 
by Indigenous people that this protocol will 
primarily be used to seek project co-
operation. 
 
The HGDP states that the research will 
help reconstruct the history of the world's 
populations, address questions about the 
history of human evolution and migration 
patterns, and identify the origins of existing 
populations. While the HGDP is looking for 
answers about human evolution, 
Indigenous peoples already possess 
strong beliefs and knowledge regarding 
their creation and histories. 
 
Danny Billie, traditional spokesman for the 
Independent Seminole Nation of Florida, 
stated in 1997 
 
“The white people are trying to play 
God. If they continue to do what they 
are doing the impact to the human 
species, insects, plant and animal life is 
going to be devastating. They think that 
they can get away with it, but they'll 
also suffer the consequences.” 
 
In response to the HGDP research 
Indigenous peoples from various parts of 
the world have mobilized against the 
project. Documents such as the Ukupseni 
Declaration from Panama and the National 
Congress of American Indians Resolution 
No. 93-118 have been signed. These 
documents represent hundreds of 
communities who declare their opposition 
to the HGDP. 
 
Karioca Declaration. In the early 1980's, 
the Karioca Declaration was signed by a 
group of Indigenous people who were 
opposed to the HGDP and who met prior 
to the 1993 United Nations Conference at 
the Earth Summit in Rio de Janeiro. 
 
Mataatua Declaration. The Karioca 
Declaration was followed ten years later 
by the Mataatua Declaration and signed 
by over 150 participants from 14 United 
Nations countries. The Declaration calls 
for an immediate halt to the ongoing 
HGDP until all aspects of it could be 
understood by Indigenous peoples. 
 
Article 29. In 1994 The United Nations' 
working group on Indigenous populations, 
along with the Sub-Commission on the 
Prevention of Discrimination and 
Protection of Minorities approved Article 
29 of the Declaration of the Rights of 
Indigenous Peoples which stated: 
 
“Indigenous Peoples are entitled to the 
recognition of the full ownership, control 
and protection of their cultural and 
intellectual property. They have the 
rights to special measures to control, 
develop and protect their sciences, 
technologies and cultural 
manifestations including human and 
other genetic resources, seeds, 
medicines, knowledge of the properties 
of fauna and flora, oral traditions, 
literatures, designs, and visual and 
performing arts.” 
 
New Zealand. In 1993 an assembly of 
representatives of the tribes from the 
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North and South Islands of Aotearoa (New 
Zealand) passed resolutions condemning 
the HGDP and the patenting of life-forms. 
 
National Congress of American Indians. In 
that same year the National Congress of 
American Indians (the oldest and largest 
national organization, comprised of  
representatives from 67l American Indian 
tribal governments in the United States) 
passed a resolution condemning the 
HGDP and called upon all related activities 
to cease immediately. 
 
Central Australian Aboriginal Congress. 
Coined as the "Vampire Project" by the 
World Congress of Indigenous Peoples, 
the Central Australian Aboriginal Congress 
Position Paper stated in 1993: 
 
“The Vampire Project is legalized 
theft. The Vampire scientists are 
planning to take and to own what 
belongs to Indigenous People. We 
must make sure that our people are 
not exploited once more by 
corporations, governments, and their 
scientists.” 
 
Maori Congress. In 1994 at the Maori 
Congress Indigenous Peoples 
Roundtable, Indigenous participants from 
the World Council of Indigenous Peoples, 
Greenland Home Rule Government, 
COICA (Peru), Treaty Six Chiefs of 
Alberta, and governmental representatives 
from Vanuatu, Papua New Guinea, and 
Fiji declared that: 
 
“The collection of genetic samples from 
Indigenous peoples such as the Human 
Genome Diversity Project, is unethical 
and immoral and must be brought to an 
immediate halt.” 
 
Patents on Indigenous Peoples. Also in 
1994 in Panama, the Guaymi Indians, 
along with citizens of Papua New Guinea 
and the Solomon Islands, discovered that 
the United States government had taken 
patent claims out on the cell lines from 
some of their people. Through effective 
campaigning they were able to have the 
patent claim abandoned. 
 
Workshop on “Intellectual Property 
Rights”. In August 1994, the International 
Academy of the Environment, along with 
the World Wildlife Federation and the 
United Nations Centre for Human Rights, 
organized an information workshop on 
"Intellectual Property Rights and 
Indigenous Peoples" stating: 
 
“The issue of HUGO, and others 
related to human genes, is a serious 
violation of our peoples' rights. Without 
consultation with the indigenous 
communities, several projects are now 
taking blood, hair, tissue and other 
samples for purposes that are not clear. 
This practice of collecting samples 
without our approval is very dangerous 
because in this way our genetic 
material can be patented or used for 
other purposes. Such practices not only 
violate ethics and human rights, but 
also violate nature, our spirituality, and 
our knowledge of creation that 
connects us with all forms of life.” 
 
Latin and South American Consultation. In 
Bolivia in September 1994, the Latin and 
South American Consultation on 
Indigenous Peoples Knowledge rejected 
the HGDP and human genetic research. 
 
Asian Consultation. Similarly in Malaysia 
in 1995, the Asian consultation on the 
Protection and Conservation of Indigenous 
Peoples Knowledge rejected the HGDP. 
 
Declaration of Indigenous Organizations. 
In Arizona, at the same time, Indigenous 
leaders from US, Canada, Panama, 
Ecuador, Peru, Bolivia, and Argentina, 
formulated a Declaration of Indigenous 
Organizations of the Western Hemisphere. 





“We have a responsibility to speak for 
all life forms and to defend the integrity 
of the natural order. We particularly 
oppose the HGDP which intends to 
collect, and make available our genetic 
materials which may be used for 
commercial, scientific and military 
purposes. We oppose the patenting of 
all natural genetic materials. We hold 
that life cannot be bought, owned, sold, 
discovered or patented, even in its 
smallest forms.” 
 
PAHO. In April 1995 the Pan-American 
Health organization passed a resolution 
opposing the HGDP, and stated: 
 
“This type of research will have a 
negative impact on future health 
programmes and projects in indigenous 
communities, by undermining 
indigenous peoples' trust in the medical 
and health professions.” 
 
The Pacific Consultation. The Pacific 
Consultation on the Protection and 
Conservation of Indigenous Peoples 
Knowledge developed a Treaty declaring a 
Life-Forms Patent Free Pacific, with 
specific objections directed to the HGDP. 
 
North American Indigenous Peoples’ 
Summit. In August of 1997, several 
hundred Indigenous peoples representing 
many tribes and over 60 organizations met 
to discuss the impact of the new 
biotechnology on their homelands and 
their people. This meeting was called "the 
North American Indigenous Peoples’ 
Summit on Biological Diversity and 
Biological Ethics" It established the “Heart 
of the People Declaration”. The preamble 
"expresses our profound concern for the 
well being of our Mother Earth and the 
Indigenous circle of Life known as 
'biological diversity'." The Declaration 
further states: 
 
“We wish to add our voices to ongoing 
global discussions regarding the 
protection of biological diversity, the 
safeguarding of traditional knowledge 
and sustainable development practices, 
and the ethical use and treatment of all 
forms of life in harmony, respect and 
the spiritual interconnectedness of the 
natural world.” 
 
Ukupseni Declaration. In November of 
1997, Indigenous people representing 25 
organizations from 15 countries met in 
Panama to discuss the HGDP and the 
issue of human genetic piracy. This 
meeting was one the first opportunities for 
Indigenous people from Latin America to 
meet with North American Indigenous 
people who were working on the HGDP 
issue. The Ukupseni Declaration on the 
Human Genome Diversity Project was 
established as a result of the two-day 
meeting. The Declaration condemns the 
HGDP: 
 
“It calls for a moratorium on the 
collection of genetic samples from 
indigenous peoples, and demands the 
repatriation of genetic samples and 
data already obtained by unethical 
measures. It opposes the application of 
intellectual property law, and patents, to 
human genes. It calls upon scientists to 
denounce any research conducted in a 
manner that violates the protocols that 
protect the human rights of human 
subjects. Finally it calls upon allies to 
work with Indigenous Peoples to 
demand protection for the human and 
collective rights of Indigenous Peoples.” 
 
The Indigenous Peoples Coalition on 
Biopiracy. The Indigenous Peoples 
Coalition on Biopiracy was established in 
1998 to address the theft of Indigenous 
blood, hair, and skin sampling, and as a 
concerted response to the HGDP. 
Coalition participants worked on strategies 
to protect their communities from 
exploitation. Members disseminated 
information to the local grass-roots levels. 
They built alliances for sharing current 
information as well as for implementing 
collaborative action and support among 
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the participating organizations and 
individuals. An extensive list of key points 
has been developed by this coalition, the 
direct quotation from the document is as 
follows: 
 
“After careful review of HGDP and 
other independent investigations on the 
genome of indigenous peoples: 
 
a. We declare absolute opposition to 
the Human Genome Diversity Project, 
and demand the immediate suspension 
of any activities to collect genetic 
samples, cell lines, or genetic data from 
indigenous peoples, including our 
deceased ancestors. 
b. We demand the fullest cooperation 
of any government agency or 
independent research institute in the 
return of all genetic materials, cell lines, 
and data they may have in their 
possession to the appropriate 
governing authorities of the tribal group. 
c. We oppose any attempt to 
monopolize or commercialize the 
genetic samples, cell lines, or data 
derived from the cell lines of Indigenous 
peoples through the application of 
intellectual property law and patent 
systems. 
d. We oppose the genetic engineering 
of Indigenous peoples’ genes and 
cloning. This includes cloning 
Indigenous peoples’ genes or gene 
fragments into bacterial, viral, 
mammalian cell lines, or other vectors. 
We demand the immediate suspension 
of activities that are currently using any 
Indigenous peoples' DNA, genes or 
fragments in any cloning 
experimentation. 
e. We demand the international 
scientific community condemn any 
research that has been carried out 
contrary to recognized human values 
and moral principles, and that violates 
the international codes of ethics 
described in the Nuremberg code and 
the World Medical Association 
Declaration of Helsinki. 
f. We reaffirm the governing entities of 
Indigenous tribal peoples/nations have 
the primary authority to deny access to, 
refuse to participate in, or to authorize 
any removal of genetic materials from 
our peoples or territories. The ethical 
principle of "individual informed 
consent" is also applicable, and is 
secondary to tribal governmental 
consent. 
g. We demand that scientific endeavors 
and resources be prioritized to support 
and improve social, economic and 
environmental conditions of Indigenous 
peoples in their environments, thereby 
directly improving health conditions and 
raising the overall quality of life. 
h. We demand an immediate 
moratorium on collections and/or 
patenting of genetic materials from 
Indigenous persons and communities 
by any scientific project, health 
organization, governments, 
independent agencies, or individual 
researchers. 
i. We demand that the US government 
and any governing agencies, to not 
participate, fund or provide any 
assistance to the HGDP, or any related 
research projects which seek to 
research the genome of indigenous 
peoples. 
j. We denounce the integrity of the 
report by the Committee on Human 
Genome Diversity of the National 
Research council which gives unethical 
endorsement to the Human Genome 
Diversity Project while acknowledging 
the "lack of a sharply defined proposal 
that it could evaluate".” 
 
 
As Indigenous peoples we have many 
unanswered questions regarding the new 
biotechnology industry, many of them 
centre around the issue of respect and 
some refer to the expropriation of the 
circle of life or biodiversity. In many of our 
communities these activities have been 
referred to as the final act of colonialism 
against Indigenous peoples. I have 
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reported the concerns that Indigenous 
Peoples have not only about the HGDP 
but about the potential threat to 
sovereignty and well being that theft of 
biodiversity has on Indigenous 
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The Internet site to which our attention is 
directed for information about the 
Canadian Biotechnology Strategy 
welcomes me with the Canadian flag, the 
Industry Canada banner and the greeting, 
"The Information Site That Means 
Business!". I am seized by a familiar panic, 
flashing back to border crossing 
interrogations of my wayward youth, job 
interviews from hell, close encounters with 
hostile canines. I feel the disapproving 
gaze of my cyberhost. This is not a site for 
casual browsers. If idle curiosity is my 
currency, I had best hasten my mouse 
BACK toward the more homely terrain of 
Yahoo.com. There is nothing for me here. 
 
I take a deep breath and press past the 
menacing greeting. I do have business 






•Acquisition through the payment of 
money or its equivalent. 
•A grip applied to move something or 
prevent it from slipping. 
•A position affording mechanical 
advantage or the means to move or 
secure a weight. 
•A means of increasing power or 
influence; an advantage used in 
exerting one's power (American 
Heritage Dictionary, 1992). 
 
I am a disabled woman. I feel something 
slipping away, something integral. I sense 
the dark approach of an icy glacial drift, its 
advance propelled by the weight of layer 
upon layer of values and ideology subtly 
hostile to my own. I doubt my capacity to 
influence the inexorable progress of 
biotechnology's powerful agenda. I need 
purchase. 
 
I have been invited to bring "a disability 
rights perspective" to a workshop for the 
Working Group on Women and the New 
Genetics. But I cannot come to the table to 
discuss the CBS strategy with only my 
gnawing, visceral, unease. I scour the site 
– the press releases, fact sheets, 
background papers, consultation 
documents and committee reports. My 
browser's find command storms through 
each document in pursuit of a single 
fugitive word. But "disability" appears 
nowhere in the documents that highlight 
the strategy's features, benefits, guiding 
principles, goals, development and 
progress. It is alluded to, in phrases like 
"recognizable problems attributed to 
chromosomal, monogenic or multifactorial 
mutations" or "genetic deficiency" (CBS 
1998a). It is implied, surely, in the promise 
that "Genetic testing will provide a number 
of diagnostic benefits such as the potential 
for ... helping potential parents make 
informed decisions..." (CBS 1998a). But 
the shadowy foe never quite declares 
itself. 
 
I find myself remembering Kenzaburo Oe's 
reference to medieval Zen poetry and its 
concern with the "linguistic impossibility of 
telling the truth" (Oe 1995:112). He spoke 
of words "confined within closed shells", 
baffling any attempt at full understanding. 
Perhaps we must plumb for meaning 
within the closed shell of the strategy's 
promise "to enhance the quality of life of 
Canadians in terms of health, safety, the 
environment, and social and economic 
development". 
 
A delicate excavation. My quest for 
meaning will cluster around four 
phrasings. Each is extracted from CBS 
documents and appears fundamental to 
the strategy's health thread. Each states a 
noble purpose, yet there is an equivocal 






Biotechnology as a Key Contributor to 
Quality of Life (CBS 1998b) 
 
How does biotechnology contribute to 
quality of life?  
 
It would appear that this is intended in part 
through the prevention of genetic disease 
or defect. This presumes first, an 
identifiable genetic "norm", and second, 
some social consensus that the "norm" is 
inherently more desirable than the 
"deviant" form. It is the latter presumption 
that is problematic from a disability 
perspective. Those of us with genetically 
non-typical characteristics are invariably 
excluded from any alleged "consensus" 
about what constitutes desired or 
acceptable life states.  
 
Implicit in the identification of "genetic 
disease" (e.g., as applied to conditions 
such as Down syndrome, Spina Bifida and 
Muscular Dystrophy) is the assertion that 
disability is a negative characteristic – "a 
priori an undesirable trait" (Rioux 1996). I 
would be the first to concur that disability – 
like gender and race – correlates strongly 
with disadvantage. But while it is widely 
recognized that the disadvantage 
experienced by women and racial 
minorities is directly attributable to the 
social and systemic evils of sexism and 
racism, the non-disabled majority seems 
to stumble again and again in applying a 
similar analysis to the human rights claims 
of persons with disabilities. Instead, 
majoritarian thinking uncritically situates 
disability disadvantage as intrinsic to 
individual impairment or nonconformance 
to physiological and intellectual norms. 
 
Disability activists and theorists have 
emphatically asserted that disability is a 
social phenomenon, rather than a 
biological one. Biotechnology’s vigorous 
focus upon disability prevention by genetic 
methods ignores the deeply embedded 
and pervasive social, economic and 
political determinants of disability 
disadvantage. Disability is located in social 
and economic structures, more than it is in 
genetic ones. How can we "popularize" 
this inherently unpopular notion? 
 
Of course I cannot deny that living with a 
non-typical body can and often does add 
to life a significant dimension of pain, loss 
and restriction. But as I have argued at 
length in other fora, the same can surely 
be said of other states generally accepted 
as socially desirable – for example, 
growing up, entry into intimate relationship 
and parenting. The point is, as Adrienne 
Asch noted in her recent debate with Peter 
Singer, that “disability is only one 
characteristic of any person's life.... Along 
with disability – whatever that disability 
happens to be – come a whole range of 
other characteristics... and redeeming 
benefits... both intrinsic and extrinsic.” 
(Singer and Asch 1999). 
 
Disability per se cannot be presumed to 
diminish quality of life. Unless, of course, 
we are talking about the quality of life 
(read privilege) enjoyed by non-disabled 
Canadian citizens. Perhaps encoded in 
the phrase "quality of life" are forecasts 
about our national standard of living, and 
embedded in these, concern for allocation 
issues arising from escalating costs in 
health care and health support. This may 
well be so, but if it is, it must be made 
explicit. How else can those of us with 
genetically non-typical bodies find solid 




Helping Potential Parents Make 
Informed Decisions (CBS 1998a) 
 
For persons with nontypical genetic 
characteristics deemed undesirable by a 
non-disabled majority, the very possibility 
of entry into the human family becomes 
contingent upon a prospective parent's 
capacity to resist institutional pressure, 
reject social stereotypes and withstand the 




Most women over 35 elect to have 
prenatal diagnosis, and if they are told that 
their infant will have a "major defect" most 
of them decide to abort. As Princeton 
ethicist Peter Singer explains tersely, "If, 
before life has begun, the prospects are 
clouded, better to consider starting again" 
(Singer and Asch 1999). His utilitarian 
logic, it seems, is irresistible to many. 
 
But what criteria or standards define an 
"informed decision"? 
 
For those of us with "undesirable" genetic 
characteristics that could have been 
detected before birth, the implications of 
such informed decision-making are 
genocidal. Had our parents or their 
physician-advisers been "better informed", 
how many more of us would have been 
denied the possibility to experience life, 
think our own thoughts or form our own 
opinions and value systems? 
 
The genetic structure of the fetus is such a 
small piece of the story of who we are and 
who we will become. Perhaps it is all that 
is knowable. The gifts and contributions of 
personhood will forever elude the 
predictive capacity of biotechnology. It is 
Singer's argument that some information is 
better than no information when decisions 
must be made in conditions of uncertainty. 
But surely a shred of information – nothing 
more than a dim flicker, enough only to 
render the purity of darkness into a 
labyrinth of shadowy distortions – surely 
this does not transform a leap of faith into 
an informed decision. After all, we withhold 
otherwise relevant evidence from juries 
when its prejudicial effect outweighs its 
probative, "informative" value. 
 
Each new reproductive technology 
challenges us "to think better and harder 
than we're used to about two mighty piers 
of life's foundation: power and love." 
(Angier 1999) How much power can we 
have over the outcomes of reproduction? 
As Angier asks, "Does that power give us 
greater freedom, or does it deprive us of 
one of life's most unsung freedoms: the 
freedom to have things happen on their 
own?" 
 
R. Alta Charo, professor of law and 
medical ethics at the University of 
Wisconsin in Madison says, "Reproductive 
technologies cumulatively reduce the 
range of events that happen by serendipity 
and increase the range of events that 
happen by active planning. This changes 
the texture of life. One of the rights we 
have is the right to not have to make 
choices." (Angier 1999)  
 
At the dawn of the Age of Reason, Blaise 
Pascal observed: "There are two equally 
dangerous extremes: to shut reason out, 
and to let nothing else in." (cited in Kumar 
2000) We cannot turn back the clock, we 
cannot suspend the knowledge that 
biotechnology offers. How then can we 
ensure that its juggernaut fury is 
contained? How can we secure a 
respected place for women's faith and 




Reflecting Canadian Values (CBS 
1998b) 
 
What is our recourse when "Canadian 
values" are at odds with the values of 
social justice and feminism? 
 
In the era of globalization, what are 
Canadian values? To what extent will they 
be shaped by those that dominate 
contemporary American culture? (Money. 
Knowledge. Social rank. Sex. 
Individualism.) Are the courts, the 
universities or the media our arbiters of 
cornerstone values? In any case, is the 
result not likely to have its roots in ideals 
of wealth, aesthetics, autonomy and 
power? 
 
"[As we develop] increasingly 
sophisticated means to detect – and 
potentially to prevent – difference in 
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genetic structure, [we find ourselves living 
in] a time when our public policies reflect 
an increasingly inhospitable climate for 
difference. More and more, the Ideal 
Citizen is seen as the individual who 
demonstrates self-reliance, efficiency and 
competitiveness." (Ticoll 1996) 
 
The values and aesthetic preferences that 
prevail in our society will determine 
biotechnology's agenda, priorities and 
presumptions. They will influence not only 
how questions are answered. More than 
this, they are the breath with which every 
question does or does not find utterance. 
The questions that we fail to ask of 
biotechnology will be of most profound 
consequence. 
 
History teaches us that determinations of 
human worth are always consistent with 
the qualities that decision-makers have 
presumed themselves to possess – “the 
sort that facilitated passage through 
schools, universities and professional 
training." (Kevles, cited in Gray 1999) Put 
in other words, as Eva Feder Kittay has 
asserted, "The 'relevant' attributes for 
personhood are invariably abstracted from 
the lives of the people doing the 
abstraction." (Montgomery, personal 
communication) 
 
Feminist economist Marilyn Waring 
proposes that time, rather than money, is 
the one commodity of intrinsic value in 
human society. She argues convincingly 
that radical transformations in economic 
policy would flow from the recognition of 
time and the natural environment in our 
measurement and distribution of wealth. In 
the same way, can we reinvent the Ideal 
Citizen as one with the capacity to form 
deep relationship, to give or experience 
joy, to create, to open new pathways for 
expression of personhood? 
 
 
Biotechnology for Public Health 
Advantage (CBS 1998b)  
 
How can those of us with genetically non-
typical bodies reconcile CBS notions of 
health promotion with our own identity and 
experience as healthy disabled women? 
 
Contrary to the expectations and 
preconceptions of non-disabled 
Canadians, many people with genetically 
non-typical bodies – once they escape 
detection and survive gestation and birth – 
develop well-honed skills in the avoidance 
of medical "attention," enjoying the quiet 
and priceless joy of medically uneventful 
living. By no means the exclusive privilege 
of the genetically typical, wellness and 
well-being correlate most strongly with 
unencumbered access to the major health 
determinants of adequate money, a clean 
and safe environment, supportive personal 
relationships, control over living 
conditions, etc. Yet people with disabilities 
are presumed to be unhealthy and 
overlooked in the establishment of public 
health standards and programming, 
having to fight for information, access and 
services at every turn. 
 
How can we unmask the aesthetic 
preferences embedded in definitions of 
health?  
 
School-aged children who are shown 
pictures of a wide range of "potential 
friends" and asked to pick the ones with 
whom they would be most likely to 
become friends choose children who look 
like themselves and reject children who 
look different. Obese children, children 
with disabilities, children of different racial 
groups are eliminated quickly, for reasons 
the children making the selection find 
difficult to articulate. Regrettably, adult 
architects and engineers of public policy 
commonly demonstrate the same 
inclinations, similarly unconscious and 
unspoken. The tyranny of designer culture 
accounts for much of my unease with the 
CBS and its squeamish reluctance to taint 
the pretty vistas of our genetically rich 






How has this group interpreted those 
pretty vistas? What is our collective 
assessment of the "public health 
advantage" of the Canadian Biotechnology 
Strategy? 
 
A review of the papers presented in this 
series suggests that contributors share a 
deep concern that enormous human and 
economic resources are being directed 
away from social, economic, cultural and 
environmental health determinants and 
used instead to fuel the development of 
biotechnology and genetic interventions. 
This point was made explicitly by Madeline 
Boscoe, Sari Tudiver and Priscilla Settee, 
it provided a starting point for Ken Bassett, 
and formed an implicit underpinning for 
most if not all of the arguments and 
critiques recorded. 
 
There is also apparent consensus that 
biotechnology and genetic engineering are 
fundamentally problematic. The papers 
collected in the "community" series locate 
the problem differently – quite naturally, 
given the impressively diverse range of 
activist perspectives from which they 
originate. Fern Brunger and Sue Cox 
alerted us to ethical issues that may arise 
for collectives or larger groups when 
individual members consent to participate 
in research. Priscilla Settee provided a 
specific example, identifying the violation 
of cultural and intellectual property as a 
colonialist assault upon the identity and 
spiritual knowing of aboriginal peoples. 
Patricia Lee warned of possible misuse of 
DNA biotechnology in forensic contexts, 
exposing women to state-sanctioned 
violations of their propriety, privacy, 
security and confidentiality. 
 
Popular opinion polls – and indeed the 
official documents of the Canadian 
Biotechnology Strategy – would suggest 
that the consensus that we appeared to 
share is absolutely atypical, perhaps even 
squarely in opposition to views espoused 
by the majority of our friends, neighbours, 
colleagues and fellow travellers. 
 
This, of course, did not surprise us. But an 
examination of the thread that linked our 
various perspectives proved instructive 
vis-à-vis our efforts to understand and 
formulate strategies in response to 
prevailing support for an aggressive 
investment in biotechnology. 
 
Surely what informs our shared opposition 
to the Canadian Biotechnology Strategy is 
a set of common values. I would suggest 
that these go beyond values about the 
meaning of health, extending to a shared 
understanding of justice, and even more 
profoundly, a set of ideas about what 
constitutes personhood. 
 
In the paper submitted by Fern Brunger/ 
Sue Cox, these values are explicitly linked 
to a feminist understanding of power. They 
are articulated in the recognition that 
"genetic testing must be placed firmly in 
the context of culture in its relation to 
power. Bioethics, like genetics, is itself 
culturally (and historically/ politically/ 
economically) shaped." Similarly, Patricia 
Lee concludes her paper with reference to 
"the new loci of power and control" in DNA 
databanks. Priscilla Settee presents a 
vivid description of a final act of 
colonialism against Indigenous peoples. 
Even Ellen Larsen, whose focus is quite 
different, introduces the idea of scientists 
"looked upon as belonging to a priesthood 
which has access to information stored in 
Temples". For each of us, the issue at the 
starting point is one of power in its cultural 
context. 
 
Concrete suggestions as to where to go 
from here display a range as broad as the 
platforms from which the papers were 
launched. Ellen Larsen proposes a 
democratization of science – a more 
fulsome integration of scientific ways of 
thinking within scholastic contexts and the 
community at large, rendering science less 
mysterious, more comprehensible and 
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accessible to non-scientists, enabling a 
more informed critique of science as a way 
of exploring our world and understanding 
technology. 
 
Ken Bassett proposes the assertion of 
alternative values in provincial and 
community settings charged with 
purchasing social and health services and 
technology. He suggests that another 
possible site of similar action is on 
university and hospital ethical review 
committees charged with determinations 
of research validity and conformance with 
standards of public good. 
 
Fern Brunger and Sue Cox propose that 
we find the commitment and the resources 
to engage in genuine community-based 
research, examining the everyday 
experiences that shape and are shaped by 
genetic testing, negotiating standards of 
collective acceptability and grasping 
collective and perhaps foreign value 
systems. 
 
Finally, I extend a challenge to re-examine 
even our own attitudes, recognizing that 
we are a very long way, still, from a 
collective recognition of disability as an 
acceptable form of human variation. We 
are still mostly complicit with the 
medicalization of disabled women's bodies 
and the construction of disability as an 
individual defect or a personal or social 
tragedy. I urge each of us to attend 
carefully to the narratives of disabled 
women who affirm themselves instead as 
whole and endowed with great strength 
and beauty. Then perhaps we can arm 
ourselves for the struggles ahead with a 
set of values that – to borrow from Nandita 
Sharma's reference – are radical enough 
to be worth the fight. 
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About the Article 
Margaret Lock interrogates received wisdom about technologies in general, and 
biotechnologies in particular. She provides a critique of the relations between 
communities and the biotechnology promised by the CBS, and comments on several 
papers in the collection which take biotechnology and community as their theme. 
Technologies are neither autonomous nor value neutral, Lock argues. Rather, their 
constitution and use reflects relations of power, and the complex ways in which they 
construct the persons and things upon which they act. Genetic biotechnologies, in 
addition, render the traditional rights of access and informed consent insufficient as 
arbiters of use, since communities, and not just individuals, are implicated. Finally, Lock 
notes that, when we talk about ‘communities,’ “we are dealing with a slippery concept.” If 
individual access and informed consent are insufficient resources for engaging 
biotechnologies, Lock suggests, adding ‘communities’ to such processes will not be a 
panacea, but will necessarily involve debates about which ‘communities’ are implicated 




The history of technology, including that of 
medical technology, is usually told as a 
narrative of progress, a means to enable 
us to overcome the limitations that nature 
places upon us. Dominant arguments, 
following Heilbroner (1967) and others, are 
that technology is, in effect, autonomous; 
that technology itself is value neutral and 
should be understood as empowering 
through the production of more freedom 
and flexibility in the world in which we live. 
 
Emphasis on the rationality of technology 
and the liberation it brings with it masks at 
least four things: first that inevitably 
relations of power are involved in the 
production and application of all 
technologies; notably the interests of 
powerful elites ensure that debate about 
new technologies does not, without great 
public outcry, take place in the public 
sphere; our institutions are designed to be 
opaque, and protective of those holding 
the reins. More troubling, is that in 
contemporary society such elites are 
located increasingly in the private sector or 
function in partnerships created between 
the private sector and universities. 
Government and universities have less 
and less say as to what should be 
invested in and developed and who should 
have access to the end product once it is 
placed on the market. An economic 
imperative has taken hold. 
 
Second, and related to the previous point, 
while some technologies, in Canada at 
least, are available to us all, others, 
notably the new reproductive technologies, 
and genetic testing and screening do not 
fall into this category, thus introducing 
inequities into the system – something 
which troubled the Royal Commission on 
New Reproductive Technologies (1993) 
but about which, as we all know too well, 
nothing has as yet been done. It is not 
only the inequities as such that are 
troubling. Such a system fosters insidious 
divisions among women to the detriment 
of everyone except those who are clearly 
wealthy. So, questions of access and 
availability mask more fundamental issues 
deserving of close attention. 
 
Third, new technologies by their very 
nature create new entities and populations 
to be worked upon. As Foucault pointed 
out, technologies and their associated 
discourse create the objects on which they 
operate and are in turn constituted by 
these same objects. Until BRCA 1 and 2 
were isolated, for example, there was no 
sub-group of women who could be singled 
out through testing as having the “gene or 
genes for breast cancer” and who today 
must face a slew of decisions to which 
there is no satisfactory resolution, whether 
the test results are positive or negative. 
With the availability of genetic testing 
many people now think of their genes as 
quasi pathogens and worse yet, as 
pathogens for which they can be held 
responsible if passed on to the next 
generation. Some individuals live their 
lives as the “pre-symptomatic ill” – having 
been labeled “at risk” for late onset chronic 
diseases with a genetic component. In this 
climate of impending danger, when great 
value is also placed on control and on 
creating “normal” populations, pressure 
mounts daily for people to undergo genetic 
testing, even when no therapies are 
available. There is a will to know who we 
are, genetically speaking. Meanwhile the 
social and environmental determinants of 
disease are relegated to the background 
once again, as they have been in the past 
decades. 
 
Fourth, half a century ago, in response to 
medical experimentation and concerns 
about human rights, the idea of informed 
consent was adopted and institutionalized 
over the years, ensuring to a considerable 
extent the protection of individuals in the 
face of new biomedical technologies. But 
protection, and the rights of families and of 
segments of society in connection with 
these same technologies, has not thus far 
been considered necessary, and in any 
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case individual rights continue to take 
priority. 
 
The emergence of the powerful 
combination of population genetics with 
molecular genetics has upped the ante 
about the powers of technology and how it 
can enable us as individuals and as a 
society. The hype associated with the 
human genome project and its associated 
technologies is utopian. We all now have 
the right, Daniel Koshland (1989) informs 
us, to a full complement of healthy genes, 
but it is clear that neither individual 
informed consent, nor individual desire, or 
the desire of couples, are adequate to deal 
with what we are now facing. Each of the 
papers under discussion makes it clear 
why. 
 
First, as Ken Bassett points out, we are 
now clearly in an era of deregulation and 
less stringent legislation, in large part 
because funding for these activities has 
been cut back. Technologies are in effect 
assumed to cause no harm unless proved 
otherwise – witness the introduction of GM 
foods. It takes repeated tragedy before 
moratoria are instated for interim periods. 
No standing committees exist that 
consider the social consequences of what 
we are doing, suggesting that even today 
biomedical technologies are thought of as 
autonomous agents of progress that bring 
us good. Bassett argues that university 
and hospital ethical review committees 
might take on the task of social evaluation. 
Such committees could indeed spot 
conflicts of interest, and even encourage 
communal advocacy, if they could first 
decide what constitutes a relevant 
community and who should represent it. 
But how can the participants in such 
committees be expected to foresee the 
larger social consequences, many of 
which will have effects beyond 
communities when, for example, 
genetically engineered foods, patents, 
xenotransplants, germ-line engineering, 
and related technologies are involved? 
Surely we need, in addition to ethical 
review committees, national and 
international bodies with legal clout who 
can instigate policies that are rigorously 
enforced? Something like the international 
court at the Hague perhaps? 
 
Brunger and Cox set out by making the 
impact of the new genetics on collectivities 
their prime focus of interest. They are 
concerned about the non-clinical impact of 
genetic testing on everyday life and 
knowledge, something about which we 
have very little information. They argue, 
like Bassett, for the inclusion of community 
representatives in research, and show 
how the outcomes of research and testing 
affect not only involved individuals, but 
families and communities. A heterogeneity 
of values must be acknowledged, leading 
to the idea of “negotiating collective 
acceptability” so that evaluation of the so-
called risks and benefits of testing are 
made communal. This is a forward looking 
approach, vastly superior to outmoded 
ideas of informed consent, but in reality 
large portions of what will be negotiated 
are things about which no one can predict 
outcomes, and that in any case, we can do 
nothing about. One can see how collective 
acceptability may assist with testing 
families for Huntingdon’s disease, in that 
this knowledge can be used to make 
marriage and reproductive choices, 
although many people would still not want 
to know this kind of information. When it 
comes to late onset diseases with complex 
and unreliable probability predictions, or 
worse still, if and when it comes to making 
decisions about genes erroneously 
believed to determine behavior, should 
families and communities be involved? 
Should we be doing such tests at all? Who 
should decide what may not go to the 
table for negotiation at all? 
 
Ellen Larsen is concerned about a dearth 
of education in connection with genetics 
because she has been startled by the 
inability of students to comprehend articles 
in the media on this subject matter. I am 
startled about yet other things where the 
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media is concerned: the relationship of the 
research community to the media, and the 
common inability of the media to report 
with accuracy findings about genetics or 
predictions of risk. How many times have 
we heard that 1 in 9 of all women are at 
risk for getting breast cancer in the next 
ten years? One of the recommendations 
made by the committee for Medical, 
Ethical, Legal, and Social Issues (MELSI), 
that was part of the now defunct Canadian 
Genome Analysis and Technology (CGAT) 
program, was that money be put into the 
training of science reporters who would 
then build up close links with research 
communities. This recommendation 
should be taken seriously. 
 
The two papers by Patricia Lee and 
Priscilla Settee take a somewhat different 
approach to problems raised by the new 
genetics, namely the collection, storage, 
and uses to which DNA materials are put. 
Controls over data banks are almost non-
existent in Canada, and this needs to be 
addressed urgently, but Lee points to a 
more insidious problem to do with the way 
in which bodies are “constructed” in 
connection with DNA analyses. As Ian 
Hacking (1998) puts it, we are dealing with 
the problem of how people are “made up” 
and to what collectivities they are assigned 
by scientists, lawyers, and government, in 
this particular case, the way in which 
victims of violence are re-victimized by 
characterization in the courts as unstable, 
bad women. The question of whether the 
forensic evidence supplied to the court is 
properly protected is also crucial. If, as 
Lee suggests, forensic evidence is not in 
the end used much in trials, then we have 
to ask two fundamental but related 
questions: is the very availability of the 
technology driving what is happening, and 
should more control be exerted at this 
point to prohibit its use? Or is there 
something darker at work: the creation of 
DNA data banks of marginalized peoples 
for the testing of hypotheses about 
stigmatized collectivities? Certainly, as 
Lee shows so well, the biotechnology has 
little value for the health and security of 
the women in question. 
 
The Human Genome Diversity Project 
(HGDP) foundered right from its inception, 
and Priscilla Settee sets out many of its 
misguided principles in her paper. 
Responses to the HGDP by indigenous 
peoples have been mostly of 
condemnation and with good reason. The 
project is both unsound scientifically and 
unethical. Among other things the 
organizers argue that the project will 
permit a better understanding of disease in 
targeted populations. This is not possible 
because DNA samples are collected in 
isolation, along with no other data, 
essential if links are to be made between 
genotypes, phenotypes, and the 
expression of disease. 
 
Interest in genetic diversity is hot stuff 
today, and by raising the issue of who 
might have rights in, or even make claims 
to own genetic material, the question is 
brought to the fore of what exactly is a 
“community.” While the papers have been 
grouped together under the heading of 
“community,” the authors either do not use 
this concept explicitly or else apply it 
rather loosely in a variety of ways, 
suggesting that we are dealing with a 
slippery concept. The papers group 
individuals together as collectivities by 
gender, ethnicity, as First nations, interest 
groups, risk groups and so on, but we do 
not know if these units should indeed be 
conceptualized as communities; nor what 
being located in a community might mean 
for involved individuals. Apart from 
anything else, individual interests usually 
cut across several “communities.” It is 
clear that authors are concerned that the 
particular interests and needs of named 
collectivities are not being attended to with 
respect to the several technologies under 
discussion, most of them related to genetic 
modifications of one kind and another. It is 
argued, and I agree, that collectivities 
should be brought systematically into 
future discussions and constituted as 
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actors in decision making, and several of 
the papers outline ways in which this might 
be brought about. Parenthetically, several 
papers argue that limiting attention to 
individual rights and autonomy is no longer 
sufficient when it comes to the new 
genetics. Discourse about genes inevitably 
presents a paradox: it reinforces 
associations among people as families 
and as genealogies having a shared 
biological heritage, but it also divides 
people, for individual genomes are unique. 
Even so, the effects of genes on health 
and knowledge about genes cannot be 
thought of as a private matter. 
 
Can body parts be owned? Whether it be 
by individuals, families, communities, 
nations, or humankind as a whole? Is it 
appropriate for individuals or organizations 
to make such claims? Do we need to find 
some language other than property law in 
order to deal with these new dilemmas? In 
theory, with the abolition of the slave trade 
we abolished the right to “own” persons, 
perhaps now is the time to make a move 
so that parts of the body are made 
inalienable. At the very least such a move 
must be debated. At present we live with 
inconsistencies. It appears that massive 
public opposition exists to the sale of 
organs for transplants, on the other hand 
eggs, sperm, and blood – repositories of 
genetic material for future generations – 
are sold daily with few controls in place. In 
effect we are prepared to make 
commodities of the stuff that produces 
children, but not of kidneys that, if 
procured in humane and sterile 
surroundings, have the potential to prolong 
the lives of recipients, sometimes for many 
years, as productive members of society. 
 
In sum, systematization of the 
management and monitoring of the 
collection and commodification of human 
cells, tissues and organs is extremely 
urgent and surely is something that cannot 
be worked out other than by internationally 
recognized legally binding agreements. 
 
In connection with the new genetics one of 
the biggest issues to be confronted is that 
of “individual interest” or what is perceived 
to be in the interest of individuals, because 
knowledge about the genes of individuals 
and their manipulation can place these 
individuals in potential conflict with the 
interests of the larger groupings of people 
of which they are a part – families, 
communities, societies. If genetic material 
is understood as belonging entirely to 
individuals, and if so-called genetic 
diseases are located entirely in the bodies 
of individuals, then the social and cultural 
issues associated with these entities will 
inevitably be ignored or at the very least 
set to one side. Depoliticization is the 
result. 
 
Disputes about disease causation being 
the result of proximate or final causes – 
due to external causes or confined to 
causes internal to the body – are hundreds 
of years old, and such disputes form the 
basis for current arguments between 
health prevention models and those of 
clinical medicine and the associated basic 
sciences. Even though we talk today about 
multifactorial diseases little middle ground 
has been created between the 
reductionistic arguments of so many 
molecular geneticists and those 
researchers who use the tools of 
epidemiology and make predictions about 
human populations. A great deal of talking 
at cross-purposes persists, permitting 
obfuscations about the goals and 
applications of the new genetics to go 
unexamined. 
 
What is particularly dangerous this time 
round is that some proponents of the new 
genetics are trying not simply to 
institutionalize gene therapy but are 
moving towards enhancement of the 
human genome. This will affect not only 
individuals, but communities everywhere 
and future generations, and can only be 
described as neoeugenics – a blatantly 
political endeavor disguised as scientific 
benevolence. Efforts at normalization of 
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the health and well being of individuals 
through techniques such as 
preimplantation genetic diagnosis followed 
by selective disposal of unwanted fetuses 
are already being put into practice, and will 
affect the composition and condition of 
future populations. Rather than limiting our 
responses as feminists to issues of 
informed consent and equal access to new 
genetic technologies, we must at the same 
time, I think, vigorously persist in 
arguments about the social determinants 
of ill health, including diseases where 
genetic factors are implicated. At the same 
time discussion of the social 
consequences of allowing individual desire 
and informed consent to shape policy 
making in connection with the new 
genetics is urgently called for. 
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